TMF-14624358  CONFIDENTIAL  
GlaxoSmithKline group of companies   207497  
 Protocol Amd 04  
 1 
 TITLE PAGE  
Protocol Title : A Phase I/II, Open -label, Dose Escalation and Expansion Study to 
Evaluate Safety, Tolerability, and Clinical Activity of the Antibody -Drug Conjugate 
GSK2857916 Administered in Combination with Lenalidomide Plus Dexamethasone 
(Arm A), or Bortezomib Plus Dexamethasone (Arm B) in Participants with 
Relapsed/Refractory Multiple Myeloma – (DREAMM 6)  
Protocol Number : 207497 / Amendment 04 
Compound Number:   GSK2857916  
Brief Title: Phase I/II study of the Antibody -Drug Conjugate GSK2857916 
Administered in Combination with Lenalidomide Plus Dexamethasone (Arm A), or 
Bortezomib Plus Dexamethasone (Arm B) in Participants with Relapsed/Refractory 
Multiple Myeloma  
Study Phase : Phase 1/Phase  2 
Acronym : DREAMM 6  
Sponsor Name and Legal Registered Address :  
GlaxoSmithKline Research & Development Limited  
980 Great West Road  
Brentford  
Middlesex, TW8 9GS  
UK 
Medical Monitor Name and Contact Information  can be found in the Study Reference 
Manual  
Sponsor Signatory:  
Timothy Crossman, BMBS MRes  
Group Sr. Director, Clinical Development Lead  
Approval Date : 30 Jun 2022  
Regulatory Agency Identifying Number( s): 
Registry  ID 
IND number  119333  
EudraCT number  2017 -004689 -93 
©202 2 GSK group of companies or its licensor . All rights reserved. Unauthorized 
copying or use of this information is prohibited.
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 2 
  
PROTOCOL AMENDMENT SUMMARY OF CHANGES TABLE  
DOCUMENT HISTORY   
Document  Date  Document Identifier  
Amendment 4  30 Jun 2022  TMF-14624358  
Amendment 3  13-Jul-2020  2017N330850_04  
Amendment 2  26-Apr-2019  2017N330850_03  
Amendment 1 (Republished)  14-May-2018  2017N330850_02  
Amendment 1  07-May-2018  2017N330850_01  
Original Protocol  28-Feb-2018  2017N330850_00  
 
Amendment 04: 30 Jun 2022  
Overall Rationale for the Amendment:   
This protocol has been amended to update the end of study definition and to include 
continued access to study intervention (Post Analysis Continued Treatment [PACT])  after 
final analysis . 
Section # and Name  Description of Change  Brief Rationale  
Section 1 Synopsis  Added  additional content to implement  
post analysis continued treatment 
(PACT) phase  and clarification of end 
of study  definition  To allow continued treatment of 
study participants who continue 
to derive clinical benefit  post the 
final analysis   
Section 3 Schedule 
of Activities  Added additional content to clarify visit 
schedule for PACT phase  To allow continued treatment of 
study participants who continue 
to derive clinical benefit post 
final analysis  
Section 4.3.1 Risk 
Assessment  Updated the summary of risk 
assessment table for the Combination 
Therapy of Belantamab Mafodotin with 
Len/Dex (Arm A) and Belantamab 
Mafodotin with Bor/Dex (Arm B)  Changes made as per the latest 
IB 
Section 5 Objectives 
and Endpoints  Included additional exploratory 
objectives   To match plans for final 
statistical analysis  
Section 6.1 Overall 
Design  Updated the language of the overall 
design section to differentiate between 
the end of data collection and the end 
of study timepoints  To allow continued treatment of 
study participants who continue 
to derive clinical benefit  post 
final analysis   
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 3 
 Section # and Name  Description of Change  Brief Rationale  
Section 6.3 
Participant Study 
Completion, S tudy 
Analysis and End of 
Study  Updated the  language of study analysis 
section  to combine the primary and 
final a nalysis Support deliverables for final 
CSR  and to implement PACT  
Section 6.4 End of 
Study Definition  Added additional content to implement 
PACT  phase  and end of study  To allow continued treatment of 
study participants  who continue 
to derive clinical benefit  post 
final analysis  
Section 8.1.4 
Pharmaceutical 
Presentations  Added additional content to dosage 
form of belantamab mafodotin as a 
lyophilized powder  To allow continued treatment of 
study participants who continue 
to derive clinical benefit post 
final analysis  
Section 8.1.5 
Preparation of Doses  Added additional content to preparation 
of belantamab mafodotin in lyophilized 
form To allow continued treatment of 
study participants who continue 
to derive clinical benefit post 
final analysis  
Section 8.8 
Treatment After the 
End of the Study  Clarification  around  treatment following 
end of the study  To allow continued treatment of 
study pa rticipants who continue 
to derive clinical benefit post 
final analysis  
Section 8.9 
Continued Access to 
Study Intervention 
after Final Data Cut  New section to align with 
implementation of PACT phase  To allow continued treatment of 
study participants who co ntinue 
to derive clinical benefit post 
final analysis   
Section 10.2.1 Time 
Period and 
Frequency for 
Collecting AE and 
SAE Information   Included additional content to align with 
implementation of PACT phase  To allow continued treatment of 
study participants who continue 
to derive clinical benefit post 
final analysis   
Section 12.4.9 Final 
Analysis  Updated the language of study analysis 
section to combine the primary and 
final analysis  Support deliverables fo r final 
CSR and to implement PACT  
  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 4 
 TABLE OF CONTENTS  
PAGE  
1. SYNOPSIS  ................................ ................................ ................................ .............  10 
2. STUDY SCHEMA  ................................ ................................ ................................ ... 25 
3. SCHEDULE OF ACTIVITIES  ................................ ................................ .................  27 
4. INTRODUCTION  ................................ ................................ ................................ .... 82 
4.1. Study Rationale  ................................ ................................ ..........................  82 
4.2. Background  ................................ ................................ ................................  83 
4.2.1.  Current Treatment of Multiple Myeloma  ................................ ....... 83 
4.2.2.  Role of B -Cell Maturation Antigen in Multiple Myeloma  ................  84 
4.2.3.  Antibody -Drug Conjugate Belantamab Mafodotin  ........................  84 
4.2.4.  Clinical Experience with Belantamab Mafodotin  ...........................  85 
4.2.4.1.  Clinical activity in studies with belantamab 
mafodotin monotherapy  ................................ ..............  85 
4.2.4.2.  Clinical Safety in belantamab mafodotin 
monotherapy studies  ................................ ..................  86 
4.2.4.3.  Pharmacokinetics and Pharmacodynamic in 
Humans  ................................ ................................ ...... 88 
4.2.4.4.  Clinical Summary  ................................ .......................  89 
4.3. Benefit/Risk Assessment  ................................ ................................ ............  89 
4.3.1.  Risk Assessment  ................................ ................................ .........  89 
4.3.2.  Benefit Assessment  ................................ ................................ ..... 93 
4.3.3.  Overall Benefit:Risk Conclusion  ................................ ...................  93 
5. OBJECTIVES AND ENDPO INTS  ................................ ................................ ...........  93 
6. STUDY DESIGN  ................................ ................................ ................................ .... 97 
6.1. Overall Design  ................................ ................................ ............................  97 
6.1.1.  Arm A - Belantamab Mafodotin with Len/Dex  ...............................  98 
6.1.1.1.  Part 1 Dose Escalation Phase  ................................ .... 98 
6.1.1.2.  Dose Escalation Decisions  ................................ ....... 103 
6.1.1.3.  Part 2 Dose Expansion  ................................ .............  103 
6.1.2.  Arm B - Belantamab Mafodotin with Bor/Dex  .............................  104 
6.1.2.1.  Part 1 Dose Escalation Phase  ................................ .. 104 
6.1.2.2.  Dose Escalation Decisions  ................................ ....... 105 
6.1.2.3.  Part 2 Dose Expansion  ................................ .............  106 
6.1.3.  Criteria for Belantamab Mafodotin DLT in Part 1  ........................  107 
6.2. Number of Participants  ................................ ................................ .............  109 
6.3. Participant Study Completion, Study Analysis and End of Study  ...............  109 
6.4. End of Study Definition  ................................ ................................ .............  109 
6.5. Scientific Rationale for Study Design  ................................ ........................  110 
6.6. Dose Justification  ................................ ................................ ......................  111 
6.6.1.  Starting Dose of Belantamab Mafodotin  ................................ ..... 111 
6.6.2.  Alternate Schedule for Belantamab Mafodotin  ...........................  112 
6.6.3.  Standard of Care Dosing  ................................ ...........................  112 
6.6.3.1.  Len/Dex Dose (Arm A)  ................................ .............  112 
6.6.3.2.  Bor/Dex Dose (Arm B)  ................................ ..............  112 
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 5 
 7. STUDY POPULATION  ................................ ................................ .........................  113 
7.1. Inclusion Criteria  ................................ ................................ .......................  113 
7.2. Exclusion Criteria  ................................ ................................ ......................  116 
7.3. Lifestyle Restrictions  ................................ ................................ .................  118 
7.4. Screen Failures ................................ ................................ .........................  119 
8. TREATMENTS  ................................ ................................ ................................ ..... 119 
8.1. Treatments Administered  ................................ ................................ ..........  119 
8.1.1.  Belantamab Mafodotin and Len/Dex Combination (Arm A) 
28-day Cycle: SINGLE,SPLIT , and STRETCH  Schedules  .........  121 
8.1.1.1.  Belantamab mafodotin  ................................ ..............  122 
8.1.1.2.  Len/Dex  ................................ ................................ .... 122 
8.1.2.  Belantamab Mafodotin and Bor/Dex Combination (Arm B) 
21-day Cycle: SINGLE and SPLIT Schedules  ............................  123 
8.1.2.1.  Belantamab Mafodotin  ................................ ..............  124 
8.1.2.2.  Bor/Dex  ................................ ................................ .... 125 
8.1.3.  Belantamab Mafodotin and Bor/De x Combination (Arm B) 
21-day Cycle: STRETCH and S/D STRETCH Dosing 
Schedule ................................ ................................ ....................  125 
8.1.3.1.  Belantamab mafodotin  ................................ ..............  126 
8.1.3.2.  Bor/Dex  ................................ ................................ .... 126 
8.1.4.  Pharmaceutical Presentation  ................................ .....................  127 
8.1.4.1.  Belantamab mafodotin  ................................ ..............  127 
8.1.4.2.  Lenalidomide  ................................ ............................  127 
8.1.4. 3. Bortezomib  ................................ ...............................  127 
8.1.4.4.  Dexamethasone  ................................ .......................  128 
8.1.5.  Preparation of Doses  ................................ ................................ . 131 
8.1.5.1.  Belantamab mafodotin  ................................ ..............  131 
8.1.5.2.  Lenalidomide  ................................ ............................  131 
8.1.5.3.  Bortezomib  ................................ ...............................  131 
8.1.5.4.  Dexamethasone  ................................ .......................  132 
8.1.6.  Treatment Duration  ................................ ................................ .... 132 
8.1.6.1.  Arm A  ................................ ................................ ....... 132 
8.1.6.2.  Arm B  ................................ ................................ ....... 132 
8.1.6.3.  Lack of tolerability in Arm A or B  ...............................  132 
8.2. Dose Modification  ................................ ................................ .....................  132 
8.2.1.  Dose Modification After Cycle  1 ................................ .................  132 
8.2.2.  Dose Modification Guidelines for Dexamethasone  .....................  144 
8.3. Method of Treatment Assignment  ................................ .............................  145 
8.4. Blinding  ................................ ................................ ................................ ..... 145 
8.5. Preparation/Handling/Storage/Accountability  ................................ ............  145 
8.6. Treatment Compliance  ................................ ................................ ..............  146 
8.7. Concomitant Therapy ................................ ................................ ................  146 
8.7.1. Permitted Concomitant Medications and Therapies  ...................  146 
8.7.2.  Prohibited Concomitant Medications and Therapies  ..................  147 
8.7.3.  Prohibited Devices  ................................ ................................ ..... 147 
8.8. Treatment After the End of the Study  ................................ ........................  147 
8.9. Continued Access to Study Intervention after Final Data cut  .....................  148 
9. DISCONTINUATION CRIT ERIA  ................................ ................................ ...........  148 
9.1. Discontinuation of Study Treatment  ................................ ..........................  148 
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 6 
 9.1.1.  Discontinuation of Individual Components of Combination 
Study Treatment  ................................ ................................ ........  149 
9.2. Safety Stopping Criteria  ................................ ................................ ............  149 
9.2.1.  Liver Chemistry Stopping Criteria  ................................ ..............  149 
9.2.2.  Study Treatment Restart or Rechallenge  ................................ ... 150 
9.2.3.  QTc Interval Stopping Crite ria ................................ ....................  150 
9.2.4.  Left Ventricular Ejection Fraction (LVEF) Stopping Criteria  ........  151 
9.2.5.  Corneal Event Stopping Criteria  ................................ .................  152 
9.2.6.  Infusion -Related Reaction Management and Stopping 
Criteria  ................................ ................................ .......................  152 
9.2.7.  Allergic and Anaphylactic Reaction Stopping Criteria  .................  152 
9.3. Withdrawal from the Study  ................................ ................................ ........  152 
9.4. Lost to Follow -Up ................................ ................................ ......................  153 
10. STUDY ASSESSMENTS AN D PROCEDURES  ................................ ...................  154 
10.1.  Assessments for Evaluation of Clinical Activity  ................................ .........  154 
10.1.1.  Imaging  ................................ ................................ ......................  154 
10.2.  Adverse Events ................................ ................................ .........................  155 
10.2.1.  Time Period and Frequency for Collecting AE and SAE 
Information  ................................ ................................ .................  155 
10.2.2.  Method of Detecting AEs and SAEs  ................................ ...........  156 
10.2.3.  Follow -up of AEs and SAEs  ................................ .......................  156 
10.2.4.  Regulatory Reporting Requirements for SAEs  ...........................  157 
10.2.5.  Cardiovascular and Death Events  ................................ ..............  157 
10.2.6.  Adverse Events of Special Interest  ................................ ............  157 
10.2.7.  Pregnancy  ................................ ................................ .................  158 
10.2.8.  Medical Device Incidents (including malfunctions)  .....................  158 
10.3.  Treatment of Overdose  ................................ ................................ .............  158 
10.3.1.  Belantamab Mafodotin Overdose  ................................ ...............  158 
10.3.2.  Lenalidomide Overdose  ................................ .............................  159 
10.3.3.  Bortezomib Overdose  ................................ ................................  159 
10.3.4.  Dexamethasone Overdose  ................................ ........................  159 
10.4.  Demographics and Medical History ................................ ...........................  159 
10.5.  Daily Study Diary  ................................ ................................ ......................  160 
10.6.  Safety Assessments  ................................ ................................ .................  160 
10.6.1.  Physical Examinations  ................................ ...............................  160 
10.6.2.  ECOG Performance Status  ................................ ........................  160 
10.6.3.  Vital Signs  ................................ ................................ ..................  160 
10.6.4.  New York Heart Association Functional Scale  ...........................  161 
10.6.5.  Electrocardiograms  ................................ ................................ .... 161 
10.6.6.  Echocardiogram ................................ ................................ .........  161 
10.6.7.  Ophthalmic Examinations  ................................ ..........................  161 
10.6.7.1.  Ocular Examinations and Procedures .......................  163 
10.6.8.  Patient -Reported Outcome Version of the Common Term 
Criteria for Adverse Events (PRO -CTCAE)  ................................  163 
10.6.9.  Visual Function Safety Assessment  ................................ ...........  164 
10.6.9.1.  National Eye Institute Visual Function 
Questionnaire -25 ................................ ......................  164 
10.6.9.2.  The Ocular Surface Disease Index  ...........................  164 
10.6.10.  Laboratory Assessments  ................................ ...........................  165 
10.6.11.  DNA Sampling for Genetic Testing  ................................ ............  166 
10.6.12.  Suicidal Risk Monitoring  ................................ .............................  167 
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 7 
 10.7.  Pharmacokinetics  ................................ ................................ .....................  167 
10.7.1. Blood Sample Collection for Pharmacokinetics  ..........................  167 
10.7.2.  Pharmacokinetic Sample Analysis  ................................ .............  168 
10.9.  Immunogenicity Assessments  ................................ ................................ ... 170 
 
10.11.  Health -Related Quality of Life  ................................ ................................ ... 171 
10.11.1.  European Organisation for Research and Treatment of 
Cancer Quality of Life Questionnaires  ................................ ........  171 
10.11.1.1.  Europ ean Organisation for Research and 
Treatment of Cancer Quality of Life 
Questionnaire 30 -item Core Module (EORTC 
QLQ -C30)  ................................ ................................ . 172 
10.11.1.2.  European Organisation for Research and 
Treatment of Cancer Quality of Life 
Questionnaire 20 -item Multiple Myeloma 
Module (EORTC QLQ -MY20)  ................................ ... 172 
11. DATA MANAGEMENT  ................................ ................................ .........................  172 
12. STATISTICAL CONSIDER ATIONS  ................................ ................................ ...... 173 
12.1.  Hypothesis(es)  ................................ ................................ ..........................  173 
12.1.1.  Arm A – Belantamab Mafodotin with Len/Dex  ............................  173 
12.1.1.1.  Part 1  ................................ ................................ ....... 173 
12.1.1.2.  Part 2  ................................ ................................ ....... 173 
12.1.2.  Arm B – Belantamab Mafodotin  with Bor/Dex  ............................  173 
12.1.2.1.  Part 1  ................................ ................................ ....... 173 
12.1.2.2.  Part 2  ................................ ................................ ....... 174 
12.2.  Sample Size Determination  ................................ ................................ ...... 174 
12.2.1.  Arm A – Belantamab Mafodotin with Len/Dex  ............................  174 
12.2.1.1.  Part 1  ................................ ................................ ....... 174 
12.2.1.2.  Part 2  ................................ ................................ ....... 174 
12.2.2.  Arm B – Belantamab Mafodotin with Bor/Dex  ............................  174 
12.2.2.1.  Part 1  ................................ ................................ ....... 174 
12.2.2.2.  Part 2  ................................ ................................ ....... 175 
12.2.3.  Sample Size Sensitivity  ................................ ..............................  175 
12.2.4.  Sample Size Re -estimation or Adjustment  ................................ . 175 
12.3.  Populations for Analyses  ................................ ................................ ..........  175 
12.4.  Statistical Analyses  ................................ ................................ ...................  175 
12.4.1.  Analyses of Clinical Activity  ................................ .......................  176 
12.4.2.  Safety Analyses  ................................ ................................ .........  176 
12.4.2.1.  Exposure Duration  ................................ ....................  176 
12.4.2.2.  Adverse Events  ................................ ........................  176 
12.4.2.3.  Clinical Laboratory Evaluations  ................................  177 
12.4.2.4.  Other Safety Measures  ................................ .............  177 
12.4.3.  Pharmacokinetic Analyses  ................................ .........................  177 
12.4.3.1.  Belantamab mafodotin pharmacokinetic  ...................  177 
CCI
CCI
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 8 
 12.4.3.2.  Lenalidomide  ................................ ............................  178 
12.4.3.3.  Bortezomib  ................................ ...............................  178 
12.4.4.  Pharmacokinetic/PD Analyses  ................................ ...................  178 
12.4.5.  Translational Research Analyses  ................................ ...............  179 
12.4.5.1.  Novel Biomarker(s) Analyses  ................................ ... 179 
12.4.5.2.  Genetic Analyses  ................................ .....................  179 
12.4.6.  Immunogenicity Assessment  ................................ .....................  179 
12.4.7.  Other Analyses  ................................ ................................ ..........  180 
12.4.8.  Interim Analyses  ................................ ................................ ........  180 
12.4.8.1.  Arm A – belantamab mafodotin with Len/Dex  ...........  180 
12.4.8.2.  Arm B – belantamab mafodotin  with Bor/Dex  ...........  181 
12.4.9.  Final Analysis  ................................ ................................ ............  181 
13. REFERENCES  ................................ ................................ ................................ ..... 182 
14. APPENDICES  ................................ ................................ ................................ ...... 187 
14.1.  Appendix 1: Abbreviations and Trademarks  ................................ ..............  187 
14.1.1.  Trademark Information  ................................ ...............................  187 
14.1.2.  Abbreviations and Acronyms  ................................ .....................  187 
14.2.  Appendix  2:  Study Governance Considerations and Informed 
Consent Process  ................................ ................................ ......................  191 
14.3.  Appendix 3: Eastern Cooperative Oncology Group (ECOG) 
Functional Status  ................................ ................................ ......................  195 
14.4.  Appendix 4:  Modified Diet in Renal Disease (MDRD) Formula  .................  196 
14.5.  Appendix 5: New York Heart Association Classification  ............................  197 
14.6.  Appendix 6: Adverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow -up, and Reporting  ................................ ..... 198 
14.7.  Appendix 7: Contraceptive Guidance and Collection of Pregnancy 
Information  ................................ ................................ ................................  205 
14.8.  Appendix 8: Corneal Event Grading and Mitigation Strategy  .....................  208 
14.9.  Appendix 9: Liver Safety : Required Actions, Follow -up 
Assessments, and Study Treatment Rechallenge Guidelines  ...................  212 
14.9.1.  Liver Safety Drug Restart or Re -Challenge Guidelines  ..............  214 
14.9.1.1.  Rechallenge Following Liver Stopping Events 
that are Possibly Related to Study Treatment  ...........  214 
14.9.1.2.  Restart Following Transient Resolving Liver 
Stopping Events NOT Related to Study 
Treatment  ................................ ................................ . 216 
14.9.1.3.  References:  ................................ ..............................  217 
14.10. Appendix 10:  Genetics  ................................ ................................ .............  218 
 
14.10.2.  Study Population  ................................ ................................ ........  219 
14.10.3.  Study Assessments and Procedures  ................................ .........  219 
14.10.4.  Informed Consent  ................................ ................................ ...... 220 
14.10.5.  Participant Withdrawal from Study  ................................ .............  220 
14.10.6.  Screen and Baseline Failures  ................................ ....................  220 
14.10.7.  Provision of Study Results and Confidentiality of 
Participant’s Genetic Data  ................................ .........................  220 
14.10.8.  Germline Control  ................................ ................................ ........  221 
CCI
CCI
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 9 
 14.10.9.  References  ................................ ................................ ................  221 
14.11.  Appendix 11: Operating Characteristics of Safety Stopping Rule for 
Expansion Cohort  ................................ ................................ .....................  222 
14.12.  Appendix 12: Eye care specialist’s qualifications and requirements  ..........  223 
14.13.  Appendix 13: Alternative Health Care Approaches  ................................ ... 224 
14.14.  Appendix 14: Protocol Amendment History  ................................ ...............  226 
14.14.1.  Protocol Amendment 3 (13 -Jul-2020)  ................................ ........  226 
14.14.2.  Protocol Amendment 2 (26 -APR-2019) from the Final 
Version (28 -FEB-2018)  ................................ ..............................  234 
14.14.3.  Protocol Amendment 1 (7 -MAY -2018):  ................................ ...... 245 
 
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 10 
 1. SYNOPSIS  
Protocol Title:  A Phase I/II, Open -label, Dose Escalation and Expansion Study to 
Evaluate Safety, Tolerability, and Clinical Activity of the Antibody -Drug Conjugate 
GSK2857916 Ad ministered in Combination with Lenalidomide Plus Dexamethasone 
(Treatment Arm A), or Bortezomib Plus Dexamethasone (Treatment Arm B) in 
Participants with Relapsed or Refractory Multiple Myeloma – DREAMM  6. 
Short Title :  Dose Escalation/Dose Expansion Study  of GSK2857916 Administered with 
Lenalidomide Plus Dexamethasone (Arm A), or Bortezomib Plus Dexamethasone (Arm 
B) in Participants with RRMM.  
Brief Rationale  
Belantamab mafodotin is a humanized IgG1 antibody drug conjugate (ADC) which binds 
specifically to  B-cell maturation antigen ( BCMA ) (Figure 3) [Tai, 2014; Montes De Oca , 
2019] .  Upon binding to the cell surface, belantamab mafodotin is rapidly internalized 
and active drug (cysteine monomethyl auristatin F [cys -mcMMAF]) is released inside the 
cell.  Belanta mab mafodotin has been produced in an afucosylated form to generate an 
enhanced ADCC /ADCP  response upon binding to Fc RIIIa receptors on the surface of 
human effector cells.  Importantly, BCMA expression is maintained at the cell surface 
over time followin g belantamab mafodotin binding and internalization due to rapid 
BCMA receptor recycling and/or new protein synthesis.  
We hypothesize that the combination of belantamab mafodotin  with standard of care 
(SoC) therapies (lenalidomide/dexamethasone [Len/Dex] or  bortezomib/dexamethasone 
[Bor/Dex]) may potentially result in additive or enhanced effects and could potentially 
translate into deeper and longer responses for relapsed/refractory multiple myeloma  
(RRMM) participants treated with either Len/Dex or Bor/Dex  alone. While there are 
some potential overlaps in the pattern of identified toxicities (primarily hematologic), 
they are expected to be manageable. Given the single agent activity of belantamab 
mafodotin  in RRMM , the combination therapy with these agents remains an attractive 
option to explore for RRMM.  
This study will evaluate the safety and tolerability profile of belantamab mafodotin  when 
administered in combination with approved SoC regimens of either Len/Dex (Arm A) or 
Bor/Dex (Arm B) in participants  with RRMM, i.e., those who have relapsed or who are 
refractory to at least 1 line of approved therapy. Part 1 of the study is a dose escalation 
phase to evaluate the safety and tolerability of up to 3 dose levels and up to 2 dosing 
schedules of belantamab  mafodotin  in combination with the two SoC regimens.  Part 2 
will further evaluate the safety and preliminary clinical activity of belantamab mafodotin  
at selected dose levels and alternate dosing schedules in combination with Len/Dex or 
Bor/Dex.  
Overall Objectives and Endpoints  
The primary  and secondary objectives, along with the corresponding endpoints for study 
207497 are listed below.  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 11 
 Objectives  Endpoints  
Primary  
Dose Escalation  
Determine safety, tolerability of 
belantamab mafodotin  in combination with 
either Len/Dex (Arm A) or Bor/Dex (Arm 
B) to establish a recommended dose 
range and schedule to evaluate in Dose 
Expansion for participants with RRMM  
 
Dose Escalation and Expansiona 
Select  the dose(s) and dosing schedule for 
further investigation based on safety  and 
tolerability of belantamab mafodotin  in 
combination with either Len/Dex (Arm A) 
or Bor/Dex (Arm B) for participants with 
RRMM      
Number (%) of participants with dose -limiting 
toxicities  (DLTs ). 
Number (%) of participants with adverse events 
(AEs) , changes in clinical signs and laboratory 
parameters.  
 
 
A comprehensive determination based on 
safety  and serious adverse events ( SAEs)/AEs .  
Dose Expansion  
To determine preliminary clinical activity of 
belantamab mafodotin  in combination with 
either Len/Dex (Arm A) or Bor/Dex (Arm 
B) for participants with RRMM      
A specific determination based on ORR defined 
as percentage (%) of participants achieving 
PR as defined by the IMWG Uniform 
Response Criteria for MM [ Kumar , 2016].  
Secondary  
Dose Escalation and Expansion  
To evaluate the pharmacokinetics profile 
of belantamab mafodotin  when 
administered in combination with Len/Dex 
(Arm A) or Bor/Dex (Arm B) in participants 
with RRMM  Belantamab mafodotin  PK parameters, as data 
permit  
To evaluate the pharmacokinetics profile 
of lenalidomide when administered in 
combination with belantamab mafodotin  
and dexamethasone  Lenalidomide PK parameters, as data permit in 
Cycle 1  
To evaluate the pharmacokinetics profile 
of bortezomib when administered in 
combination with belantamab mafodotin  
and dexamethasone  Bortezomib PK parameters, as d ata permit in 
Cycle 1  
To assess anti -drug antibodies (ADAs) 
against belantamab mafodotin  Incidence and titers of ADAs against 
belantamab mafodotin  pre-dose in Cycle 1 and 
selected subsequent cycles  
To evaluate the effect and tolerability of 
belantamab ma fodotin  in combination with 
Len/Dex (Arm A) or Bor/Dex (Arm B) on Changes from baseline in symptoms and 
related impacts as measured by OSDI, NEI -
VFQ-25 and PRO CTCAE  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 12 
 Objectives  Endpoints  
symptomatic adverse events in 
participants with RRMM  
To further characterize safety of 
belantamab mafodotin  administered in 
combination with Len/Dex (Arm A) or 
Bor/Dex (Arm B) in participants with 
RRMM  Incidence of AEs, including SAEs and AEs of 
special interest (corneal events, 
thrombocytopenia and infusion related 
reactions).  
 
Ocular findings on ophthalmic exam  
To evaluate the effect of belantamab 
mafodotin  in combination with Len/Dex 
(Arm A) or Bor/Dex (Arm B) on health -
related quality of life in participants with 
RRMM  Changes from baseline in health -related quality 
of life as measur ed by the EORTC QLQ -C30 
and QLQ -MY20  
a. Data from the both the Escalation and Expansion cohorts will be used to evaluate this composite endpoint.  
 
Overall Study Design  
This is a Phase I/II, open -label, dose escalation and expansion study to select the dose 
and dosing schedule of belantamab mafodotin  when given in combination with Len/Dex 
(Arm A) on a 28 -day cycle, or with Bor/Dex ( Arm B) on a 21 -day cycle, and to evaluate 
safety and clinical activity of the combination treatments in participants wit h RRMM. 
The study will consist of two parts.  
Part 1  is a dose escalation phase to evaluate the safety and tolerability of belantamab 
mafodotin  in combination with two SoC regimens: Arm A – belantamab mafodotin  with 
Len/Dex, and Arm B – belantamab mafodoti n with Bor/Dex.  
Part 2  is a dose expansion phase to further evaluate the safety and clinical activity of 
belantamab mafodotin in combination  with Len/Dex  (Arm A)  and Bor/Dex  (Arm B) . 
The overall study design is summarized in Schematic of Study Structure figure s (Figure 1 
and Figure 2). 
Dosing Schedules  
SINGLE  Dosing Schedule  (both Arm A and Arm B) : belantamab mafodotin  will be 
administered as a SINGLE full dose on Day 1 of each 28-day (Arm A) or 21 -day (Arm 
B) cycle.   
SPLIT  Dosing Schedule  (both Arm A and Arm B) : belantamab mafodotin  will be split 
into two equal halves  and each half dose will be administer ed on Day 1 and Day 8 of 
each 28-day (Arm A) or  21-day (Arm B) cycle . 
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 13 
 In protocol amendment 3 , the following new schedule s are being introduced to evaluate 
the safety and clinical activity of belantamab mafodotin with Len/Dex ( Arm A ) or Bor/ 
Dex (Arm B) : 
Arm A only : 
• STRETCH  Dosing Schedule: A STRETCH dosing schedule for the 1.9 mg/kg 
dose level might be considered for Arm A  if em erging data suggests that this 
schedule may further optimize the tolerability  or offers an improved benefit/risk 
profile . In STRETCH schedule, belantamab mafodotin will be administered on 
Day 1 of alternate 28-day cycles with any 2 consecutive planned belantamab 
mafodotin doses at least 56 ( 3) days apart. The treatment cycle duration will 
remain at 28 days (4 weeks).  
Arm B only : 
• STRETCH  Dosing Schedule: belantamab mafodotin will be administered on Day 
1 of alternate  cycle s with any two consecutive planned doses at least 42 ( 3) days  
apart . The treatment c ycle duration will remain at 21 days (3 weeks).  
• Step-Down (S/D) STRETCH  Dosing Schedule: belantamab mafodotin will be 
administered as a full 2.5 mg/kg dose on Day 1 of Cycle 1  followed by 
subsequent planned doses of 1.9 mg/kg S/D dose starting on Day 1 of alternate 
21-day cycles (C3, C5, C7, and so on ) with any two consecutive planned doses at 
least 42 (3) days apart . The treatment cycle duration will remain at 21 days 
(3 weeks).  
Number of  Participants  
Overall, it is estimated that approximately  152 treated participants will be enrolled in this 
two-part study ; approximately  27 participants in Part 1  and approximately  125 
participants in Part 2.  
• Part 1 (dose escalation phase): Up to 27 DLT -evaluable participants with RRMM 
(approximately  14 participants in Arm  A and approximately  13 participants in Arm  
B) will be evaluated.  
• Part 2  (dose expansion phase) : Approximately  125 participants with RRMM 
(approximately  31 participants in Arm  A and approximately  94 participants in Arm  
B will be evaluated to further assess  the safety and preliminary  clinical activity of the 
combination  treatments . 
At the time of Amendment 3 more participants have been added to Part 1 (both Arm A 
and Arm B) for the stu dy due to non -DLT evaluable participants  and the requirement for 
an additional replacement participant  to assure an adequate assessment of DLTs. Two 
participants were added to Part 2 (Arm A and Arm B) as a replacement for participants 
who either received a n incorrect dose  or failed to complete a full cycle.  
 
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 14 
 Arm A – Belantamab mafodotin  in combination with Len/Dex 
Part 1: Dose Escalation  
The modified Toxicity Probability Interval (mTPI) design [ Ji, 2010] will be  used to guide 
dose escalation in Part 1 with a slight modification  (Figure 1). Up to  2 dose levels of 
belantamab mafodotin  (1.9 mg/kg [dose  level  -1]; 2.5 mg/kg [dose  level  1] and 
alternat ive dosing schedules are planned to be evaluated in combination with the fixed 
dose of the Len/Dex treatments. Based on emerging data from Arm A, the first dose 
investigated in Protocol Amendment 2 was 1.9 mg/kg (Dose Level -1). The design 
assumes the true underlying toxicity rate for maximum tolerated dose (MTD) of 
belantamab mafodoti n falls within the range from 25% to 35% and centers at 30%. 
Cohorts will be recruited in blocks of 3 participants. Participants will be treated  in a 
staggered approach with at least 1 day between each participant’s first dose of 
belantamab mafodotin  to mi nimize the risk of inadvertently exceeding the MTD in 
multiple participants.  
Up to 2 dose levels of belantamab mafodotin  will be evaluated starting with 1.9 mg/kg . 
Data from at least 3 DLT -evaluable participants are required before a decision is made to 
escalate to the next dose level.  
Part 2: Dose Expansion  
Data from at least 3 DLT -evaluable participants are not required for enrollment of more 
participants at the same dose level in Part 2.  
Once Part 2 expansion is open for each dos ing schedule , up to 12 participants will be 
enrolled in each cohort , unless enrollment is stopped based on emerging data.  
Since the implementation of amendment 2, Part 1 has been completed and Part 2 has 
since been enrolling participants to further evaluate the safety profile and to evaluate the 
preliminary clinical activity of belantamab mafodotin in combination with Len/Dex at the 
2.5 mg/kg dose level with 2 dosing schedules (2.5 mg/kg SINGLE and 2.5 mg/kg 
SPLIT).  
In Amendment 3, in Part 2, an alternate dosing schedule of STR ETCH (Q8W) dosing 
may be explored for the 1.9 mg/kg dose level if emerging data (from either this study or 
across the program) suggests that this schedule may further optimize the tolerability or 
offers an improved benefit/risk profile . To enable this, a p otential extended dosing 
schedule has been introduced via amendment  3, where belantamab mafodotin at 1.9 
mg/kg will be administered once every 8 weeks ( STRETCH ) and will be evaluated 
dependent on emerging data. The cycle duration will remain 28 days/4 week s. Up to 12 
participants will be enrolled in this new cohort.  
Safety data from all enrolled participants will be closely monitored while the study is 
ongoing. The observed number of participants permanently discontinuing study treatment 
within the first tw o cycles due to AE s related to belantamab mafodotin  will be compared 
against defined safety stopping rules. Enrollment may stop for a given dose level/dosing 
schedule if the safety stopping rules are met.  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 15 
 Arm B – Belantamab mafodotin  in combination with Bor/Dex 
Part 1: Dose Escalation  
A mTPI design will be implemented [ Ji, 2010] to guide dose escalation in Part 1  (Figure 
2). Up to 2 dose levels of belantamab mafodotin  (2.5 mg/kg  [dose  level  1]; 3.4 mg/kg 
[dose  level  1]; 1.9 mg/kg [dose level +1] ), starting with 2.5 mg/kg, are planned to be 
evaluated in combination with a fixed dose of Bor/Dex. Cohorts will be recruited in 
blocks of 3 participants. Participants will be entered in a staggered approach with at least 
1 day between each participant’s first dose of belantamab mafodotin  to minimize the risk 
of inadvertently exceeding the MTD in multiple participants. A maximum of 6 
participants will be assigned to each dose.  
Evaluation of the available safety data over the first cycle of treatment for ea ch 
participant enrolled in that dose level is required from at least 3 participants before a 
decision is made to enrol l additional participants at the same or the subsequent dose level.  
Part 2: Dose Expansion  
Part 2 is a dose expansion phase to further ev aluate the safety and clinical activity of 
belantamab mafodotin in combination with Bor/Dex . 
Since the implementation of amendment 2, Part 2 has been enrolling  in multiple 
expansion cohorts to further evaluate the safety profile and to evaluate the prelimi nary 
clinical activity of belantamab mafodotin  in combination with Bor/Dex at 2 dose levels 
and alternate dosing schedules (2.5 mg/kg SPLIT, 2.5 mg/kg SINGLE, 3.4 mg/kg SPLIT , 
3.4 mg/kg SINGLE ). Enrollment of each cohort was conducted in blocks  of 3 partic ipants 
until 12 participants each at 2.5 mg/kg SPLIT, 2. 5 mg/kg SINGLE, 3.4 mg/kg SPLIT  and 
up to  9 participants at 3.4 mg/kg SINGLE were  enrolled.  
In Amendment 3, four new cohorts  are being introduced ( 1.9 mg/kg SINGLE , 2.5 mg/kg 
STRETCH , S/D STRETCH  and 1.9 mg/kg STRETCH ). Enrollment for each cohort  will 
be conducted in blocks of 3 participants until up to  12 participants are enrolled in each of 
the 4 new dosing cohort s.  
Safety data from all enrolled participants will be closely monitored  while the study is 
ongoing. The observed number of participants permanently discontinuing study treatment 
within the first two cycles due to AE s related to belantamab mafodotin  will be compared 
against defined safety stopping rules. Enrollment may stop for a given dose level and 
higher dose level(s) if the safety stopping rules are met.  
Treatment Groups and Treatment Duration  
Arm A – Belantamab mafodotin  in combination with Len/Dex  
In Arm A, belantamab mafodotin  is given  in up to 2 dose levels and up to 3 dosing 
schedules in combination with Len/Dex on a 28 -day cycle  (Table 1).  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 16 
 Table 1 Arm A Dosing Regimens  
Arm A  Part Dose 
Level  Cohort  Dose of 
Belantamab 
Mafodotin  Schedule of 
Belantamab 
Mafodotin  SoA  Len/Dex 
treatment  
28-day 
Cycle  1 -1 1.9 mg/kg 
SINGLE  
 1.9 mg/kg IV  Day 1 of every 
28-day cycle  
Table 5 Lenalidomide 
25mg PO QD, 
D1-D21;  
Dexamethasone 
20mg PO or IV 
on D1, 8, 15, 22  2  1.9 mg/kg 
STRETCH  Day 1 of alternate 
28-day cycles 
(i.e. C1, C3, C5, 
C7 and so on)  
1 and 
2 1 2.5 mg/kg 
SINGLE   2.5 mg/kg IV  Day 1  Table 5 
2.5 mg/kg 
SPLIT   1.25 mg/kg IV  Day 1  and Day  8 Table 6 
 
For SINGLE  dosing  schedule , belantamab mafodotin  will be administered FIRST (prior 
to Len/Dex) as a single full dose  on Day 1 (D1) of every 28 -day cycle as a 30 -60 min 
infusion, followed by a 1 to 2 h rest period.    
• 2.5 mg/kg SINGLE dos ing schedule  will administer  a 2.5 mg/kg dose on Day 1 of 
each 28-day cycle  
• 1.9 mg/kg SINGLE dosing schedule will administer a 1.9 mg/kg dose on Day 1 of 
each 28-day cycle  
For SPLIT dosing schedule , belantamab mafodotin  will be administered FIRST (prior 
to Len/Dex) in the clinic in two equal divided doses - one on Day 1 and the other on  Day 
8 of each 28 -day cycle as a 30 -60 min infusion, followed by a 1 to 2 h rest period.   
• 2.5 mg/kg SPLIT dos ing schedule  will administer  a 1.25 mg/kg dose on Day 1 
and a 1.25 mg/kg dose on Day 8 of each 28-day cycle  
For STRETCH  dosing schedule , belantamab mafodotin will be administered FIRST 
(prior to Len/Dex) as a single dose on Day 1 of every alternate 2 8-day cycle as a 30 -60 
min infusion, followed by 1 to 2 h rest period. If a planned dose of belantamab mafodotin 
was held/missed for any reason, the next dose can be administered at Day 1 of the next 
planned 2 8-day cycle, as long as the interval  between 2 consecutive doses is at least 56 
(3) days.   
• 1.9 mg/kg STRETCH  will administer a 1.9 mg/kg dose administered on Day 1 of 
every alternate 2 8-day cycles (C1, C3, C5, C7 and so on .)  
Lenalidomide will be administered  as 25 mg PO daily on Days 1 -21 of each 28 -day cycle 
in participants with estimated glomerular filtration rate  (eGFR) >60  mL/min/1.73 m2. The 
dose of lenalidomide will be reduced to 10 mg daily on Days 1 to 21 of each 28 -day cycle  
in participants with eGFR 40-60 mL/min/1.73 m2.  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 17 
 Dexamethasone will be given 40 mg weekly PO  or IV  on Day 1, 8, 15 and 22 of each 
cycle. For participants >75 years of age, with body mass index  (BMI) <18.5  kg/m2, the 
dose of dexamethasone can be reduced to 20 mg at the discretion of  the investigator.  
On days when only lenalidomide and dexamethasone are taken at home, they should be 
taken in the morning approximately at the same time each day. On lenalidomide and 
belantamab mafodotin co -administration days , lenalidomide should be admi nistered after  
administration of belantamab mafodotin. On days when lenalidomide pharmacokinetic 
(PK) samples will be collected, participants will be required to take their morning dose in 
the clinic.  For Cycle 1, the 24 h post -dose lenalidomide PK sample must be collected 
before lenalidomide dosing on Cycle 1 Day 2.  
Participants who are assigned to Arm A may continue  combination treatment until the 
occurrence of progressive disease (PD), intolerable AEs, consent withdrawal, death , or 
end of study . In case of intolerable AEs related to Len/Dex in combination, the 
participant may be allowed to continue on belantamab mafodotin  monotherapy.   
Arm B – Belantamab mafodotin  in combination with Bor/Dex  
In Arm B, belantamab mafodotin  is given  up to 3 dose levels and up to 4 dos ing 
schedules in combination with Bor/Dex on a 21 -day cycle  (Table 2).  
Table 2 Arm B Dosing Regimens  
Arm B  Part Dose 
Level  Cohort  Dose of 
Belantamab 
Mafodotin  Schedule of 
Belantamab 
Mafodotin  SoA  Bor/Dex 
treatment  
(Cycle 1 -8) 
21-day 
Cycle  1 and 
2 1 2.5 mg/kg 
SINGLE  2.5 mg/kg IV  Day 1  Table 7 
Bortezomib 
1.3mg/m2 SC or IV 
on D1, D4, D8, 
D11;  
Dexamethasone 
20mg PO or IV on 
D1, D2, D4, D5, 
D8, D9, D11, D12)  2  2.5 mg/kg 
SPLIT  1.25 mg/kg IV  Day 1, Day 8  Table 8 
1 and 
2 2 3.4 mg/kg 
SINGLE   3.4 mg/kg IV  Day 1  Table 7 
2  3.4 mg/kg 
SPLIT   1.7 mg/kg IV  Day 1, Day 8  Table 8 
2  2.5 mg/kg 
STRETCH   2.5 mg/kg IV  Day 1 in every 
alternate cycle 
(i.e. C1, C3, C5, 
C7 and so on)  Table 9 
2  S/D 
STRETCH  Cycle 1:  2.5 
mg/kg IV  
Cycle 3+:  1.9 
mg/kg IV  Day 1 in every 
alternate cycle  Table 9 
2  1.9 mg/kg 
SINGLE  1.9 mg/kg IV  Day 1  Table 7 
2  1.9 mg/kg 
STRETCH  1.9 mg/kg IV  Day 1 in every 
alternate cycle  Table 9 
 
For SINGLE  dosing schedule , belantamab mafodotin  will be administered FIRST (prior 
to Bor/Dex)  as a single full dose on Day 1 (D1) of every 21 -day cycle as a 30 -60 min 
infusion, followed by  1 to 2 h rest period.   
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 18 
 • 3.4 mg/kg SINGLE dos ing schedule  will administ er a 3.4 mg/kg dose on Day 1 of 
each 21-day cycle  
• 2.5 mg/kg SINGLE dosing schedule will administer a 2.5 mg/kg dose on Day 1 of 
each 21-day cycle  
• 1.9 mg/kg SINGLE dosing schedule will administer a 1.9 mg/kg dose on Day 1 of 
each 21-day cycle  
For SPLIT dosing schedule , belantamab mafodotin  will be administered FIRST  (prior 
to Bor/Dex)  in the clinic in two equal divided doses - one on Day 1 and the other on  Day 
8 of each 21 -day cycle as a 30-60 min infusion, followed by a 1  to 2 h rest period.   
• 3.4 mg/kg SPLIT dos ing schedule  will administer  a 1.7 mg/kg dose on Day 1 and 
a 1.7 mg/kg dose on Day 8 of each 21-day cycle  
• 2.5 mg/ kg SPLIT dosing schedule will administer a 1.25 mg/kg dose on Day 1 
and a 1.25 mg/kg dose on Day 8 of each 21-day cycle  
For STRETCH  dosing schedule , belantamab mafodotin will be administered FIRST 
(prior to Bor/Dex) as a single dose on Day 1 of every alternate 21-day cycle as a 30 -60 
min infusion, followed by 1 to 2 h rest period. If a planned dose of belantamab mafodotin 
was held/missed for any reason, the next dose can be administered at Day 1 of the next 
planned 21 -day cycle, as long as the interval between 2 consecutive doses is at least 42 
(3) days.  
• 2.5 mg/kg STRETCH  will administer a 2.5 mg/kg dose on Day 1 of every 
alternat e 21-day cy cles (C1, C3, C5, C7 and so on)  
• 1.9 mg/kg STRETCH  will administer a 1.9 mg/kg dose administered on Day 1 of 
every alternate  21-day cycles (C1, C3, C5, C7 and so on)  
For Step-Down (S/D) STRETCH dosing s chedule , belantamab mafodotin will be 
administered FIRST (prior to Bor/Dex) as a 2.5 mg/kg dose on Day 1 of Cycle 1  
followed by subsequent planned doses of 1.9 mg/kg  starting  on Day 1 of alternate 21 -day 
cycles (C3, C5, C7, and so on) , as a 30 -60 min infusion, followed by 1  to 2 h rest period.  
Bortezomib w ill be administered at 1.3 mg/m2 SC or IV (depending on participants’ and 
institutional preference) on Days 1, 4, 8, and 11 of every 21 -day cycle for a total of up to 
8 cycles. The administration of bortezomib will be after belantamab mafodotin 
administration, approximately after 1 h and after assuring that participant is clinically 
stable.  
Dexamethasone will be administered at 20  mg PO or IV on Days 1, 2, 4, 5, 8, 9, 11, and 
12 of every 21 -day cycle. Dexamethasone dose may be reduced at the inve stigator’s 
discretion for participants >75 years of age with BMI <18.5 kg/m2. Dexamethasone will 
be given for a total of up to 8 cycles.    
Participants completing 8 cycles of combination therapy will continue treatment with 
belantamab mafodotin  as monother apy until PD, intolerable AEs,  consent withdrawal, 
death , or end of study . In case of intolerable AEs related to Bor/Dex in combination, the 
participant may be allowed to continue  on belantamab mafodotin  monotherapy.  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 19 
 Study Population  
The study will enroll adult participants with RRMM, who have undergone stem cell 
transplant ( SCT), or are considered transplant ineligible, and who have been previously 
treated with at least 1 prior line of therapy, and who have documented evidence of 
disease progression during  or after their most recent therapy.  
Inclusion Criteria  
Participants are eligible to be included in the study only if all of the following criteria 
apply:  
1. Capable of giving signed informed consent which includes compliance with the 
requirements and restri ctions listed in the informed consent form (ICF) and in this 
protocol.  
2. Male or female, 18 years or older (at the time consent is obtained).  
3. Have confirmed diagnosis of Multiple Myeloma as defined by the International 
Myeloma Working Group (IMWG) criteria [Rajkumar , 2016 ]. 
4. Eastern Cooperative Oncology Group (ECOG) performance status:  
• For Arm A only: 0 to 1  
• For Arm B only: 0 to 2  
5. Have undergone autologous SCT, or are considered transplant ineligible  
6. Have been previously treated with at least 1 prior line of MM therapy and must have 
documented disease progression during or after their most recent therapy.  
7. Must have at least ONE aspect of measurable disease, defined as one of the 
following:  
a. Urine M -protein excretion ≥200  mg/24 h, or  
b. Serum M -protein concentration ≥0.5  g/dL (≥5.0  g/L), or  
c. Serum free light chain (FLC) assay:  involved FLC level ≥10  mg/dL (≥100  mg/L) 
and an abnormal serum free light chain ratio (<0.26 or >1.65).  
8. Participants with a history of autologous SCT are eligible for study participation 
provided the following eligibility criteria are met:  
a. Autologous SCT was >100 days prior to study enroll ment  
b. No active bacterial, viral, or fungal infection(s) present  
c. Participant meets the remainder of the eligibility criteria outlined in this protocol  
9. All prior treatment -related toxicities (defined by National Cancer Institute Common 
Toxicity Criteria for Adverse Events (NCI -CTCAE, Version 4.03, 2010 ) must be 
Grade 1 at the time of enrollment, except for alopecia. Patients with Grade 2 
neuropathy can be enrolled into Len/Dex treatment arm, but not into Bor/Dex 
treatment arm.  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 20 
 10. Adequate organ system functions  as defined by the laboratory assessments listed in 
the table below (Adequate Organ System Function  based on Safety Assessments).  
Adequate Organ System Function based on Safety Assessments  
Organ System and Laboratory 
Tests  Laboratory Values  
Hematologic  
Absolute neutrophil count (ANC)a 1.5 × 109/L 
Hemoglobin  8.0 g/dL  
Platelets  75 × 109/L 
Hepatic  
Total bilirubin  ≤1.5 × ULN; (Isolated bilirubin >1.5  × ULN is acceptable if bilirubin 
is fractionated and direct bilirubin is <35%)  
Alanine aminotransferase  (ALT)  2.5 × ULN  
Renal  
eGFRb 40 mL/min /1.73 m2 
Spot urine (albumin/creatinine ratio 
from spot urine)  500 mg/g (56 mg/mmol)  
Cardiac  
Left Ventricular Ejection Fraction 
(LVEF) by ECHO  40%  
Note: Laboratory results obtained during Screening should be used to determine eligibility criteria.  In situations 
where laboratory results are outside the permitted range, the investigator may re -test the participant and the 
subsequent within range screening result may be used to confirm eligib ility. 
a. Without growth factor support for the past 14 days, excluding erythropoietin  
b. As calculated by Modified Diet in Renal Disease (MDRD) formula  
 
11. Female Participants:  
Contraceptive use by women should be consistent with local regulations regarding the 
methods of contraception for those participating in clinical studies.  
A female participant is eligible to participate if she is not pregnant or breastfeeding, 
and at least one of the following conditions applies:  
• Is not a woman of childbearing potential (WO CBP)  
OR 
• Is a WOCBP and using a contraceptive method that is highly effective (with a 
failure rate of <1% per year), preferably with low user dependency during the 
intervention period and for 4 months  after the last dose of belantamab 
mafodotin  and agrees not to donate eggs (ova, oocytes) for the purpose of 
reproduction during this period.  
The investigator should evaluate the effectiveness of the contraceptive method in 
relationship to the first dose of study intervention.  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 21 
 The investigator is r esponsible for review of medical history, menstrual history, and 
recent sexual activity to decrease the risk for inclusion of a woman with an early 
undetected pregnancy.  
Additional Inclusion Criteria for WOCBP Participants Assigned to Arm A  
Due to lenalido mide being a thalidomide analogue with risk for embryo -fetal toxicity and 
prescribed under a pregnancy prevention/controlled distribution program , WOCBP 
participants will be eligible if they commit either to abstain continuously from 
heterosexual sexual in tercourse or to use two methods  of reliable birth control  (one 
method that is highly effective) , beginning 4 weeks prior to initiating treatment with 
lenalidomide, during therapy, during dose interruptions and continuing for 4 weeks  
following discontinuati on of lenalidomide treatment.  Thereafter, WOCBP participants 
must use a contraceptive method that is highly effective (with a failure rate of <1% per 
year) for a further  3 months , and agree not to donate eggs (ova, oocytes) for the purpose 
of reproduction during this period.  
Two negative pregnancy tests must be obtained prior to initiating lenalidomide  therapy. 
The first test should be performed within 10 -14 days and the second test within 24 hours 
prior to prescribing lenalidomide therapy.  
Additional Inclusion Criteria for WOCBP Participant s Assigned to Arm B  
WOCBP assigned to Arm B must have a negative highly sensitive serum pregnancy test 
within 72 hours of dosing on C1D1 and agree to use effective contraception during the 
study and for 4 months  after the last dose of belantamab mafodotin  or 7 months from the 
last dose of bortezomib , whichever is longe r. 
12. Male Participants:  
Contraceptive use by men should be consistent with local regulations regarding the 
methods of contraception for those participating in clinical studies.  
Male participants are eligible to participate if they agree to the following : 
• Arm A: from the time of first dose of study until 6 months  after the last dose 
of belantamab mafodotin or 4 weeks from  last dose of lenalidomide, 
whichever is longe r, to allow for clearance of any altered sperm . 
• Arm B: from the time of first dose of study until 6 months  after the last dose 
of belantamab mafodotin  or 4 months from the last dose of bortezomib, 
whichever is the longe r, to allow for clearance of any altered sperm.  
Refrain from donating sperm and either:  
• Be abstinent from heterosexual intercourse as their preferred and usual 
lifestyle (abstinent on a long term and persistent basis) and agree to remain 
abstinent  
OR 
• Must agree to use contraception/barrier as detailed below : 
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 22 
 Agree to use a male condom , even if they have undergone a successful vasectomy  
and female partner to use an additional highly effective contraceptive method with a 
failure rate of <1% per year when having sexual intercourse . Male participants should 
also use a condom  with pregnant  females . 
If the female partner of the male participant is pregnant at the time of enrollment, or 
becomes pregnant during the trial, the male participant must agree to remain abstinent 
(if it is consistent with their preferred and usual lifestyle) or use a male condom.  
Exclusion Criteria  
A participant will not be eligible for inclusion in this study if any of the following criteria 
apply:  
1. Systemic anti -myeloma therapy (including systemic steroids) within 14 days, or 
plasmapheresis within 7 days prior to the first dose of study drug.  
2. Use of an investigational drug within 14 days or five half -lives (whichever is longer) 
preceding the first d ose of study drug.  
3. Prior treatment with a monoclonal antibody within 30 days of receiving the first dose 
of study drugs.  
4. Prior allogenic stem cell transplant.  
Note: Participants who have undergone syngeneic transplant will be allowed only if 
they have no  history and no currently active, graft versus host disease (GvHD)  
5. Evidence of active mucosal or internal bleeding.  
6. Any major surgery within the last four weeks.  
7. Presence of active renal condition (infection, requirement for dialysis or any other 
condition  that could affect participant's safety).  Participants with isolated proteinuria 
resulting from MM are eligible, provided they fulfill criteria given in table of 
Adequate Organ System Function  based on Safety Assessments . 
8. Any serious and/or unstable pre -existing medical, psychiatric disorder or other 
conditions (including lab abnormalities) that could interfere with participant's safety, 
obtaining informed consent or compliance to the study procedures.  
9. Current active liver or biliary disease (with the exc eption of Gilbert's syndrome or 
asymptomatic gallstones, or otherwise stable chronic liver disease per investigator's 
assessment).  
10. Participants with invasive  malignancies other than multiple myeloma are excluded, 
unless the second malignancy has been consi dered medically stable for at least 2 
years. The participant must not be receiving active therapy, other than hormonal 
therapy for this disease.  
Note: Participants with curatively treated non -melanoma skin cancer are allowed 
without a 2 -year restriction  
11. Evidence of cardiovascular risk including any of the following:  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 23 
 a. Evidence of current clinically significant untreated arrhythmias, including 
clinically significant ECG abnormalities including 2nd degree (Mobitz Type II) or 
3rd degree atrioventricular (AV) bl ock. 
b. History of myocardial infarction, acute coronary syndromes (including unstable 
angina), coronary angioplasty, or stenting or bypass grafting within 3 months of 
Screening.  
c. Class III or IV heart failure as defined by the New York Heart Association 
funct ional classification system.  
d. Uncontrolled hypertension.  
12. Known immediate or delayed hypersensitivity reaction or idiosyncratic reaction to 
drugs chemically related to belantamab mafodotin , or any of the components of the 
study treatment.  
13. Pregnant or lactating female.  
14. Active infection requiring treatment.  
15. Known HIV infection.  
16. Presence of hepatitis B surface antigen (HBsAg), or hepatitis B core antibody 
(HBcAb at Screening or within 3 months prior to first dose of study treatment)  
17. Positive hepatitis C antibody test result or positive hepatitis C RNA test result at 
Screening or within 3 months prior to first dose of study treatment.  
Note: Participants with positive Hepatitis C antibody due to prior resolved disease 
can be enrolled, only if a confirmatory negative Hepatitis C RNA test is obtained. 
Hepatitis RNA testing is optional and participants with negative Hepatitis C 
antibody test are not required to also undergo Hepatitis C RNA testing  
18. Current corneal disease except for mild p unctate keratopathy.  
Note: Participants with mild punctate keratopathy are allowed.   
Additional Exclusion Criteria for Participants Assigned to Arm A ( belantamab 
mafodotin  plus Len/Dex)  
19. Participants unable to tolerate antithrombotic prophylaxis must be ex cluded.  
20. Discontinuation of prior treatment with lenalidomide due to intolerable adverse 
events.  
Additional Exclusion Criteria for Participants Assigned to Arm B ( belantamab 
mafodotin  plus Bor/Dex)  
21. Unacceptable adverse effects from previous bortezomib tre atment.  
22. Ongoing Grade 2 or higher peripheral neuropathy or neuropathic pain from previous 
bortezomib treatment.  
23. Intolerance or contraindications to anti -viral prophylaxis . 
Lifestyle Restrictions  
The following lifestyle restrictions apply while the participants are in the study:  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 24 
 • Contact lenses are prohibited while on the study treatment (from first dosing to 
the end of study treatment). Contact lens  use may be restarted after the end of 
study trea tment and a consultation with a qualified eye care specialist  confirms 
there are no other contraindications.  
Use of bandage contact lenses is permitted during study treatment as directed by a 
qualified eye care specialist.  
• Participants must not donate bloo d while receiving study treatment; participants in 
Arm A must not donate blood for 28 days following discontinuation of 
lenalidomide.  
• Intraocular pressure may become elevated with dexamethasone treatment in some 
individuals. Intraocular pressure should be monitored.  
Final Analysis and End of Study Definitions:  
Participants in all arms will be treated until confirmed PD, death, start of a new 
anticancer treatment, withdrawal of consent, or end of the study, whichever occurs first . 
Following 12 months post l ast subject first dose, the final analysis will occur and the 
study will move into the post analysis continued treatment (PACT) phase. At that time, 
the collection of new data for all recruited participants who no longer receive study 
treatment will stop e ntirely and the clinical trial database will be closed. Those 
participants still benefiting from study drug in the opinion of their treating physician may 
continue to receive study drug (s).  In case the participant meets stopping criteria for 
belantamab m afodotin, the participant will discontinue all treatment and will continue to 
be monitored as per standard of care at the participant’s particular study site . SAEs, AEs 
leading to treatment discontinuation, overdose, pregnancy cases, and pre -specified ocul ar 
data will be reported directly to GSK. The end of study is defined when the last patient 
had their last visit (last subject last dose plus 70 days SAE reporting period).  
  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 25 
 2. STUDY SCHEMA  
Figure 1 Schematic of Study Structure for Arm A (Belantamab Mafodotin with 
Len/Dex)  
 
a. Belantamab mafodotin (GSK2857916) SINGLE = full assigned dose of belantamab mafodotin administered on 
Day 1 of any 28 -day cycle.  
b. Lenalidomide (25 mg on Days 1 -21) + Dexamethasone (40 mg on Days 1, 8, 15, and 22) of any 28 -day cycle.  
c. Belantamab mafodotin 2.5 mg/kg SPLIT= 1.25 mg/kg on Day 1 and 1.25 mg/kg on Day 8 of any 28 -day cycle.  
d. *Belantamab mafodotin  1.9 mg/kg STRETCH = belantamab mafodotin 1.9 mg/kg dose administered on Day 1  of 
alternate 28 -day cycles i.e. Q8W (C1, C3, C5, C7 and so on) - this cohort may be evaluated if emerging data  
suggests that this schedule may further optimize the tolerability  or offers an improved benefit/risk profile . 
All participants will be operated under Amendment 03.  
Note: Combination therapy continued until PD, death, intolerable toxicity, consent withdrawn. Cohorts followed up for 
 and  
DE=Dose Escalation decision  
 
CCI
CCI
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 26 
 Figure 2 Schematic of Study Structure for Arm B (Bel antamab Mafodotin with 
Bor/Dex)  
 
 
a. Belantamab mafodotin (GSK2857916) SINGLE  = full assigned dose of belantamab mafodotin (1.9 mg/kg, 2.5 
mg/kg or 3.4 mg/kg) administered on Day 1 of any 21 -day cycle.  
b. Bortezomib (1.3 mg/m2 on Days 1, 4, 8, and 11) + Dexamethasone (20 mg on Days 1, 2, 4, 5, 8, 9, 11, and 12) of 
any 21 -day cycle.  
c. Belantamab mafodotin 2.5 mg/kg SPLIT = 1.25 mg/kg on Day 1 and 1.25 mg/kg on Day 8 of any 21 -day cycle.  
d. Belantamab mafodotin 3.4 mg/kg SPLIT = 1.7 mg/ kg on Day 1 and 1.7 mg/kg on Day 8 of any 21 -day cycle . 
e. Belantamab mafodotin STRETCH = belantamab mafodotin 1.9 mg/kg or 2.5 mg/kg dose administered on Day 1 of 
alternate 21 -day cycles i.e.  Q6W  (C1, C3, C5, C7 and so on) . 
f. Belantamab mafodotin Step-Down (S/D)  STRETCH  = belantamab mafodotin 2.5  mg/kg dose at C1D1 followed 
by 1.9 mg/kg step-down dose on Day 1 of alternate 21 -day cycles C3 onwards (C3, C5, C7, and so on) . 
All participants will be operated under Amendment 03.  
#New cohorts in Amendment 3.  
Note: Combination therapy continued for up to 8 combination cycles; belantamab mafodotin further continued until PD, 
death, intolerable toxicity, consent withdrawn. Cohorts followed up for  and  
DE=Dose Escalation decision; ; PD=Pr ogressive Disease; ; 
S/D=Step -down . 
 
CCI
CCI
CCI
CCI
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 27 
 3. SCHEDULE OF ACTIVITI ES 
The two treatment arms use different cycle lengths to accommodate the approved 
standard of care (SoC) regimens for lenalidomide plus dexamethasone ( Len/Dex; Arm  A, 
28-day cycle) and bortezomib plus dexamethasone ( Bor/Dex; Arm  B, 21 -day cycle) in 
combination with belantamab mafodotin . 
The different schedule of activities (SoA) tables are identified ( Table 3): 
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 28 
 Table 3 List of Schedule of Activities Tables  
Study Phase  Arm Dosing schedule Table  
Screening  All All Table 4 
 
On-Treatment  Arm A  SINGLEa and STRETCHb  Table 5 
SPLITc Table 6 
 
On-Treatment  Arm B  SINGLEa Table 7 
SPLITc Table 8 
STRETCHb and S/D STRETCHd Table 9 
 
End of Treatment  All All Table 10 
a. SINGLE  Dosing Schedule: belantamab mafodotin will be administered as a SINGLE full dose on Day 1 of 
each 28 -day (Arm A) or 21 -day (Arm B) cycle.  
b. STRETCH Dosing Schedule: belantamab mafodotin will be administered as a SINGLE full dose on Day 1 of 
every alternate  28-day (Arm A) or 21 -day (Arm B) cycle. In Arm A, Len/Dex will continue to be administered 
every 28 -day cycle as per SoC. In Arm B, Bor/Dex will co ntinue to be administered every cycle for the first 8 
cycles (21 -day cycles) as. per SoC . 
c. SPLIT  Dosing Schedule: belantamab mafodotin will be split into two equal halves and each half dose will be 
administered on Day 1 and Day 8 of each 28 -day (Arm A) or 2 1-day (Arm B) cycle.  
d. Step -Down  (S/D) STRETCH  Dosing Schedule: belantamab mafodotin will be administered as a SINGLE full 
dose on Day 1 of every alternate  28-day (Arm A) or 21 -day (Arm B) cycle. The dose of belantamab 
mafodotin will be 2.5 mg/kg in C1 foll owed by a step-down dose of 1.9 mg/kg on Day 1 of every alternate  
cycle from C3 onwards (C3, C5, C7 and so on). In Arm A, Len/Dex will continue to be administered every 
28-day cycle as per SoC. In Arm B, Bor/Dex will continue to be administered every cycle  for the first 8 cycles 
(21-day cycles) as per SoC.  
 
PACT Phase: All participants who continue to receive study treatment during the PACT 
phase will be monitored and receive follow -up care in accordance with standard local 
clinical practice. Assessments will revert to the standard of care at the participant’s 
particular stud y site and only SAEs, AEs leading to discontinuation of study treatment, 
overdoses, prespecified ocular data, and pregnancies will be reported directly to the 
Sponsor via paper forms (see Section 9 and Section 10.2). For participant  discontinuing 
treatment in the PACT phase, no end of treatment visit is required.
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 29 
 Table 4 Schedule of Activities – SCREENING  Assessments for Arm A (belantamab mafodotin in combination with 
lenalidomide plus dexamethasone) and Arm B (belantamab mafodotin in combination with bortezomib plus 
dexamethasone)  
Study Assessments1 Screen  Notes  (Screening Arm A and Arm B)  
Informed Consent  X 1. All assessments apply to Part 1 and 2 unless stated otherwise . All screening assessments must be performed 
within 21 days prior to first dose unless otherwise specified. Informed consent form must be signed before any 
study -specific assessments are performed. Screening As sessment s do not need to be repeated on Cycle 1 Day 
1 (C1D1 ), unless otherwise specified.  
2. Any SAEs assessed as related to study participation (e.g., protocol -mandated procedures or invasive tests) will 
be recorded from the time a participant  consents to pa rticipate in the study  through follow -up. See Section 
10.2.1  for details.  
3. Screening ocular examination s to be performed by a qualified eye care specialist within 21 days prior to first 
dosing. See Section 10.6.7.1  for list of ophthalmic exam procedures  and Appendix 12  for qualifications and 
requirements of the eye care specialist.  
4. Refer to Section 10.6.10  for a comprehensive list of lab tests that must be collected for all participants. If labs 
are completed within 72 h prior to the first dose, this assessment need not be repeated on C1D1.  
5. Albumin/creatinine ratio (Spot urine from first void) will be p erformed at local lab, if local testing is not available 
then by central  laboratory . 
6. Hep C RNA testing is optional but may be done to determine participant eligibility , if Hep C antibody is positive. 
If Hep C RNA is positive, participant  is ineligible. See Section 7 Study Population for details.  
7. Perform only in women of child -bearing potential  (WOCBP ). WOCBP in Arm A: Two negative serum pregnancy 
tests must be obtained prior to initiating treatment; one may be performed within 14 days of C1D1, but the 
second must be performed within 24 h of C1D1. WOCBP in Arm B: A serum pregnancy test must be performed 
at screening; if the test is completed within 72 hours prior to the first dose of belantamab mafodotin , this 
assessment does not have to be repeated on C1D1 . For questionable cases, follicle stimulating hormone (FSH) 
and estradiol (as needed in WOCBP  only) should be perfor med at local lab.  
8. Single ECG on Screening.   All ECGs will be collected centrally (refer to SRM for details).  
9. ECHO to be performed locally. Screening ECHO may be performed up to  30 days prior to C1D1.   
10. Only in participant s with IgD/IgE myeloma . 
11. Imaging is only required for participants with extramedullary disease by either CT, MRI, or PET/CT per local 
guidance. Screening assessment may be performed up to 30 days prior to C1D1. Needs to be performed by the 
same method throughout the study as was d one at baseline (i.e. if CT/PET scan was used as baseline, 
participant  needs to be followed by CT/PET scans). Selected target lesion needs to be measured and followed 
over time. Plasmacytoma measurements should be taken from the CT portion of the PET/CT, o r MRI scans, or 
dedicated CT scans where applicable. For participant s with only skin involvement, skin lesions should be Baseline Demographics  X 
Medical History, disease history and 
characteristics  X 
ECOG Performance Status  X 
Adverse Events/SAEs2 X 
Concomitant Medications  X 
 
Safety  
Physical Exam  X 
Ocular Exam3 X 
Vital Signs (BP, Heart rate, Body 
Temperature)  X 
Body Weight (BW) and Height  X 
Hematology4 X 
Clinical chemistry4 X 
HbA1c  X 
C-reactive protein (CRP)4 X 
Urinalysis (dipstick)4  X 
Estimated Glomerular Filtration Rate 
(eGFR) by MDRD formula  X 
Spot urine for albumin/creatinine ratio5 X 
HbsAg, HbcAb, and Hepatitis C 
antibody. Hepatitis C RNA optional6 X 
Pregnancy Test for WOCBP7 X 
12-lead ECG8 X 
ECHO – LVEF9 X 
Disease Evaluation  
β2 microglobulin  X 
SPEP (Serum Protein Electrophoresis)  X 
CCI
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 30 
 Study Assessments1 Screen  Notes  (Screening Arm A and Arm B)  
Serum Kappa, lambda free LC, FLC 
ratio X measured with a ruler. Measurement of tumor  size will be determined by the Sum of the Products of the 
maximal perpendicular diameters o f measured lesions (SPD).  
12. Imaging of bones for lytic lesions by method aligned with institutional guidance (X -ray, CT or MRI). Survey 
results within 30 days prior to C1D1 date are acceptable.  
13. BM aspirate/biopsy within 28 days prior to first dose is accepta ble. 
14. Fluorescence -in-situ hybridization ( FISH) testing to be performed locally at least for:  t(4;14), t(14;16) , amp(1q), 
del(1p) and del(17p13). If participant  is known to have tested positive for t(4;14)  or  t(14;16) on previous tests  
regardless of timeframe , FISH for th ese translocations does not need to be repeated . FISH results for amp(1q), 
del(1p) and del(17p13) from samples taken within 60 days prior to first dose are acceptable. If testing cannot be 
performed at a local lab the s amples can be sent to the central lab.  
15.  to be performed by the central lab  at the time of first achieving VGPR or better. 
Thereafter, testing should be repeated every 6  months until PD or CR. In case of deepening of response 
from VGPR to CR, or achieving CR without prior VGPR,  testing should be  performed at the time of 
achieving suspected CR and repeated every 6 months until PD . Whenever possible, a further BM aspirate 
sample may be taken at the same time for biom arker analysis.  
16. Samples will be submitted to central lab for BCMA analysis , any remaining b one marrow  aspirate sample will be 
used for biomarker research .  
 Serum Immunofixation  X 
UPEP (Urine Protein Electrophoresis)  
(on 24 h collected urine)  X 
Urine Immunofixation  X 
Ca corrected for Albumin (Serum)  X 
IgG, IgM, IgA  X 
IgD/IgE10 X 
Imaging for extramedullary disease11 X 
Skeletal Survey12 X 
 
Bone Marrow Tests  
BM aspirate/biopsy for Disease 
Assessment13 X 
BM for FISH testing14 X 
BM for  
testing15 X 
BM aspirate for BCMA expression  and 
biomarker research15,16 X 
CCI
CCI
CCI
CCI
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 31 
 Table 5 Schedule of Activities – On-Study Assessments for Arm A (belantamab mafodotin in combination with 
lenalidomide plus dexamethasone) [28 -Day Cycle] - belantamab mafodotin SINGLE and STRETCH Dosing  
Study Assessments1  
SINGLE 
and 
STRETCH 
Dosing   
STRETCH 
Dosing  
ONLY  SINGLE and STRETCH Dosing  
Notes (Arm A belantamab mafodotin SINGLE and STRETCH  
dosing)  
Cycle 1 Day 
12 Cycle 2 Day 
1 Every 28 Days  
(Starting at  
Week 53 
regardless of 
dosing)  Starting at  
Cycle 24 - 
SINGLE dosing 
[or Starting at 
Cycle 3 -
STRETCH 
dosing]  
 
(Prior to the first 
dose of any 
study drugs at 
the given cycle)  
ECOG Performance Status    X  1. All assessments apply to Part 1 and 2 of the study, unless 
stated otherwise.  
2. Screening assessments do not need to be repeated on Cycle 
1 Day 1 (C1D1), unless otherwise specified.  
3. All assessments starting at week 5 can be performed within 3 
days prior to the scheduled date, unless otherwise specified.  
4. Assessments scheduled on days of dosing should be done 
prior to drug administration, unless otherwise spe cified. 
Physical Exam must be conducted within 72 h prior to 1st 
dose of study drugs administrated in that cycle. Body weight 
at C1D1 (prior to dosing) will be used for dose calculation of 
belantamab mafodotin.  Body weight to be measured prior to 
each dos e. If the change of body weight is greater than 10%, Adverse Events / SAEs5 X X Ongoing  Ongoing  
Concomitant Medications  X X Ongoing  Ongoing  
Safety  
Physical Exam  X X X X4 
Ocular Exam6  X X X 
Vital Signs (BP, Heart rate, 
Body Temperature)7 X X  X 
Body Weight (BW) and Height  BW only  BW only   BW only  
Hematology8,9 X X X X 
Clinical chemistry8 X X X X 
HbA1c  As clinically indicated  
C-reactive protein (CRP)8  X X  
Urinalysis (dipstick)8 X X X  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 32 
 Study Assessments1  
SINGLE 
and 
STRETCH 
Dosing   
STRETCH 
Dosing  
ONLY  SINGLE and STRETCH Dosing  
Notes (Arm A belantamab mafodotin SINGLE and STRETCH  
dosing)  
Cycle 1 Day 
12 Cycle 2 Day 
1 Every 28 Days  
(Starting at  
Week 53 
regardless of 
dosing)  Starting at  
Cycle 24 - 
SINGLE dosing 
[or Starting at 
Cycle 3 -
STRETCH 
dosing]  
 
(Prior to the first 
dose of any 
study drugs at 
the given cycle)  
Estimated Glomerular 
Filtration Rate (eGFR) by 
MDRD formula  X X X  the dose should be re -calculated based on the actual body 
weight at the time of dosing.  
5. All AEs will be assessed for at least 70 days after the last 
dose regardless of initiation of new anticancer thera py. All 
related SAEs are to be collected from consent through  
follow -up. For reporting of ocular events see the guidance 
provided in Appendix 8. 
6. Participants will be assessed by a qualified eye care specialist 
(Appendix 12 ) on Day 1 of every cycle prior to dosing up to 
Dose 6 of belantamab mafodotin (assessment window of up 
to 5 days prior to dosing, but all effort should be made to 
schedule as close to belantamab mafodotin dosing as 
possible). If there are no significant ocular examinations 
findings, patient’s symptoms or vision changes at the time o f 
Dose 6 exam, participants may have their ophthalmologic 
exams decreased to once every 3 months. If a participant 
subsequently develops vision changes or other ocular 
symptoms, the participant should be promptly evaluated by a 
qualified eye care specialis t. In case of persistent ophthalmic Spot urine for 
albumin/creatinine ratio10  X X  
Pregnancy Test for WOCBP11 X X X X 
12-lead ECG12 X X  X 
ECHO – LVEF13   Every 12 
weeks  
(At weeks 13, 
25, 37, 49 etc)   
 
Disease Evaluation  [every 4 weeks ( 3 days) even if the cycle is delayed]14 
SPEP (Serum Protein 
Electrophoresis)   X X  
Serum Kappa, lambda free 
LC, FLC ratio   X X  
Serum Immunofixation15   At time of 
suspected CR  
CC
I
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 33 
 Study Assessments1  
SINGLE 
and 
STRETCH 
Dosing   
STRETCH 
Dosing  
ONLY  SINGLE and STRETCH Dosing  
Notes (Arm A belantamab mafodotin SINGLE and STRETCH  
dosing)  
Cycle 1 Day 
12 Cycle 2 Day 
1 Every 28 Days  
(Starting at  
Week 53 
regardless of 
dosing)  Starting at  
Cycle 24 - 
SINGLE dosing 
[or Starting at 
Cycle 3 -
STRETCH 
dosing]  
 
(Prior to the first 
dose of any 
study drugs at 
the given cycle)  
then until 
suspected PD  exam findings, newly developed ocular symptoms or vision 
changes at Dose 6 exam, the participants will have further 
ophthalmologic exams, at least every cycle until resolution (to 
Grade 1 or baseline) or more frequently as clinically indicated 
by the qualified eye care specialist. See Section 10.6.7.1  for 
full details of ocular exam procedures.  
7. On each belantamab ma fodotin dosing day, vital signs must 
be assessed within 30 min prior to Start of Infusion (SOI), 
within 15 min after End of Infusion (EOI), and at 1 h (15 min ) 
after EOI. On days where vital sign assessments align with 
PK sampling time points, vital signs  should be assessed prior 
to belantamab mafodotin PK samples being drawn . 
8. Hematology and clinical chemistry must be repeated if not 
done within 24 h prior to 1st dose of study drugs administered 
in that cycle. Refer to Table 27 for comprehensive list of lab 
tests.  
9. To be performed up to 24 h before D1, D8, D15, D22 in C1 
and C2; then up to 24  h before D1, D15 in C3 to C8 and then 
up to 24 h before D1 of each cycle from C9 onwards, or more UPEP (Urine Protein 
Electrophoresis)  
(on 24 h collected urine)   X X  
Urine Immunofixation15   At time of 
suspected CR 
then until 
suspected PD   
Ca corrected for Albumin 
(Serum)   X X  
IgG, IgM, IgA   X X  
IgD/IgE16  X X  
Imaging for extramedullary 
disease17   Week 13, 25, 
37, 49 and 
then if clinically 
indicated   
Skeletal Survey18  As clinically 
indicated  As clinically 
indicated   
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 34 
 Study Assessments1  
SINGLE 
and 
STRETCH 
Dosing   
STRETCH 
Dosing  
ONLY  SINGLE and STRETCH Dosing  
Notes (Arm A belantamab mafodotin SINGLE and STRETCH  
dosing)  
Cycle 1 Day 
12 Cycle 2 Day 
1 Every 28 Days  
(Starting at  
Week 53 
regardless of 
dosing)  Starting at  
Cycle 24 - 
SINGLE dosing 
[or Starting at 
Cycle 3 -
STRETCH 
dosing]  
 
(Prior to the first 
dose of any 
study drugs at 
the given cycle)  
Whole body PET/CT    Only once at 
time of 
achieving CR 
or sCR 
(whichever 
comes first) 
according to 
IMWG 2016   frequently, if clinically indicated. On D1 of any planned cycle, 
Absolute Neutr ophil Count (ANC) must be ≥1.0×109/L to 
administer treatment.   
10. Albumin/creatinine ratio (Spot urine from first void) every 4 
weeks 3 days  (local lab, if not available then central 
laboratory testing).  
11. Perform only in women of childbearing potential. Two 
negative serum pregnancy tests must be obtained prior to 
initiating therapy with lenalidomide; one may be performed 
within 10 -14 days of C1D1, but the second must be 
performed within 24 h of C1D1. After the first dose of 
belantamab mafodotin, pregnancy tes t will be done weekly 
during the first month, then monthly thereafter in females with 
regular menstrual cycles or every 2 weeks in females with 
irregular menstrual cycles. Subsequent pregnancy test on 
dosing days may be either serum or urine test. Each 
pregnancy test must be performed within 24 h prior to dosing.  
12. SINGLE ECG performed pre -infusion on belantamab 
mafodotin dosing days. On days when belantamab mafodotin Response assessment by 
IMWG19  X X  
Bone Marrow Tests  
BM aspirate/biopsy for 
Disease Assessment20, 24    At time of 
suspected CR 
or at time of 
suspected PD 
(only if PD not 
evident 
otherwise)   
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 35 
 Study Assessments1  
SINGLE 
and 
STRETCH 
Dosing   
STRETCH 
Dosing  
ONLY  SINGLE and STRETCH Dosing  
Notes (Arm A belantamab mafodotin SINGLE and STRETCH  
dosing)  
Cycle 1 Day 
12 Cycle 2 Day 
1 Every 28 Days  
(Starting at  
Week 53 
regardless of 
dosing)  Starting at  
Cycle 24 - 
SINGLE dosing 
[or Starting at 
Cycle 3 -
STRETCH 
dosing]  
 
(Prior to the first 
dose of any 
study drugs at 
the given cycle)  
BM biopsy to confirm sCR by 
IHC    Upon 
achieving CR  
   PK sampling is performed, PK samples should be drawn 
shortly after ECG. TRIPLICATE ECGs will  be performed as 
described below with SINGLE ECG performed at all other 
times.  All ECGs will be collected centrally (refer to SRM for 
details).  
Belantamab mafodotin Dose 1 (Cycle 1)  
Day 1: TRIPLICATE ECGs  Pre-infusion (within 30 min prior 
to SOI), EOI (up to 15 min after EOI), 2 h (±15 min) after SOI 
and 24 h (±2 h) after SOI.  
Day 4 (i.e. 72 h after SOI [±24 h]): TRIPLICATE ECG 
performed before PK sample.  
Belantamab mafodotin Dose 2  
Day 1: SINGLE ECG pre -infusion  
Belantamab mafodotin Dose 3  
Day 1:  TRIPLICATE ECGs pre -infusion (within 30 min prior 
to SOI), EOI (up to 15 min after EOI)  
13. ECHO will be performed every 12 weeks ( 7 days) and 
locally.  BM aspirate for  
 testing21    At time of 
achieving 
VGPR or 
better   
 
Biomarkers  
X   X 
X  At time of 
achieving 
VGPR or 
better21  
 
Optional  
Optional tissue sample at PD 
for BCMA expression and 
biomarker research24   X  
Genetic sample25 X    
CCI
CCI
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 36 
 Study Assessments1  
SINGLE 
and 
STRETCH 
Dosing   
STRETCH 
Dosing  
ONLY  SINGLE and STRETCH Dosing  
Notes (Arm A belantamab mafodotin SINGLE and STRETCH  
dosing)  
Cycle 1 Day 
12 Cycle 2 Day 
1 Every 28 Days  
(Starting at  
Week 53 
regardless of 
dosing)  Starting at  
Cycle 24 - 
SINGLE dosing 
[or Starting at 
Cycle 3 -
STRETCH 
dosing]  
 
(Prior to the first 
dose of any 
study drugs at 
the given cycle)  
 
 
 14. Disease evaluation (except imaging and skeletal survey) wil l 
continue to be performed, every 4 weeks ( 3 days) even if 
the cycle is delayed.  
15. At time of first achieving SPEP or Urine M protein ~0  g/dl 
(suspected CR) and until suspected PD after CR or stringent 
Complete Response (sCR).  
16. Only in participants with IgD/IgE myeloma.  
17. Imaging is only required for participants with known 
extramedullary disease at week 13, 25, 37, 49 ( 7 days) and 
then if clinically indicated by either CT, MRI, or PET/CT per 
local guidance. Needs to be performed by the same method 
through out the study as was done at baseline (i.e. if CT/PET 
scan was used as baseline, participant needs to be followed 
by CT/PET scans). Selected target lesion needs to be 
measured and followed over time. Plasmacytoma 
measurements should be taken from the CT po rtion of the 
PET/CT, or MRI scans, or dedicated CT scans where 
applicable.  PK and ADA  
Pharmacokinetic blood 
sampling for belantamab 
mafodotin 22,26 X26   X (at selected 
cycles)26 
Pharmacokinetic blood 
sampling for lenalidomide27 X27     
Anti-drug antibodies (ADA)28 X28   X (at selected 
cycles)28 
 
Treatment  
Premedication if needed29 X   X 
Administration of belantamab 
mafodotin30 X   SINGLE Dosing: 
Day 1 of each 28 -
day cycle  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 37 
 Study Assessments1  
SINGLE 
and 
STRETCH 
Dosing   
STRETCH 
Dosing  
ONLY  SINGLE and STRETCH Dosing  
Notes (Arm A belantamab mafodotin SINGLE and STRETCH  
dosing)  
Cycle 1 Day 
12 Cycle 2 Day 
1 Every 28 Days  
(Starting at  
Week 53 
regardless of 
dosing)  Starting at  
Cycle 24 - 
SINGLE dosing 
[or Starting at 
Cycle 3 -
STRETCH 
dosing]  
 
(Prior to the first 
dose of any 
study drugs at 
the given cycle)  
1.9 mg/ kg 
STRETCH : 1.9 
mg/kg on Day 1: 
at least 56 ( 3) 
days between 
consecutive doses 
of belantamab 
mafodotin.  For participants with only skin involvement, skin lesions 
should be measured with a ruler. Measurement of tumor size 
will be determined by the Sum of the Products of the maximal 
perpendicular diameters of measured lesions (SPD).  
18. Imaging of bones for lytic lesions by method aligned with 
institutional guidance (X -ray, CT or MRI). Survey results 
within 30 days prior to C1D1 date are acceptable. At later 
cycles, repeat as clinically ind icated, or if worsening clinical 
symptoms suggest PD, by the same method used as at 
screening.  
19. Response to treatment will be assessed every 4 weeks ( 3 
days), based on laboratory tests and imaging (if applicable), 
using IMWG criteria [ Kumar , 2016].  
20. Whenever CR is assessed, if possible, a further BM aspirate 
sample may be taken at the same time for biomarker 
research.  
21. ) to be perfor med by the 
central lab at the time of first achieving VGPR or better. 
Thereafter,  should be repeated every 6 months 
until PD or CR. In case of deepening of response from VGPR Administration of 
lenalidomide31 X X  25 or 10 mg PO 
Days 1 -21 of each 
28-day cycle  
Administration of 
dexamethasone32 X X  40 or 20 mg on 
Days 1, 8, 15, and 
22 of each 28 -day 
cycle  
Preservative -free artificial 
tears33 X 
Cooling eye masks33 X   X 
Venous Thrombo -Embolism 
(VTE) prophylaxis34 X 
CCI
CCI
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 38 
 Study Assessments1  
SINGLE 
and 
STRETCH 
Dosing   
STRETCH 
Dosing  
ONLY  SINGLE and STRETCH Dosing  
Notes (Arm A belantamab mafodotin SINGLE and STRETCH  
dosing)  
Cycle 1 Day 
12 Cycle 2 Day 
1 Every 28 Days  
(Starting at  
Week 53 
regardless of 
dosing)  Starting at  
Cycle 24 - 
SINGLE dosing 
[or Starting at 
Cycle 3 -
STRETCH 
dosing]  
 
(Prior to the first 
dose of any 
study drugs at 
the given cycle)  
 to CR, or achieving CR without prior VGPR,  
should be perf ormed at the time of achieving suspected CR 
and repeated every 6 months until PD. Whenever possible, a 
further BM aspirate sample may be taken at the same time for 
biomarker research. Additionally, collect blood plasma for 
analysis.  
24. The optional PD tissue sample should contain tumor cells, 
either BM aspirate clot, or other tissue in case of 
extramedullary disease. Samples will be submitted to central 
lab for BCMA analysis, any remaining bone marrow and/or 
tissue sample will be used for biomarker research.  
25. Informed consent for optional sub -studies (e.g. genetic 
research) must be obtained be fore collecting a sample. The 
sample will be collected at the first opportunity after a 
participant has met all eligibility requirements, before/ on 
C1D1 prior to infusion . If insufficient DNA was extracted, or 
the sample was damaged or otherwise could not be Health Outcomes  
EORTC QLQ -C30 AND QLQ -
MY2035 X  Every 8 weeks 
starting W9   
PRO -CTCAE35 X X X  
OSDI and NEI -VFQ-2535 X X X  
 
CCI
CCI
CCI
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 39 
 Study Assessments1  
SINGLE 
and 
STRETCH 
Dosing   
STRETCH 
Dosing  
ONLY  SINGLE and STRETCH Dosing  
Notes (Arm A belantamab mafodotin SINGLE and STRETCH  
dosing)  
Cycle 1 Day 
12 Cycle 2 Day 
1 Every 28 Days  
(Starting at  
Week 53 
regardless of 
dosing)  Starting at  
Cycle 24 - 
SINGLE dosing 
[or Starting at 
Cycle 3 -
STRETCH 
dosing]  
 
(Prior to the first 
dose of any 
study drugs at 
the given cycle)  
processed, the site may be requested to recollect the genetic 
sample where applicable  
26. PK samples to be taken in all participants for belantamab 
mafodotin measurement o n:  
Belantamab mafodotin Dose 1 (Cycle 1)  
Day 1 : at pre -infusion (within 30 min prior to Start of 
Infusion), End of Infusion (0 to 15 min after EOI) , at 2 h 
(± 15 min)  after SOI and at 24 h (± 2 h) after SOI.  
Day 4  (i.e., 72 h after SOI [± 24h]), one PK sample to be 
taken after ECG performed.  
Day 8 through and including on Day 15:  One PK sample to 
be taken.  
Day 29 (STRETCH): One PK sample to be taken . 
Belantamab mafodotin Dose 2  
Day 1 : at pre - infusion (within 30 min prior to SOI) and EOI 
(0 to 15 min after EOI) . 
If Dose 2 is delayed, collect one PK sample on this day 
(Dose 1 Day 29  for SINGLE and Dose 1 Day 5 7 for 
STRETCH ) regardless of dosing.  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 40 
 Study Assessments1  
SINGLE 
and 
STRETCH 
Dosing   
STRETCH 
Dosing  
ONLY  SINGLE and STRETCH Dosing  
Notes (Arm A belantamab mafodotin SINGLE and STRETCH  
dosing)  
Cycle 1 Day 
12 Cycle 2 Day 
1 Every 28 Days  
(Starting at  
Week 53 
regardless of 
dosing)  Starting at  
Cycle 24 - 
SINGLE dosing 
[or Starting at 
Cycle 3 -
STRETCH 
dosing]  
 
(Prior to the first 
dose of any 
study drugs at 
the given cycle)  
Belantamab mafodotin Dose 3  
Day 1 :  at p re- infusion (within 30 min prior to SOI) and EOI 
(0 to 15 min after EOI) .  
Belantamab mafodotin Dose 6   
Day 1 : at pre - infusion (within 30 min prior to SOI) and EOI 
(0 to 15 min after EOI) . 
Belantamab mafodotin Dose 9:  
Day 1 : at pre - infusion (within 30 min prior to SOI).  
Belantamab mafodotin Dose 12  
Day 1 :  at pre -infusion (within 30 min prior to SOI).  
For treatment beyond belantamab mafodotin Dose 12, pre -
infusion samples will be collected every 6th Dose of 
belantamab mafo dotin (Dose 18, Dose 24, Dose 30 and so 
on, until PD).  samples will be collected every time a 
belantamab mafodotin PK sample is collected. See footnote 
22. 
27. PK samples for lenalidomide: During C1D1, PK samples will 
be collected at pre -dose (within 30 min prior to taking drug), 
0.5 h (2 min ), 1 h (5 min ), 2 h (10 min ), and 4 h (15 min ) 
and 24 h (2 h) after the administration of lenalidomide. The 
CCI
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 41 
 Study Assessments1  
SINGLE 
and 
STRETCH 
Dosing   
STRETCH 
Dosing  
ONLY  SINGLE and STRETCH Dosing  
Notes (Arm A belantamab mafodotin SINGLE and STRETCH  
dosing)  
Cycle 1 Day 
12 Cycle 2 Day 
1 Every 28 Days  
(Starting at  
Week 53 
regardless of 
dosing)  Starting at  
Cycle 24 - 
SINGLE dosing 
[or Starting at 
Cycle 3 -
STRETCH 
dosing]  
 
(Prior to the first 
dose of any 
study drugs at 
the given cycle)  
24 h post -dose must  be collected before lenalidomide 
dosing on C1D2. 
28. All ADA samples will be collected prior to each belantamab 
mafodotin infusion at Dose 1, 2, 3, 6, 9 and 12 (at the same 
time as the pre -infusion belantamab mafodotin PK samples 
are taken); for treatment beyond 12 cycles, collect samples 
for ADA analysis prior to each infusion every 6th Dose of 
belantamab mafodotin (Dose 18, Dose 24, Dose 30 and so on 
until PD).  
29. Premedication should be considered in any participant who 
experienced an IRR during the first or any subsequent 
infusions with belantamab mafodotin.  
30. Belantamab mafodotin will be administered first as a 30 min 
to 1 h infusion, followed by 1 -2 h rest period. A window of 3 
days is acceptable for administration of study treatment after 
C1. Please refer to Section 8.2 for dose modification 
guidance. Note: “SINGLE” Dosing Schedule: belantamab 
mafodotin will be administered as a SINGLE full dose on Day 
1 of each cycle. For example: A “2.5 mg/kg SINGLE” dosing 
schedule of belantamab  mafodotin will administer a 2.5 mg/kg 
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 42 
 Study Assessments1  
SINGLE 
and 
STRETCH 
Dosing   
STRETCH 
Dosing  
ONLY  SINGLE and STRETCH Dosing  
Notes (Arm A belantamab mafodotin SINGLE and STRETCH  
dosing)  
Cycle 1 Day 
12 Cycle 2 Day 
1 Every 28 Days  
(Starting at  
Week 53 
regardless of 
dosing)  Starting at  
Cycle 24 - 
SINGLE dosing 
[or Starting at 
Cycle 3 -
STRETCH 
dosing]  
 
(Prior to the first 
dose of any 
study drugs at 
the given cycle)  
dose on D1 of each cycle. Note: STRETCH  Dosing Schedule: 
belantamab mafodotin will be administered as a full dose on 
D1 of every alternate 28 -day cycle. For example: A 1.9 mg/kg 
STRETCH  will administer a 1.9 mg/kg dos e on Day 1 of every 
alternate 28 -day cycle i.e. STRETCH  (C1, C3, C5, C7 and so 
on). 
31. Lenalidomide: 25 mg orally daily on Days 1 - 21 of each cycle 
in participants with >60  mL/min/1.73  m2, or reduced to 10 mg 
daily if the eGFR is 40 -60 mL/min/1.73 m2. [Refer to 
lenalidomide PI]. Refer to Section 8.2 for dose modification 
guidance.  
32. Dexamethasone: 40 mg weekly, orally on Days 1, 8, 15, 22 of 
each cycle, Participants who are >75  y with BMI <18.5 kg/m2, 
the dose of dexamethasone can be reduced to 20 mg weekly. 
If intolerance to dexamethasone develops, dexamethasone 
may be reduced to 20 mg. If 20 mg is not tolerated, the 
dexamethasone dose can be furt her reduced or permanently 
discontinued. Refer to Section 8.2 for dose modification 
guidance.  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 43 
 Study Assessments1  
SINGLE 
and 
STRETCH 
Dosing   
STRETCH 
Dosing  
ONLY  SINGLE and STRETCH Dosing  
Notes (Arm A belantamab mafodotin SINGLE and STRETCH  
dosing)  
Cycle 1 Day 
12 Cycle 2 Day 
1 Every 28 Days  
(Starting at  
Week 53 
regardless of 
dosing)  Starting at  
Cycle 24 - 
SINGLE dosing 
[or Starting at 
Cycle 3 -
STRETCH 
dosing]  
 
(Prior to the first 
dose of any 
study drugs at 
the given cycle)  
On days where only lenalidomide and dexamethasone are 
taken at home, they should be taken in the morning 
approximately at the same time each day. On C1D1, 
lenalidomide should be administered as close as possible to 
the end of the 1 -2 h rest period after administration of 
belantamab mafodotin and no later than 6 h after the end of 
the rest period after administration of belantamab mafodotin. 
On subsequent lenalid omide and belantamab mafodotin co -
administration days such as C2D1, C3D1 and thereafter,  
lenalidomide should be administered after the end of the 1 -2 h 
rest period after administration of belantamab mafodotin.  
Participant diary will be used to keep record of self -
administered oral study treatment(s) at home.  
33. Corneal Events Management:  
- Prophylactic preservative -free artificial tears must be 
administered in each eye at least 4 -8 times daily beginning on 
C1D1 until end of treatment. In the event of ocular s ymptoms 
(e.g., dry eyes), the use of artificial tears may be increased up 
to every 2 hours as needed.  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 44 
 Study Assessments1  
SINGLE 
and 
STRETCH 
Dosing   
STRETCH 
Dosing  
ONLY  SINGLE and STRETCH Dosing  
Notes (Arm A belantamab mafodotin SINGLE and STRETCH  
dosing)  
Cycle 1 Day 
12 Cycle 2 Day 
1 Every 28 Days  
(Starting at  
Week 53 
regardless of 
dosing)  Starting at  
Cycle 24 - 
SINGLE dosing 
[or Starting at 
Cycle 3 -
STRETCH 
dosing]  
 
(Prior to the first 
dose of any 
study drugs at 
the given cycle)  
- At the start of each infusion, participants may apply cooling 
eye masks for approximately 1 h or as long as tolerated.  
34. ASA or LMH or oral anticoagulant s according to institutional 
guidance for the duration of treatment with lenalidomide.  
35. EORTC QLQ -C30 AND QLQ -MY20 will be collected every 8 
weeks, and PRO -CTCAE, OSDI and NEI -VFQ-25 will be 
collected every 4 weeks, even if cycle is delayed. Participants 
who cannot complete the self -administered version should 
use an Interviewer -Administered format. The interview may 
be administered over the telephone. If the Interviewer -
Administered format is used, it should be read to the 
participants verbatim, and partici pant responses should be 
recorded directly without any interpretation.  Refer to SRM for 
further details.  
 
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 45 
 Table 6 Schedule of Activities – On-Study Assessments for Arm A (belantamab mafodotin in combination with 
lenalidomide plus dexamethasone) [28 -Day Cycle] – belantamab mafodotin SPLIT  Dosing Only 
Study Assessments1 Cycle 1  Every 28 
Days  
 
(Starting at  
Week 53 
regardless of 
dosing)  Starting at  
Cycle 24 
 
(Prior to the 
first dose of 
any study 
drugs at the 
given cycle)  Notes  (Arm A belantamab mafodotin SPLIT dosing only)  
Day 12 Day 8  
ECOG Performance Status    X  1. All assessments apply to Part 1 and 2 of the study unless stated otherwise.  
2. Screening assessment s do not need to be repeated on Cycle 1 Day 1 ( C1D1 ) 
unless otherwise specified.  
3. All assessments starting at week 5 can be performed within 3 days prior to the 
scheduled date unless otherwise specified.  
4. Assessments scheduled on days of dosing should be conducted prior to drug 
administration, unless otherwise specified. Physical Exam must be within 72 h 
prior to 1st dose of study drugs to be administrated in that cycle.  Body weight at 
C1D1 (prior to dosing) will be used for dose calculation of belantamab 
mafodotin . Body weight to be measured prior to each dose. If the change of 
body weight is greater than 10%, the dose should be re -calculated based on the 
actual body weight at the time of dosing.  
5. Treatment -related toxicities will be assessed  for at least 70  days after the last 
dose regardless  of initiation of new anticancer therapy. All related SAEs are to 
be collected from consent through  follow -up. For report ing of ocular events 
see the guidance provided in Appendix 8. 
6. Participants will be assessed by a qualified eye care specialist ( Appendix 12 ) on 
Day 1 of every cycle prior to dosing up to Dose 6 of belantamab mafodotin 
(assessment window of up to 5 days prior to dosing, but all effort  should be 
made to schedule as close to belantamab mafodotin dosing as possible). If 
there are no significant ocular examinations findings, patient’s symptoms or 
vision changes at the time of Dose 6 exam, participants may have their 
ophthalmologic exams de creased to once every 3 months. If a participant 
subsequently develops vision changes or other ocular symptoms, the participant Adverse Events/ SAEs5 X  Ongoing  Ongoing  
Concomitant Medications  X  Ongoing  Ongoing  
 
Safety  
Physical Exam  X X X X4 
Ocular Exam6    X 
Vital Signs (BP, Heart rate, 
Body Temperature)7 X X  X 
Body Weight (BW) and 
Height  BW only    BW only  
Hematology8,9 X X X X 
Clinical chemistry8 X  X X 
HbA1c  As clinically indicated  
C-reactive protein (CRP)8   X  
Urinalysis (dipstick)8 X  X  
Estimated Glomerular 
Filtration Rate (eGFR) by 
MDRD formula  X  X  
Spot urine for 
albumin/creatinine ratio10   X  
Pregnancy Test for 
WOCBP11 X  X X 
12-lead ECG12 X X  X 
CC
I
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 46 
 Study Assessments1 Cycle 1  Every 28 
Days  
 
(Starting at  
Week 53 
regardless of 
dosing)  Starting at  
Cycle 24 
 
(Prior to the 
first dose of 
any study 
drugs at the 
given cycle)  Notes  (Arm A belantamab mafodotin SPLIT dosing only)  
Day 12 Day 8  
ECHO – LVEF13   Every 12 
weeks  
(At week 13, 
25, 37, 49 
and so on)   should be promptly evaluated by a qualified eye care specialist. In case of 
persistent ophthalmic exam findings, newly developed  ocular symptoms or 
vision changes at Dose 6 exam, the participants will have further 
ophthalmologic exams, at least every cycle until resolution (to Grade 1 or 
baseline) or more frequently as clinically indicated by the qualified eye care 
specialist. See Section 10.6.7.1  for full details of ocular exam procedures.  
7. On each belantamab mafodotin dosing day, vital signs must be assessed within 
30 min prior to Start of Infusion (SOI), within 15 min after End of Infusion (EOI), 
and at 1 h (15 min) after EOI. On days where vital sign assessments  align with 
PK sampling time points, vital signs should be assessed prior to belantamab 
mafodotin PK samples being drawn . 
8. Hematology and clinical chemistry must be repeated , if not done within 24 h 
prior to 1st dose of study drugs to be administ ered in that cycle. Refer to Table 
27 for comprehensive list of lab tests.  
9. To be performed up to 24 h before D1, D8, D 15, D22 in C1 and C2; then up to 
24 h before D1, D15 in C3 to C8 and then up to 24 h before Day 1 of each cycle 
from C9 onwards, or more frequently, if clinically indicated.  On D1 of any 
planned cycle, Absolute Neutrophil Count (ANC) must be ≥1.0×109/L to 
administer treatment.   
10. Albumin/creatinine ratio (Spot urine from first void) every 4 weeks 3 days  (local 
lab, if not available then central  laboratory testing ). 
11. Perform only in women of childbearing potential. Two negative serum 
pregnancy tests must be obtained prior to initiating therapy with lenalidomide; 
one may be performed within 10-14 days of C1 D1, but the second must be 
performed within 24 h of C1D1. After the first dose  of belantamab mafodotin , 
pregnancy test will be done weekly during the first month, then monthly 
thereafter in females with regular menstrual cycles or every 2 weeks in females  
Disease Evaluation  [every 4 weeks ( 3 days) even if the cycle is delayed]14 
SPEP (Serum Protein 
Electrophoresis)    X  
Serum Kappa, lambda free 
LC, FLC ratio    X  
Serum Immunofixation15   At time of 
suspected CR 
then until 
suspected PD   
UPEP (Urine Protein 
Electrophoresis)  
(on 24 h collected urine)    X  
Urine Immunofixation15   At time of 
suspected CR 
then until 
suspected PD   
Ca corrected for Albumin 
(Serum)    X  
IgG, IgM, IgA    X  
IgD/IgE16   X  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 47 
 Study Assessments1 Cycle 1  Every 28 
Days  
 
(Starting at  
Week 53 
regardless of 
dosing)  Starting at  
Cycle 24 
 
(Prior to the 
first dose of 
any study 
drugs at the 
given cycle)  Notes  (Arm A belantamab mafodotin SPLIT dosing only)  
Day 12 Day 8  
Imaging for extramedullary 
disease17   Week 13, 25, 
37, 49 and 
then if 
clinically 
indicated   with irregular menstrual cycles. Subsequent pregnancy test on dosing days may 
be either serum or urine test.  Each pregnancy test must be performed within 24 
h prior to dosing.  
12. SINGLE ECG performed pre -infusion on belantamab mafodotin dosing days. 
On days when belantamab mafodotin PK sampling is performed, PK samples 
should be drawn  shortly after ECG . TRIPLICATE ECGs will be performed as 
described below , with SINGLE ECG performed at all other times .  All ECGs will 
be collected centrally (refer to SRM for details).  
Belantamab mafodotin Dose 1 (C1)  
Day 1: TRIPLICATE ECG s Pre-infusion (within 30 min prior to S OI), EOI ( up to  
15 min after EOI), 2  h (±15 min) after SOI and 24  h (±2 h) after SOI.  
D4 (i.e. 72  h after D1 SOI [24 h]): TRIPLICATE ECG performed before PK 
sample.  
D8: TRIPLICATE ECG s Pre-infusion (within 30 min prior to SOI), EOI ( up to 15 
min after EOI), 2  h (±15 min)  after SOI and 24  h (±2 h) after SOI.  
D11 (i.e. 72  h after Day 8 SOI [24 h]): TRIPLICATE ECG performed before PK 
sample.  
Belantamab mafodotin Dose 2:  
D1: SINGLE  ECG pre -infusion  
D8: SINGLE  ECG pre -infusion  
Belantamab mafodotin Dose 3 : 
D1: TRIPLICATE ECG s pre-infusion (within 30 min prior to SOI), EOI ( up to 15 
min after EOI) 
D8: TRIPLICATE ECG s pre-infusion (within 30 min prior to S OI), EOI ( up to 15 
min after EOI) 
13. ECHO will be performed every 12 weeks ( 7 days) and locally.  
14. Disease evaluation (except imaging and skeletal survey) will continue to be 
performed, every 4 weeks ( 3 days) even if the cycle is delayed.  Skeletal Survey18   As clinically 
indicated   
Whole body PET/CT    Only once at 
time of 
achieving CR 
or sCR 
(whichever 
comes first ) 
according to 
IMWG 2016   
Response assessment by 
IMWG19   X  
 
Bone Marrow Tests  
BM aspirate/biopsy for 
Disease Assessment20,24    At time of 
suspected CR 
or at time of 
suspected PD 
(only if PD not 
evident 
otherwise)   
BM biopsy to confirm sCR 
by IHC     Upon 
achieving CR  
   
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 48 
 Study Assessments1 Cycle 1  Every 28 
Days  
 
(Starting at  
Week 53 
regardless of 
dosing)  Starting at  
Cycle 24 
 
(Prior to the 
first dose of 
any study 
drugs at the 
given cycle)  Notes  (Arm A belantamab mafodotin SPLIT dosing only)  
Day 12 Day 8  
BM aspirate for  
 testing21   At time of 
achieving 
VGPR or 
better   15. At time of first achieving SPEP or Urine M protein ~0  g/dl (suspected CR) and 
until suspected PD after CR or stringent Complete Response ( sCR). 
16. Only in participants with IgD/IgE myeloma . 
17. Imaging is only required for participants with known extramedullary disease at 
week 13, 25, 37, 49 ( 7 days) and then if clinically indicated by either CT, MRI, 
or PET/CT , per local guidance. Needs to be performed by the same method 
throughout the study as was done at baseline (i.e. if CT/PET scan was used as 
baseline, participant needs to be followed by CT/PET scans).  Selected target 
lesion needs to be measured and followed over time. Plasmacytoma 
measurements should be taken from the CT portion of the PET/CT, or MRI 
scans, or dedicated CT scans where  applicable.  
For participants with only skin involvement, skin lesions should be measured 
with a ruler.  Measurement of tumor  size will be determined by the Sum of the 
Products of the maximal perpendicular diameters of measured lesions (SPD).  
18. Imaging of bones for lytic lesions by method aligned with institutional guidance 
(X-ray, CT or MRI). Survey results within 30 days prior to C1D1 date are 
acceptable. At later cycles, repeat as clinically indicated, or if worsening clinical 
symptoms suggest  PD, by the same method used as at screening . 
19. Response to treatment will be assessed every 4 weeks ( 3 days), based on 
laboratory tests and imaging (if applicable), using IMWG criteria [Kumar , 2016 ]. 
20. Whenever CR is assessed, if possible, a further BM aspirate sample may be 
taken at the same time  for biomarker analysis . 
21. ) to be performed by the central lab at the time of 
first achieving VGPR or better. Thereafter,  should be repeated 
every 6 months until PD or CR. In case of deepening of response from VGPR to 
CR, or achieving CR without prior VGPR,  should be performed at 
the time of achieving suspected CR and repeated every 6 months until PD .  
Biomarkers  
X   X 
X  At time of 
achieving 
VGPR or 
better21  
 
Optional  
Optional tissue sample at 
PD for BCMA expression  
and biomarker research24   X  
Genetic sample25 X    
 
PK and ADA  
Pharmacokinetic blood 
sampling for belantamab 
mafodotin22,26 X26 X26  X (at selected 
cycles)26 
Anti-drug antibodies 
(ADA)27 X27   X (at selected 
cycles)27 
 
Treatment  
Premedication if needed28 X   X 
CCI
CCI
CCI
CCI
CCI
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 49 
 Study Assessments1 Cycle 1  Every 28 
Days  
 
(Starting at  
Week 53 
regardless of 
dosing)  Starting at  
Cycle 24 
 
(Prior to the 
first dose of 
any study 
drugs at the 
given cycle)  Notes  (Arm A belantamab mafodotin SPLIT dosing only)  
Day 12 Day 8  
Administration of 
belantamab mafodotin29 X X  Day 1 and Day 
8 of each 28 -
day cycle  Whenever possible, a further BM aspirate sample may be taken at the same 
time for biomarker analysis . Additionally, collect blood plasma for  
analysis.  
24. The optional PD tissue sample should contain tumor cells , either BM aspirate 
clot, or other tissue in case of extramedullary disease. S amples will be 
submitted to central lab for BCMA analysis , any remaining bone marrow and/or 
tissue sample will be used for biomarker research . 
25. Informed consent for optional sub -studies (e.g. genetic research) must be 
obtained before collecting a sample. The sample will be collected at the first 
opportunity after a participant has met all eligibility requirements, before/ on 
C1D1 prior to infusion . If insufficient DNA was extracted, or the sample was 
damaged or otherwise could not be processed, the site may be requested to 
recollect the genetic sample  where applicable . 
26. PK samples to be taken in all participants for belantamab mafodotin 
measurement on: 
Belantamab mafodotin Dose 1 (Cycle 1)  
• Day 1: at pre -infusion (within 30 min prior to S OI), EOI (0 to 15 min after 
EOI), at 2 h ( 15 min) after SOI and at 24h (± 2 h) after SOI.  
• Day 4 (i.e., 72  h after SOI [ 24 h]), one PK sample to be taken after ECG 
performed.  
• Day 8: at pre -infusion (within 30 min prior to Day 8 SOI), EOI (0 to 15 min 
after Day 8 EOI), at 2 h (
 15 min) after SOI and at 24h (
 2 h) after SOI.  
• Day 11: One PK sample to be taken after ECG performed  
• Day 15 through and including on Day 21:  One PK sample to be taken.  Administration of 
lenalidomide30 X X  25 or 10 mg PO 
Days 1 -21 of 
each 28 -day 
cycle  
Administration of 
dexamethasone31 X X  40 or 20 mg on 
Days 1, 8, 15, 
and 22 of each 
28-day cycle  
Preservative -free artificial 
tears32 X 
Cooling eye masks32 X X  X 
Venous Thrombo -Embolism 
(VTE) prophylaxis33 X X X X 
 
Health Outcomes  
EORTC QLQ -C30 AND 
QLQ -MY2034 X  Every 8 
weeks 
starting at W9   
PRO -CTCAE34 X  X  
OSDI and NEI -VFQ-2534 X  X  
 
 
 
CCI
CCI
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 50 
 Study Assessments1 Cycle 1  Every 28 
Days  
 
(Starting at  
Week 53 
regardless of 
dosing)  Starting at  
Cycle 24 
 
(Prior to the 
first dose of 
any study 
drugs at the 
given cycle)  Notes  (Arm A belantamab mafodotin SPLIT dosing only)  
Day 12 Day 8  
Belantamab mafodotin Dose 2   
• Day 1: at pre - infusion (within 30 min prior to SOI) and EOI (0 to 15 min 
after EOI).  
If Dose 2 is delayed, collect one PK sample on this day  (Dose 1 Day 29)  
regardless of dosing . 
• Day 8: at pre - infusion (within 30 min prior to SOI) and EOI (0 to 15 min 
after EOI).  
Belantamab mafodotin Dose 3  
• Day 1: at pre - infusion (within 30 min prior to SOI) and EOI (0 to 15 min 
after EOI).  
• Day 8: at pre - infusion (within 30 min prior to SOI) and EOI (0 to 15 min 
after EOI).  
Belantamab mafodotin Dose 6   
• Day 1: at pre - infusion (within 30 min prior to SOI) and EOI (0 to 15 min 
after EOI).  
• Day 8: at pre - infusion (within 30 min prior to SOI) and EOI (0 to 15 min 
after EOI).  
Belantamab mafodotin Dose 9  
• Day 1  only: at pre - infusion (within 30 min prior to SOI).  
Belantamab mafodotin Dose 12  
• Day 1  only: at pre -infusion (within 30 min prior to S OI). 
For treatment beyond belantamab mafodotin Dose 12, pre -infusion samples will 
be collected on Day 1 only of every 6th Dose of belantamab mafodotin (Dose  18, 
Dose  24, Dose  30 and so on, until PD).  samples will be collected every 
time a belantamab mafodotin PK sample is collected. See footnote 22.  
NOTE: All pre -dosing samples must be collected on D8 even if belantamab 
mafodotin dosing is delayed.   Any samples that are pre -dose but dose not 
administered should be moved to unscheduled.  If belantamab mafodotin 
CCI
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 51 
 Study Assessments1 Cycle 1  Every 28 
Days  
 
(Starting at  
Week 53 
regardless of 
dosing)  Starting at  
Cycle 24 
 
(Prior to the 
first dose of 
any study 
drugs at the 
given cycle)  Notes  (Arm A belantamab mafodotin SPLIT dosing only)  
Day 12 Day 8  
D8 dosing is delayed  and D8 PK sampling were planned for that dose , pre-
dose and EOI sample must be taken on the day of dosing.   
27. All ADA samples will be collected prior to each belantamab mafodotin infusion 
at Dose 1, 2, 3, 6, 9 and 12 (at the same time as the pre -infusion belantamab 
mafodotin PK samples are taken); for treatment beyond 12 cycles, collect 
samples for ADA analysis prior to each infusion every 6th Dose of belantamab 
mafodotin (Dose  18, Dose  24, Dose  30 etc. until PD).  
NOTE: ADA samples only apply to Day 1 dose, not the Day 8 dose.  
28. Premedication should be considered in any participant who experienced an IRR 
during the first or any subsequent infusion with belantamab mafodotin . 
29. Belantamab  mafodotin will be administered first as a 30 min to 1  h infusion 
followed by 1 -2 h rest period. For D 1, a window of 3 days is acceptable for 
administration of study treatment after C1. For D8, belantamab mafodotin can 
be delayed an d administered any time up to D15. R efer to Section 8.2 for dose 
modification guidance . Note: “SPLIT” Dosing Schedule: belantamab mafodotin 
will be split into two equal halves and each half dose will be administer ed on D1 
and D8 of each cycle. For  example: A “2.5 mg/kg SPLIT” dosing schedule will 
administer  a 1.25 mg/kg dose on D1 and a 1.25 mg/kg dose on D8 of each 
cycle. A “3.4 mg/kg SPLIT” dosing schedule will administer  a 1.7 mg/kg dose on 
D1 and a 1.7 mg/kg dose on D8 of each cycle.  
NOTE: If the participant is unable to receive D1 dose, D8 dose must be 
withheld.  If belantamab mafodotin was administered on D1, participant 
should always receive belantamab mafodotin on D8 of any SPLIT dosing 
cycle unless the investigator determines that the parti cipant is clinically 
unfit to receive the dose (e.g., febrile neutropenia, active infection).  
30. Lenalidomide: 25 mg orally daily on Days 1 - 21 of each cycle in participants 
with >60  mL/min/1.73 m2, or reduced to 10 mg daily if the eGFR is 40 -60 
mL/min/1.73 m2. [Please refer to lenalidomide PI]. Refer to Section 8.2 for dose 
modification guidance . 
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 52 
 Study Assessments1 Cycle 1  Every 28 
Days  
 
(Starting at  
Week 53 
regardless of 
dosing)  Starting at  
Cycle 24 
 
(Prior to the 
first dose of 
any study 
drugs at the 
given cycle)  Notes  (Arm A belantamab mafodotin SPLIT dosing only)  
Day 12 Day 8  
31. Dexamethasone: 40 mg weekly, orally on Days 1, 8, 15, 22 of each cycle, 
Participants who are >75y with BMI <18.5 kg/m2, the dose of dexamethasone 
can be reduced to 20 mg weekly. If intolerance to dexamethasone develops, 
dexamethasone may be reduced to 20  mg. If 20  mg is not tolerated, the 
dexamethasone dose c an be further reduced or permanently discontinued. 
Please refer to Section 8.2 for dose modification guidance . 
On days where only lenalidomide and dexamethasone are taken at home, they 
should be taken in the morning approximately at the same time each day. On 
C1D1, lenalidomide should be administered as close as possible to the end of 
the 1 -2 h rest period after ad ministration of belantamab mafodotin and no later 
than 6 h after the end of the rest period after administration of belantamab 
mafodotin . On subsequent lenalidomide and belantamab mafodotin co-
administration days such as C2D1, C3D1 and thereafter,  lenalidomide should 
be administered after the end of the 1 -2 h rest period after administration of 
belantamab mafodotin . Participant Diary will be used to keep record of self -
administered oral study treatment(s) at home.  
32. Corneal Events Management  (SPLIT  Dose) :  
- Prophylactic preservative -free artificial tears must be administered in each eye 
at least 4 -8 times daily beginning on C1D1 until end of treatment.  In the event of 
ocular symptoms (e.g., dry eyes), the use of artificial tears may be increased up  
to every 2 hours as needed.  
- At the start of each infusion, participants may apply cooling eye masks for 
approximately 1 h or as long as tolerated.  
33. ASA or LMH or oral anticoagulants according to institutional guidance for the 
duration of treatment with lenalidomide.  
34. EORTC QLQ -C30 AND QLQ -MY20 will be collected every 8 weeks , and PRO -
CTCAE, OSDI and NEI -VFQ-25 will be collected every 4 weeks, even if cycle is 
delayed . Participants who cannot complete the self -administered version should 
use an Interviewer -Administered format. The interview may be administered 
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 53 
 Study Assessments1 Cycle 1  Every 28 
Days  
 
(Starting at  
Week 53 
regardless of 
dosing)  Starting at  
Cycle 24 
 
(Prior to the 
first dose of 
any study 
drugs at the 
given cycle)  Notes  (Arm A belantamab mafodotin SPLIT dosing only)  
Day 12 Day 8  
over the telephone. If the Interviewer -Administered format is used, it should be 
read to the participants verbatim, and participant responses should be recorded 
directly without any interpretation.   Refer to SRM for further details.  
 
Table 7 Schedule of Activities - On Study Assessments for Arm B (belantamab mafodotin in combination with bortezomib 
plus dexamethasone) [21 -Day Cycle] - belantamab mafodotin SINGLE Dosing Only  
Study Assessments1 Cycle 1  Every 21 
Days  
(Starting at  
Week 44 
regardless of 
dosing) 
 Starting at  
Cycle 25 
 
(Prior to the 
first dose of 
any study 
drugs at the 
given cycle)  Notes  (Arm B belantamab mafodotin SINGLE dosing only)  
Day 12 D4, D8 
and 
D113 
ECOG Performance Status    X  1. All assessments apply to Part 1 and 2 of the study, unless stated otherwise.  
2. Screening Assessment s do not need to be repeated on C1D1 unless 
otherwise specified.  
3. C1 D4, D8, and D11  are dosing days for bortezomib.   
4. All assessments starting at week 4 can be performed within 3 days prior to 
the scheduled date unless otherwise specified.  
5. Assessments scheduled on days of dosing should be done prior to drug 
administration, unless otherwise specified. Physical Exam must be within 72 h 
prior to 1st dose of study dr ugs to be administrated in that cycle. Body weight 
at C1D1 (prior to dosing) will be used for dose calculation of belantamab 
mafodotin .  Body weight to be measured prior to each dose. If the change of 
body weight is greater than 10%, the dose should be re -calculated based on Adverse Events/SAEs6 X X Ongoing  Ongoing  
Concomitant Medications  X X Ongoing  Ongoing  
 
Safety  
Physical Exam  X  X X5 
Ocular Exam7    X 
Vital Signs (BP, Heart rate Body 
Temperature)8 X X  X 
(must also be 
done with each 
dose of 
bortezomib)  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 54 
 Study Assessments1 Cycle 1  Every 21 
Days  
(Starting at  
Week 44 
regardless of 
dosing) 
 Starting at  
Cycle 25 
 
(Prior to the 
first dose of 
any study 
drugs at the 
given cycle)  Notes  (Arm B belantamab mafodotin SINGLE dosing only)  
Day 12 D4, D8 
and 
D113 
Body Weight (BW) and Height  BW only    BW only  the actual body weight at the time of dosing. Up to 8 cycles of bortezomib and 
dexamethasone in combination with belantamab mafodotin are allowed; after 
the 8th cycle of Bor/Dex, participants will continue belantamab mafodotin 
monotherapy until progressive disease, intolerable AEs, or death occurs.  
6. Treatment -related toxicities will be assessed for at least 70  days after the last 
dose regardless initiation of new anticancer therapy. All related SAEs are to 
be collected from conse nt through  follow -up. For reporting of ocular 
events see the guidance provided in Appendix 8. 
7. Participants will be assessed by a qualified eye care specialist ( Appendix 12 ) 
on Day 1 of eve ry cycle prior to dosing up to Dose 6 of belantamab mafodotin 
(assessment window of up to 5 days prior to dosing, but all effort should be 
made to schedule as close to belantamab mafodotin dosing as possible). If 
there are no significant ocular examination s findings, patient’s symptoms or 
vision changes at the time of Dose 6 exam, participants may have their 
ophthalmologic exams decreased to once every 3 months. If a participant 
subsequently develops vision changes or other ocular symptoms, the 
participant should be promptly evaluated by a qualified eye care specialist. In 
case of persistent ophthalmic exam findings, newly developed ocular 
symptoms or vision changes at Dose 6 exam, the participants will have further 
ophthalmologic exams, at least every cycle  until resolution (to Grade 1 or 
baseline) or more frequently as clinically indicated by the qualified eye care 
specialist. See Section 10.6.7.1  for full details of ocular exam procedures.  
8. On each belantamab mafodotin dosing day, vital signs must be assessed 
within 30 min prior to Start of Infusion (SOI), within 15  min after  End of 
Infusion (EOI), and at 1 h (15 min)  after EOI. On days where vita l sign time 
points align with PK sampling time points, vital signs should be assessed prior 
to belantamab mafodotin PK samples being drawn. Vital signs must be Hematology9 X X X X  
(must also be 
done with each 
dose of 
bortezomib)  
Clinical chemistry9 X X X X 
HbA1c  As clinically indicated  
C-reactive Protein (CRP) 9   X  
Urinalysis (dipstick)9 X  X  
Estimated Glomerular Filtration 
Rate (eGFR) by MDRD formula  X  X  
Spot urine for 
albumin/creatinine ratio10   X  
Pregnancy Test for WOCBP11 X  X X 
12-lead ECG12 X X  X 
ECHO – LVEF13   Every 12 
weeks  
(At week 13, 
25, 37, 49 and 
so on)   
 
Disease Evaluation [every 3 weeks ( 3 days) even if the cycle is delayed]14 
SPEP (Serum Protein 
Electrophoresis)    X  
Serum Kappa, lambda free LC, 
FLC ratio    X  
CC
I
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 55 
 Study Assessments1 Cycle 1  Every 21 
Days  
(Starting at  
Week 44 
regardless of 
dosing) 
 Starting at  
Cycle 25 
 
(Prior to the 
first dose of 
any study 
drugs at the 
given cycle)  Notes  (Arm B belantamab mafodotin SINGLE dosing only)  
Day 12 D4, D8 
and 
D113 
Serum Immunofixation15   At time of 
suspected CR 
then until 
suspected PD   assessed within 30  mins before and within 15 min after each dose of 
bortezomib.  
9. Hematology and  clinical  chemistry  must be repeated if not within 24 h prior to 
1st dose of study drugs to be administrated in that cycle. Hematology must 
be repeated prior to each dose of bortezomib.  Starting at C9, Hematology 
must be repeated prior to each dose of belantamab mafodotin . An additional 
hematology sample must be collected  on D15 24 h for Cycles 1 -8. On Day 1 
of any planned cycle, Absolute Neutrophil Count (ANC) must be ≥1.0×109/L 
to administer treatment. Refer to Table 27 for comprehensive list of lab tests.  
10. Albumin/creatinine ratio (Spot urine from first void) every 3 weeks 3 days 
(local lab, if local not available then central).  
11. Perform only in women of childbea ring potential (WOCBP). A serum 
pregnancy test must be performed at screening; if the test is completed within 
72 hours prior to the first dose of belantamab mafodotin , this assessment 
does not have to be repeated on C1D1. For questionable  cases, follicle -
stimulating hormone (FSH) and estradiol (as needed in WOCBP) should be 
performed at local lab to determine childbearing potential. WOCBP must have 
a negative highly sensitive serum pregnancy test within 72 hours of dosing on 
C1D1.  Subseque nt pregnancy test on dosing days may be either serum or 
urine test.  Each pregnancy test must be performed within 24 h prior to 
dosing.  
12. SINGLE ECG performed pre -infusion on belantamab mafodotin dosing days.  UPEP (Urine Protein 
Electrophoresis)  
(on 24 h collected urine)    
X  
Urine Immunofixation15   At time of 
suspected CR 
then until 
suspected PD   
Ca corrected for Albumin 
(Serum)    X  
IgG, IgM, IgA    X  
IgD/IgE16   X  
Imaging for extramedullary 
disease17   Week 13, 25, 
37, 49 and 
then if 
clinically 
indicated   
Skeletal Survey18   As clinically 
indicated   
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 56 
 Study Assessments1 Cycle 1  Every 21 
Days  
(Starting at  
Week 44 
regardless of 
dosing) 
 Starting at  
Cycle 25 
 
(Prior to the 
first dose of 
any study 
drugs at the 
given cycle)  Notes  (Arm B belantamab mafodotin SINGLE dosing only)  
Day 12 D4, D8 
and 
D113 
Whole body PET/CT    Only once at 
time of 
achieving CR 
or sCR 
(whichever 
comes first ) 
according to 
IMWG 2016   On days when belantamab mafodotin PK sampling is performed, PK samples 
should be drawn  shortly after ECG .  TRIPLICATE ECGs will be performed  as 
described below  with SINGLE ECG performed at all other times .  All ECGs 
will be collected centrally (refer to SRM for details).  
Belantamab mafodot in Dose 1 (C 1)  
D1: TRIPLICATE ECG s Pre-infusion (within 30 min prior to S OI), EOI (up to 
15 min after EOI), 2  h (±15 min) after SOI and 24  h (±2 h) after SOI.  
D4: TRIPLICATE ECG performed before PK sample.  
D11: TRIPLICATE ECG performed before PK sample.  
Belantamab mafodotin Dose 2   
D1: SINGLE ECG pre -infusion  
Belantamab mafodotin Dose 3   
D1: TRIPLICATE ECG s pre-infusion (within 30 min prior to S OI), and EOI (up 
to 15 min after EOI ). 
D4: TRIPLICATE ECG performed before PK sample.  
D11: TRIPLICATE ECG performed before PK sample.  
13. ECHO will be performed every 12 weeks ( 7 days) and locally.  
14. Disease evaluation (except imaging and skeletal survey) will continue to be 
performed, every 3 weeks ( 3 days) even if the cycle is delayed.  
15. At time of first achieving SPEP or Urine M protein ~0  g/dl (suspected CR) and 
until suspected PD after CR or stringent Complete Response ( sCR). 
16. Only in participant s with IgD/IgE myeloma  
17. Imaging is only required for participants with extramedullary disease at week 
13, 25, 37, 49 ( ±7 days ) and then if clinically indicated by either CT, MRI, or 
PET/CT per local guidance. Needs to be performed by the same method 
throughout the study as was done at baseline (i.e., if CT/PET scan was used 
as baseline, participant  needs to be followed by CT/PET scans).  Selected 
target lesion needs to be measured and followed over time. Plasmacytoma Response assessment by 
IMWG19   X  
 
Bone Marrow Tests  
BM aspirate/biopsy for Disease 
Assessment20,24   At time of 
suspected CR 
or at time of 
suspected PD 
(only if PD not 
evident 
otherwise)   
BM biopsy to confirm sCR by 
IHC   Upon 
achieving CR   
BM aspirate for  
 testing21     At time of first 
achieving 
VGPR or 
better   
 
Biomarkers  
 X   X 
CCI
CCI
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 57 
 Study Assessments1 Cycle 1  Every 21 
Days  
(Starting at  
Week 44 
regardless of 
dosing) 
 Starting at  
Cycle 25 
 
(Prior to the 
first dose of 
any study 
drugs at the 
given cycle)  Notes  (Arm B belantamab mafodotin SINGLE dosing only)  
Day 12 D4, D8 
and 
D113 
 
X  At time of 
achieving 
VGPR or 
better21  measurements should be taken from the CT portion of the PET/CT, or MRI 
scans, or dedicated CT scans where applicable . 
For participant s with only skin involvement, skin lesions should be measured 
with a ruler.  Measurement of tumor  size will be determined by the Sum of the 
Products of the maximal perpendicular diameters of measured lesions (SPD).  
18. Imaging of bones for lytic lesions by met hod aligned with institutional 
guidance (X -ray, CT or MRI). Survey results within 30 days prior to C1D1 date 
are acceptable. At later cycles, repeat as clinically indicated, or if worsening 
clinical symptoms suggest PD, by the same method used as at screen ing. 
19. Response to treatment will be assessed every 3 weeks ( 3 days), based on 
laboratory tests and imaging (if applicable), using IMWG criteria  [Kumar , 
2016 ]. 
20. Whenever CR is assessed, if possible, a further BM aspirate sample may be 
taken at the same time  for biomarker analysis . 
21. ) to be performed by the central lab at the time 
of first achieving VGPR or better. Thereafter,  should be repeated 
every 6 months until PD or CR. In case of deepening of response from VGPR 
to CR, or achieving CR without prior VGPR,  should be 
performed at the time of achieving suspected CR and repeated every 6 
months until PD . Whenever possible, a further BM aspirate sample may be 
taken at the same time for biomarker analysis . Additionally, collect blood 
plasma for analysis.   
Optional  
Optional tissue sample at PD 
for BCMA expression  and 
biomarker research24   
X  
Genetic sample25 X    
 
PK and ADA  
Pharmacokinetic blood 
sampling for belantamab 
mafodotin22,26 X26  
 X (at selected 
cycles)26 
Pharmacokinetic blood 
sampling for bortezomib27  X27    
Anti-drug antibodies (ADA)28 X28   X (at selected 
cycles)28 
 
Treatment  
Premedication if needed29 X   X 
Administration of belantamab 
mafodotin30 X   Day 1 of each 
21-day cycle  
CCI
CCI
CCI
CCI
CCI
CCI
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 58 
 Study Assessments1 Cycle 1  Every 21 
Days  
(Starting at  
Week 44 
regardless of 
dosing) 
 Starting at  
Cycle 25 
 
(Prior to the 
first dose of 
any study 
drugs at the 
given cycle)  Notes  (Arm B belantamab mafodotin SINGLE dosing only)  
Day 12 D4, D8 
and 
D113 
Administration of bortezomib31 X 1.3 
mg/m2 
SC or IV 
on Days 
1, 4, 8 
and 11 of 
each 21 -
day cycle   1.3 mg/m2 SC or 
IV on Days 1, 4, 
8 and 11 of each 
21-day cycle  24. The optional PD tissue sample should contain tumor cells , either BM aspirate 
clot, or other tissue in case of extramedullary disease. Samples will be 
submitted to central lab for BCMA analysis , any remaining bone marrow 
and/or tissue sample will be used for biomarker research . 
25. Informed consent for optional sub -studies (e.g. genetic research) must be 
obtained before collecting a sample. The sample will be collected  at the first 
opportunity after a par ticipant has met all eligibility requirement s, before/ on 
C1D1 prior to infusion.  If insufficient DNA was extracted, or the sample was 
damaged or otherwise could not be processed, the site may be requested to 
recollect the genetic sample  where applicable . 
26. PK samples to be taken in all participant s for belantamab mafodotin 
measurement on:  
Belantamab mafodotin Dose 1 (Cycle 1)   
Day 1 : at pre -infusion (within 30 min prior to S OI, EOI (0 to 15 min after EOI), 
at 2 h (± 15 min) after SOI and 24h (±2 h) after SOI.  
Day 4 : one PK sample to be taken prior to Bor/ Dex administration  
Day 11 : one PK sample to be taken prior to Bor/ Dex administration  
Belantamab mafodotin Dose 2   
Day 1 : at pre -infusion (within 30 min prior to SOI) and EOI (0 to 15 min after 
EOI).  
If Dose 2 is delayed, collect one PK sample  on this day  (Dose 1 Day 22) 
regardless of dosing . 
Belantamab mafodotin Dose 3  
Day 1 : at pre -infusion (within 30 min prior to SOI) and EOI (0 to 15 min after 
EOI),  
Day 4 : during visit to be taken prior to  Bor/Dex administration  
Day 11 : during visit to be taken prior to Bor/ Dex administration   Administration of 
dexamethasone32 X 20 mg 
PO or IV 
on Days 
1, 2, 4, 5, 
8, 9, 11, 
and 12 of 
each 21 -
day cycle   20 mg PO or IV 
on Days 1, 2, 4, 
5, 8, 9, 11, and 
12 of each 21 -
day cycle  
Preservative -free artificial 
tears33 X 
Cooling eye masks33 X   X 
Antiviral prophylaxis34 X 
 
Health Outcomes  
EORTC QLQ -C30 AND QLQ -
MY20 ( Part 1 and Part 2)35 X  Every 6 
weeks starting 
at W7  
PRO -CTCAE35 X  X  
OSDI and NEI -VFQ-2535 X  X  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 59 
 Study Assessments1 Cycle 1  Every 21 
Days  
(Starting at  
Week 44 
regardless of 
dosing) 
 Starting at  
Cycle 25 
 
(Prior to the 
first dose of 
any study 
drugs at the 
given cycle)  Notes  (Arm B belantamab mafodotin SINGLE dosing only)  
Day 12 D4, D8 
and 
D113 
 
 
 
 
 
 
 
 
 
 
 
 
 Belantamab mafodotin Dose 6   
Day 1 : at pre -infusion (within 30 min prior to SOI) and EOI (0 to 15 min after 
EOI) 
Belantamab mafodotin Dose 9 : 
Day 1:  at pre -infusion (within 30 min prior to SOI)  
Belantamab mafodotin Dose 12 : 
Day 1 : at pre -infusion (within 30 min prior to SOI).  
For treatment beyond belantamab mafodotin Dose 12, pre -infusion samples 
will be collected every 6th Dose of belantamab mafodoti n (Dose18, Dose24, 
Dose30 and so on, until PD).  samples will be collected every time a 
belantamab mafodotin PK sample is collected. See footnote 22.    
27. Bortezomib PK sampling  after the first bortezomib dose  in C1 :  
Serial PK samples will be collected at pre -dose (within 30 m in prior to 
administration) and, after the administration of bortezomib at 5 (± 1 min ), 15 
(± 1 min ), and 30 (±2 min) min,1 h (±5 min ), 2 h (±5 min ), 4 h (±5 min ), 6 h 
(±5 min ), 10 h (±2 h), 24 h (±2 h), 48 h (±2 h), and 72  h (± 2 h).The 72 h 
sample needs to be taken prior to bortezomib dosing on D4 . 
28. All ADA samples will be collected prior to each belantamab mafodotin infusion 
(at Dose 1  (C1) D1 , Dose 2, 3, 6, 9 and 12) both in Part 1 and Part 2 (at the 
same time as the pre -infusion belantamab mafodotin PK samples are taken); 
for treatment beyond 12 cycles, collect samples for ADA analysis prior to 
each infusion every 6th Dose of belantamab mafodotin (Dose  18, Dose  24, 
Dose  30 and so on, until PD).  
29. Premedication should be considered in any participant  who experienced an 
IRR during the first or any subsequent infusion s with belantamab mafodotin . 
30. Belantamab mafodotin will be administered first as a 30 min to 1 h infusion , 
followed by 1 -2 h rest period.  A window of 3 days is acceptable for 
administration of study treatment after C1 . Please refer to S ection 8.2 for 
CCI
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 60 
 Study Assessments1 Cycle 1  Every 21 
Days  
(Starting at  
Week 44 
regardless of 
dosing) 
 Starting at  
Cycle 25 
 
(Prior to the 
first dose of 
any study 
drugs at the 
given cycle)  Notes  (Arm B belantamab mafodotin SINGLE dosing only)  
Day 12 D4, D8 
and 
D113 
 
 
 
 
 
 
 
 
 
 
 
 
 dose modification guidance .  Note: “SINGLE” Dosing Schedule: belantamab 
mafodotin will be administered as a SINGLE full dose on Day 1 of each cycle. 
For example: A “2.5 mg/kg SINGLE” dosi ng schedule of belantamab 
mafodotin will administer  a 2.5 mg/kg dose on D1 of each cycle. A “3.4 mg/kg 
SINGLE” dosing schedule will administer  a 3.4 mg/kg dose on D1 of each 
cycle.  
31. Bortezomib 1.3 mg/m2 SC or IV (depending on participant s’ and institutional  
preference) on Days 1, 4, 8, and 11 of every 21 -day cycle for a total up to 8 
cycles . Please refer to S ection 8.2 for dose modification guidance . 
         Note: Participants will receive antiviral prophylaxis (for example acyclovir or 
other according to the institutional guidelines), for the entire duration of 
treatment with Bor/Dex (8 cycles).  
32. Dexamethasone 20 mg PO or IV will be given on Days 1, 2,  4, 5, 8, 9, 11, and 
12 of every 21 -day cycle. Dexamethasone will be given for a total of up to 8 
cycles.  If dexamethasone is taken at home, it should be taken approximately 
at the same time each day. Participant  Diary will be used to keep record of 
self-administer oral dexamethason e at home. Participants who are >75y with 
BMI <18.5 kg/m2, the dose of dexamethasone can be reduced to 10 mg. If 
intolerance to dexamethasone develops, dexamethasone may be reduced to 
10 mg. If 10 mg is not tolerated, the dexamethasone dose can be further 
reduced or permanently discontinued. Please refer to Section 8.2 for dose 
modification g uidance . 
33. Corneal Events Management:  
        - Prophylactic preservative -free artificial tears must be administered in each 
eye at least 4 -8 times daily beginning on C1D1  until end of treatment.  In the 
event of ocular symptoms (e.g., dry eyes), the use of artificial tears may be 
increased up to every 2 hours as needed.  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 61 
 Study Assessments1 Cycle 1  Every 21 
Days  
(Starting at  
Week 44 
regardless of 
dosing) 
 Starting at  
Cycle 25 
 
(Prior to the 
first dose of 
any study 
drugs at the 
given cycle)  Notes  (Arm B belantamab mafodotin SINGLE dosing only)  
Day 12 D4, D8 
and 
D113 
 
 
 
  - At the start of each infusion, participant s may apply cooling eye masks for 
approximately 1 h or as long as tolerated.  
34. Antivir al prophylaxis (for example acyclovir or other according to institutional 
guidelines) is required for the duration of bortezomib treatment.   
35. EORTC QLQ -C30 AND QLQ -MY20 will be collected every 6 weeks , and 
PRO -CTCAE, OSDI and NEI -VFQ-25 will be collected e very 3 weeks, even if 
cycle is delayed . Participants who cannot complete the self -administered 
version should use an Interviewer -Administered format. The interview may be 
administered over the telephone. If the Interviewer -Administered format is 
used, it s hould be read to the participants verbatim, and participant responses 
should be recorded directly without any interpretation.   Refer to SRM for 
further details.   
Table 8 Schedule of Activities - On Study Assessments for Arm B (belantamab mafodotin in combination with bortezomib 
plus dexamethasone) [21 -Day Cycle] – belantamab mafodotin SPLIT Dosing Only   
Study Assessments1 Cycle 1  Every 21 
Days  
 
(Starting at  
Week 44 
regardless of 
dosing) 
 Starting at  
Cycle 25 
 
(Prior to the 
first dose of 
any study 
drugs at the 
given cycle)   
Notes  (Arm B belantamab mafodotin SPLIT dosing only)  Day 12 D4, D8 
and 
D113 
ECOG Performance Status    X  1. All assessments apply to Part 1 and 2 of the study unless stated otherwise.  
2. Screening Assessment s do not need to be repeated on C1D1 unless 
otherwise specified.  
3. C1 D4, D8, and D11 are dosing days for bortezomib.  Adverse Events/SAEs6 X X Ongoing  Ongoing  
Concomitant Medications  X X Ongoing  Ongoing  
 
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 62 
 Study Assessments1 Cycle 1  Every 21 
Days  
 
(Starting at  
Week 44 
regardless of 
dosing) 
 Starting at  
Cycle 25 
 
(Prior to the 
first dose of 
any study 
drugs at the 
given cycle)   
Notes  (Arm B belantamab mafodotin SPLIT dosing only)  Day 12 D4, D8 
and 
D113 
Safety  4. All assessments starting at week 4 can be performed within 3 days prior to 
the scheduled date unless otherwise specified.  
5. Assessments scheduled on days of dosing should be done prior to drug 
administration, unless otherwise specified. Physical Exam must b e within 72 h 
prior to 1st dose of study drugs to be administrated in that cycle. Body weight 
at C1D1 (prior to dosing) will be used for dose calculation of belantamab 
mafodotin .  Body weight to be measured prior to each dose. If the change of 
body weight is greater than 10%, the dose should be re -calculated based on 
the actual body weight at the time of dosing.  Up to 8 cycles of bortezomib and 
dexamethasone in combination with belantamab mafodotin are allowed; after 
8 cycles of Bor/Dex, participants will b e allowed to continue on belantamab 
mafodotin monotherapy until progressive disease, intolerable AEs, or death 
occurs.  
6. Treatment -related toxicities will be assessed for at least 70  days after the last 
dose regardless initiation of new anticancer therapy. All related SAEs are to 
be collected from consent through follow -up. For reporting of ocular 
events see the guidance provided  in Appendix 8. 
7. Participants will be assessed by a qualified eye care specialist ( Appendix 12 ) 
on Day 1 of every cycle prior to dosing up to Dose 6 of belantamab mafodotin 
(assessment wi ndow of up to 5 days prior to dosing, but all effort should be 
made to schedule as close to belantamab mafodotin dosing as possible). If 
there are no significant ocular examinations findings, patient’s symptoms or 
vision changes at the time of Dose 6 exam,  participants may have their 
ophthalmologic exams decreased to once every 3 months. If a participant 
subsequently develops vision changes or other ocular symptoms, the 
participant should be promptly evaluated by a qualified eye care specialist. In 
case of persistent ophthalmic exam findings, newly developed ocular Physical Exam  X X (Day 8 
only)  X X5 
Ocular Exam7    X 
Vital Signs (BP, Heart rate Body 
Temperature)8 X X  X 
(must also be 
done with each 
dose of 
Bortezomib)  
Body Weight (BW) and Height  BW only    BW only  
Hematology9 X X X X  
(must also be 
done with each 
dose of 
Bortezomib)  
Clinical chemistry9 X X X X 
HbA1c  As clinically indicated  
C-reactive Protein (CRP) 9   X  
Urinalysis (dipstick)9 X  X  
Estimated Glomerular Filtration 
Rate (eGFR) by MDRD formula  X  X  
Spot urine for 
albumin/creatinine ratio10   X  
Pregnancy Test for WOCBP11 X  X X 
12-lead ECG12 X X  X 
ECHO  – LVEF13   Every 12 
weeks   
CCI
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 63 
 Study Assessments1 Cycle 1  Every 21 
Days  
 
(Starting at  
Week 44 
regardless of 
dosing) 
 Starting at  
Cycle 25 
 
(Prior to the 
first dose of 
any study 
drugs at the 
given cycle)   
Notes  (Arm B belantamab mafodotin SPLIT dosing only)  Day 12 D4, D8 
and 
D113 
(At week 13, 
25, 37, 49 and 
so on)  symptoms or vision changes at Dose 6 exam, the participants will have further 
ophthalmologic exams, at least every cycle until resolution (to Grade 1 or 
baseline) or more frequently as clinically indicated by the qualified eye care 
specialist. See Section 10.6.7.1  for full details of ocular exam procedures.  
8. On each belantamab mafodotin dosing  day, vital signs must be assessed 
within 30 min prior to Start of Infusion (SOI), within 15  min after End of 
Infusion (EOI), and at 1 h (± 15 min) after EOI.  On days where vital sign time 
points align with PK sampling time points, vital signs should be as sessed prior 
to belantamab mafodotin PK samples being drawn. Vital signs must be 
assessed within 30  mins before and within 15  min after each dose of 
bortezomib.  
9. Hematology and clinical chemistry must be repeated if not within 24 h prior to 
1st dose of study drugs to be adminis tered in that cycle. Hematology must be 
repeated prior to each dose of bortezomib.  Starting at C9, Hematology 
must be repeated prior to each dose of belantamab mafodotin . An additional 
hematology sample must be collected o n Day 15 24 h for Cycles 1 -8. On 
Day 1 of any planned cycle, Absolute Neutrophil Count (ANC) must be 
≥1.0×109/L to administer treatment.  Refer to Table 27 for comprehensive list 
of lab tests.   
10. Albumin/creatinine ratio (Spot urine from first void) every 3  weeks 3 days 
(local lab, if local not available then central).  
11. Perform only in women of c hildbea ring potential (WOCBP). A serum 
pregnancy test must be performed at screening; if the test is completed within 
72 hours prior to the first dose of belantamab mafodotin , this assessment 
does not have to be repeated on C1D1. For questionable cases, follicle -
stimulating hormone (FSH) and estradiol (as needed in WOCBP) should be 
performed at local lab to determine childbearing potential. WOCBP must have  
Disease Evaluation [every 3 weeks ( 3 days) even if the cycle is delayed]14 
SPEP (Serum Protein 
Electrophoresis)    X  
Serum Kappa, lambda free LC, 
FLC ratio    X  
Serum Immunofixation15   At time of 
suspected CR 
then until 
suspected PD   
UPEP (Urine Protein 
Electrophoresis)  
(on 24 h collected urine)    
X  
Urine Immunofixation15   At time of 
suspected CR 
then until 
suspected PD   
Ca corrected for Albumin 
(Serum)    X  
IgG, IgM, IgA    X  
IgD/IgE16   X  
Imaging for extramedullary 
disease17   Week 13, 25, 
37, 49 and 
then if  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 64 
 Study Assessments1 Cycle 1  Every 21 
Days  
 
(Starting at  
Week 44 
regardless of 
dosing) 
 Starting at  
Cycle 25 
 
(Prior to the 
first dose of 
any study 
drugs at the 
given cycle)   
Notes  (Arm B belantamab mafodotin SPLIT dosing only)  Day 12 D4, D8 
and 
D113 
clinically 
indicated  a negative highly se nsitive serum pregnancy test within 72 hours of dosing on 
C1D1.  Subsequent pregnancy test on dosing days may be either serum or 
urine test. Each pregnancy test must be performed within 24 h prior to dosing.  
12. SINGLE ECG performed pre -infusion on belantamab mafodotin dosing days.  
On days when belantamab mafodotin PK sampling is performed, ECGs 
should be performed prior to PK samples being drawn. TRIPLICATE ECGs 
will be performed as described below with SINGLE ECG performed at all 
other times .  All ECGs will be collected centrally (refer to SRM for details).  
Belantamab mafodotin Dose 1 (C1)  
Day 1: TRIPLICATE ECG s Pre-infusion (within 30 min prior to S OI), EOI (up 
to 15 min after EOI), 2  h (±15 min) after SOI and 24  h (±2 h) after SOI.  
Day 4: TRIPLICATE ECG performed before PK sample.  
Day 8: TRIPLICATE ECG s Pre-infusion (within 30 min prior to S OI), EOI (up 
to 15 min after EOI), 2  h (±15 min) after SOI and 24  h (±2 h) after SOI.  
Day 11: TRIPLICATE ECG performed before PK sample.  
Belantamab mafodotin Dose 2   
D1: SINGLE ECG pre -infusion  
D8: SINGLE ECG pre -infusion  
Belantamab mafodotin Dose 3  
D1: TRIPLICATE ECG s pre-infusion (within 30 min prior to S OI), EOI (up to 
15 min after EOI ). 
D4: TRIPLICATE ECG performed before PK sample.  
D8: TRIPLICATE ECG s pre-infusion (within 30 min prior to SOI), EOI (up to 
15 min after EOI ). 
D11: TRIPLICATE ECG performed before PK sample.  
13. ECHO will be performed every 12 weeks ( 7 days) and locally.  
14. Disease evaluation (except imaging and skeletal survey) will continue to  be 
performed, every 3 weeks ( 3 days) even if the cycle is delayed.  Skeletal Survey18   As clinically 
indicated   
Whole body PET/CT    Only once at 
time of 
achieving CR 
or sCR 
(whichever 
comes first ) 
according to  
IMWG 2016   
Response assessment by 
IMWG19   X  
 
Bone Marrow Tests  
BM aspirate/biopsy for Disease 
Assessment20,24   At time of 
suspected CR 
or at time of 
suspected PD 
(only if PD not 
evident 
otherwise)   
BM biopsy to confirm sCR by 
IHC   Upon 
achieving CR   
BM aspirate for  
 testing21     At time of first 
achieving 
VGPR or 
better   
CCI
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 65 
 Study Assessments1 Cycle 1  Every 21 
Days  
 
(Starting at  
Week 44 
regardless of 
dosing) 
 Starting at  
Cycle 25 
 
(Prior to the 
first dose of 
any study 
drugs at the 
given cycle)   
Notes  (Arm B belantamab mafodotin SPLIT dosing only)  Day 12 D4, D8 
and 
D113 
 15. At time of first achieving SPEP or Urine M protein ~0  g/dl (suspected CR) and 
until suspected PD after CR or stringent Complete Response ( sCR). 
16. Only in participants with IgD/IgE myeloma  
17. Imaging is only required for participants with extramedullary disease at week 
13, 25, 37, 49 ( ±7 days ) and then if clinically indicated by either CT, MRI, or 
PET/CT per local guidance. Needs to be performed by the same method 
throughout the study as was do ne at baseline (i.e., if CT/PET scan was used 
as baseline, participant needs to be followed by CT/PET scans).  Selected 
target lesion needs to be measured and followed over time. Plasmacytoma 
measurements should be taken from the CT portion of the PET/CT, or MRI 
scans, or dedicated CT scans where applicable . 
For participants with only skin involvement, skin lesions should be measured 
with a ruler.  Measurement of tumor  size will be determined by the Sum of the 
Products of the maximal perpendicular diameters  of measured lesions (SPD).  
18. Imaging of bones for lytic lesions by method aligned with institutional 
guidance (X -ray, CT or MRI). Survey results within 30 days prior to C1D1 date 
are acceptable. At later cycles, repeat as clinically indicated, or if worsen ing 
clinical symptoms suggest PD, by the same method used as at screen ing. 
19. Response to treatment will be assessed every 3 weeks ( 3 days), based on 
laboratory tests and imaging (if applicable), using IMWG criteria [Kumar , 
2016 ]. 
20. Whenever CR is assessed, if possible, a further BM aspirate sample may be 
taken at the same time  for biomarker analysis . 
21. ) to be performed by the central la b at the time 
of first achieving VGPR or better. Thereafter,  should be repeated 
every 6 months until PD or CR. In case of deepening of response from VGPR 
to CR, or achieving CR without prior VGPR,  should be 
performed at the time of achieving suspected CR and repeated every 6 Biomarkers  
X   X 
X  At time of 
achieving 
VGPR or 
better21  
 
Optional  
Optional tissue sample at PD 
for BCMA expression  and 
biomarker research24   
X  
Genetic sample23 X    
 
PK and ADA  
Pharmacokinetic blood 
sampling for belantamab 
mafodotin22,26 X26 X (Day 
8)26  X (at selected 
cycles)26 
     
Anti-drug antibodies (ADA)27 X27   X (at selected 
cycles)27 
 
Treatment  
Premedication if needed28 X X  X 
Administration of belantamab 
mafodotin29 X X (Day 
8)  Day 1 and Day 8 
of each 21 -day 
cycle  
CCI
CCI
CCI
CCI
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 66 
 Study Assessments1 Cycle 1  Every 21 
Days  
 
(Starting at  
Week 44 
regardless of 
dosing) 
 Starting at  
Cycle 25 
 
(Prior to the 
first dose of 
any study 
drugs at the 
given cycle)   
Notes  (Arm B belantamab mafodotin SPLIT dosing only)  Day 12 D4, D8 
and 
D113 
Administration of bortezomib30 X 1.3 
mg/m2 
SC or IV 
on Days 
1, 4, 8 
and 11 of 
each 21 -
day cycle   1.3 mg/m2 SC or 
IV on Days 1, 4, 
8 and 11 of each 
21-day cycle  months until PD .  Whenever possible, a further BM aspirate sample may be 
taken at the same time for biomarker analysis . Additionally, collect blood 
plasma for  analysis.    
24. The optional PD tissue sample should contain tumor cells , either BM aspirate 
clot, or other tissue in case of extramedullary disease. Samples will be 
submitted to central lab for BCMA analysis , any remaining bone marrow 
and/or tissue sample will be used for biomarker research . 
25. Informed consent for optional sub -studies (e.g. genetic research ) must be 
obtained before collecting a sample. The sample will be collected at the first 
opportunity after a participant has met all eligibility requirements, before/ on 
C1D1 prior to infusion.  If insufficient DNA was extracted, or the sample was 
damaged o r otherwise could not be processed, the site may be requested to 
recollect the genetic sample  where applicable .  
26. PK samples to be taken in all participants for belantamab mafodotin 
measurement on:  
Belantamab mafodotin Dose 1 (C1)  
• Day 1: at pre -infusion (within 30 min prior to SOI), End of Infusion (up 
to 15 min after EOI), at 2 h (± 15 min) after SOI and 24h (±2 h) after 
SOI.  
• Day 4: one PK sample to be taken prior to Bor/ Dex administration  
• Day 8: at pre -infusion (within 30 min pri or to S OI), End of Infusion (up 
to 15 min after EOI), at 2 h (± 15 min) after SOI and 24h (±2 h) after 
SOI.  
• Day 11: one PK sample to be taken prior to Bor/ Dex administration  
Belantamab mafodotin Dose 2   Administration of 
dexamethasone31 X 20 mg 
PO or IV 
on Days 
1, 2, 4, 5, 
8, 9, 11, 
and 12 of 
each 21 -
day cycle   20 mg PO or IV 
on Days 1, 2, 4, 
5, 8, 9, 11, and 
12 of each 21 -
day cycle  
Preservative -free artificial 
tears32 X 
Cooling eye masks32 X X (Day 
8)  X 
Antiviral prophylaxis33 X 
 
Health Outcomes  
EORTC QLQ -C30 AND QLQ -
MY20 ( Part 1 and Part 2 )34 X  Every 6 
weeks starting 
at W7  
PRO -CTCAE34 X  X  
OSDI and NEI -VFQ-2534 X  X  
CCI
CCI
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 67 
 Study Assessments1 Cycle 1  Every 21 
Days  
 
(Starting at  
Week 44 
regardless of 
dosing) 
 Starting at  
Cycle 25 
 
(Prior to the 
first dose of 
any study 
drugs at the 
given cycle)   
Notes  (Arm B belantamab mafodotin SPLIT dosing only)  Day 12 D4, D8 
and 
D113 
 
 
 
 
 
 
 
 
 
 
 
 
 • Day 1: at pre -infusion (within 30 min prior to SOI) and EOI (up to 15 
min after EOI).  
• If Dose 2 is delayed, collect one PK sample on this day  (Dose 1 D22 ) 
regardless of dosing . 
Belantamab mafodotin Dose 3   
• Day 1 : at pre -infusion (within 30 min prior to SO I) and EOI (up to 15 
min after EOI),  
• Day 4 : during visit to be taken prior to Bor/ Dex administration  
• Day 8 : at pre -infusion (within 30 min prior to SOI) and EOI (up to 15 
min after EOI),  
• Day 11 : during visit to be taken prior to Bor/ Dex administration  
Belantamab mafodotin Dose 6   
• Day 1: at pre -infusion (within 30 min prior to SOI) and EOI (up to 15 
min after EOI)  
Belantamab mafodotin Dose 9   
• Day 1: at pre -infusion (within 30 min prior to SOI)  
Belantamab mafodotin Dose 12   
• Day 1: at pre -infusion (within 30 min prior to SOI).  
For treatment beyond belantamab mafodotin Dose 12, pre -infusion samples 
will be collected every 6th Dose of belantamab mafodotin (Dose  18, Dose  24, 
Dose  30 and so on, until PD).  samples will be collected every time a 
belantamab mafodotin PK sample is collected. See footnote 22.  
NOTE: All pre -dosing samples must be collected on D8 even if 
belantamab mafodotin dosing is delayed.  Any samples that are pre -
dose but dose not administered should be moved to unscheduled.  If 
belantamab mafodotin D8 dosing is delayed  and D8 PK sa mpling were 
planned for that dose , pre-dose and EOI sample must be taken on the 
day of dosing.  
CCI
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 68 
 Study Assessments1 Cycle 1  Every 21 
Days  
 
(Starting at  
Week 44 
regardless of 
dosing) 
 Starting at  
Cycle 25 
 
(Prior to the 
first dose of 
any study 
drugs at the 
given cycle)   
Notes  (Arm B belantamab mafodotin SPLIT dosing only)  Day 12 D4, D8 
and 
D113 
27. All ADA samples will be collected prior to each belantamab mafodotin infusion 
(at Dose 1 (C1) Dose 2, 3, 6, 9 and 12) (at the same time as the pre -infusion 
belantamab mafodotin PK samples are taken); for treatment beyond 12 
cycles, collect samples for ADA analysis prior to each infusion every 6th Dose 
of belantamab mafodoti n ( and so on, until PD).  
NOTE: ADA samples only apply to Day 1 dose, not the Day 8 dose.  
28. Premedication should be considered in any participant who experienced an 
IRR during the first or any subsequent infusion s with belantamab mafodotin . 
29. Belantamab mafodotin administration: belantamab mafodotin will be 
administered first as a 30  min to 1  h infusion, followed by 1 -2 h rest period. 
For D1, a window of 3 days is acceptable for administration of study 
treatment after C1. For D8, belantamab mafodotin can be delayed and 
administered any time up to D15. Please refer to Section 8.2 for dose 
modification guidance . Note: “SPLIT” D osing Schedule: belantamab 
mafodotin  will be split into two equal halves and each half dose will be 
administer ed on D1 and D8 of each cycle. For example: A “2.5 mg/kg SPLIT” 
dosing schedule will administer  a 1.25 mg/kg dose on D1 and a 1.25 mg/kg 
dose on D 8 of each cycle. A “3.4 mg/kg SPLIT” dosing schedule will 
administer  a 1.7 mg/kg dose on Day 1 and a 1.7 mg/kg dose on D8 of each 
cycle.  
NOTE: If the participant is unable to receive Day 1 dose, D8 dose must 
be withheld.  If belantamab mafodotin was administered on D1, 
participant should always receive belantamab mafodotin on D8 of any 
SPLIT dosing cycle unless the investigator determines that the 
participant is clinically unfit to receive the dose (e.g., febrile 
neutropenia, active infection).   
30. Bortezomib 1.3 mg/m2 SC or IV (depending on participants’ and institutional 
preference) on Days 1, 4, 8, and 11 of every 21 -day cycle for a total up to 8 
cycles. Please refer to Section 8.2 for instructions on dose delays.  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 69 
 Study Assessments1 Cycle 1  Every 21 
Days  
 
(Starting at  
Week 44 
regardless of 
dosing) 
 Starting at  
Cycle 25 
 
(Prior to the 
first dose of 
any study 
drugs at the 
given cycle)   
Notes  (Arm B belantamab mafodotin SPLIT dosing only)  Day 12 D4, D8 
and 
D113 
Note:  Participants will receive antiviral prophylaxis (for example acyclovir or 
other according to the institutional guidelines), for the entire duration of 
treatment with Bor/Dex (8 cycles).  
31. Dexamethasone 20 mg PO or IV will be given on Days 1, 2, 4, 5, 8, 9, 11, and 
12 of every 21 -day cycle. Dexamethasone will be given for a total of up to 8 
cycles.  If dexamethasone is taken at home, it should be taken approximately 
at the same time each day. Participant Diary will be used to keep record of 
self-administer or al dexamethasone at home. Participants who are >75y with 
BMI <18.5 kg/m2, the dose of dexamethasone can be reduced to 10 mg. If 
intolerance to dexamethasone develops, dexamethasone may be reduced to 
10mg. If 10mg is not tolerated, the dexamethasone dose ca n be further 
reduced or permanently discontinued. [Please refer to Section 8.2 for details].  
32. Corneal Events Management:  
        - Prophylactic preservative -free artificial tears must be administered in each 
eye at least 4 -8 times daily beginning on C1D1  until end of treatment.  In the 
event of ocular symptoms (e.g., dry eyes), the use of artificial tears may be 
increased up to every 2 hours as needed.  
 - At the start of each infusion, participants may apply cooling eye masks for 
approximately 1 h or as long as tolerated.  
33. Antiviral prophylaxis (for example acyclovir or other according to institutional 
guidelines) is required f or the duration of bortezomib treatment.   
34. EORTC QLQ -C30 AND QLQ -MY20 will be collected every 6 weeks , and 
PRO -CTCAE, OSDI and NEI -VFQ-25 will be collected every 3 weeks, even if 
cycle is delayed . Participants who cannot complete the self -administered 
version should use an Interviewer -Administered format. The interview may be 
administered over the telephone. If the Interviewer -Administered format is 
used, it should be read to the participants verbatim, and participant responses 
should be recorded directly w ithout any interpretation.   Refer to SRM for 
further details.  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 70 
 Table 9 Schedule of Activities - On Study Assessments for Arm B ( belantamab mafodotin in combination with bortezomib 
plus dexamethasone) [ 21-day Cycle] - belantamab mafodotin STRETCH  and S/D STRETCH Dosing Only  
Study Assessments1 STRETCH  Dosing Schedule  
Every 21 Days  
 
(Starting at  
Week 74 
regardless of 
dosing) Starting at  
Cycle 35 
 
(Prior to the 
first dose of 
any study 
drugs at the 
given cycle)  Notes   
(Arm B  belantamab mafodotin STRETCH and S/D STRETCH dosing 
only Cycle 1  Cycle 2  
Day 
12 D4, D8 
and D113 Day 14 D4, D8 and 
D113 
ECOG Performance 
Status      X  1. All assessments apply to Part 1 and 2 of the study, unless stated 
otherwise.  
2. Screening Assessments do not need to be repeated on C1D1 unless 
otherwise specified.  
3. D4, D8, and D11 are dosing days for bortezomib.  
4. All assessments starting at C1D1 and week 7 can be performed 
within 3 days prior to the scheduled date unless otherwise specified.  
5. Assessments scheduled on days of dosing should be done prior to 
drug administration, unless otherwise specified. Physical Exam must 
be within 72 h prior to 1st dose of study drugs to be administrated in 
that cycle. Body weight at C1D1 (prior to dosing) will  be used for 
dose calculation of belantamab mafodotin.  Body weight to be 
measured prior to each dose. If the change of body weight is greater 
than 10%, the dose should be re -calculated based on the actual 
body weight at the time of dosing. Up to 8 cycles of bortezomib and 
dexamethasone in combination with belantamab mafodotin are 
allowed; after the 8th cycle of Bor/Dex, participants will be allowed to 
continue on belantamab mafodotin monotherapy until progressive 
disease, intolerable AEs, or death occurs.  
6. Treatment -related toxicities will be assessed for at least 70 days 
after the last dose regardless initiation of new anticancer therapy. All 
related SAEs are to be collected from consent through  follow -up. 
For reporting of ocular events see the guidance provided in 
Appendix 8. Adverse 
Events/SAEs6 X X X X Ongoing  Ongoing  
Concomitant 
Medications  X X X X Ongoing  Ongoing  
 
Safety  
Physical Exam  X  X  X X5 
Ocular Exam7   X  X X 
Vital Signs (BP, Heart 
rate Body 
Temperature)8 X X X X  X 
(must also 
be done with 
each dose of 
bortezomib)  
Body Weight (BW) 
and Height  BW 
only  BW only    BW only  
Hematology9 X X X  X  X X  
(must also 
be done with 
each dose of 
bortezomib)  
Clinical chemistry9 X X X X X X 
HbA1c  As clinically indicated  
CC
I
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 71 
 Study Assessments1 STRETCH  Dosing Schedule  
Every 21 Days  
 
(Starting at  
Week 74 
regardless of 
dosing) Starting at  
Cycle 35 
 
(Prior to the 
first dose of 
any study 
drugs at the 
given cycle)  Notes   
(Arm B  belantamab mafodotin STRETCH and S/D STRETCH dosing 
only Cycle 1  Cycle 2  
Day 
12 D4, D8 
and D113 Day 14 D4, D8 and 
D113 
C-reactive Protein 
(CRP)9     X  7. Participants will be assessed by a qualified eye care specialist 
(Appendix 12 ) on Day 1 (window of up to 5 days) of every 21 -day 
cycle up to Dose 6 of belantamab mafodotin. All effort should be 
made to schedule the ophthalmologic exams prior to and as close to 
the belantamab mafodotin dosing as possible. If there are no 
significant  ocular examinations findings, patient symptoms or vision 
changes at the time of the Dose 6 exam, participants may have their 
ophthalmologic exams decreased to once every 3 months. If a 
participant subsequently develops vision changes or other ocular 
sympt oms, the participant should be promptly evaluated by a 
qualified eye care specialist. In case of persistent ophthalmic exam 
findings, newly developed ocular symptoms or vision changes at the 
Dose 6 exam, the participants will have further ophthalmologic 
exams, at least every 21 -day cycle (regardless of dosing) until 
resolution (to Grade 1 or baseline) or more frequently as clinically 
indicated by the qualified eye care specialist. See Section 10.6.7.1  
for full details of ocular exam procedures.  
8. On each belantamab mafodotin dosing day, vital signs must be 
assessed within 30 min prior to Start of Infusion (SOI), within 15  min 
after End of Infusion (EOI) , and at 1 h ( 15 min) after EOI. On days 
where vital sign time points align with PK sampling time points, vital 
signs should be assessed prior to belantamab mafodotin PK 
samples being drawn. Vital signs must be assessed within 30  mins 
before and within 15  min after each dose of bortezomib.  
9. Hematology and clinical chemistry must be repeated if not within 24 
h prior to 1st dose of study drugs to be administrated in that cycle. 
Hematology must be repeated prior to each dose of bortezomib.  Urinalysis (dipstick)9 X    X  
Estimated Glomerular 
Filtration Rate (eGFR) 
by MDRD formula  X    
X  
Spot urine for 
albumin/creatinine 
ratio10     
X  
Pregnancy Test for 
WOCBP11 X  X  X X 
12-lead ECG12 X  X   X 
ECHO – LVEF13     Every 12 
weeks  
(At week 13, 
25, 37, 49 and 
so on)   
 
Disease Evaluation [every 3 weeks ( 3 days) even if the cycle is delayed]14 
SPEP (Serum Protein 
Electrophoresis)      X  
Serum Kappa, lambda 
free LC, FLC ratio      X  
Serum 
Immunofixation15     At time of 
suspected CR 
then until 
suspected PD   
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 72 
 Study Assessments1 STRETCH  Dosing Schedule  
Every 21 Days  
 
(Starting at  
Week 74 
regardless of 
dosing) Starting at  
Cycle 35 
 
(Prior to the 
first dose of 
any study 
drugs at the 
given cycle)  Notes   
(Arm B  belantamab mafodotin STRETCH and S/D STRETCH dosing 
only Cycle 1  Cycle 2  
Day 
12 D4, D8 
and D113 Day 14 D4, D8 and 
D113 
UPEP (Urine Protein 
Electrophoresis)  
(on 24 h collected 
urine)      
X  Starting at C9, hema tology must be repeated prior to each dose of 
belantamab mafodotin. An additional hematology sample must be 
collected on D15 24 h for Cycles 1 -8. On Day 1 of any planned 
cycle, Absolute Neutrophil Count (ANC) must be ≥1.0×109/L to 
administer treatment. Refer to Table 27 for comprehensive list of lab 
tests.  
10. Albumin/creatinine ratio (Spot urine from first void) every 3  weeks 3 
days (local lab, if local not available then central).  
11. Perform only in women of childbearing potential (WOCBP). A serum 
pregnancy test must be performed at screening; if the test is 
completed within 72 hours prior to the first dose of belantamab 
mafodot in, this assessment does not have to be repeated on C1D1. 
For questionable cases, follicle -stimulating hormone (FSH) and 
estradiol (as needed in WOCBP) should be performed at local lab to 
determine childbearing potential. WOCBP must have a negative 
highly sensitive serum pregnancy test within 72 hours of dosing on 
C1D1. Subsequent pregnancy test on dosing days may be either 
serum or urine test.  Each pregnancy test must be performed within 
24 h prior to dosing.  
12. SINGLE ECG performed pre -infusion on belantam ab mafodotin 
dosing days. All ECGs will be collected centrally (refer to SRM for 
details).  
 
13. ECHO will be performed every 12 weeks ( 7 days) and locally.  
14. Disease evaluation (except imaging and skeletal survey) will 
continue to be performed, every 3 weeks ( 3 days) even if the cycle 
is delayed.  Urine 
Immunofixation15     At time of 
suspected CR 
then until 
suspected PD   
Ca corrected for 
Albumin (Serum)      X  
IgG, IgM, IgA      X  
IgD/IgE16     X  
Imaging for 
extramedullary 
disease17     Week 13, 25, 
37, 49 and then 
if clinically 
indicated   
Skeletal Survey18     As clinically 
indicated   
Whole body PET/CT      Only once at 
time of 
achieving CR 
or sCR 
(whichever 
comes first ) 
according to 
IMWG 2016   
Response 
assessment by 
IMWG19     X  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 73 
 Study Assessments1 STRETCH  Dosing Schedule  
Every 21 Days  
 
(Starting at  
Week 74 
regardless of 
dosing) Starting at  
Cycle 35 
 
(Prior to the 
first dose of 
any study 
drugs at the 
given cycle)  Notes   
(Arm B  belantamab mafodotin STRETCH and S/D STRETCH dosing 
only Cycle 1  Cycle 2  
Day 
12 D4, D8 
and D113 Day 14 D4, D8 and 
D113 
 15. At time of first achieving SPEP or Urine M protein ~0  g/dl (suspected 
CR) and until suspected PD after CR or stringent Complete 
Response (sCR).  
16. Only in participants with IgD/IgE myeloma  
17. Imaging is only required for p articipants with extramedullary disease 
at week 13, 25, 37, 49 ( ±7 days ) and then if clinically indicated by 
either CT, MRI, or PET/CT per local guidance. Needs to be 
performed by the same method throughout the study as was done at 
baseline (i.e., if CT/PET scan was used as baseline, participant 
needs to be followed by CT/PET scans).  Selected target lesion 
needs to be measured and followed over time. Plasmacytoma 
measurements should be taken from the CT portion of the PET/CT, 
or MRI scans, or dedicate d CT scans where applicable . 
For participants with only skin involvement, skin lesions should be 
measured with a ruler.  Measurement of tumor size will be 
determined by the Sum of the Products of the maximal perpendicular 
diameters of measured lesions (SPD ).  
18. Imaging of bones for lytic lesions by method aligned with institutional 
guidance (X -ray, CT or MRI). Survey results within 30 days prior to 
C1D1 date are acceptable. At later cycles, repeat as clinically 
indicated, or if worsening clinical symptoms sug gest PD, by the 
same method used as at screening.  
19. Response to treatment will be assessed every 3 weeks ( 3 days), 
based on laboratory tests and imaging (if applicable), using IMWG 
criteria.   
20. Whenever CR is assessed, if possible, a further BM aspirate samp le 
may be taken at the same time  for biomarker analysis.  Bone Marrow Tests  
BM aspirate/biopsy for 
Disease 
Assessment20,24     At time of 
suspected CR 
or at time of 
suspected PD 
(only if PD not 
evident 
otherwise)   
BM biopsy to confirm 
sCR by IHC      Upon achieving 
CR  
BM aspirate for 
 
 testing21       At time of first 
achieving 
VGPR or better   
 
Biomarkers  
X  X   X 
X    At time of 
achieving 
VGPR or 
better21  
 
Optional  
Optional tissue 
sample at PD for 
BCMA expression and 
biomarker research24     
X  
CCI
CCI
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 74 
 Study Assessments1 STRETCH  Dosing Schedule  
Every 21 Days  
 
(Starting at  
Week 74 
regardless of 
dosing) Starting at  
Cycle 35 
 
(Prior to the 
first dose of 
any study 
drugs at the 
given cycle)  Notes   
(Arm B  belantamab mafodotin STRETCH and S/D STRETCH dosing 
only Cycle 1  Cycle 2  
Day 
12 D4, D8 
and D113 Day 14 D4, D8 and 
D113 
Genetic sample25 X      21.  to be performed by the central lab at 
the time of first achieving VGPR or better. Thereafter,  
should be repeated every 6 months until PD or CR. In case of 
deepening of response from VGPR to CR, or achieving CR without 
prior VGPR,  should be performed at the time of 
achieving suspected CR and repeated every 6 months until PD. 
Whenever possible, a further BM aspirate sample may be taken at 
the same t ime for biomarker analysis . Additionally, collect blood 
plasma for  analysis.  
24. The optional PD tissue sample should contain tumor cells, either BM 
aspirate clot, or other tissue in case of extramedullary disease. 
Samples will be submitted to central lab for BCMA analysis, any 
remaining bone marrow and/or tissue sample will be used for 
biomarker research.  
25. Informed consent for optional sub -studies (e.g. genetic research) 
must be obtained before collecting a sample. The sample will be 
collected at the first opportunity after a participant has met all 
eligibility requirements, before/ on C1D1  prior to infusion. If 
insufficient DNA was extracted, or the sample was damaged or 
otherwise could not be processed, the site may be requested to 
recollect the genetic sample where applicable.  
26. PK samples to be taken in all participants for belantamab mafo dotin  
measurement on:   
PK and ADA  
Pharmacokinetic 
blood sampling for 
belantamab 
mafodotin22,26 X26  
X26  
 X (at 
selected 
cycles)26 
       
Anti-drug antibodies 
(ADA)27 X27     X (at 
selected 
cycles)27 
 
Treatment  
Premedication if 
needed28 X     X 
Administration of 
belantamab 
mafodotin29 2.5 
mg/kg 
on 
C1D1     
 2.5 mg/ kg 
STRETCH : 
2.5 mg/kg on 
Day 1: at 
least 42 (3) 
days 
between 
consecutive 
doses of 
belantamab 
mafodotin.  
CCI
CCI
CCI
CCI
CCI
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 75 
 Study Assessments1 STRETCH  Dosing Schedule  
Every 21 Days  
 
(Starting at  
Week 74 
regardless of 
dosing) Starting at  
Cycle 35 
 
(Prior to the 
first dose of 
any study 
drugs at the 
given cycle)  Notes   
(Arm B  belantamab mafodotin STRETCH and S/D STRETCH dosing 
only Cycle 1  Cycle 2  
Day 
12 D4, D8 
and D113 Day 14 D4, D8 and 
D113 
S/D 
STRETCH : 
1.9 mg/kg on 
Day 1: at 
least 42 (3) 
days 
between 
consecutive 
doses of 
belantamab 
mafodotin.  Belantamab mafodotin Dose 1 (Cycle 1)   
• Day 1: at pre -infusion (within 30 min prior to SOI), End of 
Infusion (0 to 15 min after EOI), at 2 h (± 15 min) after SOI 
and 24h (±2 h) after SOI.  
• Day 4: one PK sample to be taken prior to Bor/Dex 
administration  
• Day 11: one PK sample to be taken prior to Bor/Dex 
administration  
• Day 22 (C2D1): one PK sample to be taken prior to Bor/Dex 
administration  
Belantamab mafodotin Dose 2   
• Day 1: at pre -infusion (within 30 min prior to SOI) and EOI (0 
to 15 min after EOI).  
• If Dose 2 is delayed, collect one PK sample on this day (Dose 
1 Day 43) regardless of dosing.  
• Day 4: one PK sample to be taken prior to Bor/Dex 
administration  
• Day 11: one PK sample to be taken prior to Bor/Dex 
administration  
Belantamab  mafodotin Dose 3  
• Day 1: at pre -infusion (within 30 min prior to SOI) and EOI (0 
to 15 min after EOI).  
• Day 22: one PK sample to be taken prior to Bor/Dex  
Belantamab mafodotin Dose 4  
• Day 1: at pre -infusion (within 30 min prior to SOI) and EOI (0 
to 15 min  after EOI).  
Belantamab mafodotin Dose 5  
• Day 1:  at pre -infusion (within 30 min prior to SOI).  1.9 
mg/kg 
on 
C1D1   
  
 1.9 mg/ kg 
STRETCH : 
1.9 mg/kg on 
Day 1 : at 
least 42 (3) 
days 
between  
consecutive 
doses of 
belantamab 
mafodotin.  
Administration of 
bortezomib30 X 1.3 mg/m2 
SC or IV 
on Days 
1, 4, 8 
and 11 of 
each 21 -
day cycle  X 1.3 mg/m2 SC 
or IV on Days 
1, 4, 8 and 11 
of each 21 -
day cycle   1.3 mg/m2 
SC or IV on 
Days 1, 4, 8 
and 11 of 
each 21 -day 
cycle  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 76 
 Study Assessments1 STRETCH  Dosing Schedule  
Every 21 Days  
 
(Starting at  
Week 74 
regardless of 
dosing) Starting at  
Cycle 35 
 
(Prior to the 
first dose of 
any study 
drugs at the 
given cycle)  Notes   
(Arm B  belantamab mafodotin STRETCH and S/D STRETCH dosing 
only Cycle 1  Cycle 2  
Day 
12 D4, D8 
and D113 Day 14 D4, D8 and 
D113 
Administration of 
dexamethasone31 X 20 mg PO 
or IV on 
Days 1, 2, 
4, 5, 8, 9, 
11, and 
12 of 
each 21 -
day cycle  X 20 mg PO or 
IV on Days 1, 
2, 4, 5, 8, 9, 
11, and 12 of 
each 21 -day 
cycle   20 mg PO or 
IV on Days 
1, 2, 4, 5, 8, 
9, 11, and 12 
of each 21 -
day cycle  Belantamab mafodotin Dose 6  
• Day 1: at pre -infusion (within 30 min prior to SOI) and EOI (0 
to 15  min after EOI)  
• Day 22: one PK sample to be taken prior to Bor/Dex  
Belantamab mafodotin Dose 9:  
• Day 1: at pre -infusion (within 30 min prior to SOI)  
For treatment beyond Dose 9 of belantamab mafodotin, pre -infusion 
samples will be collected every 3rd Dose of belantamab ma fodotin 
(Dose 12, Dose 15, Dose 18 and so on, until PD).  samples 
will be collected every time a belantamab mafodotin PK sample is 
collected. See footnote 22.   
27. All ADA samples will be collected prior to each belantamab 
mafodotin infusion (at Dose 1 ( C1) D1, Dose 2, 3, 6, 9 and 12) both 
in Part 1 and Part 2 (at the same time as the pre -infusion 
belantamab mafodotin PK samples are taken); for treatment beyond 
12 cycles, collect samples for ADA analysis prior to each infusion 
every 6th Dose of belantamab  mafodotin (Dose 18, Dose 24, Dose 
30 and so on, until PD).  
28. Premedication should be considered in any participant who 
experienced an IRR during the first or any subsequent infusion with 
belantamab mafodotin.  
29. Belantamab mafodotin will be administered first as a 30  min to 1  h 
infusion, followed by 1 -2 h rest period. A window of 
 3 days is 
acceptable for administration of study treatment after C1. Please 
refer to Section 8.2 for dose modification guidance.  Note: STRETCH  
Dosing Schedule: belantamab mafodotin will be administered as a 
full dose on D1 of every alternate 21 -day cycle. For example: A 2.5 
mg/kg STRETC H will administer a 2.5 mg/kg dose on Day 1 of every 
alternate 21 -day cycles i.e. STRETCH  (C1, C3, C5, C7 and so on) . A Preservative -free 
artificial tears32 X 
Cooling eye masks32 X  X   X 
Antiviral prophylaxis33 X 
 
Health Outcomes  
EORTC QLQ -C30 
AND QLQ -MY20 (Part 
1 and Part 2)34 X    Every 6 weeks 
starting a t W7  
PRO -CTCAE34 X    X  
OSDI and NEI -VFQ-
2534 X    X  
 
CCI
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 77 
 Study Assessments1 STRETCH  Dosing Schedule  
Every 21 Days  
 
(Starting at  
Week 74 
regardless of 
dosing) Starting at  
Cycle 35 
 
(Prior to the 
first dose of 
any study 
drugs at the 
given cycle)  Notes   
(Arm B  belantamab mafodotin STRETCH and S/D STRETCH dosing 
only Cycle 1  Cycle 2  
Day 
12 D4, D8 
and D113 Day 14 D4, D8 and 
D113 
S/D STRETCH  will administer a 2.5 mg/k g dose on C1 D1 and for 
subsequent cycles a 1.9 mg/kg dose will be admi nistered on Day 1 
of all alternate 21 -day cycles C3 onwards (C3, C5, C7 and so on) .   
1.9 mg/kg STRETCH  will administer a 1.9 mg/kg dose administered 
on Day 1 of every alternate 21 -day cycles i.e. STRETCH  (C1, C3, 
C5, C7 and so on).  
30. Bortezomib 1.3 mg/m2 SC or IV (depending on participants’ and 
institutional preference) on Days 1, 4, 8, and 11 of every 21 -day 
cycle for a total up to 8 cycles. Please refer to Section 8.2 for dose 
modification guidance.  
         Note: Participants will receive antiviral prophylaxis (for example 
acyclovir or other according to the institutional guidelines), for the 
entire duration of treatment with Bor/Dex (8 cycles).  
31. Dexamethasone 20 mg PO or IV will be given on Days 1, 2, 4, 5, 8, 
9, 11, and 12 of every 21 -day cycle. Dexamethasone will be given 
for a total of up to 8 cycles.  If dexamethasone is taken at home, it 
should be taken approximately at the same time each day . 
Participant Diary will be used to keep record of self -administer oral 
dexamethasone at home. Participants who are >75y with BMI <18.5 
kg/m2, the dose of dexamethasone can be reduced to 10 mg. If 
intolerance to dexamethasone develops, dexamethasone may be  
reduced to 10  mg. If 10  mg is not tolerated, the dexamethasone 
dose can be further reduced or permanently discontinued. Please 
refer to Section 8.2 for dose modification guidance.  
32. Corneal Events Management:  
        - Prophylactic preservative -free artificial tears must be administered 
in each eye at least 4 -8 times daily beginning on C1D1 until end of 
treatment. In the event of ocular symptoms (e.g. , dry eyes), the use 
of artificial tears may be increased up to every 2 hours as needed.  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 78 
 Study Assessments1 STRETCH  Dosing Schedule  
Every 21 Days  
 
(Starting at  
Week 74 
regardless of 
dosing) Starting at  
Cycle 35 
 
(Prior to the 
first dose of 
any study 
drugs at the 
given cycle)  Notes   
(Arm B  belantamab mafodotin STRETCH and S/D STRETCH dosing 
only Cycle 1  Cycle 2  
Day 
12 D4, D8 
and D113 Day 14 D4, D8 and 
D113 
 - At the start of each infusion, participants may apply cooling eye 
masks to for approximately 1 h or as long as tolerated.  
33. Antiviral prophylaxis (for example acyclov ir or other according to 
institutional guidelines) is required for the duration of bortezomib 
treatment.   
34. EORTC QLQ -C30 AND QLQ -MY20 will be collected every 6 weeks , 
and PRO -CTCAE, OSDI and NEI -VFQ-25 will be collected every 3 
weeks, even if cycle is dela yed. Participants who cannot complete 
the self -administered version should use an Interviewer -
Administered format. The interview may be administered over the 
telephone. If the Interviewer -Administered format is used, it should 
be read to the participants v erbatim, and participant responses 
should be recorded directly without any interpretation.   Refer to SRM 
for further details.  
 
Table 10 Schedule of Activities – End of Treatment & Follow -Up Assessments Both for Arm A (belantamab mafodotin in 
combination with lenalidomide plus dexamethasone) and Arm B (belantamab mafodotin in combination with 
bortezomib plus dexamethasone)  
Study Assessments1 End of 
Treatment 
Visit2  Follow -up 
Visit3  
Follow -
up Visit4 Notes  (Arm A and Arm B End of Treatment and Follow -up) 
ECOG Performance Status  X X  1. All assessments apply to Part 1 and 2 unless stated otherwise. All assessments 
can be performed within 3 days prior to the scheduled date unless otherwise 
specified.   Adverse Events/  SAEs 5 X X  
Concomitant Medications  X X  
 
CCI
CC
I
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 79 
 Study Assessments1 End of 
Treatment 
Visit2  Follow -up 
Visit3  
Follow -
up Visit4 Notes  (Arm A and Arm B End of Treatment and Follow -up) 
Safety  2. End of Treatment (EOT)  visit will occur within 45 days from the last dose of any 
study m edication, or prior to initiation of new anti -cancer therapy (whichever occurs 
first). AEs and SAEs will be collected up to at least 70 days after the last dose, 
either via phone or a follow up visit .  
3. The ) Follow -up Visit, (for participants who 
discontinue study treatment for a reason other than PD) should be conducted every 
4 weeks (3 days) for Arm A and every 3 weeks ( 3 days) for Arm B until 
confirmed PD, death, start of a new anticancer treatment, withdrawal of consent,  or 
end of the study whichever occurs first.  
4. The  Follow -up Visit will be performed in all participant s who 
come off treatment completely.  Participants will be followed for survival and 
subsequent anticancer therapy by chart review, p hone call, or any form of 
communication every 3 months (±7 days) until study ends.  Record the participant’s 
survival status and whether subsequent treatment for disease was given. 
Participant does not need to come in for visit.  
5. Treatment -related toxicitie s will be assessed for at least 70  days after the last dose 
of treatment regardless initiation of new anticancer therapy. All related SAEs are to 
be collected from consent through  follow -up. For reporting of ocular events see 
the guidance provided in  Appendix 8. 
6. End of Treatment visit ophthalmic exam to be performed by a qualified eye care 
specialist . Participant s with corneal signs  per the GSK scale  at the End of 
Treatment Visit will be followed once every 3  month s (7 days) by a qualified eye 
care specialist  until resolution to their baseline, starting another anti -cancer 
therapy, or up to 1 year (whichever comes first). See Section 10.6.7.1  for list of 
ophthalmic exam procedures  and Appendix 12  for qualifications and requirements 
of the eye care specialist.  
7. Refer to Table 27 for comprehensive list of lab tests.  
8. Final pregnancy test (serum or urine) must be performed in women of child -bearing 
potential at the EOT Visit, the Follow -up Visit, and (1) Arm A: 4 months  after 
the last dose of belantamab mafodotin  or 4 weeks after the last dose of 
lenalidomide, whichever is longe r; or (2) Arm B: 4 months after the last dose of 
belantamab mafodotin or 7 months after the last dose of bortezomib whichever is 
longe r (may be via a urine pregnancy test kit mailed to the participant’s home with 
results reported by telephone).  Physical Exam  X X  
Ocular Exam6 X X X 
Vital Signs (BP, Heart rate Body 
Temperature) X X  
Body Weight (BW) and Height  BW only  BW only   
Hematology7 X X  
Clinical chemistry7 X X  
HbA1c  As clinically 
indicated    
C-reactive Protein (CRP)7 X   
Urinalysis (dipstick) 7 X X  
Estimated Glomerular Filtration Rate 
(eGFR) by  MDRD formula  X   
Pregnancy Test for W OCBP8 X X X 
12-lead ECG9 X   
ECHO  – LVEF10 X   
 
Disease Evaluation11 
SPEP (Serum Protein Electrophoresis)  X X  
Serum Kappa, lambda free LC, FLC 
ratio X X  
Serum Immunofixation12 At time of 
suspected CR 
until 
suspected PD  At time of 
suspected CR 
until suspected 
PD  
UPEP (Urine Protein Electrophoresis)  
(on 24 h collected urine)  X X  
Urine Immunofixation12 At time of 
suspected 
CR, then  until 
suspected PD  At time of 
suspected CR , 
then until 
suspected PD   
Ca corrected for Albumin (Serum)  X X  
CCI
CCI
CCI
CC
I
CCI
CC
I
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 80 
 Study Assessments1 End of 
Treatment 
Visit2  Follow -up 
Visit3  
Follow -
up Visit4 Notes  (Arm A and Arm B End of Treatment and Follow -up) 
IgG, IgM, IgA  X X  9. One SINGLE  ECG at End of Treatment Visit.  
10. ECHO to be performed locally.  
11. Disease evaluation (except imaging) will continue to be performed, every 4 weeks 
(3 days) for Arm A and every 3 weeks ( 3 days) for Arm B, until confirmed PD, 
death, start of a new anticancer treatment, withdrawal of consent, or end of the 
study whichever occurs first.  
12.  At time of first achieving SPEP or Urine M protein ~0  g/dl (suspected CR) and until 
suspected PD after CR or sCR . 
13. Only in participant s with IgD/IgE myeloma . 
14. Imaging is only required for participants with known extramedullary disease by 
either CT, MRI, or PET/CT per local guidance. Needs to be performed by the same 
method throughout the study as was done at baseline (i.e., if CT/PET scan was 
used as baseline, participant  needs to be followed by CT/PET scans).  Selected 
target lesion needs to be measured and followed over time. Plasmacytoma 
measurements should be taken from the CT portion of the PET/CT, or MRI scans, 
or dedicated CT scans where applicable. A wind ow of  7days  is acceptable for 
imaging . 
For participant s with only skin involvement, skin lesions should be measured with a 
ruler.  Measurement of tumor  size will be determined by the Sum of the Products of 
the maximal perpendicular diameters of measured lesions (SPD).  
15. Imaging of bones for lytic lesions by method aligned with institutional guidance (X -
ray, CT or MRI). As clinically indicated, or if worsening clinical symptoms suggest 
PD, by the same method used as at screening . 
16. Response to treatment will b e assessed, based on laboratory tests and imaging (if 
applicable), using IMWG criteria  [Kumar , 2016 ]. 
17. Whenever CR is assessed, if possible, a further BM aspirate sample may be taken 
at the same time  for biomarker analysis.  
18.  is not to be done at each  visit.  ) 
to be performed by the central lab if the participant enters  with a VGPR or 
better. Thereafter,  should be repeated every 6 months until PD , death, 
start of a new anticancer treatment, withdrawal of consent, or end of the study  
whichever occurs first. The 6 -month window is intended to be a continuation of the 
interval whenever the  was last performed prior to participant moving IgD/IgE13 X X  
Imaging for extramedullary disease14 As clinically 
indicated  As clinically 
indicated   
Skeletal Survey15 As clinically 
indicated  As clinically 
indicated   
Response assessment by IMWG16 X X  
 
Bone Marrow Tests  
BM aspirate/biopsy for Disease 
Assessment17,19 At time of 
suspected CR 
or at time of 
suspected PD 
(only if PD not 
evident 
otherwise)  At time of 
suspected CR or 
at time of 
suspected PD 
(only if PD not 
evident 
otherwise)   
BM biopsy to confirm sCR by IHC  Only if CR has 
been achieved 
by this visit  Only if CR has 
been achieved 
by this visit   
BM aspirate for  
 testing   X18   
 
X   
X   
 
Optional  
Optional tissue sample at PD for BCMA 
expression  and biomarker research19 Optional at PD  Optional at PD   
 
PK and ADA  
Pharmacokinetic blood sampling for 
belantamab mafodotin20 X   
CCI
CCI
CCI
CCI
CCI
CCI
CC
I
CCI
CCI
CCI
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 81 
 Study Assessments1 End of 
Treatment 
Visit2 Follow -up 
Visit3  
Follow -
up Visit4 Notes  (Arm A and Arm B End of Treatment and Follow -up) 
Anti-drug antibodies (ADA)21 X   into follow -up. Whenever possible, a further BM aspirate sample may be taken 
at the same time for biomarker analysis. Additionally, collect blood plasma for 
analysis.  
19. The optional PD tissue sample should contain tumor cells , either BM aspirate clot,  
or other tissue in case of extramedullary disease. Samples will be submitted to 
central lab for BCMA analysis , any remaining bone marrow and/or tissue sample 
will be used for biomarker research . 
20. A pharmacokinetic sample will be collected from each partici pant at the EOT Visit . 
It should be accompanied by a  sample.  
21. A final ADA sample will also be drawn at the End of Treatment Visit.  
22. EORTC QLQ -C30, QLQ -MY20 , PRO -CTCAE, OSDI and NEI -VFQ-25 will be 
collected at the EOT Visit. Participants who still show corneal signs per the GSK 
scale at EOT will continue to receive the OSDI and NEI -VFQ-25 assessments 
during follow -up visit or via telephone  for up to 1 year or until ocular exams are 
completed (whichever comes first). For all measures, p articipants who can not 
complete the self -administered version should use an Interviewer -Administered 
format. The interview may be administered over the telephone. If the Interviewer -
Administered format is used, it should be read to the participants verbatim, and 
participant responses should be recorded directly without any interpretation.   Refer 
to SRM for further details.   
Health Outcomes  
EORTC QLQ -C30 AND QLQ -MY20 
(Part 1 and Part 2)22 X   
PRO -CTCAE22 X   
OSDI and NEI -VFQ-2522 X X X 
 
Others  
Survival Status phone call    X 
Subsequent anti -MM Treatment  X X 
 
Abbreviations:    
ADA = Anti -drug Antibody; BM= Bone marrow; BCMA= B -cell maturation antigen; BCVA = best -corrected visual acuity; BW = body weight; C1D1 = Cycle 1 Day 1, etc.;  
; CRP = C -reactive protein; ECHO  = Echocardiogram; EM = extramedullary; EOI = End of Infusion; EORTC QLQ -C30  = European Organisation for Research and 
Treatment of Cancer Quality of Life Questionnaire 30 -item Core module; EORTC QLQ -MY20 = European Organisation for Research and Treatment of Cancer Quality of Life 
Questionnaire 20 -item Multiple Myeloma module;  FISH= Fluorescence -in-situ hybridization; FLC = free light chain; IHC = immunohistochemistry; IMWG  = International Myeloma 
Working Group; LVEF  = Left ventricular ejection fraction; ; NEI-VFQ-25 = National Eye Institute 25 -item Visual Function Questionnaire; OSDI = Ocular 
Surface Disease Index; PD = progressive disease; PET/CT  = Positron emission tomography/computed tomography; PK = Pharmacokinetics; PO = orally; PRO -CTCAE = Patient -
Reported Outcomes Version of the Common Term Criteria for Adverse Events; QD = once/day (on specified days); SAEs  = Serious adverse events; SOI = start of infusion; SPEP = 
serum protein electrophoresis; UPEP = urine protein electrophoresis; VGPR  = Very good partial response; W OCBP = women of child -bearing potential.  
CCI
CCI
CCI
CCI
CCI
CCI
CC
I
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 82 
 4. INTRODUCTION  
4.1. Study Rationale  
The incorporation of proteasome inhibitors (PIs) and immunomodulatory drugs (IMIDs) 
into the standard of care (SoC) treatment has improved outcomes in patients with 
multiple myeloma over the past 10 years [ Kumar , 2014 ; Kumar, 2008 ; Richardson , 
2007], but most patients still eventually relapse and will require su bsequent treatments 
[Moreau , 2015].  
Bortezomib and lenalidomide are used in combination with dexamethasone to treat the 
relapsed disease . The r ecent addition of monoclonal antibodies ( elotuzumab and 
daratumumab) to the treatment paradigm has demonstrated that the results achieved can 
be improved significantly. Elotuzumab, an immunostimulatory monoclonal antibody (that 
targets signaling lymphocytic acti vation molecule F7, or SLAMF7)  has no anti -myeloma 
activity on its own, but when combined with lenal idomide -dexamethasone (Len /Dex) 
superior activity to Len /Dex alone was shown in a Phase 3 study (Eloquent -2 study) 
[Lonial , 2015]. The m edian Progression -free Survival (PFS) in the elotuzumab group was 
19.4 months, versus 14.9 months in the control group; yielding a hazard ratio (HR) for 
progression or death in the elotuzumab group of 0.70 (95%  CI: 0.57 to 0.85; p<0.001). 
The Overall Response Rate (ORR)  in the elotuzumab group was 79%, versus 66% in the 
control group (p<0.001).  
Similarly, t he addition of daratumumab to lenalidomide and dexamethasone significantly 
lengthened PFS among patients with relapsed or refractory multiple myeloma (RRMM) 
[Dimopoulos , 2016].  A median follow -up of 13.5  months, and 169 events of disease 
progression or death were observed (in 53 of 286 patients [18.5%] in the daratumumab 
group vs. 116 of 283 [41.0%] in the control group; hazard ratio, 0.37; 95% CI: 0. 27 to 
0.52; p<0.001 by stratified log -rank test). The Kaplan -Meier rate of PFS at 12 months 
was 83.2% (95% CI:  78.3 to 87.2) in the daratumumab group, compared to 60.1% (95% 
CI: 54.0 to 65.7) in the control group. A significantly higher rate of overall res ponse was 
observed in the daratumumab group than in the control group (92.9% vs. 76.4%, 
p<0.001). Daratumumab was associated with infusion -related reactions and a higher rate 
of neutropenia than the control therapy.  
Daratumumab in combination with bortezom ib and dexamethasone also resulted in 
significantly longer PFS than bortezomib and dexamethasone alone [ Dimopoulos , 2016]. 
The 12 -month PFS rate was 60.7% in the daratumumab group versus 26.9% in the 
control group. After a median follow -up period of 7.4 months, the median PFS was not 
reached in the daratumumab group, but was 7.2 months in the control group, with the HR 
for progression or death with dar atumumab vs. control, 0.39 (95% CI: 0.28 to 0.53; 
p<0.001). The rate of overall response was higher in the daratumumab group than in the 
control group (82.9% vs. 63.2%, p<0.001). Treatment with daratumumab combined with 
bortezomib plus dexamethasone  was as sociated with infusion -related reactions and 
higher rates of thrombocytopenia and neutropenia than bortezomib plus dexamethasone 
alone [ Palumbo , 2016].  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 83 
 Belantamab mafodotin  is an antibody  drug conjugate targeting B cell maturation antigen 
(BCMA) , which has demonstrated single -agent activity in the first -time-in-human trial 
(BMA117159)  [Trudel , 2018 ; Trudel , 2019 ]. The ORR was 60% (95% CI: 42.1, 76.1) 
and the median PFS was 12 months in a heavily pretr eated RRMM population (57% of 
patients had 5 or more prior lines of therapy). In the Phase 2 study 205678, at 2.5 mg/kg 
the ORR was 32% (97.5%CI: 21.7,43.6) and the median duration of response was 11.0 
months (95%CI: 4.2,NR).   
Given the previous experience with monoclonal antibodies , which exhibited lower single 
agent activity as monotherapy in similar populations, the combination therapy of 
belantamab mafodotin  with SoC agents is an attractive option to explore for patients with 
RRMM who have bee n pre -treated with at least one prior line.  The combination with 
SoC therapies (Len/Dex, or Bor /Dex) is expected to result in additive, or enhanced  
effects which could potentially translate into a deep and long lasting response over what 
has been achieved  with other available agents.  This study will evaluate the safety and 
tolerability profile of different doses and dosing schedule for belantamab mafodotin  when 
administered in combination with approved regimens of either Len/Dex  (Arm A) or 
Bor/Dex  (Arm B).  Part 2 of the study will evaluate the preliminary  clinical activity at the 
multiple dose levels  and schedules  for belantamab mafodotin  in combination with 
Len/Dex  (Arm A) or Bor/Dex  (Arm B) in additional participant s with RRMM.  
4.2. Background  
4.2.1.  Current Treatment of Multiple Myeloma  
Multiple myeloma (MM) is an incurable malignancy and accounts for 1% of all cancers 
and for 10% of all hematologic malignancies. Worldwide, approximately 103,000 new 
cases are diagnosed annually, and an estimated 30,330 new ca ses and 12,650 deaths will 
occur in the U.S. in 2016 [ Siegel , 2016]. Despite significant advances, current novel 
therapies and hematopoietic stem cell transplant (HSCT) cannot achieve cure, and most 
MM patients will die of relapse. Thus, new treatments are urgently needed.  
A variety of drugs and combination treatm ents have been evaluated and found effective 
in treating multiple myeloma [ Moreau , 2017 ; National Comprehensive Cancer Network , 
2016] ; however, most, if not all patients treated with these combinations inevitably 
relapse [Hanley , 2017; Jagannath , 2008 ; Richardson , 2003 ; Richardson , 2006]. Each 
relapse requires salvage therapy, and the duration of response (DoR) to each subsequent 
line of salvage therapy typically decreases. For example, in a retrospective chart review 
of pa tients who become refractory to bortezomib and IMIDs, the median overall survival 
(OS) time was disappointingly short (~ 9 months), with 7% achieving VGPR, 24% 
achieving partial response (PR), and 10% with stable disease after retreatment [ Kumar , 
2012]. While the main treatment goal for RRMM is usually the preservation of organ 
function, control of the disease, and maintaining quality of life, the depth of response is 
also considered a p redictor of durability of response and patient survival [ Lonial , 2014].  
There is an urgent need to develop treatment combinations with mechanism s of action 
that do not overlap with the current SoC treatments, and where cross -resistance with prior 
treatments could be overcome. This approach is exemplified by the combination of 
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 84 
 monoclonal antibodies (mAb) such as daratumumab (targeting CD38) or elotuzumab 
(targ eting signaling lymphocyte activation molecule [SLAMF7]) in combination with 
standard of care drugs [ Lokhorst , 2015 ; Lonial , 2014 ; National Comprehensive Cancer 
Network , 2016].  
The immunomodulatory agents (IMIDs) and PIs which are often administered in 
combination with dexamethasone are considered corner stone treatments for MM, and are 
therefore good candidates for combinations where additional improvements in efficacy 
could be achieved when combined with belantamab mafodotin .  
4.2.2.  Role of B -Cell Maturation Antigen in Multiple Myeloma  
B-cell maturation antigen (BCMA), also designated as tumor necrosis factor receptor 
superfamily member 17 (TNFRSF17) , is expressed on the surface of no rmal and 
malignant B lymphocytes at later stages of differentiation as they mature [ Novak , 2004]. 
Ligands targeting BCMA such as B-cell activating factor (BAFF , TNFSF13B ), along 
with a proliferation -inducing ligand (APRIL, TNFSF13) activate cell proliferation 
pathways and upregulate anti -apoptotic proteins in MM cell lines [ Bellucci , 2005 ; 
Moreaux , 2004 ; Thompson , 2000 ]. ) is present in the serum of 
MM patients  [Laurent , 2015] , and its levels have been postulated to correlate with 
response to therapy and OS [ Sanchez , 2012]. Mice deficient for BCMA are viable, have 
normal B -cell development, and exhibit normal humoral responses [ Belnoue , 2008 ; 
Jiang , 2011 ; Varfolomeev , 2004].  BCMA is widely expressed on malignant plasma cells 
in MM and to a lesser degree in other B -cell malignancies [ Tai, 2015 ; Tai, 2006]. The 
restricted expression profile of BCMA makes it a very good target for a therapeutic 
antibody with direct cell kil ling activity and expected to have limited off target effects 
[Tai, 2015].  
BCMA has been validated as a therapeutic target in MM in preclinical studies [ Tai, 
2015], and with belantamab mafodotin  as single agent. Single -agent activity of 
belantamab mafodotin  in heavily pre -treated RRMM patients has been shown in clinical 
trials [Trudel , 2019; Lonial , 2020].  
4.2.3.  Antibody -Drug Conjugate  Belantamab Mafodotin   
Belantamab mafodotin binds to BCMA and kills MM cells via a multi -modal mechanism 
including delivery of cytotoxic, MMAF (cysteine maleimidocaproyl MMAF 
[cys-mcMMAF]) to BCMA -expressing MM cells, thereby inducing apoptosis, enhancing 
antibody -dependent cellular cytotoxicity and antibody -dependent cellular phagocytosis, 
and inducing immunogenic cell death (Figure 3) [Tai, 2014; Montes De Oca , 2019]. 
Exposure of dendritic cells to tumor cells undergoing immunogenic cell death is expected 
to result in an antigen -specific T -cell response, enhancing the immunogenic response 
against MM.  
CCI
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 85 
 Figure 3 Belantamab Mafodotin Mechanism of Action  
 
ADCC /ADCP= antibody -dependent cell -mediated cytotoxicity /antibody -dependent cellular phagocytosis  
4.2.4.  Clinical Experience with Belantamab Mafodotin  
Single -agent belantamab mafodotin has demonstrated to have a strong single -agent 
activity  with a well-defined  manageable safety profile in heavily pre -treated participants 
with RRMM  (Q3W schedule via IV administration).    Safety data for single -agent 
belantamab mafodotin were pooled (data as of 20Sep2019) for study 205678 
(DREAMM -2; [STUDY_ID_REMOVED])  and suppo rtive FTIH study BMA117159 (DREAMM -1; 
[STUDY_ID_REMOVED]) , by treatment cohorts of 2.5 mg/kg and 3.4 mg/kg.  
4.2.4.1.  Clinical activity  in studies with belantamab mafodotin  monotherapy  
FTIH study BMA117159/DREAMM -1 
In the FTIH DREAMM -1 study , which consist ed of a dose esca lation phase (Part 1, 
n=38) and a dose expansion phase (Part 2, n=35), as of the primary analysis cut -off date 
of 31 August 2018, a total of 73 participants with RRMM received at least 1 dose of 
belantamab mafodotin [ GSK Document Number 2013N175128  V08, 2020 ; Trudel , 
2019]. Estimated  target engagement , as indicated by  binding >90% , was seen at 
doses of 1.92 mg/kg and higher.  
As of the efficacy cut -off date of 31 August 2018, a total of 35 participants were treated 
at the 3.4  mg/kg dose in Part 2 of the DREAMM -1 study. Participants were heavily pre -
treated: 57% of participants had 5 or more prior lin es of therapy. The ORR was 60% 
(95% CI: 42.1, 76.1): comprised of PR, 6%; VGPR, 40%; CR, 9%; and stringent CR 
(sCR), 6%. The median duration of response (DoR) was 14.3 months (95% CI: 10.6, 
NR). The median PFS (mPFS) in this population was 12.0 months (95%  CI: 3.1, not 
estimable [NE]). For participants refractory to both IMiDs and PIs (n = 32/35), the 
CCI
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 86 
 confirmed ORR was 56% (95% CI: 37.7, 73.6) and mPFS was 7.9 months (95% CI: 2.3, 
NE) [ Trudel , 2019].  
Phase II study 205678/DREAMM -2 
The ongoing Phase II study 205678/DREAMM -2 is evaluating these two IV single agent 
doses (2.5 and 3.4 mg/kg) administered Q3W until disease progression in participants 
who have failed at least 3 prio r lines of anti -myeloma therapy, including an anti -CD38 
antibody, and who are refractory to an IMiD and a proteasome inhibitor.  A total of 194 
participants received frozen drug product in the main cohort and 24 participants received 
3.4 mg/kg lyophilized drug product.  Primary analysis data from this study indicated no 
new safety signals, and the profile of adverse events was similar to the experience in the 
DREAMM -1 study for both arms. Both dose levels, 2.5 and 3.4 mg/kg, were shown to 
have a positive be nefit/risk profile [ Li, 2017; Lonial , 2020].  
As of the cut-off date of 31 January 2020 , the study met its primary endpoint for ORR in 
both the 2.5 mg/kg [ORR 31% (97.5% CI 21.7,43.6)] and 3.4 mg/kg [ORR 35% (97.5% 
CI 24.8,47.0)] frozen treatments, and the benefit of belantamab mafodotin was supported 
by the secondary endpoints.  The median DoR  was 11.0 months (95% CI: 4.2, NR)  at 2.5 
mg/kg and 6.2  months ( 95% CI: 4.8, NR) at 3.4 mg/kg. The mPFS in this population was 
2.8 months (95% CI: 1.6, 3.6) and 3.9 months (95% CI: 2.0, 5.8), respectively and the 
median Overall Survival (mOS) was 13.7 months (95% CI: 9.9, NR) at 2.5 mg/kg and 
13.8 months (95% CI: 10.0, NR) at 3.4 mg/kg. Positive clinical activity was also 
demonstrated at the 3.4 mg/kg lyophilized  dose [ ORR 52% (97.5% CI 28.9,74.5) ] [GSK 
Document Number 2013N175128  V08, 2020] . 
4.2.4.2.  Clinical Safety  in belantamab mafodotin monotherapy studies  
Single -agent belantamab mafodotin was demonstrated to have a manageable safety 
profile in heavily pre -treated  participants with RRMM. Safety data for single -agent 
belantamab mafodotin were pooled (data as of 20Sep2019) for DREAMM -2 study and 
supportive FTIH study DREAMM -1 by treatment cohorts of 2.5 mg/kg and 3.4 mg/kg  
[GSK Document Number 2013N175128  V08, 2020] . 
The most common AEs in both treatment cohorts were keratopathy (corneal epithelium 
changes observed on ophthalmic examination), thrombocytopenia and anemia. The 
incidence of AEs, including Grade 3/4 AEs was comparable between belantamab 
mafodotin 2.5 mg/kg  and 3.4 mg/kg cohorts. Adverse events leading to dose delays , and 
reductions  were less frequent in 2.5 mg/kg cohort, 51% and 32% compared with the 3.4 
mg/kg cohort, 67% and 52%, respectively. AEs leading to permanent treatment 
discontinuation occurred in 10% and 11% of participants in the 2.5 and 3.4 mg/kg 
cohorts, respectively. More participants in the 3.4 mg/kg cohort experienced SAEs ( 50%) 
and fatal SAEs (6%) compared with the 2.5 mg/kg cohort (41% and 3% , respectively ). 
Single agent belantamab mafodoti n 2.5 mg/kg was selected as the recommended dose 
based on comparable efficacy with a more favorable safety profile ( i.e. lower incidence 
of thrombocytopenia and neutropenia and less frequent dose delays or reductions) 
compared with the 3.4 mg/kg dose.  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 87 
 Adve rse Events of Special Interest  
Adverse events of special interest (AESIs) for belantamab mafodotin are corneal events, 
thrombocytopenia and infusion -related reactions, and are summarized in the IB [GSK 
Document Number 2013N175128  V08, 2020] . 
Corneal Events  
Corneal events, reported in most cases as keratopathy, blurred vision and dry eye events  
are the most frequently reported AEs with belantamab mafodotin.  
In DR EAMM -2 (data as of 31Jan2020), events in the E ye disorder s SOC occurred in 
78% of pa rticipants treated with belantamab mafodotin 2.5 mg/kg.  The most common 
ocular AEs were  keratopathy (71%, changes in corneal epithelium identified on eye 
exam, with or without symptoms ), blurred vision  (22%), and dry eye  (13%). Decreased 
vision defined as Snellen score worse than 20/50 in the better seeing eye was reported in 
18% of participant s receiving belantamab mafodotin 2.5mg/kg . Severe vision loss 
defined as 20/20 0 or worse  in the better seeing eye  was reported in 1% of participant s 
receiving belantamab mafodotin 2.5 mg/kg.  
The median time to onset of Grade 2 or above corneal findings (best corrected visual 
acuity or corneal examination) was 36 days (range: 19 to 1 43 days) in pa rticipants  
receiving belantamab mafodotin 2.5 mg/kg. The median time to resolution of these 
corneal findings was 9 1 days (range: 21 to 201 days).  
Participants with history of dry eye were more prone to develop corneal examination  
finding s. Therefore, active management of dry eye symptoms prior to and during  
treatment is recommended  (i.e. administration of preservative -free artificial tears ). 
The ocular sub -study of DREAMM -2 provided no evidence that corticosteroid eye drops 
are beneficial in  preventing or mitigating corneal events.  
Thrombocytopenia  
In DREAMM -2 (data as of 31Jan2020), t hrombocytopenic events (thrombocytopenia and 
platelet count decreased) occurred in 38% participant s treated with belantamab mafodotin 
2.5 mg/kg ; severity ranging between Grade 1 and 4. The incidence of Grade 3 bleeding 
events was low (2 %), with no Grade 4 or 5 events  reported i n participants treated with 
belantamab mafodotin 2.5 mg/kg.  
Most participants had a decrease from baseline in their platelet count s during the study. 
In general, participants who initiated treatment with lower platelet numbers tended to  
continue to have thrombocytopenia while on treatment with belantamab mafodotin.  
Infusion -related reactions  
Infusion -related reactions (IRRs) are expec ted for biologic agents. In DREAMM -2 (data 
as of 31Jan2020), IRRs occurred in 21% of participants in the belantamab mafodotin 2.5 
mg/kg, which were Grade 1 - 3 in severity. Most IRRs occurred with the first infusion 
and few participants experienced IRRs wi th subsequent infusions.  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 88 
 Although not protocol -mandated, pre -medications for IRR prophylaxis (including 
paracetamol, antihistamines, and steroids) were administered to 26%–27% of 
participants. One participant (2.5 mg/kg cohort) discontinued treatment due t o IRRs 
(Grade 3 IRRs at first and second infusion).   
4.2.4.3.  Pharmacokinetics  and Pharmacodynamic  in Humans  
The pharmacokinetics and pharmacodynamics of belantamab mafodotin (antibody -drug 
conjugate, including complex)  and total monoclonal antibody (total mAb; inc luding 
complex) were investigated in 291 participants with RRMM following IV administration 
at doses from 0.03 to 4.6 mg/kg Q3W in Study BMA117159 (n=73) and at doses of 2.5 
or 3.4 mg/kg Q3W in Study 205678 (n=218).  
Maximum concentrations (Cmax) of belanta mab mafodotin and total monoclonal 
antibody were observed at or shortly after the end of infusion (EOI) . There was limited 
accumulation (less than 2 -fold) of belantamab mafodotin during subsequent cycles.   
Belantamab mafodotin pharmacokinetics were well de scribed by a linear, two -
compartment population model, with a time -varying decrease in clearance in a population 
pharmacokinetic analysis. At Cycle 1, b elantamab mafodotin had a systemic clearance of 
0.924  L/day, steady -state volume of distribution of 10.8  L, and an elimination half -life  of 
11.8 days in participant s with RRMM in Study 205678 . Over time, clearance was 
reduced to 0.725 L/day, with an elimination half -life  of 14.0 days. The time to 50% 
change in clearance was approximately 50 days.   
No clinically significant differences in the pharmacokinetics of belantamab mafodotin 
were observed based on age (34 to 89 years), sex, race ( African American/Black and 
White ), body weight (42 to 130 kg), mild or moderate renal impairment (eGFR ≥ 
30 ml/min/1. 73m2) or mild hepatic impairment (NCI -ODWG classification ). Higher 
serum levels of 2-microglobulin, IgG, and ) and lower levels of 
albumin are associated with more advanced multiple myeloma or a higher multiple 
myeloma disease burden. H igher baseline IgG  and  levels, and lower baseline 
albumin  levels were associated with higher belantamab mafodotin clearance leading to 
lower average and trough concentrations (Ctau) of belantamab mafodotin.   
In nonclinical studies, cys -mcMMAF had li mited metabolic clearance.  In vitro  data 
suggested that belantamab mafodotin and cys -mcMMAF  are unlikely to perpetrate a 
drug-drug interaction or to be a victim of a drug -drug interaction with inhibitors or 
inducers of cytochromes (CYP) P450. Cys -mcMMAF w as an in vitro  substrate of organic 
anion transporting polypeptides (OATP)1B1 and OATP1B3, multidrug resistance 
associated proteins (MRP)1, MRP2, and MRP3, a borderline substrate of bile salt export 
pump (BSEP), and a possible substrate of P -glycoprotein ( P-gp). Following the 
administration of belantamab mafodotin to participants with RRMM, only intact cys -
mcMMAF was detected in pooled human urine, with no evidence of other MMAF -
related urinary metabolites.   
Free  levels were measured in Study BMA117159  and Study 205678 .  All 
subjects exhibited reductions in free  concentration at end of infusion compared 
to baseline at Cycle  1, with a return to near -baseline level by seven days after dosing, 
CCI
CCI
CCI
CCI
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 89 
 reflecting binding of belantamab mafodotin to .  Maximum decreases ranged 
from 2% to 97%, which were qualitatively dose -dependent, with larger reductions in free 
 at higher doses.  
Exposure -response analyses performed for Study 205678 and/or Study BMA117159 
found that ocular safety endpoints w ere most strongly associated with belantamab 
mafodotin exposure, while efficacy endpoints had a weaker association with belantamab 
mafodotin exposure. Both safety and efficacy endpoints were associated with patient 
characteristics. Belantamab mafodotin Cta u was associated with probability of corneal 
events and keratopathy. Probability of occurrence of dry eye, blurred vision, neutropenia 
and infusion related reaction were not associated with an exposure measure. In addition, 
the results of the concentration -QTc analysis demonstrated that belantamab mafodotin 
did not have a significant effect on cardiac repolarization.  
Additional information related to belantamab clinical PK, PD, and exposure -response 
relationships can be found in the Investigator’s Brochure [GSK Document Number 
2013N175128  V08, 2020]  
4.2.4.4.  Clinical Summary  
These results suggest that belantamab mafodotin  has an acceptable safety profile and 
demonstrates  significant clinical activity in RRMM that warrant s further exploration in 
combinations with SoC.  
Additional summaries of nonclinical and clinical findings and information regarding 
warnings, precautions, contraindications, adverse events, and other pertinent information 
on belantamab mafodotin  that may i mpact participant eligibility are  provided in th e 
Investigator’s Brochure [GSK Document Number  2013N175128  V08, 2020].  
4.3. Benefit/Risk Assessment  
4.3.1.  Risk Assessment  
More detailed information about the known and expected benefits and risks and 
reasonably expected adverse events of belantamab mafodotin  may be found in the 
Investigator’s Brochure; more detailed information on lenalidomide, bortezomib, or 
dexamethasone may be found in their respective package inserts , provided in the SRM.  
 
CCI
CCI
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 90 
 Table 11 Summary of Risk Assessment for the Combination Therapy of Belantamab Mafodotin  with Len/Dex ( Arm A) and 
Belantamab Mafodotin  with Bor/Dex ( Arm B) 
Potential Risk of 
Clinical Significance  Summary of Data/Rationale for Risk  Mitigation Strategy  
 
Thrombocytopenia  Belantamab mafodotin may cause transient thrombocytopenia in some 
participants  which, for most cases , recovered between doses.  
In the pooled safety population of study 205678, which included 
participants treated with belantamab mafodotin 2.5 and 3.4 mg/kg, 
thrombocytopenia was noted in 46% of participants and ranged between 
Grade 1 to 4 in severity.  
 Routine monitoring of hematologic  panels  as outlined in the SoAs.  
Supportive therapy per local medical practice ( e.g., platelet transfusion).  
Dose modification guidelines are outlined in Section  8.2. 
Pneumonitis  Non-clinical safety experiments have demonstrated the presence of 
progressive microscopic changes in the lungs (prominent alveolar 
macrophages associated with eosinophilic material; mixed 
perivascular /neutrophilic  inflammation) in rats at all doses tested.  
Cases of pneumonitis, including fatal events, have been observed with 
belantamab mafodotin although a causal association has not been 
established.  
 Monitoring for clinical  signs and symptoms related to pulmonary toxicity.  
If a participant experiences new or worsening pulmonary symptoms, (e.g., 
cough, dyspnea) without obvious etiology, further diagnostic tests and 
management should be performed as described in Section  8.2 and further 
treatment with belantamab mafodotin delayed (refer to Section  8.2). 
An overall benefit/risk assessment should be considered for the participant 
prior to continuing belantamab mafodotin treatment.  
Further diagnostic tests and management will be implemented immediately  
in cases of suspected pneumonitis  as described in Table 16.  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 91 
 Potential Risk of 
Clinical Significance  Summary of Data/Rationale for Risk  Mitigation Strategy  
Increased Infections 
due to  
Immunosuppression or 
neutropenia  In non -clinical studies, belantamab mafodotin has been associated with 
decrease in immunoglobulins in monkeys, at all doses. An increase in 
immunoglobulins was seen in rats (rats are not an antigen -specific 
species for belantamab mafodotin).  
Immunosuppress ion is frequently associated with an increased risk of 
infection. Serious and non -serious infections have been reported in 
belantamab mafodotin studies, including respiratory infections, 
pneumonia, and sepsis.  
Neutropenic events, including febrile neutrope nia have been observed 
with belantamab mafodotin.  
In a study of belantamab mafodotin in combination with lenalidomide / 
dexamethasone, two fatal cases of severe infections associated with 
neutropenia were observed. Arm A subjects include belamaf,+len/dex.  Participants with an active infection are excluded.  
Monitoring for infections and immediate treatment of immunosuppression  
according to standard practice.  
Routine monitoring of hematologic panels as outlined in the SoA.  
Supportive therapy per local medical  practice (e.g. growth factors).  
Prophylactic antibiotics, per local institutional guidance, in participants with 
Grade 3 -4 neutropenia.  
Immediate  hospitalization of participants with febrile neutropenia.  
Dose modification guidelines are outlined in Section 8.2 
Keratopathy (changes 
to the corneal 
epithelium, potentially 
resulting in vision 
changes)  Changes in corneal epithelium on ocular examination have been 
frequently observed with belantamab mafodotin  and was most commonly 
associated with keratopathy (changes in the corneal epithelium upon 
examination),  blurred vision, dry eyes , photophobia , and c hanges in 
visual acuity . 
Participants with a history of dry eye were more prone to develop 
changes in the corneal epithelium.  Active monitoring of the  corneal epithelium  and visual acuity  as outlined in  
the SoA . 
Evaluation and management by an eye care professional.  
Dose modification guidelines are outlined in Section 8.2. 
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 92 
 Potential Risk of 
Clinical Significance  Summary of Data/Rationale for Risk  Mitigation Strategy  
Based on available follow -up data, vision returned to, or near , baseline in 
most cases . 
 
Infusion -Related 
Reactions (IRR s) IRRs were reported in participants treated with belantamab mafodotin . 
Most IRRs were Grade 1 -2 and manageable with  medical  treatment.  Close monitor ing for signs of IRR.  
Consider premedication for IRR  in participants at risk . 
If an IRR occurs , follow the guidance in Section 8.2. 
Nephrotoxicity  Non-clinical safety experiments have demonstrated primary glomerular 
injury and tubular degeneration/regeneration (in rat and monkey). These 
morphologic changes were accompanied by large molecular weight 
proteinuria (albuminuria) and enzymuria. Single cell nec rosis of the 
kidney and bladder urothelium was also noted in the chronic study . The 
renal changes were dose dependent and reversible.  Severe tubular 
degeneration/regeneration and marked glomerulonephritis as a result of 
immune complex disease associated wi th ADA led to the early 
euthanasia of 1 monkey following 5 weekly doses of 10 mg/kg.  
Increase d albumin/creatinine ratio (albuminuria) has been reported in 
participants receiving belantamab mafodotin not indicative of disease 
progression and , in such cases,  appropriate monitoring and dose 
modification should be considered.  Kidney function monitoring including albumin/creatinine ratio  (ACR) . 
Educat ion of participants on  the need to maintain  adequate urinary output.  
Dose modification guidelines for increased serum creatinine and urinary 
albumin/creatinine ratio are outlined in  Section 8.2. 
 
 
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 93 
 4.3.2.  Benefit Assessment  
As of 31 August 2018 , results from the FTIH Study BMA117159 indicate that 
belantamab mafodotin  monotherapy administered at 3.4 mg/kg (n=35) is active in the 
MM participant  population and demonstrated an ORR of 60% with a 95% confidence 
interval (CI of 42.1% to 76.1%) and medi an PFS of 12 months.  Preliminary data from 
the on -going Phase II study 205678 indicate that both dose levels of belantamab 
mafodotin  (2.5 and  3.4 mg/kg) have a positive benefit/risk profile. The dose of 2.5 mg/kg 
appears to have a lower incidence of adverse events  and less frequent dose delays and 
reductions, and it results in similar efficacy with 3.4  mg/kg dose as measured by ORR . 
The combination treatment of the highly active drug belantamab mafodotin  with SoC is 
expected to result in improved outc omes, and to provide additional control of symptoms 
or disease progression.  It is reasonable to hypothesize that such combination will benefit 
MM participant s, who are refractory to currently available treatments.  
4.3.3.  Overall Benefit:Risk Conclusion  
As of Ame ndment 03 there is limited  clinical experience with the combination of 
belantamab mafodotin  with Len/Dex  and Bor/Dex . Preliminary safety data from Arm B 
of 207497  suggests that the combination of belantamab mafodotin  2.5 mg/kg IV Q3W 
with standard doses of bortezomib and dexamethasone has an acceptable safety profile, 
consistent with individual components.  Belantamab mafodotin  is a highly active agent in 
RRMM [ Trudel , 2019; Lonial , 2020]. Taking into account the measures to minimize risks 
to participants in this study, the potential risks identified in association with belantamab 
mafodotin  in combination with Len/Dex and Bor/Dex are justified  by the anticipated 
benefits that may be afforded to participants with RRMM .  
5. OBJECTIVES AND ENDPO INTS  
The purpose of this Phase I/II dose escalation/dose expansion study is to determine if 
belantamab mafodotin  can be safely administered in combination with two approved SoC 
regimes treatments for RRMM (Len/Dex or Bor/Dex in Part  1). The objective of Part 2 is 
to further evaluate the safety and preliminary clinical activity of selected doses of 
belantamab mafodotin  with Len/Dex or Bor/Dex to identify the optimal dose(s) and 
schedule for each arm  of combination treatment of belantamab mafodotin  when 
administer ed with Len/Dex, or Bor/Dex . 
The primary, secondary, and exploratory objectives, along with the corresponding 
endpoints for study 207497 are listed in Table 12. 
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 94 
 Table 12 Objectives of Study 207497 – Dose Escalation and D ose Expansion  
Objectives  Endpoints  
Primary  
Dose Escalation  
Determine safety, tolerability of belantamab 
mafodotin  in combination with either Len/Dex 
(Arm A) or Bor/Dex (Arm B) to establish a 
recommended dose range and schedule to 
evaluate in Dose Expansion for participants with 
RRMM  
 
Dose Escalation and Expansiona 
Select the dose(s) and dosing schedule for 
further investigation based on safety  and 
tolerability of belantamab mafodotin  in 
combination with either Len/Dex (Arm A) or 
Bor/Dex (Arm B) for participants with RRMM      
Number (%) of participants with DLTs.  
Number (%) of participants with AEs, 
changes i n clinical signs and laboratory 
parameters.  
 
 
 
A comprehensive determination based on 
safety  and SAE/AEs . 
Dose Expansion  
To determine preliminary clinical activity of 
belantamab mafodotin  in combination with either 
Len/Dex (Arm A) or Bor/Dex (Arm B) for 
participants with RRMM      
A specific determination based on ORR 
defined as percentage (%) of participants 
achieving PR as defined by the IMWG 
Uniform Response Criteria for MM [ Kumar , 
2016].  
Secondary  
Dose Escalation and Expansion  
To evaluate the pharmacokinetics profile of 
belantamab mafodotin  when administered in 
combination with Len/Dex (Arm A) or Bor/Dex 
(Arm B) in participants with RRMM  Belantamab mafodotin  PK parameters, as 
data permit  
To evaluate the pharmacokinetics profile of 
lenalidomide when administer ed in combination 
with belantam ab mafodotin  and dexamethasone  Lenalidomide PK parameters, as data permit 
in Cycle 1  
To evaluate the pharmacokinetics profile of 
bortezomib when administered in combination 
with belantamab mafodotin  and dexamethasone  Bortezomib PK parameters, as data perm it in 
Cycle 1  
To assess anti -drug antibodies (ADAs) against 
belantamab mafodotin  Incidence and titers of ADAs against 
belantamab mafodotin  pre-dose in Cycle 1 
and selected subsequent cycles  
To evaluate the effect and tolerability of 
belantamab mafodotin  in combination with 
Len/Dex (Arm A) or Bor/Dex (Arm B) on Changes from baseline in symptoms and 
related impacts as measured by OSDI, NEI -
VFQ-25 and PRO CTCAE  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 95 
 Objectives  Endpoints  
symptomatic adverse events in participants with 
RRMM  
To further characterize safety of belantamab  
mafodotin  administered in combination with 
Len/Dex (Arm A) or Bor/Dex (Arm B) in 
participants with RRMM  Incidence of AEs, including SAEs and AEs of 
special interest (corneal events, 
thrombocytopenia and infusion related 
reactions).  
 
Ocular findings on ophthalmic exam  
To evaluate the effect of belantamab mafodotin  
in combination with Len/Dex (Arm A) or Bor/Dex 
(Arm B) on health -related quality of life in 
participants with RRMM  Changes from baseline in health -related 
quality of life as measured by the EO RTC 
QLQ -C30 and QLQ -MY20  
CCI
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 96 
 
CCI
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 97 
 6. STUDY DESIGN  
6.1. Overall Design  
Part 1  of the study is a dose escalation phase to evaluate the safety and tolerability of up 
to 3 dose levels and up to 2 dosing schedules of belantamab mafodotin  in combination 
with two SoC regimens  (Arm A - belantamab mafodotin  with Len/De x [Figure 1] and 
Arm B - belantamab mafodotin  with Bor/Dex  [Figure 2]).   
Part 2:  
For Arm A  (belantamab mafodotin  with Len/Dex) : Part 2  of the study will further 
evaluate the safety and preliminary clinical activity of up to 2 dose levels and up to 3 
dosing schedules of belantamab mafodotin  with Len/Dex ( Table 18). Additional dosing  
schedules may be considered if subsequent analyses of PK properties and the emerging  
safety profile support the exploratio n. Preclinical data with belantamab mafodotin 
suggest significant ly greater activity  when combined with lenalidomide in in vitro and in 
vivo in two established MM xenograft models  [GSK internal data] .  We hypothesize that 
the clinical combination of belantamab mafodotin with len/dex may result in significant ly 
greater  activity than that seen with the individual  components.  Given th is and  the 
emerging preliminary clinical data from evaluation of 2.5 mg /kg dosing cohorts in 
amendm ent 2, for Arm A , the maximum planned dose of belantamab mafodotin is 2.5 
mg/kg and higher doses will not be investigated in this Arm. However, an alternate 
dosing schedule of STRETCH (Q8W) dosing may be explored for the 1.9 mg/ kg dose 
level if emerging data (from either this study or across the program) suggests that this 
schedule may further optimize the tolerability  or offers an improved benefit/risk profile . 
For Arm B (belantamab mafodotin with Bor/Dex) : Part 2  of the study will further 
evaluate the safety and preliminary clinical activity of up to 3 dose levels and up to 4 
dosing schedules of belantamab mafodotin  with Bor/Dex ( Table 18). Additional dosing 
schedules may be considered if subsequent analyses of PK properties and the emerging 
safety profile support the exploration.  For Arm  B, the maximum planned dose of 
belantamab mafodotin  is 3.4  mg/kg , and higher doses will not  be investigated in this 
study .  
Administration of belantamab mafodotin  at 2.5 mg/kg (Arm A & Arm B) and 3.4 mg/kg 
(Arm B only)  as a SINGLE dose was tested in Pr otocol  Amendment 1. It is hypothesized 
that the administration of belantamab mafodotin  split in to two equal halves with each half 
dose administered on Day 1 and Day 8 of each cycle  could result in improvement of 
benefit/risk due to ~25% reduction in the maximum concentration while maintaining 
similar exposure over a cycle compared to the administration of a full dose on Day 1. To 
facilitate this, SPLIT dosing at the 3.4 mg/kg dose lev el (administer ing 1.7 mg/kg of 
belantamab mafodotin  each at Day 1 and Day 8 of each dosing cycle) was introduced 
with Amendment 2 to deliver the same AUC of the dose with lowering of the Cmax. 
Accordingly, in addition to the planned 2.5 mg/kg SINGLE dosing  of belantamab 
mafodotin , 2.5 mg/kg SPLIT dosing at belantamab mafodotin  (admin istering 1.25 mg/kg 
of belantamab mafodotin  each at Day 1 and Day 8 of each dosing cycle) is being  tested 
under  Protocol Amendment 2 . SPLIT dosing  will continue to be tested und er Protocol 
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 98 
 Amendment 3  to help explore alternative dosing schedules in order to optimize the 
administration of belantamab mafodotin  in combination with SoC.   
Although in Amendment 2, it was planned to test the 3.4 mg/kg dose as both SINGLE & 
SPLIT doses for Arm A, as described above, preclinical data from xenograft mouse 
models and emerging clinical data from Arm A in Amendment 2 suggests greater activity 
of be lantamab mafodotin in combination with lenalidomide. Given this, in Amendment 3, 
the maximum planned dose of belantamab mafodotin  in combination with 
lenalidiomide/dexamethasone in Arm A  is 2.5 mg/kg and higher doses will not be 
investigated in Arm  A. 
For Arm B, however, w ith Amendment 3, to reduce increased exposure over time and 
potentially improve the benefit /risk for the participants , an extended inteval of 6 weeks 
(STRETCH  schedule)  between 2 consecutive planned doses of belantamab mafodotin  
will be ev aluated  in Arm B Part 2. As  6 weeks represents 3 half -lives of belantamab 
mafodotin, it  is anticipated to lead to minimal accumulation. In addition, a S tep-Down 
(S/D) STRETCH schedule with a first dose of 2.5 mg/kg at Cycle 1 Day 1 followed by 
1.9 mg/kg every 6 weeks (42 [ 3] days) from Cycle 3 onwards will also be studied as an 
alternative to 2.5 mg/kg repeating every 6 weeks (42 [3] days). Similarly , dosing 
cohort s evaluating  belantamab mafodotin  1.9 mg/kg dose  every 3 weeks (1.9 mg/kg 
SINGLE ) and 1.9 mg/kg dose every 6 weeks ( 1.9 mg/kg STRETCH ) are also being 
introduced  in Amendment 3 .   
For participants who discontinue study treatment for reasons other than PD, disease 
evaluations will continue to be performed at every 28 days  (±3 days) for Arm  A 
(belantamab mafodotin  with Len/Dex)  and at every 21 days  (±3 days) for Arm  B 
(belantamab mafodotin  with Bor/Dex) , until confirmed PD, death, start of a new 
anticancer treatment, withdrawal of consent, or end of the study, whichever occ urs first. 
After PD is documented, participants will continue to be followed for survival and 
subsequent anticancer therapy every 3 months (±7 days) until the study ends.  
Following 12 months post last subject first dose ( LSFD ), DRE AMM -6 study will move 
into the post analysis continued treatment (PACT) phase. At that time, the collection of 
new data for all recruited participants who no longer receive study treatment will stop 
entirely and the clinical trial database will be closed. Those participants sti ll benefiting 
from study drug in the opinion of their treating physician may continue to receive study 
drugs. In case the participant meets stopping criteria for belantamab mafodotin, the 
participant will discontinue all treatment and will continue to be m onitored as per 
standard of care at the participant’s particular study site. O nly SAEs, AEs leading to 
treatment discontinuation, overdose and pregnancy cases,  and pre -specified ocular data 
will be reported directly to GSK.  
6.1.1.  Arm A - Belantamab Mafodotin  with Len/Dex  
6.1.1.1.  Part 1 Dose Escalation Phase  
The modified Toxicity Probability Interval (mTPI) design [ Ji, 2010] will be  used to guide 
dose escalation in Part 1 with a slight modification ( Figure 1). Up to 2 dose levels of 
belantamab mafodotin  (1.9 mg/kg  [dose -1]; 2.5 mg/kg  [dose 1] ) and alternate dosing 
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 99 
 schedules  are planned to be evaluated in combination with the fixed dose of the Len/Dex  
treatments. Based on emerging data under Protocol Amendment 1 from  Arm A , the first 
dose investigated under  Protocol Amendment 2 was 1.9 mg/kg  (Dose Level -1). The 
design assumes the true underlying toxicity rate for maximum tolerated dose (MTD) of 
belantamab mafodotin  falls within the range from 25% to 35% and cent ers at 30%.   The 
rules for guiding dose escalations are provided in Figure 4. Columns provide the numbers 
of participants treated at the current dose level, and rows provide the corresponding 
numbers of participants experiencing toxicity. Cohorts will be recruited  in blocks of three 
participants. Participants will be treated  in a staggered approach with at least 1 day 
between each participant’s first dose of belantamab mafodotin  to minimize the risk of 
inadvertently exceeding the MTD in multiple participants.  
In Part 1 u p to 2 dose levels of belantamab mafodotin  and up to 2 dosing schedules will 
be evaluated ( Figure 1 and Table 13). Data from at least 3 DLT -evaluable participant s are 
required before a decision  is made to escalate to the next dose level . However , this is not 
required for enro llment of more participant s at the same dose level in Part 2 .   
 
Figure 4 Dose -finding Criteria for the Modified Toxicity Probability Interval 
(mTPI) Dose -Finding Method  Number of DLTs  Number of Subjects treated at current dose   
1 2 3 4 5 6 
0 E E E E E E 
1 D S S S S E 
2  
DU D S S S 
3   
DU DU D S 
4    
DU DU DU 
5     
DU DU 
6      
DU 
The spreadsheet was generated based on a beta/binomial model and precalculated before trial initiation.   The letters in 
different colors are computed based on the decision rules under the mTPI method and represent different dose -finding 
actions.   In addition to actions de -escalate the dose (D), stay at the same dose (S), and escalate the dose (E), the 
table includes action unacceptable toxicity (DU), wh ich is defined as the execution of the dose -exclusion rule in mTPI.  
Excerpted from Ji, et al. [ Ji, 2010].  
The entries of Figure 4 are dose-finding decisions (i.e., E, S, and D) representing 
escalating the dose, staying at the same dose, and de -escalating the dose.   In addition, 
decision DU means that  the current dose level is unacceptable because of high toxicity; 
the current dose level and any higher dose level should be excluded from the trial.    
For example, when 1 of 3 participants experiences toxicity, the decision can be located at 
row 1 and col umn 3, which is S – to stay at the current dose level.   Consequently, the 
next cohort of participants will be treated at the same dose level currently being used.   If 
zero of three participants experience  toxicity, the decision is at row 0 and column 3, 
which is E – to escalate.   Thus, the next cohort of participants will be treated at the next -
higher dose level.   If 3 of 3 participants experience toxicity, the decision is DU – to de -
escalate to the next -lower dose level and exclude the current dose and any  higher dose 
from the trial, because toxicity levels are unacceptable. In dose escalation (E)/de -
escalation (D), no dose skipping is allowed.  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 100 
 Table 13 Dose Levels: Arm A, Part 1  
Dose Level  Belantamab mafodotin  Lenalidomide  Dexamethasone  
Permissible 
Actions  Increase/Decrease  No changes  No changes  
Dose Level -1 
(de-escalation)  1.9 mg/kg IV q28 days  25 or 10 mg PO, QD on 
Days 1 to 21 of each 28 -
day cycle  40 or 20 mg/week PO or 
IV on Days 1, 8, 15, and 
22 of each 28 -day cycle  
Dose Level 1  2.5 mg/kg IV q28 daysa 25 or 10 mg PO, QD on 
Days 1 to 21 of each 28 -
day cycle  40 or 20 mg/week PO or 
IV on Days 1, 8, 15, and 
22 of each 28 -day cycle  
IV = intravenous; PO = orally; QD = once daily; SC = subcutaneous  
Alternate dosing schedule could be investigated such as 2.5 mg/kg SPLIT dosing schedule where belantamab 
mafodotin  will be administered at 1.25 mg/kg each on Day 1 and Day 8  
 
Any participant from Part  1 in Arm A who received at least 1 full dose of belant amab 
mafodotin  and at least 75% of planned doses of Len/Dex  by the end of Cycle 1 (Day 28 
for Arm A) is considered DLT -evaluable. Participants in Part 1 who have received less 
than 1 full dose of belantamab mafodotin , or <75% of planned doses of Len/Dex , or who 
have been withdrawn from the study for reasons other than toxicity but prior to 
completion of DLT observation period will be replaced.   
Part 1 start s with a cohort of 3 participant s at a dose level of 1.9 mg/kg  SINGLE . Safety 
data over the first cycle of treatment for each participant will be evaluated. Data from at 
least 3 DLT evaluable -participant s are required before a decision is made  to escalate to 
the next dose level . The study will enroll participants in Part 1 will have staggered start 
times, but will run simultaneously  as outlined below . If dose levels are open for both Part 
1 and Part 2, priority for enro llment will be given to Part 1.  
 
Rules for of mTPI dose escalation pertaining to Arm A only:  
• If dose escalation decision is E, enrollmen t for Part 1 will be open at 2.5 mg/kg  
SINGLE  and 2.5 mg/kg SPLIT . At the same time, Part 2 expansion could be 
opened to enrol l additional pa rticipa nts at 1.9 mg/kg  SINGLE . 
• If dose escalation decision is S, three additional participant s will be enrolled at  
1.9 mg/kg SINGLE in Part 1 to achi eve at least  6 DLT -evaluable participant s at 
1.9 mg/kg  SINGLE . After review of data from the 6 participants:  
o If dose escalation decision is E, 2.5  mg/kg SINGLE and 2.5 mg/kg SPLIT  
will be open for enrollment  in Part 1. Part 2 expansion will not be open  for 
the 1.9 mg/kg SINGLE dose level unless emerging data suggest 2.5 mg/kg 
SINGLE and 2.5mg/kg SPLIT are not tolerable . 
o If dose escalation decision is S, enrollment  will not open for dose levels 
higher than 1.9 mg/kg SINGLE  in Part 1. Part 2 expansion will be open to 
enrol l additional participant s at 1.9 mg/kg  SINGLE .  
o If dose escalation decision is D or DU, no more participants will be 
enrolled at 1.9 mg/kg SINGLE  or higher dose levels in Part 1.  
Once the 2.5 mg/kg  SINGLE  and 2.5 mg/kg SPLIT cohorts  are open for enrollment in 
Part 1, a cohort of at least 3 participants will be enrolled  for each dose . When Part 1 is 
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 101 
 filled, Part 2 expansion will open for  enrollment at 2.5 mg/kg SINGLE and 2.5 mg/kg 
SPLIT.  Data from at least 6 DLT -evaluable participants at 2.5 mg/kg SINGLE and 2.5 
mg/kg SPLIT are not required for enrollment of additional participants in Part 2.  
Operating  characteristics of the dose escalation rules are shown in  Table 14. 
 
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 102 
 Table 14 Operating Characterist ics of the Dose Escalation Rules for Arm A  
 Underlying True Toxicity Rate  Average n. of participants dosed at each dose 
level1 Prob. of Selecting as MTD2 
Scenario  1.9 SINGLE  2.5 SPLIT  2.5 SINGLE  1.9 SINGLE3 2.5 SPLIT  2.5 SINGLE  <1.9 1.9 SINGLE  2.5 SINGLE /  
2.5 SPLIT  
1 0.2 0.30 0.30 11 9 9 0.11 0.23 0.66 
2 0.2 0.30 0.35 11 9 9 0.11 0.25 0.64 
3 0.2 0.40 0.40 11 8 8 0.11 0.31 0.58 
4 0.2 0.40 0.45 11 9 9 0.11 0.34 0.56 
5 0.3 0.40 0.40 10 6 6 0.23 0.37 0.40 
6 0.3 0.40 0.45 10 6 6 0.23 0.38 0.39 
7 0.1 0.30 0.30 12 11 11 0.03 0.13 0.84 
8 0.1 0.25 0.30 12 11 11 0.03 0.11 0.86 
9 0.1 0.25 0.25 12 11 11 0.03 0.10 0.87 
10 0.1 0.20 0.20 12 11 11 0.03 0.08 0.89 
11 0.1 0.20 0.25 12 11 11 0.03 0.09 0.88 
Red: Dose too toxic/n of participants exposed to a toxic dose/prob. of selecting toxic dose as MTD  
Blue: True MTD dose/prob. of selecting true MTD as MTD  
1. Average n. of participants dosed at each dose level include n. of participants dosed in Part 2 assuming participants for each  dose level in Part 2 are enrolled before dose 
escalation decision is ma de in Part 1, except for dose 1.9 mg/kg , for which Part 2 will not open for enrollment prior to dose escalation decision.  
2. Based on participants enrolled in Part 1 and assume the underlying true MTD is 30%.  
3. Number in this column represents maximum estimate  where dose is escalated to 2.5 mg/kg but is de -escalated to 1.9 mg/kg based on Part 1 and Part 2 data from 2.5 mg/kg.  
 
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 103 
 6.1.1.2.  Dose Escalation Decisions  
During Part 1, t he decisions on dose escalation will be made based on the mTPI 
guidance, as well as the totality of the safety, pharmacokinetics data as appropriate. The 
decisions will occur following review of all available data including participant s data 
from Part 2 and joint discussion by the GSK  medical monitor, participating investigators, 
and others as described in the Dose Escalation Plan.  
The GSK study team,  which  includes but is not limited to, the GSK medical monitor, 
clinical scientist, safety physician, stat istician and clinical pharmacologist, will review 
critical safety data defined in the Dose Escalation Plan prior to making a recommendation 
for dose escalation. This includes review of all adverse events including non -DLT 
toxicities, laboratory assessments  and other defined safety evaluations, as well as PK 
and/or PD data, when appropriate. The results from the mTPI method will be included in 
the decision for dose modification as described in Section 12.4.8 .  Quality control of 
critical safety data will be described in the Dose Escalation Plan, which includes ongoing 
study monitoring visits, GSK review of the clinical database, and confirmation by 
participating investigators and/or delegate that the data are accurate and complete prior to 
making dose modification decisions.   
The GSK medical monitor, in joint discussion with participating investigators , and others 
as described in the D ose Escalation Plan will be responsible for making dose escalation 
decisions.  The dose -escalation decision and rationale for each cohort will be discussed 
with investigators during teleconference(s) and documented in writing, with copies 
maintained at each study site and in the study master file.  
6.1.1.3.  Part 2 Dose Expansion  
Once Part 2 expansion is open for the 2.5 mg/kg SINGLE and 2.5 mg/kg SPLIT dose 
levels , up to 9 participant s will be enrolled at each dos ing schedule , unless enrollment  is 
stopped based on emerging data.  
In addition, up to 12 more participants maybe potentially enrolled to evaluate an extended 
(STRETCH) dosing schedule  for belantamab mafodotin  at the 1.9 mg/kg dose level  if 
emerging data suggests that this schedule may further optimize the tolerability  or offers 
an improved benefit/risk profile . 
For STRETCH  Dosing Schedule, belantamab mafodotin will be administered FIRST 
(prior to Len/Dex) as a single dose on Day 1 of every alternate 28 -day cycle (C1, C3, C5, 
C7 and so on) as a 30 -60 min infusion, follow ed by 1 to 2 h rest period. If a planned dose 
of belantamab mafodotin was held/missed due to any reason, the next dose can be 
administered at Day 1 of the next planned 28 -day cycle, as long as the interval between 2 
consecutive doses is at least 56 ( 3) da ys.  
Safety data from all enrolled participants will be closely monitored while the study is 
ongoing. In addition, participants permanently discontinuing study treatment within the 
first two cycles due to AE s related to belantamab mafodotin  will be continuously 
monitored starting from when 5 participants are dosed at each dose level following pre -
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 104 
 defined safety stopping rules (Section 12.4.8.1 ). If safety concerns arise at a dose level, 
enrollment  will stop for that dose level and higher dose level(s) . 
6.1.2.  Arm B - Belantamab Mafodotin  with Bor/Dex  
6.1.2.1.  Part 1 Dose Escalation Phase  
A mTPI desi gn will be implemented [ Ji, 2010] to guide dose escalation in Part 1.  Up to 3 
dose levels of belantamab mafodotin  (2.5 mg/kg  [dose 1] ; 3.4 mg/kg [dose +1]; 1.9  
mg/kg [dose -1]), starting with 2.5 mg/kg, are planned to be evaluated in combination 
with the fixed dose of Bor/Dex . Cohorts will be recruited in blocks of three participants. 
Participants will be entered in a staggered approach with at least 1 day betwee n each 
participant’s first dose of belantamab mafodotin  to minimize the risk of inadvertently 
exceeding the maximum tolerated dose (MTD) in multiple participants. A maximum of 6 
participants will be assigned to each dose  (Table 15). 
Table 15 Dose Levels: Arm B, Part 1  
Treatment Group 
and Dose Level  Belantamab mafodotin  Bortezomib  Dexamethasone  
Permissible 
Actions  Increase/Decrease  No changes  No changes  
Dose Level -1 
(de-escalation)  1.9 mg/kg IV q21 days  1.3 mg/m2 SC/IV on 
Days 1, 4, 8, and 11 of 
every 21 -day cycle for a 
total of up to 8 cycles  20 mg PO or IV on Days 
1, 2, 4, 5, 8, 9, 11, and 12 
of every 21 -day cycle  for 
a total of up to 8 cycles . 
Dose Level 1 
Cohort  2.5 mg/kg IV q21 daysa 1.3 mg/m2 SC/IV on 
Days 1, 4, 8, and 11 of 
every 21 -day cycle for a 
total of up to 8 cycles  20 mg PO or IV on Days 
1, 2, 4, 5, 8, 9, 11, and 12 
of every 21 -day cycle  for 
a total of up to 8 cycles . 
Dose Level +1 
Cohort  3.4 mg/kg IV q21 daysb 1.3 mg/m2 SC/IV on 
Days 1, 4, 8, and 11 of 
every 21 -day cycle for a 
total of up to 8 cycles  20 mg PO or IV on Days 
1, 2, 4, 5, 8, 9, 11, and 12 
of every 21 -day cycle  for 
a total of up to 8 cycles . 
IV = intravenous; PO = orally; QD = once daily; SC = subcutaneous  
a. Alternate dosing schedule could be investigated such as SPLIT dosing schedule where belantamab mafodotin  
will be administered at 1.25 mg/kg each on Day 1 and Day 8  
b. Alternate dosing schedule could be investigated such as SPLIT dosing schedule where belantamab mafodotin  
will be administered at 1.7 mg/kg each on Day 1 and Day 8  
 
Evaluation of the available safety data over the first cycle of treatment for each 
participant enrolled in that dose level is required from at least 3 participants before a 
decision is made to enrol l additional participants at the same or the subsequent dose level.  
However , this is not required for enrollment  of more participants at the same dose level in 
Part 2.  
The mTPI rule applied is explained in Section 6.1.1.1 . 
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 105 
 An additional dose  level -1 of 1.9 mg/kg may be evaluated in case the starting dose of 
2.5 mg/kg is considered not tolerated.  
Rules for mTPI  dose escalation  pertaining to Arm B only : 
• If 2.5 mg/kg is the current dose level and the decision is S, and if less than 6 
participants have been evaluated for DLT and the planned maximum sample size is 
not reached, an additional cohort of 3 participants will be enrolled for DLT 
evaluation. If the dose escalation decision is S after this additional cohort, dose 
escalation is complete . 
• If 2.5 mg /kg is the current dose level and the decision is U or DU, additional lower 
dose (e.g., 1.9 mg/kg) may be explored. If the dose of 1.9 mg/kg is not tolerated (i.e., 
results in excessive toxicity) the trial will be terminated early for lack of tolerability.   
• If 3.4 mg/kg is the current dose level and the decision is E or S, and if less than 6 
participants have been evaluated for DLT at the current dose, and the planned 
maximum sample size is not reached, an additional cohort of 3 participants will be 
evaluat ed for DLT at the current dose. If dose escalation is E or S after this additional 
cohort, dose escalation is complete.  
• Otherwise, the dose escalation will continue until the planned maximum sample size 
(12 DLT -evaluable participants for each treatment) i s reached. At the end of dose 
escalation, the rule proposed by Ji, et al. [ Ji, 2010] used to guide the selection of the 
estimated MTD, from dose levels at which 3 o r more participants have been evaluated 
for DLT.  
During Part 1, the decisions on dose escalation will be made based on this guidance, as 
well as the totality of the safety, pharmacokinetics data as appropriate.  
The decisions will occur following review of  these data and joint discussion by the GSK 
medical monitor, participating investigators, and others as described in the Dose 
Escalation Plan . 
Any participant in Arm  B who received at least 1 full dose of belantamab mafodotin  and 
75% of planned doses of Bor/Dex by the end of Cycle 1 (Day 21) will be evaluated for 
DLTs.  Participants who have received less than 1 full dose of belantamab mafodotin , or 
<75% of planned doses of Bor/Dex , or who have been withdrawn from the study for 
reasons other than toxicity  but prior to completion of DLT observation period will be 
replaced.   
The dose escalation of belantamab mafodotin  will not include doses higher than 3.4 
mg/kg.  
6.1.2.2.  Dose Escalation Decisions  
The GSK study team, which includes but is not limited to, the GSK med ical monitor, 
clinical scientist, safety physician, statistician and clinical pharmacologist, will review 
critical safety data defined in the Dose Escalation Plan prior to making a recommendation 
for dose escalation. This includes review of all adverse eve nts including non -DLT 
toxicities, laboratory assessments and other defined safety evaluations, as well as PK 
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 106 
 and/or PD data, when appropriate. The results from the mTPI method will be included in 
the decision for dose modification as described in Section 12.4.8 .  Quality control of 
critical safety data will be described in the Dose Escalation Plan, which includes ongoing 
study monitoring visits, GSK review of the clinical database, and confirmation by 
participating investigators and/or delegate that the data are  accurate and complete prior to 
making dose modification decisions.   
The GSK medical monitor, in joint discussion with participating investigators and GSK 
study team, will be responsible for making dose escalation decisions.  The dose -
escalation decision and rationale for each cohort will be discussed with investigators 
during teleconference(s) and documented in writing, with copies maintained at each study 
site and in the study master file.  
6.1.2.3.  Part 2 Dose Expansion  
In Part 2 enrollment  will proceed in multip le expansion cohorts to further evaluate the 
safety profile and to evaluate the preliminary clinical activity of belantamab mafodotin  in 
combination with Bor/Dex at 3 dose levels and 4 dosing schedules  (2.5 mg/kg SPLIT, 2.5 
mg/kg  SINGLE , 3.4 mg/kg SPLIT , 3.4 mg/kg  SINGLE , 2.5 mg/kg STRETCH , S/D 
STRETCH , 1.9 mg/kg SINGLE  and 1.9 mg/kg STRETCH ) (Figure 2).   
In Amendment 2, enrollment of each cohort was conducted by blocks  of 3 participants 
each at 2.5  mg/kg SPLIT , 2.5 mg/kg SINGLE , 3.4 mg/kg  SPLIT , and 3.4 mg/kg SINGLE  
with Bor/ Dex for up to  12 participants  each at 2.5 mg/kg SPLIT, 2.5 mg/kg SINGLE, 3.4 
mg/kg SPLIT and up to 9 participants at 3.4 mg/kg SINGLE .  
Similarly , in Amendment 3, enrollment of each cohort will be conducted by blocks of 3 
participants each in 2.5 mg/kg STRETCH , S/D STRETCH , 1.9 mg/kg SINGLE and 1.9 
mg/kg STRETCH, until approximately  12 participants  are enrolled in each cohort.  
For the SINGLE dosing schedule, belantamab mafodotin  will be administered as a 
SINGLE full dose on Day 1 of each 21-day cycle. For example: A 3.4 mg/kg SINGLE 
dosing schedule will administer a 3.4 mg/kg dose on Day 1 of each cycle.  A 2.5 mg/kg 
SINGLE dosin g schedule of belantamab mafodotin  will administer a 2.5 mg/kg dose on 
Day 1 of each cycle. A 1.9 mg/kg  SINGLE  dosing schedule of belantamab mafodotin 
will administer a 1.9 mg/kg dose on Day 1 of each cycle  
For the SPLIT dosing schedule, belantamab mafodot in will be split into two equal halves 
and each half dose will be administered on Day 1 and Day 8 of each 21-day cycle. For 
example: A “2.5 mg/kg SPLIT” dosing schedule will administer a 1.25 mg/kg dose on 
Day 1 and a 1.25 mg/kg dose on Day 8 of each cycle. A “3.4 mg/kg SPLIT” dosing 
schedule will administer a 1.7 mg/kg dose on Day 1 and a 1.7 mg/kg dose on Day 8 of 
each cycle.  
For STRETCH  Dosing Schedule, belantamab mafodotin will be administered FIRST 
(prior to Bor/Dex) as a single dose on Day 1 of e very alternate  21-day cycle (C1, C3, C5, 
C7 and so on) as a 30 -60 min infusion, followed by 1 to 2 h rest period. If a planned dose 
of belantamab mafodotin was held/missed due to any reason, the next dose can be 
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 107 
 administered at Day 1 of the next planned 21 -day cycle, as long as the interval between 2 
consecutive doses is at least 42 ( 3) days.   
For the S /D STRETCH s chedule, belantamab mafodotin will be administered FIRST 
(prior to Bor/Dex) as a 2.5 mg/kg dose on Day 1 of Cycle 1, followed by  1.9 mg/kg S/D 
dose on Day 1 of all subsequent alternate 21 -day cycles  (C3, C5, C7 and so on) , as a 30 -
60 min infusion, followed by 1 to 2 h rest period.   
Safety data from all enrolled participants will be closely monitored while the study is 
ongoing. In addition, participants permanently discontinuing study treatment within the 
first two cycles due to AE s related to belantamab mafodotin  will be continuously 
monitored starting from when 5 participants are dosed at each dose level following pre -
defined safety stoppin g rules (Section 12.4.8.2 ). If safety concerns arise at a dose level, 
enrollment  will stop for that dose level and higher dose level(s).  
6.1.3.  Criteria for Belantamab Mafodotin  DLT in Part 1  
Any participant in Part 1 who received at least 1 full dose of belantamab mafodotin  and 
≥75% of the planned doses of the combination with Len/Dex (Arm  A), or Bor/Dex 
(Arm  B) in Cycle 1 will be evaluated for DLTs using NCI -CTCAE Vers ion 4.03 
[National Cancer Institute , 2010]. Any participant that experiences a DLT in Cycle 1 
prior to receiving a full dos e of belantamab mafodotin  or <75% of the respective Arm 
SoC (Len/Dex – Arm A or Bor/Dex – Arm B) will also be considered DLT -evaluable. 
Participants that are not DLT -evaluable will be replaced.  
Dose -limiting toxicity (DLT) is assessed during DLT observatio n period defined as 
follows:   
• The first 28 days (=  1 cycle) for Arm A   
• The first 21 days (=  1 cycle) for Arm B  
An event will be considered a DLT if it is attributed (definitely, probably, or possibly) to 
the investigational agent, occurs within the DLT reporting period, and meets one of the 
criteria provided in Table 16. 
A participant who develops a DLT will be allowed to continue on study if the toxicity did 
not meet predefined stopping criteria and recovered to Grade 1 and if the investigator 
and Medical Monitor agree that for a given participant the potential benefits may 
outweigh the risks.  
The lowest full dose of belantamab mafodotin  to be evaluated in this study is 1.9 mg/kg 
IV.  If 1.9  mg/kg is not tolerated, the respective treatment arm will be closed for lack of 
tolerability.  Independent dose escalation rules wil l apply to each treatment arm.  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
108 
 Table 16 Dose -Limiting Toxicity Criteria for Belantamab Mafodotin  in Part 1 Cycle 1  
Criteria for Identification and Grading of Belantamab Mafodotin  DLTs in Part 1  
Toxicity Type and Grade  DLT Definition and Grade  
Hematologic  • Grade 3 or greater febrile neutropenia lasting >48 h despite adequate treatment:  
• Grade 3 is defined as ANC <1.0×109/L with a single temperature of >38.3 C (101F) or a sustained 
temperature of ≥  38C (100.4F) for more than 1 h.  
• Grade 4 is defined as ANC <1.0×109/L with a single temperature of >38.3 C (101F) or a sustained 
temperature of ≥38 C (100.4F) for more than  1 h, with life -threatening consequences and urgent 
intervention indicated.  
• Grade 4 Thrombocytopenia <25,000/mm3 accompanied by clinically significant bleeding.  
Non-hematologic except 
corneal events  • Any Grade 3 or greater non -hematologic toxicity (other than corneal events) which is more severe than expected 
for an individual agent * or which does not resolve with appropriate supportive treatment within 48 h  
• Any Grade 3 or greater non -hematologic laboratory value if  
• The laboratory abnormality persists fo r >48 h despite supportive treatment  
• The abnormality leads to hospitalization.  
Corneal events  • Grade 4 per the GSK corneal grading scale provided in Table 33. 
Other organ -specific 
toxicities  • Liver toxicity meeting prespecified GSK liver stopping criteria.  
*For a l ist of most frequent adverse events for belantamab mafodotin  see Investigator’s Brochure, [GSK Document Number 2013N175128  V08, 2020]; for lenalidomide  see Celgene  
Corporation (2019), REVLIMID Prescribing Information, and for bortezomib  see VELCADE  (bortez omib) Prescribing Information (2019) . 
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
109 
 6.2. Number of Participants  
Overall, it is estimated that approximately  152 treated participants will be enrolled in this 
two-part study ( approximately 27 in Part 1, and approximately 125 in Part 2).  
• Up to 27 DLT -evaluable participants with RRMM (approximately  14 participants in 
Arm  A and approximately  13 participants in Arm  B) will be evaluated during the 
Part 1 dose escalat ion phase.  
• Part 2 will enroll  approximately 125 participants with RRMM ( approximately 31 
participants in Arm  A and approximately 94 participants in Arm  B) in order to 
further evaluate the safety and preliminary  clinical activity of the combination  
treatments .  
At the time of Amendment 3 more participants have been added to Part 1 (Arms A and 
B) for the study due to non -DLT evaluable participants and the requirement for an 
additional replacement participant to assure an adequate assessment of DLTs. Two 
participants were added to Part 2 (Arms A and B) as a replacement for participants who 
either received a n incorrect dose or  failed to complete a full cycle.  
6.3. Participant Study Completion , Study Analys is and End of 
Study  
Participant Study Completion  
A participant will be considered to have completed the study if he or she received at least 
one dose of study treatment and  has progressed or died before the end of the study, has 
not been lost to Follow -up, or has not withdrawn consent from study participat ion, or the 
study or a treatment arm has been  terminated . 
A participant will be considered to have withdrawn from the study if the patient  
• has not died and is lost to Follow -up, or  
• has withdrawn consent, or  
• is no longer being followed at the investigator’s  discretion  
Documentation of the cause of death in the electronic case report form (eCRF) is required  
for all participants who die in the study regardless of the cause of death.  
 
Study Analys is 
Final  analysis will be conducted approximately 12 months  from the last subject  first visit 
(LSFV) in either arm . 
6.4. End of Study Definition  
Following the final analysis , the study will move into the PACT phase and the clinical 
study database will be closed to new data. Participants who are receiving belantamab 
mafodotin monotherapy or in combination with Len/Dex  (Arm A)  or Bor/Dex (Arm B)  
may continue to receive belantamab mafodotin monotherapy or in combination with 
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
110 
 either Len/Dex (Arm A) or Bor/Dex (Arm B) if they are gaining clinical benefit as 
assessed by the investigator  until they meet any criterion for permanent discontinuation 
of study intervention ( see section 9 and Section 10.2). 
The end of study is defined when the last patient had their last visit (last subject last dose 
plus 70 days SAE reporting period). GSK retains the right t o request additional 
information for any patient with ongoing AE(s)/SAE(s)  ocular data at the end of the 
study. All participants will be monitored and receive follow -up care in accordance with 
standard local clinical practice.  
6.5. Scientific Rationale for Study Design  
The recent addition of monoclonal antibodies (el otuzumab and daratumumab) to  SoC 
treatment s, such as Len/Dex or Bor/Dex has demonstrated that the results achieved can 
be improved significantly.  [Lonial , 2015] , [Dimopoulos , 2016].   
Belantamab mafodotin  is being studied in MM participant s as monotherapy in the stud ies 
BMA117159  and 205678 . The selected RP2D of 3.4 mg/kg was considered well tolerated  
in BMA117159 .  Belantamab mafodotin  montherapy  when used as a single agent in 
BMA117159 had  an ORR of 60% (95% CI: 42.1, 76.1) and the median PFS was 12 
months [Trudel , 2018; Trudel , 2019 ].  In the Phase 2 study 205678 in RRMM patients, 
belantamab monotherapy showed an ORR of 31% (97.5%CI:  20.8, 42.6)  [Lonial , 2020]. 
Given the previous experience with monoclona l antibodies which exhibited lower single 
agent activity as monotherapy in similar populations, the combination therapy of 
belantamab mafodotin  with S oC agents is an attractive option  and is expected to result in 
additive, or enhanced effects which could potentially translate into a deep and long 
lasting response over what has been achieved with available agents . 
Since belantamab mafodotin  has not been combined with Len/ Dex or Bor/Dex  outside of 
this study , Part 1 will explore the safety and tolerability o f escalating doses and alternate 
dosing schedule(s) of belantamab mafodotin  administered in combination with Len/Dex  
(Arm  A) or Bor/Dex (Arm  B).  Part 2 will further evaluate the safety and preliminary 
clinical activity of selected doses of belantamab mafodotin  with Len/Dex or Bor/Dex to 
identify the optimal dose(s) and schedule for each arm in participants with RRMM  who 
have relapsed or who are refractory to at least 1 prior line of treatment.  
While there are some potential overlaps in the pattern of toxicities (primarily 
hematological)  of the study treatments , these are expected to be manageable with 
appropriate supportive care . Combination  therapy with these agents remains an attractive 
option to explore for the treatment of RRMM.   
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
111 
 6.6. Dose  Justification  
6.6.1.  Starting Dose of Belantamab Mafodotin  
The starting dose for both arms of this study is 2.5 mg/kg, which is one dose level below 
the RP2D of 3.4 mg/kg for the monotherapy of belantamab mafodotin  in the FTIH study 
BMA117159  when administered o n a Q3W schedule. In addition to being safe and 
tolerated in a monotherapy setting, the starting dose of 2.5 mg/kg may potentially offer 
some benefit to participant s if enhanced  or additive effects occur  with the combinations 
of belantamab mafodotin  with L en/Dex or Bor/Dex , respectively . While the 2.5 mg/kg 
dose did not result in high ORR in the FTIH study BMA117159 , this dose was later 
found to be effective in study 205678 with an ORR of 31% in a heavily pre -treated 
relapsed refractory patient population ; 2.5 mg/kg Q3W is the proposed monotherapy dose 
for this population .  
The starting dose of 2.5 mg/kg Q3W for this combination study will allow for careful 
assessment  of safety , while still providing potential benefit to participant s. It is to be 
noted that a dose of 1.9 mg/kg could also provide benefit  as target engagement for this 
dose was greater than 90% at the end of the first infusion based on decrease from baseline 
in serum  free s oluble BCMA (BMA117159 ). Responses have also been seen at lower 
doses of 0.96 and 1.92 mg/kg (1 out of 3 and 1 out of 4 participants respectively)  in that 
study.    
Treatment in Arm B (combination with Bor/Dex) will be administered on a 21 -day 
schedule which is identical as for monotherapy with belantamab mafodotin  and aligned 
with dosing schedule of Bor/Dex.  
Treatment in Arm A (combination with Len/Dex) will be administered on a 28 -day 
schedule. The cycle length has been adjusted to reflect the schedule of administration for 
Len/Dex. Given the mechanism of action and the fact that responses achieved with 
monotherapy with belantamab mafodotin  were durable even in participant s who had 
prolonged intervals between dosing s due to toxicity, it is felt that a cycle length of 28 
days is appropriate for Arm A.  
For Arm A, i f Dose Level -1 combination regimen ( 1.9 mg/kg) is tolerable, escalation to 
the higher dose of 2.5 mg/kg will proceed and additional participants will be enrolled to 
this next dose cohort.   
For Arm B, i f Dose Level 1 combination regimen (2.5 mg/kg) is tolerable, escal ation to 
the higher dose of 3.4 mg/kg will proceed and additional participant s will be enrolled to 
this next dose cohort.   
Safety assessments and dose escalation will proceed independently for Arm A and Arm 
B. 
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
112 
 6.6.2.  Alternate Schedule for Belantamab Mafodotin  
SPLIT  Dosing  
Administration of belantamab mafodotin  divided as two equal administrations a week 
apart (i.e. SPLIT  dosing) will be evaluated  to determine  if this  dosing schedule results in 
an improvement to the  benefit /risk due to reduction in the maximum concentration while 
maintaining similar  exposure over a cycle compared to the Q3W dosing . With anticipated 
accumulation, it is predicted that a 3.4 mg/kg dose administered with a SPLIT  dosing of 
1.7 mg/kg on Day 1 and Day 8 will le ad to maximum concentration similar to the one 
observed with 2.5 mg/kg Q3W while achieving the same exposure (AUC) as 3.4 mg/kg 
Q3W.  
STRETCH  and S /D STRETCH Schedule : 
Based on the population pharmacokinetics performed on the DREAMM -1 and 2 studies, 
belanta mab mafodotin clearance decreases over time  with an elimination half-life of 14 
days after repeated administration . This leads to a moderate accumulation  over time . It 
has been noted that s afety events related to corneal toxicity occurred more frequently 
after repeated administration  than after the first dose and tended to still occur after 
repeated administration at a reduce d dose . These findings may be relat ed to the long half -
life and the decrease in clearance over time , both leading to drug accumulation.  
To reduce increase d exposure over time  and potentially improve the benefit/risk , an 
extended interval of every 8 weeks for Arm A or 6 weeks  for Arm B  (STRETCH 
schedule) will be evaluated ; 6-8 weeks represents 3-4 half-lives  and is anticipated to le ad 
to minimal accumulation . In addition , in Arm B, a S/D STRETCH schedule with a first 
dose of 2.5 mg/kg followed  by 1.9 mg/kg every 6 weeks from Cycle 3 onwards will also 
be studied  as an alternative to 2.5 mg/kg repeating every 6  weeks . 
6.6.3.  Standard of Care Dosing  
6.6.3.1.  Len/Dex Dose ( Arm A) 
Len/Dex will be administered at the approved and clinically used dose, and there will be 
no dose escalation for Len/Dex.  Details on Len/Dex administration are provided in 
Section 8.1.1.2 . 
6.6.3.2.  Bor/Dex Dose ( Arm B) 
Bor/Dex will be administered at the approved and clinically used dose, and there will be 
no dose escalation for Bor/Dex . Details on Bor/Dex administration are provided in 
Section  8.1.2.2 . 
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
113 
 7. STUDY POPULATION  
Prospective approval of protocol deviations to recruitment and enrollment  criteria, also 
known as protocol waivers or exemptions, is not permitted.  
7.1. Inclusion Criteria  
The study will enroll adult participants with RRMM, who have undergone autologous 
stem cell transplant (SC T), or are considered transplant ineligible, and who have been 
previously treated with at least 1 prior line of therapy, and who have documented 
evidence of disease progression during or after their most recent therapy .    
Inclusion Criteria  
Participants ar e eligible to be included in the study only if all of the following criteria 
apply:  
1. Capable of giving signed informed consent which includes compliance with the 
requirements and restrictions listed in the informed consent form (ICF) and in this 
protocol.  
2. Male or female, 18 years or older (at the time consent is obtained).  
3. Have confirmed diagnosis of Multiple Myeloma as defined by the International 
Myeloma Working Group (IMWG) [Rajkumar , 2016 ]. 
4. Eastern Cooperative Oncology Group (ECOG) performance status : 
• For Arm A only: 0 to 1 (Appendix 3, Section 14.3). 
• For Arm B only: 0 to 2 ( Appendix 3, Section 14.3). 
5. Have undergone autologous SCT or are considered transplant ineligible.  
6. Have been previously treated with at least 1 prior line of MM therapy  and must have 
documented disease progression during or after their most recent therapy.  
7. Must have at least ONE aspect of measurable disease, defined as one of the 
following:  
a. Urine M -protein excretion ≥200  mg/24h, or  
b. Serum M -protein concentration ≥0.5  g/dL (≥5.0  g/L), or  
c. Serum free light chain (FLC) assay:  involved FLC level ≥10  mg/dL 
(≥100  mg/L) and an abnormal serum free light chain ratio (<0.26 or >1.65).  
8. Participants with a history o f autologous stem cell transplant ( SCT) are eligible for 
study participation provided the following eligibility criteria are met:  
a. Autologous SCT was >100 days prior to study enrollment  
b. No active bacterial, viral, or fungal infection(s) present  
c. Participant meets the remainder of the eligibility criteria outlined in this protocol  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
114 
 9. All prior treatment -related toxicities (defined by National Cancer Institute Common 
Toxicity Criteria for Adverse Events [NCI -CTCAE], Version 4.03, 2010) must be 
Grade 1 at the time of enrollment , except for alopecia . Participant s with  Grade 2 
neuropathy  can be enrolled into Len/Dex treatment arm, but not into Bor /Dex 
treatment arm. 
10. Adequate organ system functions as defined by the laboratory assessments listed in 
Table 17. 
Table 17 Adequate Organ System Function Based on Safety Assessments  
Organ System and Laboratory 
Tests  Laboratory Values  
Hematologic  
Absolute neutrophil count (ANC)a  1.5 × 109/L 
Hemoglobin a 8.0 g/dL  
Platelets  a 75 × 109/L 
Hepatic  
Total bilirubin  1.5 × ULN; (isolated bilirubin >1.5  × ULN is acceptable if bilirubin 
is fractionated and direct bilirubin is <35%)  
ALT 2.5 × ULN  
Renal  
eGFRb 40 mL/min /1.73 m2 
Spot urine (albumin/creatinine ratio 
from spot urine)  500 mg/g (56 mg/mmol)  
Cardiac  
Left Ventricular Ejection Fraction 
(LVEF) by ECHO  40%  
Note :  Laboratory results obtained during Screening should be used to determine eligibility criteria.  In situations 
where laboratory results are outside the permitted range, the Investigator may re -test the participant and the 
subsequent within range screening result may be used to confirm eligibility.  
a. Without Growth factor support for the past 14 days, exclu ding erythropoietin. Transfusions are allowed  
b. As calculated by Modified Diet in Renal Disease (MDRD) formula ( Appendix 4, Section 14.4) 
 
 
11. Female Participants:  
Contraceptive use by women should be consistent with local regulations regarding the 
methods of contraception for those participating in clinical studies.  
A female participant is eligible to participate if she is not pregnant or breastfeeding, and 
at least one of the following conditions applies:  
• Is not  a woman of childbearing potential (WOCBP)  
OR 
• Is a WOCBP and using a contraceptive method that is highly effective (with a failure 
rate of <1% per year), preferably with low user dependency  (Appendix  7, Section 
14.7) during the intervention period and for 4 months  after the last dose of 
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
115 
 belantamab mafodotin  and agrees not to donate eggs (ova, oocytes) for the  purpose 
of reproduction during this period.  
The investigator should evaluate the effectiveness of the contraceptive method in 
relationship to the first dose of study intervention.  
The investigator is responsible for review of medical history, menstrual history, and 
recent sexual activity to decrease t he risk for inclusion of a woman with an early 
undetected pregnancy.  
WOCBP Participants Assigned to Arm A  
Due to lenalidomide being a thalidomide analogue with risk for embryo -fetal toxicity and 
prescribed under a pregnancy prevention/controlled distribution program , WOCBP 
participants will be eligible if they commit either to abstain continuously from 
heterosexual sexual intercourse or to use two methods  of reliable birth control  (one 
method that is highly effective ; see Appendix  7, Section 14.7), beginning 4 weeks prior 
to initiating treatment with lenalidomide , during therapy, during dose interruptions and 
continuing for 4 weeks  following discontinuation of lenalidomide treatment.  Thereafter, 
WOCBP participants must use a contraceptive method that is highly effective (with a 
failure rate of <1% per year) for a further 3 months , and agree not to donate eggs (ova, 
oocytes) for the purpose of reproduction during this period.  
Two negative pregnancy tests must be obtained prior to initiating lenalidomide  therapy. 
The first test should be performed within 10 -14 days and the second test within 24 hours 
prior to prescribing lenalidomide therapy.  
WOCBP Participant s Assigned to Arm B  
WOCBP assigned to Arm B must have a negative highly sensitive serum pregnancy test 
within 72 hours of dosing on C1D1 and agree to use effect ive contraception during the 
study and for 4 months  after the last dose of belantamab mafodotin  or 7 months from the 
last dose of bortezomib , whichever is longe r. 
12. Male Participants:  
Contraceptive use by men should be consistent with local regulations regar ding the 
methods of contraception for those participating in clinical studies.  
Male participants are eligible to participate if they agree to the following :  
• Arm A: from the time of first dose of study until 6 months  after the last dose of 
belantamab mafodotin  4 weeks after the last dose of lenalidomide, whichever is 
longe r, to allow for clearance of any altered sperm:  
• Arm B:  from the time of first dose of study until 6 months  after the last dose of 
belantamab mafodotin  or 4 months from the last dose o f bortezomib (whichever is 
the longe r) to allow for clearance of any altered sperm . 
Refrain from donating sperm  and either:  
• Be abstinent from heterosexual intercourse as their preferred and usual lifestyle 
(abstinent on a long term and persistent basis) and agree to remain abstinent  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
116 
 OR 
• Must agree to use contraception/barrier as detailed below . 
Agree to use a male condom even i f they have undergone a successful vasectomy and 
female partner to use an additional highly effective contraceptive method with a failure 
rate of <1% per year as described in Appendix  7, Section 14.7 when having sexual 
intercourse . Male participants should also use a condom  with pregnant females . 
If the female partner of the male participant is pregnant at the time of enrollment , or 
becomes pregnant during the trial, the male participant must agree to remain abstinent (if 
it is consistent with their preferred and usual lifestyle) or use a male cond om. 
7.2. Exclusion Criteria  
A participant will not be eligible for inclusion in this study if any of the following criteria 
apply:  
1. Systemic anti -myeloma therapy (including systemic steroids) within 14 days, or 
plasmapheresis within 7 days prior to the first dose of study drug.  
2. Use of an investigational drug within 14 days or five half -lives (whichever is longer) 
preceding the first dose of study drug.  
3. Prior treatment with a monoclonal antibody within 30 days of receiving the first dose 
of study drugs.  
4. Prior allogenic stem cell transplant.  
Note: Participants who have undergone syngeneic transplant will be allowed only if  
they have  no history and no c urrently active, graft versus host disease (GvHD)  
5. Evidence of active mucosal or internal bleeding.  
6. Any major surgery within the last four weeks.  
7. Presence of active renal condition (infection, requirement for dialysis or any other 
condition that could affect participant’s safety).  Participants with isolated proteinuria 
resulting from MM are eligible, provided the y fulfill criteria given in Table 17. 
8. Any serious and/or unstable pre -existing medical, psychiatric disorder or other 
conditions (including lab abnorm alities) that could interfere with participant’s safety, 
obtaining informed consent or compliance to the study procedures.  
9. Current active liver or biliary disease (with the exception of Gilbert’s syndrome or 
asymptomatic gallstones, or otherwise stable ch ronic liver disease per investigator’s 
assessment).  
10. Participants with invasive  malignanc ies other than multiple myeloma are excluded, 
unless the second malignancy has been considered medically stable for at least 2 
years. The participant must not be receiv ing active therapy, other than hormonal 
therapy for this disease.  
Note: Participants with curatively treated non -melanoma skin cancer are allowed 
without a 2 -year restriction .  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
117 
 11. Evidence of cardiovascular risk including any of the following:  
• Evidence of current clinically significant untreated arrhythmias, including 
clinically significant ECG abnormalities including 2nd degree ( Mobitz Type II) 
or 3rd degree atrioventricular (AV) block.  
• History of myocardial infarction, acute coronary syndromes  (including unstable 
angina), coronary angioplasty, or stenting or bypass grafting within 3 months 
of Screening.  
• Class III or IV heart failure as defined by the New York Heart Association 
functional classification system ( Appendix 5, Section 14.5).  
• Uncontrolled hypertension.  
12. Known immediate or delayed hypersensitivity reaction or idiosyncratic reaction to 
drugs chemically related to belantamab mafodotin , or any of the components of the 
study treatment.  
13. Pregnant or lactating female.  
14. Active infection requiring treatment.  
15. Known H IV infection.  
16. Presence of hepatitis B surface antigen (HBsAg), or hepatitis B core antibody 
(HBcAb at Screening or within 3 months prior to first dose of study treatment)  
17. Positive hepatitis C antibody test result or positive hepatitis C RNA test result at 
Screening or within 3 months prior to first dose of study treatment.  
Note: Participants with positive Hepatitis C antibody due to prior resolved disease can 
be enrolled, only if a confirmatory negative Hepatitis C RNA test is obtained. 
Hepatitis RNA testi ng is optional and participants with negative Hepatitis C antibody 
test are not required to also undergo Hepatitis C RNA testing  
18. Current corneal disease except for mild punctate keratopathy ( Appendix 8, Section 
14.8). 
Note : Participant s with mild punctate keratopathy are allowed.   
Additional Exclusion Criteria for Participants Assigned to Arm  A (belantamab 
mafodotin  plus Len/Dex)     
19. Participants unable to tolerate antithrombotic prophylaxis must be excluded.  
20. Discontinuation of prior treatment with lenalidomide due to intolerable a dverse 
events.  
Additional Exclusion Criteria for Participants Assigned to Arm  B (belantamab 
mafodotin  plus Bor/Dex)  
21. Unacceptable adverse effects from previous bortezomib treatment.  
22. Ongoing Grade 2 or higher peripheral neuropathy or neuropathic pain from previous 
bortezomib treatment.  
23. Intolera nce or contraindications  to anti -viral prophylaxis . 
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
118 
 7.3. Lifestyle Restrictions  
The following lifestyle restrictions apply while the participants are in the study:  
• Contact lenses are prohibited while on the study treatment (from first dosing to the 
end of study treatment). Contact lens use may be restarted after the end of study 
treatment and a consultation with a qualified eye care specialist confirms there are no 
other contraindications.   Use of bandage contact l enses is permitted during study 
treatment as directed by a qualified eye care specialist.  
• Participants must not donate blood while receiving study treatment; Participants in 
Arm A must not donate blood for 28 days following discontinuation of lenalidomide.  
• Intraocular pressure may become elevated with dexamethasone treatment in some 
individuals. Intraocular pressure should be monitored.  
Injection Site:  
When bortezomib in Arm B is administered via SC injection, sites for each injection 
(thigh or abdomen) should be rotated.  New injections should be given at least one inch 
from an old site and never into areas where the site is tender, bruised, erythematous, or 
indurated.  
If local injection site reactions occur following administration of bortezomib SC in Arm 
B, a less concentrated solution (1 mg/mL instead of 2.5 mg/mL) may be administered SC.  
Alternatively, the IV route of administration should be considered.  
Meals and Dietary Restrictions  
There are no recognized dietary restrictions for the individual co mponents of Arm  A or 
Arm  B. 
• For participant s assigned to Arm  A, lenalidomide capsules should be swallowed 
whole with water; the capsules should not be opened, broken, or chewed.  
Lenalidomide should be taken orally at approximately the same time each day 
[Celgene  Corporation (2019), REVLIMID REVLIMID (lenalidomide) P rescribing  
Information , 2019 ] or most recent label . 
• Lenalidomide capsules contain lactose. The risk -benefit of Arm  A should be 
evaluated in participant s with lactose intolerance.  
Caffeine, Alcohol, and Tobacco  
No restrictions  
Activity  
No restrictions  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
119 
 7.4. Screen Failures  
Screen Failures are defined as participan ts who consent to participate in the clinical study 
but are not subsequently assigned to either Arm  A or Arm  B, or were assigned but did not 
receive treatment, because they did not satisfy all the Inclusion/Exclusion criteria 
provided in Section 7.   
A minimal set of screen failure information is required to ensure transparent reporting of 
screen failure participants to meet the Consolidated Standards of Reporting Trials 
(CONSORT) publishing requirements and to respond to queries from regulatory 
authorities. Minimal information includes: the participant ID number; demography; 
eligibility ( Inclusion/Exclusion criteria failed); reason for screen  failure; any serious 
adverse events (SAE) related to study participation; and protocol deviations, if any.  
Individuals identified as Screen Failures may be rescreened if the failure was based on 
elements of eligibility that may change, e.g., laboratory te st results.  Rescreened 
participants should be assigned a different participant number from that assigned for the 
initial screening.  
8. TREATMENTS  
“Study Treatment” is defined as any investigational treatment(s), marketed product(s), 
placebo, or medical devic e(s) intended to be administered to a study participant according 
to the study protocol.  
8.1. Treatments Administered  
Details of the identity and characteristics of the individual components of the Study 
Treatments are shown in Table 19.  A summary of the treatment regimens and schedules 
is contained in Table 18. 
 
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
120 
 Table 18 Summary of Treatment Regimens and Schedules  
Treatment Arm Part Cohort  Dose of Belantamab Mafodotin  Schedule  SoA  
Arm A: 28 -Day Cycle  
Lenalidomide 25mg PO QD, D1 -D21;  
Dexamethasone 20mg PO or IV, D1, 8, 
15, 22  1 and 2  2.5 mg/kg SINGLE   2.5 mg/kg IV  Day 1  Table 5 
1 and 2  2.5 mg/kg SPLIT   1.25 mg/kg IV  Day 1, 8  Table 6 
1 1.9 mg/kg SINGLE   1.9 mg/kg IV  Day 1  Table 5 
2 1.9 mg/kg STRETCH  1.9 mg/kg IV  Day 1 in every alternate 28 -day 
cycle  Table 5 
Arm B: 21 -Day Cycle  
Bortezomib 1.3mg/m2 SC or IV BIW, D1, 
4, 8, 11;  
Dexamethasone 20mg PO or IV QIW, 
D1, 2, 4, 5, 8, 9, 11, 12)  
Cycle 1 -8 
Monotherapy ≥ Cycle 9  1 and 2  3.4 mg/kg SINGLE   3.4 mg/kg IV  Day 1  Table 7 
2 3.4 mg/kg SPLIT   1.7 mg/kg IV  Day 1, 8  Table 8 
1 and 2  2.5 mg/kg SINGLE   2.5 mg/kg IV  Day 1  Table 7 
2 2.5 mg/kg SPLIT   1.25 mg/kg IV  Day 1, 8  Table 8 
2 1.9 mg/kg SINGLE  1.9 mg/kg IV  Day 1 Table 7 
2 2.5 mg/kg STRETCH   2.5 mg/kg IV  Day 1 in every alternate 21 -day 
cycle  Table 9 
2 S/D STRETCH  Cycle 1:  2.5 mg/kg IV STRETCH  
Cycle 3+:  1.9 mg/kg IV STRETCH  Day 1 in every alternate 21 -day 
cycle  Table 9 
2 1.9 mg/kg STRETCH 1.9 mg/kg IV  Day 1 in every alternate 21 -day 
cycle  Table 9 
 
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
121 
 8.1.1.  Belantamab Mafodotin  and Len/Dex Combination ( Arm A) 28 -day 
Cycle : SINGLE ,SPLIT , and STRETCH  Schedule s 
The schedules for dosing of belantamab mafodotin and Len/Dex on a 28 -day schedule is 
shown in Figure 5. 
Figure 5 Arm A: 28-day Dosing Schedules   
 
 

TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
122 
 8.1.1.1.  Belantamab mafodotin   
For SINGLE  day dosing  schedule,  belantamab mafodotin  will be administered FIRST  
(prior to Len/Dex)  in the clinic  as a single full dose  on Day 1 of each 28 -day cycle as a 
30-60 minute ( min) infusion, followed by a 1  to 2 h rest period.  For example, a  2.5 mg/kg 
SINGLE dos ing schedule  will administer  a 2.5 mg/kg dose on Day 1 of each cycle.  
For SPLIT  day dosing schedule, belantamab mafodotin  will be administered FIRST 
(prior to Len/Dex) in the clinic in two equal divided doses - one on Day 1 and the other 
on Day 8 of each 28 -day cycle as a 30 -60 min in fusion, followed by a 1  to 2 h rest period.  
For example, a  2.5 mg/kg SPLIT dos ing schedule  will administer  a 1.25 mg/kg dose on 
Day 1 and a 1.25 mg/kg dose on Day 8 of each cycle.  
For the STRETCH  dosing schedule, belantamab mafodotin  will be administered FIRST 
(prior to Len/Dex) in the clinic on Day 1 of every alternate 28 -day cycle as a 30 -60 min 
infusion, followed by a 1 to 2 h rest period. A 1.9 mg/kg STRETCH  dosing schedule will 
administer a 1.9 mg/kg dose on Day 1 of all alternate 2 8-day cycles (C1, C3, C5, C7 and 
so on) .  
Starting dose in Part 1 will be 2.5 mg/kg IV for belantamab mafodotin  (Dose Level 1). If 
the 2.5 mg/kg dose is not tolerated an additional, lower dose (1.9 mg/kg [Dose Level –1]) 
will be evaluated. Additional ly, alternate dosing schedules will also be explored , 
including SPLIT dosing where the belantamab mafodotin  dose will be split into two 
equal halves  with each half dose administered on Day 1 and Day 8  of each cycle .  
Note : 2.5 mg/kg IV is the highest dose (dose level 1)  that will be assessed in Arm A .  
The actual body weight in kg at baseline (assessed on C1D1 prior to dosing) will be used 
for dose calculation of belantamab mafodotin  in all participants during the treatment 
period.  If the change of body weight is greater than 10%, the dose should be re -
calculated based on the actual body weight at the time of dosing.  Participants must be 
weighed prior to dosing for each cycle.  
8.1.1.2.  Len/Dex  
Lenalidomide will be administered as 25  mg PO daily on days 1 -21 of each 28 -day cycle, 
in the participants with eGFR 60 mL/min/1.73 m2.  The dose of lenalidomide will be 
reduced to 10 mg daily on Days 1 to 21 in participants with eGFR of 40 -60 mL/min/1.73 
m2. Lenalidomide is administered at a fixed dose level, with no adjustments needed for 
body weight or BSA [ REVLIMID  (lenalidomide) P rescribing  Information  2019]. 
On lenalidomide and belantamab mafodotin  co-administration days , lenalidomide should 
be administered as close as possible to the end of the 1 -2 h rest period after  
administration of belantamab mafodotin  and no later than  6 h after the end of the rest 
period after administration of belantamab mafodotin . 
Dexamethasone will be given 40 mg weekly PO or IV on Days 1, 8, 15 and 22 of each 
cycle. Dexamethasone is administered at a fixed dose of 40 or 20 mg PO  or IV , with no 
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
123 
 adjustments needed for body weight or BSA. For dexamethasone refer to dexamethasone 
prescribing information .  
Participants who are >75 years old, with BMI <18.5 kg/m2, the dose of dexamethasone 
can be reduced to 20 mg at the discretion of the investigator.  
In the event of  tolerability issues, the dose of dexamethasone can be reduced from 40  mg 
to 20 mg ; if 20 mg is not tolerated, dexamethasone may be permanently discontinued.   
On days where only lenalidomide and dexamethasone are taken at home, they should be 
taken in the morning approximately at the same time each day.  On day s when 
lenalidomide PK samples will be collected, participant s will be required to take their 
morning dos e in the clinic.  For Cycle 1, the 24 h post -dose lenalidomide PK sample must 
be collected before lenalidomide dosing on Cycle 1 Day 2.  
8.1.2.  Belantamab Mafodotin  and Bor/Dex Combination ( Arm B) 21 -day 
Cycle : SING LE and SPLIT Schedules  
The schedules for dosing of belantamab and Bor/Dex on a 21 -day schedule is shown in 
Figure 6 
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
124 
 Figure 6 Arm B: 21-day Dosing Schedules  
 
8.1.2.1.  Belantam ab Mafodotin  
For SINGLE  day dosing schedule, belantamab mafodotin  will be administered FIRST  
(prior to Bor/Dex)  in the clinic  as a single full dose  on Day 1 of each 21-day cycle as a 
30-60 min in fusion, followed by a 1  to 2 h rest period.  For example, a  3.4 mg/kg 
SINGLE dosing schedule will administer a 3.4 mg/kg dose on Day 1 of each cycle , a 2.5 
mg/kg SINGLE dos ing schedule  will administer  a 2.5 mg/kg dose on Day 1 of each 
cycle , a 1.9 mg/kg  SINGLE dosing schedule  will administer a 1.9 mg/kg dose on Da y 1 
of each cycle .   
For SPLIT  day dosing schedule, belantamab mafodotin  will be administered FIRST  
(prior to Bor/Dex)  in the clinic  in two equal divided doses - one on Day 1 and the other 
on Day 8 of each 21-day cycle as a 30 -60 min in fusion, followed by a 1 to 2 h rest period.  
For example, a  2.5 mg/kg SPLIT dos ing schedule  will administer  a 1.25 mg/kg dose on 
Day 1 and a 1.25 mg/kg dose on Day 8 of each cycle , a 3.4 mg/kg SPLIT dos ing schedule  
will administer  a 1.7 mg/kg dose on Day 1 and a 1.7 mg/kg dose  on Day 8 of each cycle.  

TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
125 
 The starting dose in Part 1 will be 2.5 mg/kg IV for belantamab mafodotin  (Dose Level 
1). If safety and tolerability of the starting dose is confirmed, a n escalation of the dose of 
belantamab mafodotin  to 3.4 mg/kg (Dose Level  +1) will be performed in the next cohort 
of participant s.  If the 2.5 mg/kg dose is not tolerated , or if emerging data were to indicate 
potential improved benefit/risk at reduced dose, an additional, lower dose (1.9 mg/kg 
(Dose Level –1) will be evaluated.  
Note:  3.4 mg/kg IV is the highest dose (Dose level +1) that will be assessed in Arm B    
8.1.2.2.  Bor/Dex  
Bortezomib 1.3 mg/m2 SC or IV (depending on participant s’ and institutional preference) 
will be administered on Days 1, 4, 8, and 11 of every 21 -day cycle for a  total of up to 8 
cycles. The administration of bortezomib will be after belantamab mafodotin  
administration, approximately after 1 h and after assuring that participant  is clinically 
stable. Bortezomib doses are calculated based on the participant’s BSA ( West , 2000), 
ranging from a recommended starting dose of 1.3 mg/m2 to a reduced dose of 1.0 mg/m2 
or 0.7 mg/m2 [VELCADE  (bortezomib) Prescribing Information (2019) ]. Formulae used 
to calculate the administered volume of bortezomib for SC or IV administration are given 
in Section 8.1.5.3 . 
For participant s who experience an IRR during belantamab mafodotin , bortezomib 
administration will be delayed until the IRR has resolved , and the participant  is 
considered clinically stable.    
Dexamethasone will be administered at 20 mg PO or IV on Days 1, 2, 4, 5, 8, 9, 11, and 
12 of every 21 -day cycle. Dexamethasone is administered at a fixed dose of 20 mg PO  or 
IV, with no adjustments needed for body weight or BSA.  Dexamethasone dose may be 
reduced at investigator’s discretion for participants who are older than 75 years of age, 
for participants who have BMI <18.5 kg/m2, or for participants who had previous 
unacceptable side effects associated with glucocorticoid the rapy. Dexamethasone will be 
given for a total of up to 8 cycles. For dexamethasone refer to dexamethasone prescribing 
information.   
In case of lack of tolerability , dexamethasone can be reduced from 20  mg to 10 mg and if 
10 mg is not tolerated, may be perm anently discontinued.   
Dexamethasone should be taken at the same time of the day and  may be taken at home.  
8.1.3.  Belantamab Mafodotin and Bor/Dex Combination (Arm B) 21-day 
Cycle : STRETCH  and S/D STRETCH Dosing Schedule  
The schedule for dosing of belantamab  mafodotin  and Bor/Dex on a STRETCH  schedule 
is shown in  Figure 7. 
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
126 
 Figure 7 Arm B: STRETCH  Dosing Schedule  
 
 
8.1.3.1.  Belantamab mafodotin  
For the STRETCH  dosing schedule, belantamab mafodotin  will be administered FIRST 
(prior to Bor/Dex) in the clinic on Day 1 of every alternate  21-day cycle s as a 30 -60 min 
infusion, followed by a 1  to 2 h rest period. A 2.5 mg/kg STRETCH  dosing schedule will 
admini ster a 2.5 mg/kg dose on Day 1 of all alternate 21 -day cycles  (C1, C3, C5, C7 and 
so on) . A 1.9 mg/kg STRETCH  dosing schedule will administer a 2.5 mg/kg dose on Day 
1 of all alternate 21 -day cycles  (C1, C3, C5, C7 and so on).  
For the S/D STRETCH  dosing schedule, belantamab mafodotin  will be administered 
FIRST  (prior to Bor /Dex) in the clinic at 2.5 mg/kg as a dose on Day 1 of Cycle 1  
followed by 1.9 mg/kg  step-down dose on Day  1 of all alternate 21 -day cycles C3 
onwards  (C3, C5, C7 and so on) , as a 30-60 min infusion, followed by a 1  to 2 h rest 
period.   
8.1.3.2.  Bor/Dex  
Bortezomib 1.3 mg/m2 SC or IV (depending on participants’ and institutional preference) 
will be administered on Days 1, 4, 8, and 11 of every 21 -day cycle for a total of up to 8 
cycles. The administration of bortezomib will be after belantamab mafodotin  
administration, approximately after 1 – 2 h and after assuring that participant is clinically 
stable. Bortezomib doses are calculated based on the participant’s BSA ( West , 2000), 
ranging from a recommended starting dose of 1.3 mg/m2 to a reduced dose of 1.0 mg/m2 
or  0.7 mg/m2 [VELCADE  (bortezomib) Prescribing Information (2019) ]. Formulae used 
to calculate the administered volume of bortezomib for SC or IV administration are given 
in Section 8.1.5.3 . 

TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
127 
 For participants who experience an IRR during belantamab mafodotin , bortezomib 
administration will be delayed until the IRR has resolved , and the participant is 
considered clinically stable.   
Dexamethasone will be administered at 20 mg PO or IV on Days 1, 2, 4, 5, 8, 9, 11, and 
12 of every 21 -day cycle. Dexamethasone is administered at a fixed dose of 20 mg PO  or 
IV, with no adjustments needed for body weight or BSA.  Dexame thasone dose may be 
reduced at investigator’s discretion for participants who are older than 75 years of age, 
for participants who have BMI <18.5 kg/m2, or for participants who had previous 
unacceptable side effects associated with glucocorticoid therapy. Dexamethasone will be 
given for a total of up to 8 cycles. For dexamethasone refer to dexamethasone prescribing 
information.   
In case of lack of tolerability , dexamethasone can be reduced from 20  mg to 10 mg and if 
10 mg is not tolerated, may be permanentl y discontinued.   
Dexamethasone should be taken at the same time of the day and may be taken at home.  
8.1.4.  Pharmaceutical Presentation  
8.1.4.1.  Belantamab mafodotin  
Belantamab mafodotin  solution, 20 mg/mL, 1.5 mL is supplied as a sterile, preservative -
free aqueous solution of purified monoclonal ADC in type 1 untreated borosilicate clear 
glass, stoppered vials. The drug product solution appears as a clear or opalescent; 
colorless, yellow  to brown liquid; essentially free from particles. The drug is supplied as 
a single -use vial. Each vial of belantamab mafodotin  solution, 20 mg/mL; 1.5 mL is filled 
with 1.6 mL of solution to provide a 1.5  mL extractable  volume.   
Subjects continuing treatm ent during  PACT phase after final analysis may receive 
lyophilized study drug. Lyophilized b elantamab mafodotin 100 mg/vial  is supplied  as a 
white to yellow  powder  in a single -dose vial for reconstitution and further dilution .  
8.1.4.2.  Lenalidomide  
Lenalidomide ( REVLIMID ) capsules, for oral use is available in 2.5 mg, 5 mg, 10 mg, 
15 mg, 20 mg and 25 mg capsules for oral administration. For d etails of pharmaceutical 
presentation or prescribing information refer to the local prescribing information for 
lenalidomide .  
8.1.4.3.  Bortezomib  
Bortezomib ( VELCADE ) for Injection is supplied as individually -cartoned 10 mL vials 
containing 3.5 mg of bortezomib as a white to off -white cake or powder.  Retain in 
original package to protect from light. For d etails of pharmaceutical prese ntation or 
prescribing information refer to the local prescribing information for bortezomib .  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
128 
 8.1.4.4.  Dexamethasone  
Dexamethasone is available in a tablet formulation for oral administration and as 
Dexamethasone Sodium Phosphate Injection (USP) , a sterile solution of dexamethasone 
sodium phosphate in water for injection for intravenous (IV) use. For details of 
pharmaceutical presenta tion or  prescribing information refer to the local prescribing 
information for dexamethasone.
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 129 
 Table 19 Description and Identity of Study Treatments  
Study Treatment Name  Belantamab 
mafodotin  
Arm A and Arm B Arm A Standard of Care (28-Day Cycle)  Arm B Standard of Care (21 -Day Cycle)  
Lenalidomide  Dexamethasone  Bortezomib  Dexamethasone  
Dosage Formulation  20 mg/mL, 1.5 mL via l  
or 
Lyophilized powder, 
100 mg/vial in single -
use vial for 
reconstitution  (Subjects 
continuing treatment in 
PACT phase after final 
analysis may receive 
lyophilized study drug ) Capsules, for oral use  Tablets for oral 
administration  / 
Injection for IV use  Solution for injection, 
for subcutaneous (2.5 
mg/mL) or intravenous 
(1 mg/mL) use Tablet for oral 
administration / 
Injection for IV use  
Route of Administration  IV Infusion  (See SRM 
for details ) Oral Oral or IV  IV as a 3 to 5 second 
bolus Infusion or SC  Oral or IV  
Dosing Instructions  30-60 min IV infusion  Days 1 to 21 of each    
28-day cycle  Days 1, 8, 15, and 22 of 
each 28 -day cycle  Days 1, 4, 8, and 11 of 
every 21 -day cycle  Days 1, 2, 4, 5, 8, 9, 11, 
and 12 of every 21 -day 
cycle  
Packaging and Labelling  Open -label  Open -label  Open -label  Open -label  Open -label  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 130 
 Study Treatment Name  Belantamab 
mafodotin  
Arm A and Arm B Arm A Standard of Care (28-Day Cycle)  Arm B Standard of Care (21 -Day Cycle)  
Lenalidomide  Dexamethasone  Bortezomib  Dexamethasone  
Manufacturer/ Source of  
Procurement  GlaxoSmithKline /Baxter  Celgene Corporation 
(US & Europe)  
Refer to SRM for 
country -specific details  Refer to SRM for 
country -specific details  Millennium 
Pharmaceuticals, Inc. 
(US) 
Janssen Pharmaceutica 
(Europe)  
Refer to SRM for 
country -specific details  Refer to SRM for 
country -specific details                                   
 
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 131 
 8.1.5.  Preparation of Doses  
8.1.5.1.  Belantamab mafodotin  
Belantamab mafodotin  will be administered intravenously over 30 min  to 1 h . The 
maximum dose to be administered to participant s in this trial is 3.4 mg/kg. Dilute 
belantamab mafodotin  solution in normal 0.9% saline to the appropriate concentration for 
the dose. For lyophilize d powder, reconstitute belantamab mafodotin lyophilized powder 
100 mg/vial 2.0mL of water for injection (WFI); dilute with saline to the appropriate 
concentration for the dose before use.  
Refer to the SRM for more details on preparation and handling, and administration 
instructions for belantamab mafodotin . 
8.1.5.2.  Lenalidomide  
Lenalidomide is administered at a fixed dose level of 25 or 10 mg PO, depending upon 
renal function. Refer to the SRM for more details on preparation, handling, and 
administration instructions for lenalidomide. Dose modifications may be required for 
safety ; see Table 23 for further  informati on. 
8.1.5.3.  Bortezomib  
Bortezomib dosing is based on the participant’s body surface area (BSA ; West , 2000 ). 
The reconstituted concentration of bortezomib for subcutaneous administration 
(2.5 mg/mL) is greater than the reconstituted concentration of bortezomib for intravenous 
administration (1 mg /mL). Because each route of administration has a different 
reconstituted concentration, caution should be used when calculating the volume to be 
administered. Dose modifications may be required for safety , see Table 24 for further  
information.  
After determining the participant ’s BSA in m2, use the following equations to calculate 
the total volume (mL) of reconstituted bortezomib to be administered:  
For Intravenous Administration (1 mg/mL concentration)  
[bortezomib dose (mg/m2) × participant BSA (m2)]  [1 mg⁄mL] = Total bortezomib 
volume (mL) to be administered  
For Subcutaneous Administration (2.5 mg/mL concentration)  
[bortezomib dose (mg/m2) × participa nt BSA (m2)]  [2.5 mg⁄mL] = Total bortezomib 
volume (mL) to be administered  
Refer to the SRM for more details on preparation, handling, and administration 
instructions for bortezomib.  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 132 
 8.1.5.4.  Dexamethasone  
Dexamethasone is administered at a fixed dose level of 40  mg or 20 mg (PO or IV) at the 
discretion of the investigator, and is not adjusted for weight or BSA. Refer to the SRM 
for more details on preparation and handling, and administration instructions for 
dexamethasone.  
8.1.6.  Treatment Duration  
8.1.6.1.  Arm A 
For participant s assigned to Arm A (belantamab mafodotin  in combination with L en/Dex, 
28-day cycle), participants may continue combination treatment until the occurrence of 
PD, intolerable AEs, consent withdrawal, death , or end of study . 
8.1.6.2.  Arm B 
For participants assigned t o Arm B (belantamab mafodotin  in combination with B or/Dex, 
21-day cycle), participants may continue combination treatment for a total of up to 8 
cycles, as per p rescribing information for bortezomib for the treatment of RRMM. 
Participants completing 8 cycles of combination therapy will continue treatment with 
belantamab mafodotin  as monotherapy until PD, intolerable AEs,  consent withdrawal, 
death , or end of study .  
8.1.6.3.  Lack of tolerability in Arm A or B  
In case a participant  meets stopping criteria for Len/Dex or Bor/Dex treatment and cannot 
continue on Len/Dex or Bor/Dex treatment due to related safety/tolerability issues, the 
participant  may continue on study with belantamab mafodotin  monotherapy. In ca se the 
participant meets stopping criteria for belantamab mafodotin , the participant will 
discontinue all treatment but will continue to be monitored  as described in the SoA tables 
for follow -up activities.  Cross over between arms is not allowed.  
8.2. Dose Modi fication  
After the completion of Cycle 1, dose modifications for all study drugs are allowed 
(within restrictions) to manage tolerability or adverse events.  
8.2.1.  Dose Modification After Cycle  1 
In both Part 1  and Part 2 of the study  after Cycle 1 , and dose modifications may be made 
for individual participants, based on safety findings. Dose  interruptions and reductions 
are permitted throughout the study  per guidance  below .    
The dose allowed for belantamab mafodotin  may be reduced twice by 25% of the 
originally  assigned dose. The rule of 25% dose reduction always refers to the originally 
assigned dose. If the participant is unable to tolerate at least a full dose of belantamab 
mafodotin  1.9 mg/kg (including SPLIT dose of 0.95 mg/kg on Day 1 and Day 8),  they 
will be withdrawn from the trial due to unacceptable toxicity  (Table 21).  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 133 
 For the S/D STRETCH  dosing schedules, b elantamab mafodotin will be  administered at 
2.5 mg/kg on D1 of Cycle 1 followed by 1.9 mg/kg dose in all subsequent alternate 
planned cycles starting a t Cycle 3 Day 1 throughout the rest of treatment. As 1.9 mg/kg is 
the lowest full dose evaluated in this study, no dose reductions  for belantamab mafodotin , 
except for dose delays and  interruptions, will be allowed . If the participant is unable to 
tolerate  the dose of belantamab mafodotin at 1.9 mg/kg, they will be withdrawn from the 
trial due to unacceptable toxicity ( Table 21).  
In Arm A, for the 1.9 mg/kg STRETCH dosing schedule, if a planned dose of belantamab 
mafodotin was held/missed due to any reason, the next dose can be administered at Day 1 
of the next planned 28 -day cycle, as long as the interval between 2 consecutive dos es is at 
least 56 (3) days.  
In Arm B, f or the S/D STRETCH , 2.5 mg/ kg STRETCH  and 1.9 mg/kg STRETCH  
dosing schedule s, if a planned dose of belantamab mafodotin was held/missed due to any 
reason, the next dose can be administered at Day 1 of the next plann ed 21 -day cycle, as 
long as the interval between 2 consecutive doses is at least 42 ( 3) days .  
• Detailed guidance for belantamab mafodotin  dose reductions and delays is shown in  
Table 20, Table 21, and Table 22.   
• Detailed guidance for lenalidomide dose reductions and delays is shown in Table 23. 
• Detailed guidance for bortezomib dose reductions and delays is shown in Table 24. 
• Detailed guidance fo r dexamethasone dose reductions and delays is shown in Table 
25 (Arm A) and Table 26 (Arm B) . 
Dosing delays also are permitted for medical/surgical events or for logistical  reasons not 
related to study therapy (e.g., COVID -19 related restrictions, ophthalmology services 
unavailable, elective surgery, unrelated medical events, participant vacation, and/or 
public holidays, but not for a participants’ decision to delay treatment). The reason for 
any dose delay must be documented in the participant's eCRF and clinic record s. 
Refer to the SRM for more details on dose modification scenarios.  
 
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 134 
 Table 20 Recommendations for Dose Reduction of Belantamab Mafodotin   
 SINGLE Dosing  SPLIT Dosing  STRETCH Dosing  
Treatment 
Arm Arm A and Arm B  Arm B only  Arm A and Arm B  Arm Aa and Arm 
B Arm B only  
Assigned 
Dose  1.9 mg/kg 
on Day 1  2.5 mg/kg on 
Day 1  3.4 mg/kg on 
Day 1  2.5 mg/kg 
SPLIT into 1.25 
mg/kg on Day 1 
and Day 8  3.4 mg/kg SPLIT 
into 1.7 mg/kg on 
Day 1 and Day 8  1.9 mg/kg 
STRETCH  2.5 mg/kg 
STRETCH  S/D STRETCH  
Dose upon 
First 25% 
Dose 
Reduction 
from 
Assigned 
Dose  No dose 
reduction 
allowed  1.9 mg/kg (no 
dose 
reductions 
below a full 
dose of 1.9 
mg/kg 
allowed)  2.5 mg/kg  1.9 mg/kg 
SPLIT into 0.95 
mg/kg on Day 1 
and Day 8 (no 
dose reductions 
below a full 
dose of 1.9 
mg/kg allowed)  2.5 mg/kg SPLIT 
into 1.25  mg/kg 
on Day 1 and 
Day 8  No dose reduction 
allowed  1.9 mg/kg 
STRETCH (no 
dose reductions 
below a full dose 
of 1.9 mg/kg 
allowed)  No dose 
reduction below 
1.9 mg/kg 
allowed  
Dose upon 
Second 25% 
Dose 
Reduction 
from 
Assigned 
Dose  No dose 
reduction 
allowed  No dose 
reduction 
allowed  1.9 mg/kg (no 
dose 
reductions 
below a full 
dose of 1.9 
mg/kg 
allowed)  No dose 
reduction 
allowed  1.9 mg/kg SPLIT 
into 0.95 mg/kg 
on Day 1 and 
Day 8 (no dose 
reductions below 
a full dose of 1.9 
mg/kg allowed)  No dose reduction 
allowed  No dose 
reduction 
allowed  No dose 
reduction 
allowed  
a. The 1.9 mg/kg STRETCH dosing schedule for Arm A may be evaluated  if emerging data suggests that this schedule may further 
optimize the tolerability  or offers an improved benefit/risk profile .  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 135 
 Table 21 Dose Modification Guidelines for Adverse Events Associated with Belantamab Mafodotin  (Arm A and B)  
Toxicity  Grade/Symptoms  Recommendations  
Serum creatinine elevation which cannot be 
explained by concomitant sepsis, TLS, other 
severe infection with fever or dehydration  
 If absolute serum 
creatinine increase 
from baseline of 
>0.5 mg/dL   Repeat within 48 h  
• If confirmed: withhold therapy, institute treatment and monitoring as clinically 
indicated, and follow for resolution.  
• Discuss  any further dosing  with Medical Monitora. 
Serum creatinine Grade >3 >3.0 mg/dL from 
baseline  
or 
3.0-6.0 × ULN • Provide appropriate medical treatment  
• Permanently discontinue treatment with belantamab mafodotin  
Spot urine (creatinine / albumin ratios)  >2000  mg/g 
(224 mg/mmol)  • Re-test (at least 7 days apart)  
• If not confirmed, continue belantamab mafodotin  at 100% dose  
• If confirmed on re -test and no clear evidence of disease progressiona 
• Interrupt treatment with belantamab mafodotin  
• Repeat testing within 4 weeks  
• If spot urine ≤  2000  mg/g (224  mg/mmol) may restart belantamab 
mafodotin  with 25% dose reduction b.  
• If spot urine remains >2000  mg/g (224  mg/mmol) after 4 weeks, 
permanently discontinue belantamab mafodotin  and withdraw 
participant  from study; provide treatment as clinically indicated and 
follow for resolution.  
Thrombocytopenia (on days of dosing)  
 
Graded according to NCI -CTCAE criteria  Grade 3  SINGLE  and 2.5 mg/kg  STRETCH  Dosing:  
• No bleeding: continue treatment with 25% dose reduction b. Consider reverting to 
previous dose once thrombocytopenia recovered to Grade 2, or less.   
• With bleeding: withhold dose. Treatment with a 25% dose reductiona may continue 
after thrombocytopenia has recovered to Grade 2 or less .  
• Consider  additional supportive treatment ( e.g., transfu sion), as clinically indicated  
and per local practice . 
 
 
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 136 
 Toxicity  Grade/Symptoms  Recommendations  
SPLIT  Dosing:  
• If noted on Day 1  of any cycle , follow guid ance  outlined above for SINGLE  Day 
dosing  for “No bleeding” vs “With bleeding” scenarios as appropriate.  
• If noted on Day 8  of any cycle ; and participant has received belantamab mafodotin  
on Day  1: 
o No bleeding:  continue belantamab mafodotin  Day 8 dosing with a 25% 
dose reductionb. Consider reverting  to previous dose once 
thrombocytopenia recover s to Grade 2, or less.  
o If the dose is unable to be administered on Day 8 of the cycle, it can be 
withheld and administered at any time, up to, and including Day 15 of the 
same cycle, and once the inv estigator determines the participant is 
clinically fit to receive the dose.  
o If belantamab mafodotin  is withheld on Day 8 through  Day 15 due to 
clinical reasons, then belantamab mafodotin  will not be administered  until 
Day 1 of the next planned 28 -day cycle  for Arm A or Day 1 of the next 
planned 21 -day cycle for Arm B . 
o With bleeding: withhold belantamab mafodotin  and provide supportive care 
to stop the bleeding.   
o Continue treatment after recovery with the 25% dose reduction b.   
o If the dose is unable to be administered on Day 8 of the cycle, it can be 
withheld and administered at any time, up to, and including Day 15 of the 
same cycle, and once the investigator determines the participant is 
clinically fit to receive the dose.  
o If belantamab mafodotin  is withh eld on Day 8  and up to Day 15 due to 
clinical reasons, then belantamab mafodotin  will not be administered  until 
Day 1 of the next planned 28 -day cycle for Arm A or Day 1 of the next 
planned 21 -day cycle for Arm B.  
 
S/D STRETCH  and 1.9 mg/kg STRETCH  Dosing:  
• No bleeding: withhold dose.  Treatment at 1.9 mg/kg dose  may continue after 
thrombocytopenia has recovered to Grade 2 or less . 
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 137 
 Toxicity  Grade/Symptoms  Recommendations  
• With bleeding: withhold dose. Treatment at 1.9 mg/kg  dose  may continue after 
thrombocytopenia has recovered to Grade 2 or  less. 
• Consider additional supportive treatment ( e.g., transfusion), as clinically indicated 
and per local practice.  
Grade 4  • Withhold the belantamab mafodotin  dose. Consider restarting with 25% dose 
reductiona if thrombocytopenia recover s to Grade 3 and only if there is no active 
bleeding at time of treatment restart . 
If thrombocytopenia is considered disease -related, and is not accompanied by 
concurrent bleeding, and which recovers following transfusion to >25 x109/L belantamab 
mafodotin  treatment with 25-50% dose reductiona may be considered following 
discussion with the GSK Medical Monitor.  
Febrile neutropenia  
 
Graded according to NCI -CTCAE criteria  Defined as: single 
temp of 38.3C, or 
sustained 38 C for 
>1 h AND ANC 
<1.0×109/L   • Withhold belantamab mafodotin  and immediately hospitalize participant with 
appropriate management, per local institutional guidance.  
• Consider additional supportive treatment per local practice (e.g. growth factors).b 
Upon recovery, c onsider a 25% dose reduction a of belantamab mafodotin , if 
neutropenia was drug -related.   
Neutrophil Count Decreased  (Neutropenia)  
 
Graded according to NCI -CTCAE criteria  Grade 3 -4 • Defined as ANC < 1.0x109/L 
SINGLE , STRETCH  and S/D STRETCH Dosing:  
• If noted on Day 1 of any cycle, withhold belantamab mafodotin . Repeat hematology 
(CBC ) as clinically indicated.  
• Resume belantamab mafodotin  at pre -held dose once neutropenia recover s to 
Grade ≤ 2 (ANC ≥ 1.0x109/L) on D ay 1 of the subsequent cycle.   
• Consider prophylactic antibiotics, per physician discretion and local institutional 
guidance, in participants with Grade 3 -4 neutropenia (ANC <1.0x109/L), even if 
afebrile . Consider growth factorsb. 
SPLIT  Dosing  
• If noted on Day 1 of any cycle, follow guidelines as outlined above for single Day 1 
dosing  
• If noted on Day 8 of any cycle, and participant has received belantamab mafodotin  
on Day 1, then continue belantamab mafodotin  Day 8  dosing unless the investigator 
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 138 
 Toxicity  Grade/Symptoms  Recommendations  
determines that the participant is clin ically unfit to receive the dose ( e.g., febrile 
neutropenia).  
• If the dose is unable to be administer ed on  Day 8 of the cycle, it can be withheld and 
administered at  any time , up to , and including on Day 15 of the same  cycle , and  
once the investigator determines the participant is clinically fit to receive the dose.  
• If belantamab mafodotin  is withheld on Day 8 up to Day 15 due to clinical reasons, 
then belantamab mafodotin  will not be administered  until Day 1 of the next planned 
28-day cycle for Arm A or Day 1 of the next planned 21 -day cycle for Arm B.  
For a subsequent 
drop in ANC to 
<1.0 × 109 /L • Consider 25% dose reduction b of belantamab mafodotin , if it was drug -related.  
Infusion Reaction 
Graded according to NCI -
CTCAE criteria  Note: If symptoms resolve within 1 h of stopping drug infusion, the infusion may be restarted at 50% of the 
original infusion rate (e.g., from 100  mL/h to 50 mL/h).  Otherwise dosing will be held until symptoms resolve 
and the participant should b e premedicated at the next scheduled dose   
Grade 2  • Stop infusion, provide medical treatment and continue at slower infusion rate after 
resolution to Grade 0 -1 
Grade 3  • Further treatment with belantamab mafodotin  needs to be discussed with Medical 
Monitor. Continuation only allowed after recovery to  Grade 1 and with 
premedication, and extension of infusion time to 2 -4 h. Any future infusion needs to 
be premedicated.  
Grade 4  • Permanently discontinue  
Pneumonitis  
Graded according to NCI -CTCAE criteria  Grade 1  Withhold dose and follow recommendations below:  
• Obtain high resolution chest CT if possible.  
• CT scan (high -resolution with lung windows) recommended  
• Clinical evaluation and laboratory work -up for infection  
• Monitoring of oxygenation via pulse -oximetry recommended  
• Consultation with pulmonologist recommended  
• If resolved: Retreatment at the full dose is possible  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 139 
 Toxicity  Grade/Symptoms  Recommendations  
 
Grade 2  Withhold treatment with belantamab mafodotin   
Follow recommendations below:  
• Obtain high resolution chest CT if possible.  
• CT scan (high -resolution with lung windows)  
• Clinical evaluation and laboratory work -up for infection  
• Consult pulmonologist  
• Pulmonary function tests (PFT) – if abnormal, repeat every 8 weeks until back to 
baseline  
• Bronchoscopy with biopsy and/or bronchoalveolar lavage (BAL) recommended  
• Symptomatic therapy including corticosteroids if clinically indicated  
 
If resolved: Restart treatment with 50% dose reduction b.  
Grade 3 -4 Permanently discontinue treatment with belantamab mafodotin  and follow 
recommendations below.  
• Obtain CT scan (high -resolution with lung windows)  
• Clinical evaluation and laboratory work -up for infec tion  
• Consult pulmonologist  
• PFT – if abnormal, repeat every 8 weeks until back to baseline bronchoscopy with 
biopsy and/or BAL if possible.  
• Symptomatic therapy including corticosteroids as clinically indicated  
a. Medical monitor may consult GSK’s Nephrology safety panel regarding treatment continuation .  
b. Dose reduction strategy : see Table 20. 
 
  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 140 
 Table 22 Dose Modification Guidelines for Belantamab Mafodotin  Treatment -Related Corneal Events  
 Grade 1 per GSK Scalea Grade 2 per GSK Scalea Grade 3 per GSK Scalea Grade 4 per GSK Scalea 
Belantamab Mafodotin  
Dosing Actions  Continue treatment with current 
dose of belantamab mafodotin . If either  ophthalmic exam 
findings or visual acuity findings 
are Grade 1,  continue dosing 
with belantamab mafodotin at 
current dose.  
 
If visual acuity and exam 
findings are both Grade2, 
HOLD belantamab mafodotin.  
 
• Upon improvement of 
either visual acuity or 
ophthalmic exam findings 
to Grade 1 or baseline, 
resume with current dose  Hold belantamab mafodotin.  
 
• Upon improvement of 
either visual acuity or 
ophthalmic exam findings 
to Grade 1 or baseline, 
resume with 25% dose 
reduction*  
(* for participants receiving 
1.9 mg/kg dose continue at 
1.9 mg/kg)  
 
In case of recurring ≥Grade 3 
events, consult GSK Medical 
monitor  Stop treatment with belantamab 
mafodotin.  
 
Additional topical treatment may 
be prescribed, as recommended 
by ophthalmologist*  
 
Treatment re -start may be 
possible after discussion and 
agreement between the treating 
qualified eye  care specialist, 
treating physician, the GSK 
Medical Monitor and possibly a 
GSK ophthalmologist  
 
 
Corneal Management 
Care Regardless of 
Grade  Preservative -free artificial tears:  
• Increase to 1 drop as frequently as every 2 h, as needed  
Cooling Eye Masks:  
At the start of each infusion, participants may apply cooling eye masks to their eyes for approximately 1 h or as long as tolerated.  
Steroid Eye Drops:  
Corticosteroid eye drops are not required as prophylaxis but can be used therapeutically if clinically indicated per discretion of an eye  care 
specialist. Allow at least 5 -10 minutes between administration of artificial tears and steroid eye drops (if administered).  
a.  See Appendix 8 for GSK Scale for belantamab mafodotin  Corneal Events  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 141 
 Table 23 Dose Modification Guidelines for Hematologic and Other Toxicities Associated with Lenalidomide Plus 
Dexamethasone ( Arm A) 
Toxicity  Grade/Symptoms  Recommendations  
Thrombocytopeniaa Platelets fall to <30 × 109 /L • Interrupt lenalidomide, follow by weekly  hematology assessment  
Platelets return to ≥30 × 109 /L • Resume lenalidomide at next lower dose. Do not dose below 2.5 mg daily  
For each subsequent drop in platelets 
to <30 × 109 /L • Interrupt lenalidomide treatment. Do not dose below 5 mg daily for Days  1 to 21 of 
28-day cycle  
Platelets return to ≥30 × 109 /L • Resume lenalidomide at 5 mg daily for Days 1 to 21 of 28 -day cycle. Do not dose 
below 5 mg daily for Days 1 to 21 of 28 -day cycle  
Neutropeniab 
Absolute Neutrophil Counts 
(ANC)  ANC fall to <1.0  × 109 /L • Interrupt lenalidomide, hematology ( CBC ) at least once a  week   
• Consider prophylactic anti microbials  per physician discretion and institutional 
guidelines   
• Consider additional supportive treatment, per local practice (e.g., growth factors ) 
• Immediate hospitalization for febrile neutropenia  is required  
When ANC returns to ≥  1.0 × 109 /L • Resume lenalidomide at next lower dose, continuously for Days 1-21 of repeated 
28-day cycle  
For a subsequent drop in ANC to 
<1.0 × 109 /L • Interrupt lenalidomide treatment.  
When ANC returns to ≥1.0  × 109 /L • Resume lenalidomide at next lower dose  daily for Days 1 to 21 of 28 -day cycle. Do 
not dose below 5 mg daily for Days 1 to 21 of 28 -day cycle  
Cutaneous Reactions  Grade 2 -3 • Consider dose  interruption or discontinue lenalidomide  
Grade 4  • Permanently discontinue lenalidomide  
Hypersensitivity  Angioedema and anaphylaxis  • Permanently discontinue lenalidomide  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 142 
 Toxicity  Grade/Symptoms  Recommendations  
For other non-hematological 
toxicities judged to be related 
to lenalidomide  Grade 3 to 4  • Hold lenalidomide treatment and restart at the physician ’s discretion at next lower 
dose level when toxicity has resolved to Grade 2 
a. Note that in the REVLIMID  (lenalidomide ) PI, platelet counts and neutrophil counts are presented as 30,000/mcL; those values have been converted to 30×109/L to maintain 
consistency with protocol laboratory conventions.  
b. Note that in the REVLIMID (lenalidomide ) PI, platelet counts and neutrophil counts are presented as 1,000/mcL; those values have been converted to 1.0×109/L to maintain 
consistency with protocol laboratory conventions  
Data Source: REVLIMID (lenalidomide ) Approved Labelling.  
Table 24 Dose Modification Guide lines for Hematologic and Other Toxicities Associated with Bortezomib Plus 
Dexamethasone ( Arm B) 
Toxicity  Gradea/Symptoms  Recommendations  
Hematological toxicity  
Graded according to NCI -
CTCAE criteria  Grade 4 • Withhold bortezomib therapy until symptoms of toxicity have resolved.  
• Bortezomib may be reinitiated with 1 dose level reduction (from 1.3 mg/m2 to 1 mg/m2, 
or from 1 mg/m2 to 0.7 mg/m2) 
Non-hematological toxicities 
(exclu ding peripheral 
neuropathy)c Grade ≥ 3  • Withhold bortezomib therapy until symptoms of toxicity have resolved. Then, 
bortezomib may be reinitiated with 1 dose level reduction (from 1.3  mg/m2 to 1 mg/m2, 
or from 1 mg/m2 to 0.7 mg/m2).  
• For bortezomib -related neuropathic pain and/or perip heral neuropathy, hold or modify 
bortezomib as outlined in the bortezomib Approved Labelling.  
Peripheral Neuropathyb 
 
 Grade 1  (asymptomatic; loss of 
deep tendon reflexes or 
paresthesia) without pain or loss of 
function  • No action  
Grade 1 with pain, or  
Grade 2  (moderate symptoms; 
limiting instrumental Activities of 
Daily Living [ADLc]) • Reduce bortezomib to 1 mg/m2 
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 143 
 Toxicity  Gradea/Symptoms  Recommendations  
Grade 2 with pain or  
Grade 3 (severe symptoms; 
limiting self care ADLd) • Withhold bortezomib therapy until toxicity resolves. When toxicity resolves , reinitiate 
with a reduced dose of bortezomib at 0.7 mg/m2 once per week.  
Grade 4  (life threatening 
consequences; urgent intervention 
indicated)  • Discontinue bortezomib.  
a. Criteria and Recommendations from bortezomib  Approved Labelling.  
b. Criteria and Recommendations for Peripheral Neuropathy from bortezomib  Approved Labelling.  
c. Instrumental ADL: refers to preparing meals, shopping for groceries or clothes, using telephone, managing money etc.  
d. Self-care ADL: refers to bathing, dressing and u ndressing, feeding self, using the toilet, taking medications, and not bedridden.  
Data Source: bortezomib  Approved Labelling.  
  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 144 
 8.2.2.  Dose Modification Guidelines for Dexamethasone  
For participants who are intolerant to full dose of dexamethasone, the dose of dexamethasone can be reduced as per guidance below:  
Table 25 Dose Modification Guidelines for Toxicities Related to Dexamethasone in Arm A 
Toxicity  Recommendations  
For participants who are >75 with BMI 
<18.5 kg/m2  Reduce the dose of dexamethasone by 50% (i.e . from 40 mg to 20 mg) at the discretion of the investigator.  
Lack of tolerance or significant toxicities 
related to dexamethasone  Reduce dexamethasone dose by 50% (i.e . from 40 mg to 20 mg). If 20 mg is not tolerated, the dexa methasone dose 
can be further reduced, or permanently discontinued.  
  
Table 26 Dose Modification Guidelines for Toxicities Related to Dexamethasone in Arm B 
Toxicity  Recommendations  
For participants who are >75 years, with 
BMI <18.5 kg/m2  Reduce the dose of dexamethasone by 50% (i.e . from 20 mg to 10 mg) at the discretion of the investigator.  
Lack of tolerance or significant toxicities 
related to dexamethasone  Reduce dexamethasone dose by 50% (i.e . from 20 mg to 10 mg). If 10 m g is not tolerated, the dexamethasone dose 
can be further reduced or permanently discontinued.  
 
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 145 
 8.3. Method of Treatment Assignment  
A unique participant  number will be assigned to all participants who sign the ICF and are 
screened in the study.  
Participants, who satisfy the Inclusion and Exclusion criteria for entry, will be assigned to 
either Arm A or Arm B at the discretion of the investigator, until th e maximum planned 
number of participants is obtained in each treatment group.   
Crossover between arms is not permitted in this study.  
Study treatment will be dispensed at the study visits summarized in the Schedule of 
Activities  (Section 3). Returned study treatments (lenalidomide, bortezomib, or 
dexamethasone) should not be re -dispensed to the participants.  
8.4. Blinding  
This is an open -label study; therefore , no blinding o f treatment identity is needed for 
either Arm A or Arm B.   
8.5. Preparation/Handling/Storage/Accountability  
• The investigator or designee must confirm appropriate temperature conditions have 
been maintained during transit for all study treatment received and any discrepancies 
are reported and resolved before use of the study treatment.  
• Only participants enrolled in the study may receive study treatment and only 
author ized site staff may supply or administer study treatment. All study treatments 
must be stored in a secure, environmentally controlled, and monitored (manual or 
automated) area in accordance with the labelled storage conditions with access 
limited to the investigator and autho rized site staff.  
• The investigator, designee, or the head of the medical i nstitution (where applicable) is 
responsible for study treatment accountability, reconciliation, and record maintenance 
(i.e., receipt, reconciliation, and final disposition records).  
• Further guidance and information for the final disposition of unused stu dy treatment 
are provided in the SRM.  
• Under normal conditions of handling and administration, study treatment is not 
expected to pose significant safety risks to site staff . Take adequate precautions to 
avoid direct eye or skin contact and the generation of aerosols or mists. In the case of 
unintentional occupational exposure notify the monitor, Medical Monitor and/or 
GSK study contact.  
• A Material Safety Data Sheet (MSDS)/equivalent document describing occupational 
hazards and recommended handling precauti ons either will be provided to the 
Investigator, where this is required by local laws, or is available upon request from 
GSK.  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 146 
 8.6. Treatment Compliance  
When participants have parenteral study treatments ( belantamab mafodotin  or bortezomib 
or dexamethasone ) admi nistered at the site, they will receive study treatment in the clinic 
under supervision of the investigator or designee. The date and time of each dose 
administered in the clinic will be recorded in the participant’s CRF and source 
documents. The dose of s tudy treatment and study participant identification will be 
confirmed at the time of dosing by a member of the study site staff other than the person 
administering the study treatment.  
When participants self -administer oral study treatment(s) at home, dosi ng with Len/Dex 
(Arm A) or with dexamethasone ( Arm B) will be recorded in the Participant’s Study 
Diary. The entries in the Diary will be assessed through querying the participant during 
the site visits and documented in the source documents and CRF. A rec ord of the number 
of doses dispensed to and taken by each participant must be maintained and reconciled 
with study treatment and compliance records. Treatment start and stop dates, including 
dates for treatment delays and/or dose reductions will also be re corded in the CRF.  
In addition, a complete list of all prior anti -cancer therapies will be recorded in the eCRF.  
8.7. Concomitant Therapy  
Participant s will be instructed to inform the investigator prior to starting any new 
medications from the time of first dos e of study treatment until the End of the Study 
Treatment Visit. Any concomitant medication (including over -the-counter or prescription 
medicines, vitamins, and/or herbal supplements) that the participant is receiving at the 
time of enrollment  or receives during the study must be recorded along with:  
• reason for use  
• dates of administration including start and end dates  
• dosage information including dose and frequency  
The Medical Monitor should be contacted if there are any questions regarding 
concomitant therapy.  
8.7.1.  Permitted Concomitant Medications and Therapies  
Participant s should receive full supportive care during the study, including transfusions, 
growth factors, and treatment with antibiotics, anti -emetics, antidiarrheals, and 
analgesics, as appropriate.  
Concomitant therapy with bisphosphonates is allowed.  
Concomitant  prophylactic treatment for tumor lysis syndrome (according to local 
standards) in participant s with high tumor load should be considered.  
Participant s may receive local irradiation for pain control or stability control.  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 147 
 Several permitted concomitant medic ations may need special monitoring if used. Please 
refer to the SRM for details.  
8.7.2.  Prohibited Concomitant Medications and Therapies  
Chronic treatment with oral steroids other than part of the study treatment is prohibited 
while the participant  is on study wi th the exception of low dose prednisolone (<10  mg/d) 
as substitution in participant s with adrenal insufficiency.  
A short course (up to 7 days) of steroids is allowed to manage rash, treatment -induced 
diarrhea, or other acute complications. Steroids may be  used to treat infusion related 
reactions. Inhaled steroids are allowed.  
Plasmapheresis is prohibited from 7 days prior to first dose of study drug through the end 
of study treatment.  
Administration of live or live -attenuated vaccines are contraindicated 3 0 days prior to the 
first dose of study treatment and while receiving study treatment. Use of live or live -
attenuated vaccines is further contraindicated for at least 70 days following the last dose 
of belantamab mafodotin.  Killed or inactivated vaccines may be administered; however, 
the response to such vaccines cannot be predicted.  
Elimination pathways for belantamab mafodotin  and cys -mcMMAF have not been 
characterized in humans; however, cys -mcMMAF was shown to be a substrate of P -gp 
and OATP transporte rs and to be a poor substrate of CYP enzymes in vitro .  Caution 
should be exercised when belantamab mafodotin  is combined with strong inhibitors of P -
gp, and strong inhibitors of OATP should be avoided unless considered medically 
necessary.  
A list of Prohibited Concomitant Medications is provided in SRM , based on known 
interactions or characteristics of each component of the Study Treatment.  
8.7.3.  Prohibited Devices  
Contact lenses are prohibited while the participant is on study treatment.   
8.8.  Treat ment After the End of the Study  
Study participants that continue to benefit from study intervention beyond the DCO date 
will continue to have access to study intervention until the EOS as defined in Section 8.9. 
There is no planned intervention following the EOS.  
The Investigator is responsible for ensuring that consideration has been given to the post -
study care of the participant’s medical condition . 
Refer to End of Treatment & Follow -Up Assessments for participants who are to be 
followed for disease progression and/or survival after they permanently discontinue from 
study treatment  (Table 10). 
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 148 
 8.9. Continued Access to Study Intervention after Final Data cut   
Participants receiving belantamab mafodotin monotherapy or in combination with either 
Len/Dex (Arm A) or Bor/Dex (Arm B)  at the t ime of the final analysis data cut -off date,  
may continue to receive belantamab mafodotin monotherapy or in combination with 
either Len/Dex (Arm A) or Bor/Dex (Arm B) , if in the opinion of their treating physician, 
they are continuing to derive clinical b enefit from continued treatment. In case the 
participant meets stopping criteria for belantamab mafodotin, the participant will 
discontinue all treatment and will continue to be monitored as per standard of care at the 
participant’s particular study site.  Study treatment will continue until a study 
discontinuation (see Protocol Section 9.3) as assessed by the investigator has been met.  
Participants who continue study treatment in the PACT phase will be cared for in 
accordance with local standard clinical practice Investigators must  report all SAEs, AEs 
leading to treatment discontinuation, overdose and pregnancy cases until 70 days after 
receipt of their last dose of study treatment in accordance with Section 10.2.4  (Reporting 
of Serious Adverse Events). Pre -specified ocular data ( refer to the  SRM) will be reported 
for up to 12 months from the end of PACT treatment or until resolution (to Grade 1 or 
baseline), whichever comes f irst.  
Post final analysis data cut -off, reporting and follow up of SAEs, AEs leading to 
treatment discontinuation, overdose and pregnancy cases and pre -specified ocular data 
will be done via paper forms (see SRM for details) .  
For dispensing of study treatment and drug accountability in the PACT phase please refer 
to the SRM.  
9. DISCONTINUATION CRIT ERIA  
9.1. Discontinuation of Study Treatment  
All participants who discontinue from study treatment will have safety assessments at the 
time of discontinuation and during EOT Follow -up as specified in  Table 10. Participants 
will receive study treatment until disease progression, death or unacceptable toxicity.  
Study treatment may be permanently discontinued for any of the following reasons:  
• Partici pant has met any of the protocol defined safety stopping criteria (Section 
9.2) 
• Deviation(s) from the protocol  
• Request of the participant or proxy (withdrawal of consen t by participant or 
proxy)  
• Investigator’s discretion  
• Pregna ncy 
• Participant is lost to Follow -up  
• The study is closed or terminated  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 149 
 If the participant voluntarily discontinues from treatment due to toxicity, ‘adverse event 
(AE)’ will be recorded as the prim ary reason for permanently discontinuation on the 
electronic case report form (eCRF).    
Once a participant has permanently discontinued from study treatment, the participant 
will not be allowed to re -start taking study treatment.  
9.1.1.  Discontinuation of Indivi dual Components of Combination Study 
Treatment  
The primary reason study treatment was permanently discontinued must be documented 
in the participant’s medical records and eCRF.  
• At the discretion of the investigator and in consultation with the Medical Moni tor, 
participants assigned to Arm A and meeting Stopping Criteria for lenalidomide plus 
dexamethasone may continue to receive belantamab mafodotin  monotherapy on the 
approved schedule until PD, unacceptable toxicity, or death occurs. The primary 
reason each study treatment was discontinued must be documented in the medical 
record and on the eCRF.   
• At the discretion of the investigator and in consul tation with the Medical Monitor , 
participants assigned to Arm B and meeting Stopping Criteria for bortezomib plus 
dexamethasone prior to completing 8  cycles, may still continue to receive 
belantamab mafodotin  monotherapy until PD, unacceptable toxicity, or  death occurs.  
The primary reason each study treatment was discontinued must be documented in 
the medical record and on the eCRF.  
The reason for discontinuing each agent in the combination Arm A and B must be 
recorded independently; the reason for each c omponent of the combination may differ 
from each other.  
9.2. Safety Stopping Criteria  
9.2.1.  Liver Chemistry Stopping Criteria  
Liver chemistry stopping and increased monitoring criteria  have been designed to 
assure participant safety and evaluate liver event etiology  (in alignment with the FDA 
premarketing clinical liver safety guidance [ Food and Drug Administration , 2009]) . 
Discontinuation of study treatment for abnormal liver tests is requi red when the 
participant satisfies any of the stopping rules as shown in Figure 8. 
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 150 
 Figure 8 Liver Stopping and Monitoring Event Algorithm  
 
Refer to Appendix 9 (Section 14.9) for required Liver Safety Actions and Follow -up Assessments.  
9.2.2.  Study Treatment Restart or Rechallenge  
A participant who met liver chemistry stopping criteria cannot resume study intervention 
unless all of the following conditions are met:  
• GSK approval is granted  (see Section 9.1.1 ), 
• Institutional Review Board/Independent Ethics Committee (IRB/IEC) approval  
is obtained and  
• Separate ICF for study intervention  restart/rechallenge is signed by the 
participant and participant is informed of any associated risks  
If GSK approval to restart/rechallenge participant with study intervention  is not  granted , 
then participant  must permane ntly discontinue study intervention  and may continue in the 
study for protocol -specified follow up assessments . 
Refer to Study Procedural Manual for full guidance.  
9.2.3.  QTc Interval Stopping Criteria  
If a participant that meets the corre cted QT (QTc) interval duration criteria below, study 
treatment(s) will be withheld.   
• QTcF >530 msec  

TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 151 
 Based on average QTcF value of triplicate electrocardiograms (ECGs) to include manual 
over-read.  
For example, if an ECG demonstrates a prolonged QT interval, obtain 2 additional ECGs 
over a brief period ( e.g., within approximately 10 min of the abnormal ECG, if possible, 
and approximately 10 min apart from each other), and then use the averaged QTc values 
of the 3 ECGs to determine whether the partici pants should have study treatment(s) 
withheld.  The QTc should be based on single or averaged QTc values of triplicate ECGs  
obtained over a brief (e.g., 5 -10 min) recording period.   
The QT interval should be corrected for heart rate by Fr idericia’s formul a (QTcF).   
See the Schedule of Activities for data to be collected at the time of treatment 
discontinuation and Follow -up and for any further evaluations that need to be completed.  
9.2.4.  Left Ventricular Ejection Fraction (LVEF) Stopping Criteria  
ECHO  must be p erformed at Screening and then every 12 weeks  (7 days),  and at the 
End of Study Treatment Visit as outlined in the Schedule of Activities (Section  3). 
Participants who have an asymptomatic, absolute decrease of >10% in left ventricular 
ejection fraction (LVEF) compared with baseline and the ejection fraction is below the 
institution’s lower  limit of normal (LLN) should temporarily discontinue study treatment 
and have a repeat evaluation of LVEF within 1 week.  ECHO should be repeated every 1 
to 2 weeks for 4  weeks or until LVEF recovery to above institutional LLN and within 
10% of baseline.  
• If the LVEF  recovers (defined as LLN and an absolute decrease 10% 
compared with baseline) at any time during the next 4 weeks, after consultation 
and approval of the Medical Monitor , the participant may be restarted on study 
treatment at a reduced dose. For such participants, monitoring of LVEF will be 
performed 2 and 4 weeks after rechallenge, and every 4 weeks thereafter for 16 
weeks and then per protocol.  
• If repeat LVEF does not recover within 4 weeks, study treatment should be 
permanently discontinued . Ejection fraction should be monitored every 4  weeks 
for a total of 16 weeks or until resolution.  
Participants with Grade 3 or 4 (symptomatic) left ventricular systolic dysfunction must 
discontinue study treatment. Ejection fraction should be monitored ev ery 4  weeks for a 
total of 16 weeks or until resolution. If recovery occurs (LVEF institutional LLN and 
symptom resolution) within 4 weeks, then study treatment may be restarted at a reduce 
dose in consultation with the Medical Monitor.  
ECHOs for participants who experience a >10% decrease in LVEF from baseline and 
whose cardiac ejection fraction is < institution’s LLN will be reviewed by the Sponsor. 
Instructions for submitting qualifying ECHOs are provided in the SRM.  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 152 
 9.2.5.  Corneal Event Stopping Crite ria 
Corneal events, which commonly manifests as a superficial microcystic keratopathy, has 
been observed with antibody drug conjugates, including those conjugated to MMAF.  
Further information regarding corneal event associated with belantamab mafodotin , 
including the GSK grading scale and prophylactic measures are in Appendix 8, Section 
14.8. 
All belantamab mafodotin  dose modifications and stopping criteria are to be based on the 
GSK Scale provided in Appendix 8, Section 14.8. Corneal events will be graded 
according to both CTCAE criteria for eye disorders and the  guidelines provided in 
Appendix 8. 
The treating physician or qualified eye care specialist ( Appendix 12 ) must discuss the 
participants who develop a Grade 4 corneal event according to the GSK scale with the 
Medical Monitor or a GSK eye care specialist  to determine whether the participant can be 
allowed to restart treatment with belantamab mafodotin  or whether belantamab mafodotin  
should be permanently discontinued. If a participant is allowed to continue on study, the 
dose of belantamab mafodotin  will be reduced after discussion with Medical Monit or. 
The decision will be documented in study files, together with individual assessment of 
risk-benefit.  
9.2.6.  Infusion -Related Reaction Management and Stopping Criteria  
Premedication is not required prior to infusion unless deemed medically appropriate by 
the investigator. Premedication should be considered in any participant who experienced 
an IRR at first or any subsequent infusion with belantamab mafodotin . For infusion 
reactions of any  grade/severity, immediately interrupt the belantamab mafodotin  infusion 
and manage  symptoms. Once reaction symptoms resolve, resume the infusion at a 
reduced rate.  Premedication may be administered  with subsequent infusions  per 
institutional guidelines . IRRs should be managed by guidelines provided in  Table 20. 
A participant that experiences a Grade 4 IRR associated with belantamab mafodotin  
should be permanently withdrawn from the study.  
9.2.7.  Allergic and Anaphylactic Reaction Stopping Criteria  
All participants will be monitored carefully for evidence of allergic response  to study 
treatments . A participant that exhibits signs or symptoms of severe hypersensitivity or 
anaphylaxis will receive appropriate medical treatment and be permanently withdrawn  
from the study.  
9.3. Withdrawal from the Study  
A participant may withdraw from the study at any time at his/her own request, or may be 
withdrawn at any time at the discretion of the investigator for safety, behavioral, 
compliance, or administrative reasons.  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 153 
 If the participant withdraws consent for disclosure of future information, the Sponsor 
may retain and continue to use any data collected before such a withdrawal of consent.  
If a participant withdraws from the study, he/she may request destruction of any samples 
taken and not tested, and the Investigator must document this in the site study records.  
Refer to End of Treatment & Follow -Up Assessments ( Table 6) for informatio n to be 
collected at the time of study discontinuation . 
9.4. Lost to Follow -Up 
A participant  will be considered lost to Follow -up if they repeatedly fail to return for 
scheduled visits and is unable to be contacted by the study site.  
The following actions must  be taken if a participant fails to return to the clinic for a 
required study visit:  
• The site must attempt to contact the participant and reschedule the missed visit as 
soon as possible and counsel the participant on the importance of maintaining the 
assig ned visit schedule and ascertain whether or not the participant wishes to and/or 
should continue in the study.  
• Before a participant is deemed lost to Follow -up, the investigator or designee must 
make every effort to regain contact with the participant (whe re possible, 3  telephone 
calls and, if necessary, a certified letter to the participant’s last known mailing 
address or local equivalent methods). These contact attempts should be documented 
in the participant’s medical record.  
• Should the participant conti nue to be unreachable, he/she will be considered to have 
withdrawn from the study with a primary reason of lost to Follow -up.  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 154 
 10. STUDY ASSESSMENTS AN D PROCEDURES  
Study procedures and their timing are summarized in the Schedule of Activities 
(Section  3). Key assessments to be performed during the study are briefly described 
below, with more detailed information provided for some specific assessments in the 
Protocol  Appendices or the SRM. Protocol waivers or exemptions for study assessments 
will not be allowed.  
The investigators will maintain screening logs to record details of all participants 
screened and to confirm eligibility or record reasons for screening failure, as appropriate. 
Procedures conducted as part of the participant’s routine clinical management (e.g., blood 
count) and obtained before signing of ICF may be utilized for screening or baseline 
purposes provided the procedure met the protocol -specified criteria and was performed 
within the time frame defined in the Schedule of Activities (Table 4).   
Where applicable country and local regulations and infrastructure allow,  home healthcare  
and telemedicine may be permitte d (Appendix 1 3 Section 14.13 )  
10.1.  Assessments for Evaluation of Clinical Activity  
Clinical activity will be evaluated in all participants in the study.  Standard Response 
assessments for RRMM will be applied to clinical activity data, and will include: Overall 
Response Rate (ORR),  
 – as defined by 2016 IMWG 
response criteria [Kumar , 2016 ], and as data permits. In addition, the number (%) of 
participants achieving  will be assessed 
according to IMWG criteria 2011 and 2016 [ Kumar , 2016], as data permits.  
Clinica l activity assessments and/or diagnostic criteria will be evaluated during treatment, 
per IMWG and other current practice guidelines for the management of RRMM [ Bennett , 
2016 ; Kumar , 2016 ; Moreau , 2017 ; National Comprehensive Cancer Network , 2016 ; 
Rajkumar , 2016].  These may  include : 
• Laboratory tests (serum and urine M -protein test, immunofixation, free light chains 
[FLC])  
• Bone marrow (BM) aspirate/biopsy for disease assessment,  
 testing  
• Imaging for extramedullary disease and skeletal survey  
10.1.1.  Imaging  
Imaging is only required for participants with extramedullary disease by either CT, MRI, 
or PET/CT per local guidance. The screening assessment may be performed up to 
30 days prior to C1D1. The imaging method used at baseline should be used throughout 
the study (i.e. if CT/PET scan was used as baseline, the participant should be followed by 
CT/PET scans). A selected target lesion should be measured and followed over time. 
Plasmacytoma measurements should be taken from the CT portion of the PET/CT, or 
MRI sc ans, or dedicated CT scans, where applicable. For participants with only skin 
CCI
CCI
CCI
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 155 
 involvement, skin lesions should be measured with a ruler. Measurement of tumor  size 
will be determined by the Sum of the Products of the maximal perpendicular diameters of 
measu red lesions (SPD).  
10.2.  Adverse Events  
The definitions of an AE or SAE can be found in Appendix 6, Section 14.6. 
The investigator and any designees are responsible for detecting, documenting, and 
reporting events that meet the definition of an AE or SAE and remain responsible for 
following up AEs that are serious, considered related to the study treatment or the stud y, 
or that caused the participant to discontinue the study treatment (see Section 9.1). 
Adverse events, including  corneal events, will be graded by  the investigator according to 
the NCI -CTCAE, (version 4.03). For dosing decisions, c orneal events associated with 
belantamab mafodotin  will also be graded according to the GSK grading scale provide d 
in Appendix 8. 
10.2.1.  Time Period and Frequency for Collecting AE and SAE 
Information  
All SAEs will be collected from the start of treatment until at least 70  days following 
discontinuation of study treatment regardless of  initiation of a new cancer therapy or 
transfer to hospice at the time points specified in the Schedule of Activities (SoA) 
(Section 3). 
• However, any SAEs assessed as r elated to study participation (e.g., study treatment, 
protocol -mandated procedures, invasive tests, or change in existing therapy) or 
related to a GSK product will be recorded from the time a participant  consents to 
participate in the study up to and inclu ding any follow -up. 
• All AEs will be collected from the start of treatment until at least 70  days following 
discontinuation of study treatment regardless of initiation of a new cancer therapy or 
transfer to hospice at the time points specified in the SoA.  
• Medical occurrences that begin before the start of study treatment but after obtaining 
informed consent will be recorded on the Medical History/Current Medical 
Conditions section of the electronic case report form (eCRF) not the AE section.  
• All SAEs will b e recorded and reported to the Sponsor or designee immediately and 
under no circumstance should this exceed 24 h, as indicated in Appendix 6, Section 
14.6. The investigator will submit any updated SAE data to the Sponsor within 24 h 
of it being available.  
• Investigators are not obligated to actively seek AEs or SAEs in fo rmer study 
participants. However, if the investigator learns of any SAE, including a death, at 
any time after a participant has been discharged from the study, and he/she considers 
the event to be reasonably related to the study treatment or study particip ation, the 
investigator must promptly notify the Sponsor.  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 156 
 • The method of recording, evaluating, and assessing causality of AEs and SAEs and 
the procedures for completing and transmitting SAE reports are provided in 
Appendix 6, Section 14.6.  
• For participants in the PACT phase of the study, GSK will continue to c ollect safety 
information including SAEs, AEs leading to treatment discontinuation, overdose and 
pregnancy cases and pre -specified ocular data via paper forms, emails (preferably), 
and fax which will be reported directly to GSK (see SRM for details). SAE, overdose 
and pregnancy and cases will go to the Global Safety database (ARGUS) . 
• SAEs, overdose and pregnancy cases will be reported during the PACT treatment 
period and for up to 70 days after last dose. Additionally, any SAE that are ongoing 
at the time of the final data cut -off must be followed up to resolution unless the event 
is considered by the investigator unlikely to resolve, or the patient is lost to follow -
up.   
• Pre-specified ocular data will continue to be collected for participants receiving 
belantamab mafodotin after the start of PACT as follows: Participants without 
signi ficant ocular examinations findings, symptoms or vision changes when entering 
the PACT phase will be required to have an ocular assessment at least every 3 
months until the end of treatment. Participants who at the time of entering PACT 
have ocular symptom s or vision changes, or develop these during PACT treatment, 
the ocular assessment will occur every cycle until resolution (KVA Grade 1 or 
baseline). After the end of PACT treatment, participants with treatment -related 
ocular examination findings, ocular s ymptoms, or vision changes will be followed at 
least every 3 months for up to 12 months from the end of treatment or until 
resolution (to KVA Grade 1 or baseline), whichever comes first. For participants 
without ocular examination findings, ocular symptoms , or vision changes at the end 
of PACT treatment, no further ocular exams are required. In addition, participants 
who stopped belantamab mafodotin prior to PACT but have ongoing ocular events at 
the time of final study data -cut-off/start of PACT, will be f ollowed at least every 3 
months for up to 12 months from the end of treatment or until resolution (KVA 
Grade 1 or baseline), whichever comes first . GSK retains the right to request 
additional information for any patient with ongoing AE(s)/SAE(s) at the end  of the 
study, if judged necessary.  
10.2.2.  Method of Detecting AEs and SAEs  
Care will be taken not to introduce bias when detecting AEs and SAEs. Open -ended and 
non-leading verbal questioning of the participant is the preferred method to inquire about 
AE occurre nce.  
10.2.3.  Follow -up of AEs and SAEs  
After the initial AE/SAE report, the investigator is required to proactively follow each 
participant at subsequent visits/contacts. All SAEs, and non -serious AEs of special 
interest, will be followed until the event is resolved, stabilized, otherwise explained, or 
the participant is lost to Follow -up (as defined in Section 9.4). Further information on 
follow -up procedures is given in  Appendix 6, Section 14.6. 
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 157 
 10.2.4.  Regulatory Reporting Requirements for SAEs  
• Prompt notification by the investigator to the Sponsor of an SAE is essential so that 
legal obligations and ethical responsibilities towards the safety of participants and 
the safety of a study treatment under clinical investigation are met.  
• The Sponsor h as a legal responsibility to notify both the local regulatory authority 
and other regulatory agencies about the safety of a study treatment under clinical 
investigation. The Sponsor will comply with country -specific regulatory 
requirements relating to safe ty reporting to the regulatory authority, Institutional 
Review Boards (IRB)/Independent Ethics Committees (IEC), and investigators.  
• Investigator safety reports must be prepared for suspected unexpected serious 
adverse reactions (SUSAR) according to local r egulatory requirements and Sponsor 
policy and forwarded to investigators as necessary.  
• An investigator who receives an investigator safety report describing an SAE or 
other specific safety information e.g., summary or listing of SAE) from the Sponsor 
will review and then file it along with the Investigator’s Brochure and will notify the 
IRB/IEC, if appropriate according to local requirements.  
10.2.5.  Cardiovascular and Death Events  
The Death CRF is provided immediately after the occurrence or outcome of death is 
reported. Initial and follow -up reports regarding death must be completed within one 
week of when the death is reported.  
For any cardiovascular events detailed in Appendix 5, Section 14.5 and all deaths, 
whether or not they are considered SAEs, specific Cardiovascular (CV) and Death 
sections of the eCRF will be required to be completed. These sections include questions 
regarding cardiovascular (including sudden cardiac death) and non -cardi ovascular death.  
The CV eCRFs are presented as queries in response to reporting of certain CV medical 
dictionary for regulatory activities (MedDRA) terms. The CV information must be 
recorded in the specific cardiovascular section of the eCRF within 1 week  of receipt of a 
CV Event data query prompting its completion.  
10.2.6.  Adverse Events of Special Interest  
Adverse events of special interest (AESI) for belantamab mafodotin  are corneal events, 
thrombocytopenia and infusion related reactions.  Severity of all AESI will be graded 
using National Cancer Institute -Common Toxicity Criteria for Adverse Events (CTCAE, 
v4.03; Appendix 8). Severity of corneal events will also be graded using th e GSK scale 
for corneal events provided in Table 33. Guidelines for dose modifications and 
interruptions for management of common toxicities associated  with the study treatment(s) 
are provided in Table 20. 
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 158 
 10.2.7.  Pregnancy  
Do not collect pregnancy information for female participants known to be pregnant 
during the screening phase or before exposure to study.  
The need for a screening pregnancy test depe nds on whether a female participant is of 
childbearing potential or non -childbearing potential.  
If a female participant is of childbearing potential, she must have a serum β -human 
chorionic gonadotropin (β –HCG) pregnancy test performed within 24 h prior t o the first 
dose of study treatment. Participants with positive pregnancy test result must be excluded 
from the study. Participants with negative pregnancy test result must agree to use an 
effective contraception method as described below during the study until 4 months  
following the last dose of study treatment.  
• Details of all pregnancies in female participants will be collected after the start of 
study treatment and  
• Arm A: for 4 months following last dose of belantamab mafodotin  or 4 weeks 
after the last  dose of lenalidomide, whichever is longer  (by telephone for 
WOCBP only) 
• Arm B: for 4 months following last dose of belantamab mafodotin or 7 months 
following last dose of bortezomib whichever is longe r (by telephone for 
WOCBP only)  
• Details of all pregnancies for female partners of male participants will be collected 
after the start of study treatment and 6 months following the last dose of belantamab 
mafodotin  (by telephone for WOCBP partners only)  
• If a pregnancy is reported, the inv estigator must inform GSK within 24 h of learning 
of the pregnancy and must follow the procedures outlined in Appendix  7, as well as 
those outlined in REVLIMI D (lenalidomide)  Patient Exposure Registry (Refer to 
SRM). 
• Abnormal pregnancy outcomes (e.g., spontaneous abortion, fetal death, stillbirth, 
congenital anomalies, ectopic pregnancy) are considered SAE s. 
10.2.8.  Medical Device Incidents (including malfunctions)  
Not applicable for this study  
10.3.  Treatment of Overdose  
10.3.1.  Belantamab Mafodotin  Overdose  
There is no specific information on overdose of belantamab mafodotin . GSK does not 
recommend specific treatment for an overdose of belantamab mafodotin . 
In the event of an overd ose (defined as administration of more than the protocol -specified 
dose) of belantamab mafodotin , the investigator should:  
• contact the GSK Medical Monitor immediately  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 159 
 • closely monitor the participant for AEs, SAEs, and laboratory abnormalities 
until they ar e resolved and belantamab mafodotin  concentrations are predicted to 
be within the anticipated range in absence of the overdose   
• obtain an additional PK and serum  sample as soon as the overdose 
situation is recognized and contact the GSK Medical Monitor for further 
guidance with regard s to additional sample collection (determined on a case -by-
case basis)  
• document the quantity of the excess dose as well as the duration of the 
overdosing in the eCRF  
Decisions regarding  belantamab mafodotin  or administrat ion of SoC agents following an 
overdose will be made by the investigator in consultation with the GSK Medical Monitor 
based on the clinical evaluation of the participant.  
10.3.2.  Lenalidomide  Overdose  
There is no specific experience in the management of lenalidomide overdose in 
participant s with MM. In dose -ranging studies in healthy participant s, some were 
exposed to up to 200  mg (administered 100 mg BID) and in single -dose studies, some 
participant s were exposed to up to 400 mg. Pruritis, urticaria, rash, and elevated liver 
transaminases were the primary reported AEs.  In clinical trials, the dose -limiting toxicity 
was neutropenia and  thrombocytopenia.  
10.3.3.  Bortezomib  Overdose  
There is no known specific ant idote for bortezomib  over-dosage. In humans, overdose  of 
more than twice the recommended dose ha s been  associated with the acute onset of 
symptomatic hypotension and thrombocytopenia  with fatal outcomes . In the event of an 
overdos e, the participant ’s vital signs should be monitored,  and appropriate supportive 
care given  to maintain blood pressure (such as fluids, pressors, and/or inotrophic agents) 
and body temperature . 
10.3.4.  Dexamethasone  Overdose  
Overdosage or prolonged use may exaggerate glucocorticoid  adverse effects. Treatment 
should be symptomatic and supportive with the dosage of  dexamethasone being reduced 
or slowly withdrawn where possible.  
10.4.  Demographics and Medical History  
Demographic and medical history data will be collected at Screening and ver ified pre -
dose on Day 1 Cycle 1 in both Part 1 and Part 2.  
Demographic data we can collect may differ in different regions but should include: year 
of birth, sex, and race/ethnicity (if permitted). The medical history data that may be 
collected can be divi ded into two sections:  
• Standard Medical History of Prior Conditions: may include the condition/diagnosis, 
body system (if appropriate), date of diagnosis, intensity (if appropriate), date of 
resolution, and any interventions or treatments (with dates).  
CCI
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 160 
 • History of RRMM and Current Comorbid Conditions may include: the 
condition/diagnosis (for non -RRMM), body system (if appropriate, for non -RRMM), 
date of diagnosis, intensity or Grade (as appropriate), prior treatment regimens with 
start and stop dates, and an y interventions or treatments.  
10.5.  Daily Study Diary  
Depending on assigned treatment, participant will be issued Daily Study Diary that will 
be reviewed at each clinic visit. Participant Diary will be used to record drug 
accountability information:  doses of le nalidomide or dexamethasone taken at home 
during a treatment cycle; drug name, dose (or number of tablets or capsules), the date the 
dose was taken, and the time the dose was taken will all be recorded in the Diary.  
10.6.  Safety Assessments  
10.6.1.  Physical Examinations  
Physical examinations will be performed during Screening, pre -dose on Day 1 (and on 
Day 8 for SPLIT dosing) of each Cycle, and upon discontinuation form Study Treatment 
(End of Treatment Visit and  FU Visit). A physical examinatio n 
will include, at a minimum, assessments of the head, eyes, ears, nose, throat, skin, 
thyroid, lungs, cardiovascular, abdomen (liver and spleen), lymph nodes and extremities. 
Height and weight will also be measured at Screening and recorded, with weight r epeated 
at the start of each cycle ( Schedule of Activities, Section 3). Body weight at C1D1 (prior 
to dosing) will be used for dose calculation of belantamab mafodotin . Body weight will 
also be measured prior to each dose. If the change of body weight is greater than 10%, 
the dose should be re -calculated based on the actual body weight at the time of dosing.  
During the physical examinations, investigator s should pay special attention to clinical 
signs related to previous serious illnesses and record any changes noted during study 
treatment, if any.  
10.6.2.  ECOG Performance Status  
The participant’s performance status will be assessed using the ECOG scale ( Appendix 3, 
Section 14.3) as specified in the Schedule of Activiti es (Section 3). 
10.6.3.  Vital Signs  
Vital sign measurements will include systolic and diastolic blood pressure, temperature, 
and heart rate. Vital signs should be measured aft er resting for at least 5 min. Vital signs 
will be measured more frequently if warranted by the clinical condition of the participant . 
On days where vital signs are measured multiple times, temperature does not need to be 
repeated unless clinically indicat ed. 
On each dosing day, vital signs must be assessed prior to each infusion of belantamab 
mafodotin  at pre -dose, defined as within 30 min prior to start of infusion (SOI), within 15 
min after End of Infusion ( EOI), and at 1 h (±5 min)  after EOI. On days where 
bortezomib is administered, vital signs must be assessed within 30 mins prior and within 
CCI
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 161 
 15 min after each dose of bortezomib . On days where vital sign time points align with PK 
sampling time points, vital signs should be assessed prior to PK  samples being drawn.  
In general, participants must also be monitored for at least 1 h after the completion of the 
infusion of belantamab mafodotin  and may be discharged if considered clinically stable 
and all other study procedures have been completed.  
In case of IRRs monitoring will be performed with higher frequency (as clinically 
indicated).  
10.6.4.  New York Heart Association Functional Scale  
Criteria for rating participants for heart failure status according to the New York Heart 
Association (NYHA) criteria ar e provided in Appendix 5, Section 14.5. 
10.6.5.  Electrocardiograms  
Triple 12-lead electrocardiogram (ECGs) will be obtained at designated time points 
specified in the Schedule of Activities  (Section 3) during the study using an ECG 
machine th at automatically calculates the heart rate and measures PR, QRS, QT, and 
corrected QT (QTc) intervals.   
At each assessment, a 12 -lead ECG will be performed by qualified personnel at the site 
after the participant  has at least a 5 -min rest.   
The QT interv al should be corrected for heart rate by Fr idericia’s formula (QTcF). Refer 
to Section 9.2.3  for QTc withdrawal criteria. Refer to the Study Procedures Manual for 
details regarding ECG procedures.  
Instructions for submission of ECGs are provided in the SRM.  
10.6.6.  Echocardiogram  
ECHOs must be performed at baseline and then every 12 weeks (  7 days) to assess 
cardiac ejection fraction for the purpose of study eligibility, as specified in the SoA. A 
final ECHO will also be performed at the End of Treatment Visit. The evaluation of the 
echocard iographer must include an evaluation for left ventricular ejection fraction 
(LVEF). If an ECHO is performed on study the results must be documented in the e -
CRF.  
10.6.7.  Ophthalmic Examinations  
Study sites are required to establish a close collaboration with a qualified eye care 
specialist  who will be responsible for assessing participants while they are on -study and 
managing participants who develop a corneal event  in close communication with the 
GSK Medical Monitor . Participants will be assessed by a qualified eye care specialist at 
screening/baseline and then on Day 1 of every cycle prior to belantamab mafodotin 
dosing up to Dose 6 of belantamab mafodotin (assessment window of up to 5 days prior 
to dosing, but all ef fort should be made to schedule as close to belantamab mafodotin 
dosing as possible). For STRETCH schedule, belantamab mafodotin dosing is scheduled 
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 162 
 on Day 1 of every alternate 21 -day cycle, but participants will be assessed by a qualified 
eye care special ist on Day 1 of every 21 -day cycle up to the Dose 6 of belantamab 
mafodotin   regardless of dosing (assessment window of up to 5 days before Day 1 of 
every 21 -day cycle prior to dosing, but all effort should be made to schedule as close to 
belantamab mafodo tin dosing as possible). See Appendix 12  for qualifications and 
requirements of the eye care specialist.  
• If there are no significant ocular examinations findings, patient’s symptoms or 
vision changes at the time of the Dose 6 exam, participants may have their 
ophthalmologic exams decreased to once every 3 months.  
• If a participant subsequently develops vision changes or other ocular symptoms, 
the participant should be promptl y evaluated by a qualified eye care specialist.  
• In case of persistent ophthalmic exam findings, newly developed ocular 
symptoms or vision changes at the Dose 6 exam, the participants will have 
further ophthalmologic exams, at least every cycle until resolu tion (to Grade 1 
or baseline) or more frequently as clinically indicated by the qualified eye care 
specialist.  
Participants who have corneal signs per the GSK scale for Corneal Events at the End of 
Treatment Visit will be followed once every 3 months  (7 days) until full resolution of 
ophthalmic changes (Grade 1 or baseline ) by a qualified eye care specialist  or start a new 
anti-cancer therapy, or up to 1 year (whichever comes first).  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 163 
 10.6.7.1.  Ocular Examinations and Procedures  
A full screening/ baseline  ophthalmic examination for all participant s must include  for 
both eyes (OU) : 
1. Best corrected visual acuity  
2. Documentation of manifest refraction and the method  used to obtain best corrected 
visual acuity  
3. Current glasses prescription (if applicable)  
4. Anterior segment (slit lamp) examination with focus on the cornea and lens, including 
fluorescein staining of the cornea   
5. Intraocular pressure measurement  
6. Dilated funduscopic exam  
The on treatment  and follow -up ophthalmic exam  should be performed for both eyes 
(OU), as described below  (and in the SoA)  and must include :  
1. Best corrected visual acuity  
2. Documentation of manifest refraction and the method used to obtain best corrected 
visual acuity  
3. Anterior segment (slit lamp) examination with focus on the cornea and lens, 
including fluorescein staining of the cornea  
4. Intraocular pressure measurement (if clinically indicated)  
5. Dilated funduscopic exam (if clinically indicated)  
The end of treatment and last follow -up ophthalmic exam should match the screeni ng/ 
baseline  exam.  
Additional examinations should be performed at the discretion of the treating eye 
specialist.  
10.6.8.  Patient -Reported Outcome Version of the Common Term Criteria 
for Adverse Events (PRO -CTCAE)  
The Patient -Reported Outcomes Version of the Common Terminology Criteria for 
Adverse Events is a patient -reported outcome measure developed to evaluate 
symptomatic toxicity in patients on cancer clinical trials [ Basch , 2014]. The PRO -
CTCAE was designed to be used as a companion to the Common Terminology Criteria 
for Adverse Events (CTCAE), the standard lexicon for adverse event reporting in cancer 
trials. The PRO -CTCAE includes an item library of 124 items representing 8 0 
symptomatic toxicities drawn from the CTCAE.  PRO -CTCAE provides a systematic yet 
flexible tool for descriptive reporting of symptomatic treatment side effects in cancer 
clinical trials. In the present study, a subset of items selected from the PRO -CTCAE  
Version 1.0 item library will be administered, as shown in the Schedule of Activities 
(Section 3). The PRO -CTCAE will be administered to participant s in different reg ions 
based on the availability of translated versions.  All participants will complete the self -
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 164 
 administered version of this assessment unless  they are unable to do so  due to site 
restrictions or the PI or site feels it is in the best interest of the partic ipant not to come to 
the site. Participants who cannot complete the self -administered version  should use an 
Interviewer -Administered format. The interview may be administered  over the telephone . 
If the Interviewer -Administered format is used, it should be read to the participants 
verbatim, and participant responses should be recorded directly without any 
interpretation.  
10.6.9.  Visual Function Safety Assessment  
The impact of potential ocular toxicity on function and health -related quality of life will 
be assessed w ith the use of 2 visual function questionnaires: the National Eye Institute 
Visual Function Questionnaire -25 (NEI -VFQ -25), and the Ocular Surface Disease Index 
(OSDI). All participant s will complete the self -administered version of these two 
assessments, u nless their vision prevents them from being able to complete the 
questionnaire on their own , they are unable to complete  the self-administered version  due 
to site restrictions, or the PI or site feels it is in the best interest of the participant not to 
come to the site . Participant s who are not able to complete the self-administered version  
should use an Interviewer -Administered format. If the Interviewer -Administered format 
is used, it should be read to the participant s verbatim, and participant  responses  should be 
recorded directly without any interpretation. For any additional assessments conducted 
via telephone (either during participation in the treatment period or during Follow -up), 
the Interviewer -Administered format should be used.  
10.6.9.1.  National Eye Inst itute Visual Function Questionnaire -25 
The NEI -VFQ -25 consists of a base set of 25 vision -targeted questions representing 11 
vision -related constructs, plus an additional single -item general health rating question. 
These include a global vision rating (1 i tem); difficulty with near vision activities (3 
items); difficulty with distance vision activities (3 items); limitations in social functioning 
due to vision (2 items); role limitations due to vision (2 items); dependency on others due 
to vision (3 items);  mental health symptoms due to vision (4 items); driving difficulties (3 
items); limitations with peripheral vision (1 item), limitations with color vision (1 item); 
and Ocular pain (2 items). The NEI -VFQ -25 will be completed by the participants at the 
times shown in the Schedule of Activities ( Section 3). 
10.6.9.2.  The Ocular Surface Disease Index  
The Ocular Surface Disease Index (OSDI) is a 12 -item questionnaire designed to assess 
both the frequency of dry eye symptoms and their impact on vision -relate d functioning 
[Dougherty , 2011, Schiffman , 2000]. The OSDI has demonstrated g ood reliability, 
validity, sensitivity, and specificity, and can be used as a complement to other clinical 
and participative measures of dry eye disease by providing a quantifiable assessment of 
dry eye symptom frequency and the impact of these symptoms on  vision -related 
functioning. The OSDI will be completed by the participants at the times shown in the 
Schedule of Activities ( Section 3). 
 
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 165 
 10.6.10.  Laboratory Assessments  
All protocol -required laboratory assessments should be performed according to the 
Schedule of Activities ( Section 3). 
Details for the preparation and shipment of samples are provided in the SRM.  
Local laboratory results will be used to make decisions regarding treatment or 
management of AEs.  
Prior to administration of the first dose of study treatment, results of laboratory 
assessments should be reviewed.  Any laboratory test with a value outside the normal 
range may be repeated (prior to the first dose) at the discretion of the Investigator.  
If additional non -protocol -specified laboratory assessments are performed at the 
institution’s local laboratory and result in a chan ge in participant  management or are 
considered clinical significant by the investigator (for example SAE or AE or dose 
modification) the results must be recorded in the participant ’s CRF.  Clinically significant 
abnormal laboratory findings are those which are not associated with the underlying 
disease, unless judged by the investigator to be more severe than expected for the 
participant ’s condition.  
All laboratory tests with values that are significantly abnormal during participation in the 
study or within 70 days after the last dose of study treatment should be repeated until the 
values return to normal or baseline. If such values do not return to no rmal within a period 
judged reasonable by the Investigator, the etiology should be identified and the Sponsor 
notified.  
Hematology, clinical chemistry, urinalysis and additional parameters to be tested are 
listed in Table 27 with detailed instructions and timing in the SRM.  
Refer to the SRM for appropriate processing and handling of samples to avoid duplicate 
and/or additional blood draws.  
Table 27 List of Clinical Laboratory Tests  
Hematology1 
Platelet Count   Red Blood Cell 
(RBC) Indices : Automated WBC Differential : 
Red Blood Cell ( RBC ) Count  MCV  Neutrophils  
White Blood Cell (WBC) Count 
(absolute)  MCH  Lymphocytes  
Reticulocyte  Count  MCHC  Monocytes  
Hemoglobin   Eosinophils  
Hematocrit   Basophils  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 166 
 Clinical Chemistry1 
Blood urea nitrogen 
(BUN)  Potassium  Aspartate aminotransferase 
(AST)  Total and direct bilirubin  
Creatinine  Chloride  Alanine aminotransferase 
(ALT)  Uric Acid  
Glucose  Total carbon 
dioxide (CO 2) Gamma glutamyl transferase 
(GGT)  Albumin  
Sodium  Calcium  Alkaline phosphatase  Total Protein  
Magnesium  Phosphorous  Creatine kinase (CK)  LDH 
Urinalysis1 
Specific gravity; pH, glucose, protein, blood and ketones by dipstick  
Microscopic examination (if blood or protein is detected by dipstick)  
Other Laboratory Tests  
Spot urine ( albumin/creatinine ratios) 1, 3; HbA1c1; C-reactive protein (CRP)1; Pregnancy Test (urine or 
blood)1; Follicle -stimulating hormone (FSH)1 and estradiol1 (as needed in women of non -child-bearing 
potential only); Hepatitis B (H bsAg)1; HbcAb, Hepatitis C antibody1, Hepatitis C RNA test1 (optional)  
Note: H ep C RNA testing is optional but may be done to determine participant eligibility if Hep C antibody 
positive.  
eGFR1 
PK and ADA2 
Pharmacokinetics (PK)  
Anti-Drug Antibodies (ADA)  
Disease Evaluation Laboratory Tests1, 3 
Beta2 microglobulin; S PEP (Serum Protein Electrophoresis); Serum M -protein calculation; Serum Kappa, 
lambda free LC, FLC ratio; Serum Immunofixation; UPEP (Urine Protein Electrophoresis); 24 -h urine 
collection for M -protein; Urine Immunofixation; Ca corrected for Albumin (Serum); IgG, IgM, IgA, IgD/IgE4  
Bone Marrow Aspiration/Biopsy  
BM for FISH analysis1, 3, 5; BM aspirate for BCMA expression  and biomarker research2; BM biopsy to 
confirm sCR ( by IHC) 2; BM aspirate for  testing2 
Biomarker Measurements2   
 Genetic Sample6 
1. To be performed at local laboratory  
2. To be performed at central laboratory  
3. If not available locally it can be performed centrally  
4. Only for participant s with IgD/E myeloma  
5. FISH testing at least for: t(4;14), t(14;16), amp(1q), del(1p) and del(17p13) .  If participant is known to have 
tested positi ve for t(4;14)  or  t(14/16) on previous tests regardless of timeframe, FISH for these 
translocations does not need to be repeated. FISH results for amp(1q), del(1p) and del(17p13) from 
samples taken within 60 days prior to first dose are acceptable.  
6. Informed consent for optional sub -studies (e.g. genetic research) must be obtained before collecting a 
sample.  
 
10.6.11.  DNA Sampling for Genetic Testing  
Genetic variation may impact a participant’s response to therapy, susceptibility, severity 
and progression of disease. Variable response to therapy may be due to genetic 
determinants that impact drug absorption, distribution, metabolism, and excretion; 
mechanism of action of the drug; disease etiology; and/or molecular subtype of the 
disease being treated. Therefo re, where local regulations and IRB/IEC allow, and pending 
CCI
CCI
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 167 
 the consent of the participant, a 6 mL of blood sample will be collected for DNA 
analysis.  If insufficient DNA is extracted from the original sample, or if the sample was 
damaged or otherwise could  not be processed, the site may be requested to recollect the 
genetic sample where applicable  and if the participant consents .   
DNA samples will be used for research related to belantamab mafodotin  or RRMM and 
related diseases. They may also be used to de velop tests/assays including diagnostic tests) 
related to belantamab mafodotin  and RRMM. Detailed Guidance relating to sampling, 
analysis of genetic material in this study is provided in Appendix 1 0 – Genetics.  
Genetic research may consist of the analysis of one or more candidate genes or the 
analysis of genetic markers throughout the genome (or analysis of the entire genome as 
appropriate).  DNA samples will be analyzed by using appropriate descriptive and/or 
statistical analysis methods. A detailed description of any planned analyses will be 
documented in a RAP prior to initiation of the analysis.  Additional analyses may be 
conducted if it is hypothesized that this may help further understand the clinical data.   
The samples may be analyzed as part of a multi -study assessment of genetic factors 
involved in the response to belantamab mafodotin  or study treatments of this class. The 
results of genetic analyses may be reported in the clinical study report or in a se parate 
study summary.  
The Sponsor will store the DNA samples in a secure storage space with adequate 
measures to protect confidentiality.  
The samples will be retained while research on belantamab mafodotin  (or study 
treatments of this class) or RRMM continues but no longer than 15 years after the last 
participant  last visit or other period as per local requirements.  
10.6.12.  Suicidal Risk Monitoring  
Not applicable . 
10.7.  Pharmacokinetics  
10.7.1.  Blood Sample Collection for Pharma cokinetics  
Blood samples for pharmacokinetic (PK) analysis of belantamab mafodotin  (ADC and 
total antibody) and cys -mcMMAF will be collected for all participants at the time points 
indicated in the Schedule of Activities table s (Section 3). 
For participants assigned to Arm A and receiving belantamab mafodotin  Q4W , additional 
blood samples for lenalidomide pharmacokinetics will also be collected at Cycle 1 at the 
time points indi cated  in SoA (Table 5).  
For participants assigned to Arm B and receiving belantamab mafodotin  Q3W , additional 
blood samples for bortezomib pharmacokinetics will be also collected at Cycle 1  at the 
time points indicated  in SoA ( Table 7).  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 168 
 Each PK sample should be collected as close as possible to the planned time relative to 
the administration of the drug being measured on PK days (i.e., belantamab mafodotin  
samples collecte d relative to belantamab mafodotin  dosing, lenalidomide samples 
collected relative to lenalidomide dosing, and bortezomib samples collected relative to 
bortezomib dosing). The actual date and time of each blood sample collection will be 
recorded. Details o n PK blood sample collection including blood volumes, processing, 
storage, and shipping procedures are provided in the SRM.  
 samples should be collected at all PK time points as close as 
possible to the belantamab mafodotin  PK sample.  
All PK,  and ADA samples once collected (regardless of dosing) will be 
analyzed if the sample date and time have been recorded . 
10.7.2.  Pharmacokinetic Sample Analysis  
Plasma analysis will be performed under the control of GSK, the details of which will be 
included in the  SRM. Concentrations of belantamab mafodotin  (ADC and total antibody) 
and cys -mcMMAF will be determined in plasma samples using the currently approved 
bioanalytical  methodology. Concentrations of lenalidomide and bortezomib will be 
determine d in plasma samples using validated bioanalytical methods. Raw data will be 
archived at the bioanalytical site (as described in the SRM).  
Once the plasma has been analyzed for belantamab mafodotin  (ADC and total antibody) 
and cys -mcMMAF, any remaining plas ma may be analy zed for other compound -related 
metabolites and the results reported separately . 
CCI
CCI
CCI
TMF-14624358  CONFIDENTIAL  
  207497  
 169 
 
CCI
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 170 
 10.9.  Immunogenicity Assessments  
Serum samples for determination of a nti- belantamab mafodotin  antibodies will be taken 
from all participants at the time points specified in the Schedule of Activities ( Section 3). 
These samples will be t ested by the sponsor or sponsor’s designee.  
Anti-belantamab mafodotin antibody samples will be tested for anti -belantamab 
mafodotin antibodies using a tiered -testing scheme consisting of validated screening, 
confirmation, and titration assays.  Briefly, all samples will be tested in the screening 
assay.  Samples that screen positive are considered potentially positive and will be tested 
for specificity in a confirmation assay.  Finally, titer values will be obtained for 
confirmed positive samples  using a titration assay.  The sample results (e.g., positive or 
negative) and titer values (positive samples only) will be reported.  Samples that test 
positive for anti -belantamab mafodotin antibodies may be further characterized in a 
validated neutraliz ing antibody assay to determine the neutralizing activity of the 
antibodies.   
The detection and characterization of antibodies to belantamab mafodotin will be 
performed using validated assays. The anti -belantamab mafodotin antibody assay was 
designed to d etect antibodies to belantamab mafodotin, the unconjugated monoclonal 
antibody and the linker -payload  portion of the belantamab mafodotin .  Additionally, 
plasma samples will be collected at the same time points (see SoA) as the 
immunogenicity samples and a nalyzed to determine the belantamab mafodotin plasma 
concentration.  The belantamab mafodotin plasma concentration results will enable 
interpretation of the anti -belantamab mafodotin antibody data.  Anti -belantamab 
mafodotin antibody samples will be dispos ed three months after final approved results are 
CCI
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 171 
 provided to the Clinical Study Team or its designee or upon documented study 
termination.  
10.11.  Health -Related Quality of Li fe 
Two validated health -related quality of life (QoL) instruments will be employed in this 
study, to assess disease severity, disease symptoms, adverse events associated with the 
study treatment, and general quality of life in study participants with RRMM ass igned to 
either Arm A or Arm B. All participants will complete the self -administered version of 
these assessments unless  they are unable to do so  due to site restrictions or the PI or site 
feels it is in the best interest of the participant not to come to the site. Participants who 
cannot complete the self -administered version  should use an Interviewer -Administered 
format. The interview  may be administered over the telephone . If the Interviewer -
Administered format is used, it should be read to the participa nts verbatim, and 
participant responses should be recorded directly without any interpretation.  
10.11.1.  European Organisation for Research and Treatment of Cancer 
Quality of Life Questionnaires  
The symptoms related to multiple myeloma and its treatment, and the i mpact of these 
symptoms on daily functioning will be assessed using the European Organisation for 
CCI
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 172 
 Research and Treatment of Cancer Quality of Life Questionnaires; EORTC QLQ -C30 
and QLQ -MY20. The EORTC QLQ -C30 AND QLQ -MY20 will be completed at the 
times sho wn in the Schedule of Activities ( Section 3). 
10.11.1.1.  European Organisation for Research and Treatment of Cancer Quality 
of Life Questionnaire 30 -item Core Module (EORTC QLQ -C30)  
The EORTC QLQ -C30 is a 30 -item questionnaire containing both single - and multi -item 
measures [ Aaronson , 1993]. These include five functional sc ales (Physical, Role, 
Cognitive, Emotional, and Social Functioning), three symptom scales (Fatigue, Pain, and 
Nausea/Vomiting), a Global Health Status/QoL scale, and six single items (Constipation, 
Diarrhea, Insomnia, Dyspnea, Appetite Loss, and Financial Difficulties). Scores for each 
scale and single -item measure are averaged and transformed linearly to a score ranging 
from 0 –100. A high score for functional scales and for Global Health Status/QoL 
represent better functioning ability or HRQoL, whereas a h igh score for symptom scales 
and single items represents significant symptomatology [ Proskorovsky , 2014].  
10.11.1.2.  European Organisation for Research and  Treatment of Cancer Quality 
of Life Questionnaire 20 -item Multiple Myeloma Module (EORTC QLQ -
MY20)  
The EORTC QLQ -MY20 is a supplement to the QLQ -C30 instrument used in 
participant s with multiple myeloma [ Aaronson , 1993; Cocks , 2007]. The module 
comprises 20 questions that address four myeloma -specific HRQoL domains: Disease 
Symptoms, Side Effects of Treatment, Future Perspective, and Body Image. Three of the 
four QLQ -MY20 domains are multi -item scales: Disease Symptoms (includes bone aches 
or pain, back pain, hip pain, arm or shoulder pain, chest pain, and pain increasing with 
activity); Side Effects of Treatment (includes drowsiness, thirst, feeling ill, dry mouth, 
hair loss, upset by hair loss, tingling hands or feet, restlessness/agitation, acid 
indigestion/heartburn, and burning or sore eyes); and Future Perspective (includes worry 
about death and health in the future, and thinking about illness). The Body Image sca le is 
a single -item scale that addresses physical attractiveness. As with the QLQ -C30, QLQ -
MY20 domain scores are averaged and transformed linearly to a score ranging from 0 –
100. A high score for Disease Symptoms and Side Effects of Treatment represents a high 
level of symptomatology or problems, whereas a high score for Future Perspective and 
Body Image represents better outcomes [ Proskorovsky , 2014].  
11. DATA MANAGEMENT  
For this study participant  data will be entered into GSK -defined CRFs, transmitted 
electronically to GSK or designee and combined with data provided from other sources in 
a validated data system.   
Management of clinical data will be performed in accordance with applicable GSK 
standards and data cleaning procedures to ensure the integrity of the data, e.g., removing 
errors and inconsistencies in the data.  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 173 
 Adverse events and concomitant medications terms will be coded using MedDRA 
(Medi cal Dictionary for Regulatory Activities)  and an internal validated medication 
dictionary, GSKDrug.   
CRFs (including queries and audit trails) will be retained by GSK or designee  and copies 
will be sent to the Investigator to maintain as the Investigator copy.  Participant  initials 
will not be collected or transmitted to GSK according to GSK policy.  
12. STATISTICAL CONSIDER ATIONS  
This section briefly describes the planned analyses to be performed for Study 207497.  
Statistical analyses will either  be performed separately or by combining data from  Part 1 
(Dose Escalation) and Part 2  (Dose Expansion) as well as being performed independently 
for Arm A and Arm B. 
Actual analyses to be perf ormed for each Treatment may be dependent on the outcomes 
of Part 1 and Part 2 for both Arm A and Arm B.  Ultimately those analyses will be 
described fully in the Reporting and Analysis Plan (RAP) that will be finalized prior to 
the final database release or interim database release.  
12.1.  Hypothesis(es)  
12.1.1.  Arm A  – Belantamab Mafodotin  with Len/Dex  
12.1.1.1.  Part 1  
No formal statistical hypotheses are being tested in Part 1. Analysis of the data obtained 
from Part 1 will only utilize descriptive methods.   
12.1.1.2.  Part 2   
No formal statistical hypotheses are being tested in Part 2. Analysis of the data obtained 
from Part 1 will only utilize descriptive methods.   
For Part 2,  the number of participants  who permanently discontinue study treatment due 
to AE s related to belantamab mafodotin  within the first two cycles will be continuously 
monitored. For STRETCH dos ing schedule, a cycle is a SoC cycle of 28 days. If the 
observed number of p articipant s permanently discontinuing belantamab mafodotin  is 
significantly higher  than 12% (at 1-sided alpha of 0.01 ), then the combination treatment 
at that dose level or higher dose level will be considered to have unacceptable toxicity 
and the dose level  as well as higher dosed levels will be closed.  
12.1.2.  Arm B  – Belantamab Mafodotin  with Bor/Dex  
12.1.2.1.  Part 1  
No formal statistical hypotheses are being tested in Part 1.  Analysis of the data obtained 
from Part 1 will only utilize descriptive methods.   
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 174 
 12.1.2.2.  Part 2  
No formal statistical hypotheses are being tested in Part 2.  Analysis of the data obtained 
from Part 2 will only utilize descriptive methods.   
For Part 2, the number of participants who permanently discontinued study treatment due 
to AE related to belantamab mafodotin  within the first two cycles will be continuously 
monitored starting from when 5 pa rticipants  are dosed . For STRETCH dos ing schedule, a 
cycle is a SoC cycle of 21 days . If the observed number of participant s permanently 
discontinuing belantamab mafodotin  is significantly higher than 12%  (at 1-sided alpha of 
0.01), then the combination treatment at that dose level or higher dose level will be 
considered to have unacceptable toxicity and the dose level as well as higher dose levels 
will be closed.  
12.2.  Sample Size Determination  
12.2.1.  Arm A  – Belantamab Mafodotin  with Len/Dex  
12.2.1.1.  Part 1  
The total number of participants to be enrolled into Part 1 will depend on the number of 
participants  needed to characterize individual dose cohorts . The sample size is not driven 
by statistical considerations.  However, based on assumptions that 2 differe nt dose levels 
will be evaluated , it is anticipated that approximately  14 evaluable participants will be 
enrolled in Part 1.  
12.2.1.2.  Part 2  
The sample size is not driven by statistical considerations. Up to 2 dose levels and up to 3 
dosing schedules will be evaluated , approximately  9 participant s each will be enrolled at 
the 2.5 mg/kg SINGLE  and,  2.5 mg/kg SPLIT dose level s.  
• In addition, an alternate dosing schedule of STRETCH (Q8W) dosing may be 
explored for the 1.9 mg/kg dose level if emerging data (from either this study or 
across the program) suggests that this schedule may further optimize the tolerability 
or offers an improved benefit/risk profile . Up to 12 participants will be enrolled in 
this new cohort.   
Approximately  31 participant s will be enrolled  in Part 2 . 
12.2.2.  Arm B  – Belantamab Mafodotin  with Bor/Dex  
12.2.2.1.  Part 1  
The total number of participants to be enrolled into Part 1 will depend on the number of 
participants  needed to characterize individual dose cohorts . The sample size is not driven 
by statistical considerations.  However, based on assumptions that 2 different dose levels 
will be evaluated , an additional  lower dose level may be explored using the mTPI design. 
It is anticipated that approximately  13 evaluable participants will be enrolled in Part 1.  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 175 
 12.2.2.2.  Part 2  
The sample size is not driven by statistical considerations. Up to 3 dose levels  and up to  4 
dosing schedules  will be evaluated and up to 12 participant s will be enrolled at each 
dosing schedule  (up to 9 participants in the 3.4 mg/kg SINGLE) , it is anticipated that 
approximately  94 participant s will be enrolled  in Part 2 . 
12.2.3.  Sample Size Sensitivity  
There is no need to perform sample size sensitivity analysis.  
12.2.4.  Sample Size Re -estimation or Adjustment  
Samp le size re -estimation is not planned for this study.  
12.3.  Populations for Analyses  
For purposes of analysis, the following populations are defined in Table 28.  Each of the 
following population will be created separately for Arm A and Arm B and by each part as 
appropriate.  Additional analysis populations may be defined in the RAP.  
Table 28 Definitions of Study Analysis Populations  
Population  Description  
All Screened  All participants who sign the ICF to participate in the clinical trial. 
Participants in this population will be used for screen failure summary.  
All Treated  All participants who take at least 1 dose of any study treatment. 
Analyses of demographic, baseline characteristics, safety and all 
efficacy endpoints will be based on this population.  
Pharmacokinetic  Participants in the All Treated Population from whom a t least one PK 
sample was obtained, analyzed, and was measurable. Separate PK 
populations will be defined for each drug ( belantamab mafodotin , 
lenalidomide, and bortezomib). This population will be the primary 
population for PK analyses.  
 
12.4.  Statistical Anal yses  
All statistical analyses will be performed by GSK ( sponsor ) or under the authority of the 
Sponsor.  A general description of the statistical methods to be used to analyze the 
clinical activity and safety data is outlined below. Statistical analyses wi ll be performed 
for each treatment group separately. There will be no comparison between treatment 
groups or parts.  
Data will be listed and summarized mostly by doses. In general, separate analyses will be 
provided for Part 1 and Part 2 where applicable.  Data from Part 1 and Part 2 may be  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 176 
 combined at interim , and final analyses.  Final analysis will be performed following 12 
months post LSFD . 
Specific details will be provided in the Reporting and Analysis Plan (RAP).  
12.4.1.  Analyses of Clinical Activity  
The primary endpoint for Part 2 will be based on the responses assessed by the 
investigator.  
The primary  efficacy endpoint will be analyzed based on the All Treated Population 
unless otherwise specified.  
The analytical methods planned for the primary effi cacy endpoint  are described in Table 
29. 
Table 29 Statistical Analysis Methods for Clinical Activity Endpoints (Part 2)  
Endpoint  Statistical Analysis Methods  
Primary  Overall Response Rate (ORR) defined as percentage (%) of participants with a 
confirmed PR or better (i.e., PR, VGPR, CR and sCR), according to the International 
Myeloma Working Group (IMWG) Response Criteria).  
The number and percentage of participants in the following response categories will be 
presented: sCR, CR, VGPR, PR, overall response (sCR+CR+VGPR+PR), minimal 
response (MR), stable disease (SD), progressive disease (PD), and not evaluable 
(NE). The corre sponding 95% CI for ORR will also be provided. Participants with 
unknown or missing responses will be treated as non -responders, i.e., these 
participants will be included in the denominator when calculating percentages of 
response.   
 
12.4.2.  Safety Analyses  
All s afety analyses will be performed on the All Treated Population.  Complete details of 
the safety analyses will be provided in the RAP.  
12.4.2.1.  Exposure Duration  
The number of participants administered study treatment will be summarized for Arm A 
and Arm B independently, according to the duration of therapy.   
12.4.2.2.  Adverse Events  
All adverse events whether serious or non -serious, will be collected from the start of 
treatment until at least 70  days following discontinuation of study treatment regardless of 
initiation of a new cancer therapy or transfer to hospice at the time points specified in the 
Schedule of Activities (SoA).  AEs will be recorded using standard medical terminology 
and graded according to the NCI -CTCAE, Version 4.03. For AE reporting, the verbatim 
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 177 
 term used in the CRF by investigators to identify adverse events will be coded using the 
latest version of Medical Dictionary for Regulatory Activities (MedDRA) coding 
dictionary.  
12.4.2.3.  Clinical Laboratory Evaluations  
The evaluation of clinical laboratory tests will focus on selected laboratory analytes from 
the hematology and blood chemistry panel.  
Descriptive statistics (mean, standard deviation, median, range) will be used to 
summarize ob served laboratory values and change from baseline in observed value at 
each scheduled visit or worst -case postbaseline, as appropriate.  
The worst -case toxicity grade in hematology and chemistry results during the treatment 
will be summarized according to N CI-CTCAE, Version 4.03 [ National Cancer Institute , 
2010]. Shift tables from baseline to the worst toxicity grade during tre atment will be 
provided for each laboratory analyte as appropriate. Laboratory test results outside the 
reference ranges that do not have associated NCI -CTCAE criteria will be summarized 
using proportions.  Further details will be provided in the RAP.  
12.4.2.4.  Othe r Safety Measures  
Data for vital signs, ECGs and ECHOs will be summarized.  For continuous variables, 
these summaries will include sample size, mean, median, standard deviation, minimum, 
and maximum. For categorical variables, the summaries will include fre quencies and 
corresponding percentages. Further details will be provided in the Reporting and Analysis 
Plan (RAP).  
12.4.3.  Pharmacokinetic Analyses  
12.4.3.1.  Belantamab mafodotin  pharmacokinetic  
Belantamab mafodotin  pharmacokinetic data will be reported separately for Arm A and 
Arm B as well as combined, if appropriate.  
Concentration -Time Data:  Linear and semi -logarithmic individual concentration -time 
profiles and mean and median profiles (when appropriate) will be plotted for belantamab 
mafodotin  (ADC and total mAb) and c ys-mcMMAF). Concentrations of belantamab 
mafodotin  (ADC and total mAb) and cys -mcMMAF) will be listed for each participant 
and summarized (when appropriate) by planned time point and dose level.  
Derived Pharmacokinetic Parameters:   Pharmacokinetic analyses  will be the 
responsibility of Clinical Pharmacokinetics/Modelling and Simulation, GSK. Plasma 
belantamab mafodotin  (ADC, total mAb) and cys -mcMMAF concentration -time data will 
be analysed using standard noncompartmental methods, data permitting .  
Pharmaco kinetic parameters will be listed and summarized descriptively (mean, standard 
deviation, median, minimum, maximum, geometric mean, and the standard deviation, 
CV%, and 95% CI of log -transformed parameters) by cycle and dose level.  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 178 
 Plasma belantamab mafod otin, total mAb, and /or cys-mcMMAF concentration -time data 
may be combined with data from other studies and analyzed using a population 
pharmacokinetic approach. The initial analysis will use the then-current  population 
pharmacokinetic model to generate post hoc pharmacokinetic parameter estimates . 
Summary exposure measures (e.g., Cmax, AUC) will also be computed.  Results of this 
analysis may be provided in a separate report.  
12.4.3.2.  Lenalidomide  
Concentration -Time Data:  Linear and semi -logarithmic individual c oncentration -time 
profiles and mean and median profiles (when appropriate) will be plotted for 
lenalidomide. Concentrations of lenalidomide will be listed for each participant and 
summarized (when appropriate) by planned time point.  
Derived PK Parameters:   Lenalidomide pharmacokinetics in the presence of 
belantamab mafodotin  will be analyzed using standard noncompartmental methods, data 
permitting, or using a published population pharmacokinetic model [ Guglieri -Lopez , 
2017]. Results of th e population PK analysis , if performed,  may be provided in a separate 
report.  
Pharmacokinetic parameters will be listed and summarized descriptively (mean, standard 
deviation, median, minimum, maximum, geometric mean, and the standard deviation, 
CV%, and 95% CI of log -transformed parameters) by dose level, if appropriate.  
12.4.3.3.  Bortezomib  
Concentration -Time Data:   Linear and semi -logarithmic individual concentratio n-time 
profiles and mean and median profiles (when appropriate) will be plotted for bortezomib. 
Concentrations of bortezomib will be listed for each participant and summarized (when 
appropriate) by planned time point.  
Derived PK Parameters:  Bortezomib phar macokinetics in the presence of belantamab 
mafodotin  will be analyzed using standard noncompartmental methods, data permitting.   
Pharmacokinetic parameters will be listed and summarized descriptively (mean, standard 
deviation, median, minimum, maximum, ge ometric mean, and the standard deviation, 
CV%, and 95% CI of log -transformed parameters) by dose level, if appropriate.  
12.4.4.  Pharmacokinetic/PD Analyses  
If deemed appropriate and if data permit, exposure -response relationships between 
belantamab mafodotin  exposure (e.g., dose, dose intensity, concentration, Cmax, or 
AUC) and clinical activity and/or toxicity (e.g., response, corneal event) may be explored 
using population methods ; data from this study may be combined with data from other 
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 179 
 studies  for these analyses . If data permit, the effects of covariates may be explored.  
Results may be reported separately.  
12.4.5.  Translational Research Analyses  
The results of translational research investigations will be reported either within or 
separately from the main clinica l study report (CSR). All endpoints of interest from all 
comparisons will be descriptively and/or graphically summarized as appropriate to the 
data. Further details on the translational research analyses will be addressed in the RAP.  
12.4.5.1.  Novel Biomarker(s) Ana lyses  
The results of these biomarker investigations may be reported separately from the main 
CSR. All endpoints of interest from all comparisons will be descriptively and/or 
graphically summarized as appropriate to the data. Additional exploratory analyses  may 
be performed to further characterize novel biomarker s. 
12.4.5.2.  Genetic Analyses  
Further details on genetic analyses can be found in Section 10.10  
12.4.6.  Immunogenicity Assessment  
For each pa rticipant, the results and titers of anti - belantamab mafodotin  binding 
antibodies will be listed for each assessment time point, along with plasma belantamab 
mafodotin  concentration. The frequency and percentage of participants with positive and 
negative results will be summarized for each assessment time and overall for each 
participant  by dose cohort. The detailed information will be included in the RAP.  
CCI
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 180 
 12.4.7.  Other Analyses  
All other exploratory analyses will be described in the RAP.  
12.4.8.  Interim Analyses  
12.4.8.1.  Arm A  – belantamab mafodotin  with Len/Dex  
Part 1  
During dose escalation, no formal interim analysis will be performed. Data will be 
reviewed through data visualization tool to inform dose escalation decisions. The mTPI 
design will be utilized to guide dose escalation/de -escalation decisions. More details of 
the dose escalation procedure are described in Section 6.1.1.1 . 
Part 2  
Continuous monitoring will be conducted for Part 2  starting from when 5 participant s are 
dosed at each dose level within  each arm. The observed number of participant s 
permanently discontinuing study treatment within the first two cycles due to AE related 
to belantamab mafodotin  will be compared against the safety stopping rule in Table 30. 
Enrol lment  may stop if the safety stopping rule is met based on totality of safety data. For 
example, if 4 or more out of 5 participant s permanently discontinued study treatment 
within the first 2 cycles due to AE related to belantamab mafodotin , enrollment  may stop 
after review of all safety data; otherwise enrollment  will continue. Operating 
characteristics for the stopping rule are provided in Appendix 1 1. 
Table 30 Safety Stopping Rules for Arm A Part 2   
Number of dosed participant s Stop if number of participant s 
discontinuing study treatment 
within the first two cycles due 
to AE related to belantamab 
mafodotin  is larger or equal to 
this this number  Observed rate  
5-8 4 0.5-0.8 
9-12 5 0.42-0.56 
An interim analysis may be conducted when the last participant within each arm is 
followed for at least 1 cycle to evaluate  safety, efficacy and PK profiles at each dose 
level. Following the interim analysis, additional analyses may be performed to  continue 
to evaluate safety, efficacy and PK profiles at each dose level, prior to the final analys es. 
If any dose level is not  enrolled due to safety concerns, it will not  be included in the 
interim or final analyses. Additionally, if enrollment is stopped  within a dose group, data 
may be analyzed for participants within the dose group who take at least 1 dose of any 
study treatment .  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 181 
 12.4.8.2.  Arm B  – belantamab mafodotin  with Bor/D ex 
Part 1  
During dose escalation, no formal interim analysis will be performed. Data will be 
reviewed through the data visualization tool to inform dose escalation decisions. The 
mTPI design will be utilized to guide dose escalation/de -escalation decisions . More 
details of the dose escalation procedure are described in Section 6.1.2 . 
Part 2  
Continuous monitoring will be conducted for Part 2 starting from when 5 participant s are 
dosed at each dose level within each arm.  The observed number of participant s 
permanently discon tinuing study treatment within the first two cycles due to AE related 
to belantamab mafodotin  will be compared against the safety stopping rule in Table 31. 
Enrol lment  may stop if the safety stopping rule is met based on totality of safety data. For 
example, if 4 or more out of 5 participant s permanently discontinued study treatment 
within the first 2 cycles due to AE related to belantamab mafodotin , enrollm ent may stop 
after review of all safety data; otherwise enrollment  will continue. Operating 
characteristics for the stopping rule are provided in Appendix 1 1. 
Table 31 Safety Stopping Rules for Arm B Part 2  
Number of dosed participants  Stop if number of participant s 
discontinuing study treatment 
within the first two cycles due 
to AE related to belantamab 
mafodotin  is larger or equal to 
this this number  Observed rate  
5-8 4 0.5-0.8 
9-12 5 0.42-0.56 
 
An interim analysis may be conducted when the last participant within each arm is 
followed for at least 1 cycle to evaluate safety, efficacy and PK profiles at each dose 
level. Following the interim analysis, additional analyses may be performed to continue 
to evaluate safety, e fficacy and PK profiles at each dose level, prior to the final analys es. 
If any dose level is not enrolled due to safety concerns, it will not be included in the 
interim or final analyses. Additionally, if enrollment is stopped within a dose group, data 
may be analyzed for participants within the dose group who take at least 1 dose of any 
study treatment . 
12.4.9.  Final Analysis  
Final analysis of the data captured in Part 1 and Part 2 for both Arm A and Arm B will be 
undertaken following 12 months post LSFD . (Sect ion 6.3). Within each arm, data from 
the two parts may be combined for some analyses at the final analysis , as appropriate.  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 182 
 13. REFERENCES  
Aaronson, NK, Ahmedzai  A, Bergman  B, Bullinger  M, Cull  A, Duez  NJ, et al . The 
European Organization for Research and Treatment of Cancer QLQ -C30: a quality -of-life 
instrument for use in international clinical trials in oncology. J Natl Cancer Inst . 
1993;85:365 –376 
Basch E, Reeve BB , Mitchell SA, Clauser SB, Minasian LM, Dueck AC, et al.  
Development of the National Cancer Institute ’s patient -reported outcomes version of the 
common terminology criteria for adverse events (PRO -CTCAE). J Natl Cancer Inst . 
2014;106(9).  
Bellucci  R, Alyea EP, Chiaretti S, Wu CJ, Zorn E, Weller E, et al. Graft -versus -tumor 
response in patients with multiple myeloma is associated with antibody response to 
BCMA, a plasma -cell membrane receptor. Blood . 2005;105: 3945 -3950.  
Belnoue , E, Pihlgren, M, McGaha, TL, Tougne C, Rochat AF, Bossen C, et al. APRIL is 
critical for plasmablast survival in the bone marrow and poorly expressed by early -life 
bone marrow stromal cells. Blood . 2008;111: 2755 -2764.  
Bennett JM. Changes in the Updated 2 016: WHO Classification of the Myelodysplastic 
Syndromes and Related Myeloid Neoplasms. Clin Lymphoma Myeloma Leuk . 2016;16: 
607-609.  
Celgene Corporation (2019), REVLIMID (lenalidomide) P rescribing  Information.   
https://www.accessdata.fda.gov/drugsatfda_d ocs/label/2019/021880s060lbl.pdf  
Chen H, Yu KD and Xu, GZ. Association between variant Y402H in age -related macular 
degeneration (AMD) susceptibility gene CFH and treatment response of AMD: a meta -
analysis. P loS One . 2012;7: e42464.  
Cocks K, Cohen  D, Wislø ff F, Sezer  O, Lee S, Hippe  E, et al. An international field study 
of the reliability and validity of a disease -specific questionnaire module (the QLQ -
MY20) in assessing the quality of life of patients with multiple myeloma. Eur J Cancer. 
2007;43:1670 –1678  
Dimopoulos MA, Oriol A, Nahi H, White D, Benboubker L, Cook G, et al. 
Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med . 
2016;375:1319 -1331.  
Dougherty BE, Nichols JJ and Nichols, KK. Rasch analysis of the Ocular Surface 
Disea se Index (OSDI). Invest Ophthalmol Vis Sci . 2011;52:8630 -8635.  
Food and Drug Administration (2009). Guidance for Industry.  Drug -Induced Liver 
Injury:  Premarketing Clinical Evaluation. Services , UdoHaH. Rockville, MD.  
GSK2857916 IB, 20 20. GlaxoSmithKline Document Number 2013N175128  V08.  
Effective July 2020. 
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 183 
 Gorin, MB. Genetic insights into age -related macular degeneration: controversies 
addressing risk, causality, and therapeutics. Mol Aspects Med . 2012;33: 467 -486. 
Guglieri -Lopez B, Per ez-Pitarch A, Moes DJ, Porta -Oltra B, Climente -Martí M, 
Guchelaar HJ, et al. Population pharmacokinetics of lenalidomide in multiple myeloma 
patients. Cancer Chemother Pharmacol . 2017;79:189 -200. 
Hanley M, Mould D R, Taylor TJ, Gupta N, Surynarayan K, Neuwi rth R, et al. Population 
pharmacokinetic analysis of bortezomib in pediatric leukemia patients: model -based 
support for body surface area -based dosing over the 2 - to 16 -year age range. J Clin 
Pharmacol. 2017;57:1183 –1193.  
Jagannath  S, Barlogie B, Berenson JR, Siegel DS, Irwin D, Richardson PG, et al. 
Updated survival analyses after prolonged follow -up of the phase 2, multicenter CREST 
study of bortezomib in relapsed or refractory multiple myeloma. Br J Haematol . 
2008;143:537 -540. 
Ji Y, Liu P, Li Y, Bekele BN . A modified toxicity probability interval method for dose -
finding trials. Clin Trials . 2010;7:653 -663. 
Jiang C, Loo WM, Greenley EJ, Tung KS, Erickson LD . B cell maturation antigen 
deficiency exacerbates lymphoproliferation and a utoimmunity in murine lupus. J 
Immunol . 2011;186:6136 -6147.  
Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International 
Myeloma Working Group consensus criteria for response and minimal residual disease 
assessment in multiple myeloma . Lancet Oncol . 2016;17:e328 -346. 
Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, et al. Continued 
improvement in survival in multiple myeloma: changes in early mortality and outcomes 
in older patients. Leukemia . 2014;28:1122 -1128.  
Kumar SK , Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J, et al. Risk of 
progression and survival in multiple myeloma relapsing after therapy with I miDs and 
bortezomib: a multicenter international myeloma working group study. Leukemia . 
2012;26:149 -157. 
Kumar SK, Rajkumar SV, Dispenzieri A,  Lacy MQ, Hauman SR, Buadi FK, et al. 
Improved survival in multiple myeloma and the impact of novel therapies. Blood . 
2008;111:2516 -2520.   
Laurent SA, Hoffmann FS, Kuhn PH, Cheng Q, Chu Y, Schmidt -Supprian M, et al. 
Gamm a-secretase directly sheds the survival receptor BCMA from plasma cells. Nat 
Commun. 2015;6:7333.   
Li X, Wulfsohn MS, Koch GG. Considerations on testing secondary endpoints in group 
sequential design. Statistics in Biopharmaceutical Research. 2017 Oct 2;9(4):333 -7. 
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 184 
 Lokhorst HM, Plesner T, Laubach JP, Nahi H, Gimsing P, Hansson M, et al. Targeting 
CD38 wit h daratumumab monotherapy in multiple myeloma. N Engl J Med . 
2015;373:1207 -1219.  
Lonial S and Anderson KC. Association of response endpoints with survival outcomes in 
multiple myeloma. Leukemia . 2014;28:258 -268. 
Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, et al. Elotuzumab 
therapy for relapsed or refractory multiple myeloma. N Engl J Med . 2015;373:621 -631. 
Lonial S, Lee H C, Badros A, Trudel S, Nooka A K, Chari A, Abdallah A -O, et al. 
Belantamab mafodotin for relapsed or refractory mul tiple myeloma (DREAMM -2): a 
two-arm, randomised, open -label, phase 2 study. Lancet Oncology, 2019, e -pub ahead of 
print. https://doi.org/10.1016/S1470 -2045(19)30788 -0https://doi.org/10.1016/S1470 -
2045(19)30788 -0. 
Lonial S, Lee HC, Badros A, Trudel S, Nooka  AK, Chari A, et al. Belantamab mafodotin 
for relapsed or refractory multiple myeloma (DREAMM -2): a two -arm, randomized, 
open -label, phase 2 study. Lancet Oncol. 2020:21:207 -21. 
Montes De Oca R, Bhattacharya S, Vitali N, et al. The anti -BCMA antibody -drug 
conjugate GSK2857916 drives immunogenic cell death and immune -mediated anti -tumor 
responses, and in combination with an OX40 agonist potentiates in vivo activity. 
HemaSphere. 2019;1: 231.  
Moreau P and Touzeau C. Multiple Myeloma: From Front -Line to Relapse d Therapies. 
American Society of Clinical Oncology Educational Book 35. 
http://meetinglibrary.asco.org/record/104109/edbook#fulltext, American Society of 
Clinical Oncology 2015;e504 -511. 
Moreau P, San Miguel J, Sonneveld P, Mateos MV, Zamagni E, Avet -Loise au H, et al. 
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and 
follow -up. Ann Oncol. 2017; 28(suppl_4):iv52 -iv61 . 
Moreaux J, Legouffe E, Jourdan E, Quittet P, Rème T, Lugagne C,  et al. BAFF and 
APRIL protect myeloma cells fro m apoptosis induced by interleukin 6 deprivation and 
dexamethasone. Blood . 2004;103:3148 -3157.  
National Cancer Institute (2010). NCI Common Terminology Criteria for Adverse 
Events, Version 4.03  ( http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010 -06-
14_Quic kReference_8.5x11.pdf ). 
National Comprehensive Cancer Network (2016) Multiple Myeloma. Version 3.2017 – 
Novenber 28, 2016. NCCN Clinical Practice Guidelines in Oncology (NCCN 
Guidelines), 58.  
New York Heart Association (1994). The Criteria Committee of the  New York Heart 
Association (NYHA). Nomenclature and Criteria for Diagnosis of Diseases of the Heart 
and Great Vessels. 9th Ed. Boston, MA : 253-256. 
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 185 
 Novak AJ, Darce JR, Arendt BK, Harder B, Henderson K, Kindsvogel W, et al. 
Expression of BCMA, TACI, and BAFF -R in multiple myeloma: a mechanism for 
growth and survival. Blood . 2004;103(2):689 -694. 
Oken, MM, Creech, RH, Tormey, DC, Horton J, Davis TE, McFadden ET, et al. Toxicity 
and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol . 
1982;5:649 -655. 
Palumbo A, Chanan -Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, et al. 
Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med . 
2016;375:754 -766. 
Proskorovsky I, Lewis  P, Williams  CD, Jordan  K, Kyriakou  C, Ishak  J, et al.  Mapping 
EORTC QLQ -C30 and QLQ -MY20 to EQ -5D in patients with multiple 
myeloma.   Health Qual Life Outcomes. 2014;12:35 . 
Rajkumar SV. Updated Diagnostic Criteria and Staging System for Multiple Myeloma. 
Am Soc Clin Oncol Educ Book 2016;35:e418 -423. 
Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. A phase 2 
study of bortezomib in relapsed, refractory myeloma. N Engl J Med . 2003;348:2609 -
2617.  
Richardson, PG, Barlogie, B, Berenson, J, Singhal S, Jagannath S, Irwin DH, et al. 
Extended follow -up of a phase II trial in relapsed, refractory multiple myeloma: final 
time-to-event results from the SUMMIT trial. Cancer . 2006;106:1316 -1319.  
Richardson PG, Hideshima T, Mitsiades C, Anderson KC . The emerging role of novel 
therapies for  the treatment of relapsed myeloma. J Natl Compr Canc Netw . 2007;5:149 -
162. 
Sanchez E, Li M, Kitto A, Li J, Wang CS, Kirk DT, et al. Serum B -cell maturation 
antigen is elevated in multiple myeloma and correlates with disease status and survival. 
Br J Haematol . 2012;158:727 -738. 
Schiffman RM, Christianson MD, Jacobsen G, Hirsch JD, Reis BL . Reliability and 
validity of the Ocular Surface Disease Index. Arch Ophthalmol . 2000;118:615 -621. 
Siegel RL, Miller KD , Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7 -30. 
Tai YT and Anderson KC. Targeting B -cell maturation antigen in multiple myeloma. 
Immunotherapy . 2015;7:1187 -1199.  
Tai YT, Mayes PA, Acharya C, Zhong MY, Cea M, Cagnetta A, Craigen J, Yates J, 
Gliddon L, Fieles W, Hoang B. Novel anti –B-cell maturation antigen antibody -drug 
conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood. 2014 
May 15;123(20):3128 -38. 
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 186 
 Tai YT, Li XF, Breitkreutz I, Song W, Neri P, Catley L, et al. Role of B -cell-activating 
factor in adhesion and  growth of human multiple myeloma cells in the bone marrow 
microenvironment. Cancer Res . 2006;66:6675 -6682.  
Thompson JS, Schneider P, Kalled SL, Wang L, Lefevre EA, Cachero TG, et al. BAFF 
binds to the tumor necrosis factor receptor -like molecule B cell ma turation antigen and is 
important for maintaining the peripheral B cell population. J Exp Med . 2000;192:129 -
135. 
Trudel  S, Lendvai N, Popat R, Voorhees PM, Reeves B, Libby EN, et al. Targeting B -cell 
maturation antigen with GSK2857916 antibody -drug conjugate in relapsed or refractory 
multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial. Lancet 
Oncol.  2018;19:1641 -1653 . 
Trudel S, Lendvai N, Popat R, Voorhees PM, Reeves B, Libby EN, et al. Antibody -drug 
conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety 
and efficacy from dose expansion phase I study. Blood Cancer J. 2019 ;9:37 . 
Varfolomeev E, Kischkel F, Martin F, Seshasayee D, Wang H, Lawrence D, et al. 
APRIL -deficient mice have normal immune system development. Mol Cell Biol . 
2004;24:997 -1006.  
VELCADE (bortezomib) Prescribing Information (2019). Millen nium Pharmaceutical s, 
Inc. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021602s044lbl.pdf  
West CD and Boyd E (2000). Nomogram for Body Surface Area Calculation, modified 
from data of E. Boyd by C.D. West. Nelson textbook of pediatrics (16th ed.). Behrman, 
RE, Kl iegman, RM and Jenson, HB. Philadelphia, W.B.Saunders.  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 187 
 14. APPENDICES  
14.1.  Appendix 1: Abbreviations and Trademarks  
14.1.1.  Trademark Information  
Trademarks of the GlaxoSmithKline 
group of companies   Trademarks not owned by the 
GlaxoSmithKline group of companies  
NONE   MedDRA  
  REVLIMID  
  VELCADE  
 
14.1.2.  Abbreviations and Acronyms  
Acronym  Definition  
ADA Anti-drug antibodies  
ADC  Antibody -drug conjugate  
ADCC  Antibody -dependent cellular cytotoxicity  
ADL Activities of daily living  
AE Adverse event  
AESI  Adverse events of special interest  
ALT Alanine aminotransferase  
AMD  Age-related macular degeneration  
ANC  Absolute neutrophil count  
AST Aspartate aminotransferase  
AUC  Area under the concentration time curve  
BCMA  B-cell maturation antigen  
BCVA  Best-corrected visual acuity  
BIB Bioanalysis, immunogenicity and biomarkers  
BID Twice daily  
BOR  Bortezomib  
BM Bone marrow  
BMI Body mass index  
BSA Body surface area  
BW Body weight  
C1D1  Cycle 1 Day 1  
CBC  Complete blood count  
CIOMS  Council for International Organizations of Medical Sciences  
CK Creatine kinase  
Cmax  Maximum plasma concentration  
CONSORT  Consolidated Standards of Reporting Trials  
CR Complete Response  
CRF Case Report Form  
CRP  C-reactive protein  
CSR  Clinical study report  
CTCAE  Common Terminology Criteria for Adverse Events  
CCI
CCI
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 188 
 Acronym  Definition  
CV Cardiovascular  
DCO  Data cut -off 
Dex Dexameth asone  
DILI Drug -Induced Liver Injury  
DLT Dose -limiting toxicities  
DVT Deep vein thrombosis  
EC Ethics  committee  
ECG  Electrocardiogram  
ECHO  Echocardiogram  
ECOG  Eastern Cooperative Oncology Group  
eCRF  Electronic Case Report Form  
eGFR  Estimated glomerular filtration rate  
EOI End of infusion  
EOS  End of study  
EOT End of Treatment  
FDA Food and Drug Administration  
FISH  Fluorescence -in-situ hybridization  
FLC Free light chain  
FSH Follicle -stimulating hormone  
FTIH  First–Time -in-Human  
GCP  Good Clinical Practice  
GFR  Glomerular filtration rate  
GVHD  Graft -versus -host disease  
GSK  GlaxoSmithKline  
HbsAg  hepatitis B surface antigen  
HCV  Hepatitis C virus  
HIPAA  Health Insurance Portability and Accountability Act  
HRT Hormone replacement therapy  
HSCT  Hematopoietic stem cell transplant  
IB Investigator’s Brochure  
ICD immunogenic cell death  
ICF Informed Consent Form  
ICH International Council for Harmonization of Technical Requirements for 
Pharmaceuticals for Human Use   
IHC Immunohistochemistry  
IMID  Immunomodulatory drugs  
IMP Investigational Medicinal Product  
IMWG  International Myeloma Working Group  
INR International normalization ratio  
IRB Institutional Review Board  
IRR Infusion -related reaction  
LDH Lactate dehydrogenase  
LEN Lenalidomide  
LLN Lower limit of normal  
LSFD  Last subject first dose  
LSFV  Last subject first visit  
LVEF  Left ventricular ejection fraction  
MDRD  Modified Diet in Renal Disease  
CCI
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 189 
 Acronym  Definition  
MedDRA  Medical Dictionary for Regulatory Activities  
MI Myocardial infarction  
MM Multiple myeloma  
MMAF  Monomethyl auristatin -F 
MoA Mechanism of action  
MR Minimal Response  
MSDS  Material Safety Data Sheet  
MTD  Maximum tolerated dose  
mTPI  modified Toxicity Probability Interval  
NCCN  National Comprehensive Cancer Network  
NCI National Cancer Institute  
NOS  Not otherwise specified  
NYHA  New York Heart Association  
ORR  Overall Response Rate  
OSDI  Ocular Surface Disease Index  
PACT  Post analysis continued treatment  
PCR  Polymerase chain reaction  
PD Progressive Disease  
PE Pulmonary embolism  
PET Positron Emission Tomography  
PI Proteasome inhibitors  
PK Pharmacokinetic(s)  
PO Per os (oral)  
PR Partial Response  
PRO  Patient -Reported Outcome  
PRES  Posterior Reversible Encephalopathy Syndrome  
QD Once daily  
QID Four times daily  
QoL Quality of life  
RAP Reporting and Analysis Plan  
RBC  Red blood cell  
RP2D  Recommended Phase 2 dose  
RPLS  Reversible Posterior Leukoencephalopathy Syndrome  
RRMM  Relapsed/Refractory Multiple Myeloma  
SAE Serious adverse event  
SC Subcutaneous  
sCR stringent Complete Response  
SCT Stem cell transplant  
SD Standard deviation of the mean  
S/D Step-down dosing  
SoA Schedule of Activities  
SoC Standard of Care  
SOI Start of infusion  
SPEP  Serum Protein Electrophoresis  
SPM  Second Primary Malignancies  
SRM  Study Reference Manual  
CCI
CCI
CCI
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 190 
 Acronym  Definition  
t1/2  Serum half -life 
TLS Tumor lysis syndrome  
tmax  Time to maximum plasma concentration  
TNF Tumor necrosis factor  
TTP Time to Disease Progression  
ULN Upper limit of normal  
UPEP  Urine protein electrophoresis  
VGPR  Very good partial response  
VZIG  Varicella zoster immune globulin  
WBC  White blood cell  
WFI Water for injection  
WOCBP Woman of child -bearing potential  
 
CCI
CCI
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 191 
 14.2.  Appendix  2:  Study Governance Considerations and 
Informed Consent Process  
Regulatory and Ethical Considerations  
• This study will be conducted in accordance with the protocol and with:  
• Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizations of Medical 
Sciences (CIOMS) International Ethical Guidelines  
• Applicable international council for harmonization of technical requirements for 
pharmaceuticals for human use (ICH) Good Clinical Practice (GCP) Guidelines  
• Applicable laws and regu lations  
• The protocol, protocol amendments, ICF, Investigator Brochure, and other relevant 
documents (e.g., advertisements) must be submitted to an IRB/IEC by the 
Investigator and reviewed and approved by the IRB/IEC before the study is initiated.  
• Any amen dments to the protocol will require IEC/IRB approval before 
implementation of changes made to the study design, except for changes necessary to 
eliminate an immediate hazard to study participants.  
• The investigator will be responsible for the following:  
• Providing written summaries of the status of the study to the IRB/IEC annually 
or more frequently in accordance with the requirements, policies, and 
procedures established by the IRB/EC  
• Notifying the IRB/IEC of SAE or other significant safety findings as req uired by 
IRB/IEC procedures  
• Providing oversight of the conduct of the study at the site and adherence to 
requirements of 21 CFR, ICH guidelines, the IRB/IEC, European regulation 
536/2014 for clinical studies (if applicable), and all other applicable local 
regulations  
Financial Disclosure  
Investigators and sub -investigators will provide the Sponsor with sufficient, accurate 
financial information as requested to allow the Sponsor to submit complete and accurate 
financial certification or disclosure statements  to the appropriate regulatory authorities. 
Investigators are responsible for providing information on financial interests during the 
course of the study and for 1 year after completion of the study.  
Informed Consent Process  
• The Investigator or his/her rep resentative will explain the nature of the study to the 
participant or his/her legally authori zed representative and answer all questions 
regarding the study.  
• Participants must be informed that their participation is voluntary.  Participants or 
their lega lly authori zed representative will be required to sign a statement of 
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 192 
 informed consent that meets the requirements of 21 CFR 50, local regulations, ICH 
guidelines, Health Insurance Portability and Accountability Act (HIPAA) 
requirements, where applicable, and the IRB/IEC or study cent er.  
• The medical record must include a statement that written informed consent was 
obtained before the participant was enrolled in the study and the date the written 
consent was obtained. The authori zed person obtaining the inf ormed consent must 
also sign the ICF.  
• Participants must be re -consented to the most current version of the ICF(s) during 
their participation in the study.  
• A copy of the ICF(s) must be provided to the participant or the participant’s legally 
authori zed rep resentative.  
• Participants who are rescreened are required to sign a new ICF.  
The ICF may contain a separate section that addresses the use of remaining mandatory 
samples for optional exploratory research in accordance with SOP -GSKF -410. The 
investigator o r authori zed designee will explain to each participant the objectives of the 
exploratory research. Participants will be told that they are free to refuse to participate 
and may withdraw their consent at any time and for any reason during the storage period . 
A separate signature will be required to document a participant's agreement to allow any 
remaining specimens to be used for exploratory research.  Participants who decline to 
participate will not provide this separate signature.  
Data Protection  
• Participa nts will be assigned a unique identifier by the Sponsor.  Any participant 
records or datasets that are transferred to the Sponsor will contain the identifier only; 
participant names or any information which would make the participant identifiable 
will not be transferred.  
• The participant must be informed that his/her personal study -related data will be 
used by the Sponsor in accordance with local data protection law. The level of 
disclosure must also be explained to the participant.  
• The participant must be  informed that his/her medical records may be examined by 
Clinical Quality Assurance auditors or other authori zed personnel appointed by the 
Sponsor, by appropriate IRB/IEC members, and by inspectors from regulatory 
authorities.  
Committees Structure  
Public ation Policy  
• The results of this study may be published or presented at scientific meetings. If this 
is foreseen, the investigator agrees to submit all manuscripts or abstracts to the 
Sponsor before submission. This allows the Sponsor to protect proprietar y 
information and to provide comments.  
• The Sponsor will comply with the requirements for publication of study results. In 
accordance with standard editorial and ethical practice, the Sponsor will generally 
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 193 
 support publication of multicent er studies only in their entirety and not as individual 
site data. In this case, a coordinating investigator will be designated by mutual 
agreement.  
• Authorship will be determined by mutual agreement and in line with International 
Committee of Medical Journal  Editors authorship requirements.  
Dissemination of Clinical Study Data  
• Where required by applicable regulatory requirements, an Investigator signatory will 
be identified for the approval of the CSR.  The Investigator will be provided 
reasonable access to s tatistical tables, figures, and relevant reports and will have the 
opportunity to review the complete study results at a GSK site or other mutually -
agreeable location.  
• GSK will also provide the investigator with the full summary of the study results.  
The investigator is encouraged to share the summary results with the study 
participant s, as appropriate.  
• The procedures and timing for public disclosure of the results summary and for 
development of a manuscript for publication will be in accordance with GSK P olicy.  
• A manuscript will be progressed for publication in the scientific literature if the 
results provide important scientific or medical knowledge.  
Data Quality Assurance  
• All participant data relating to the study will be recorded on printed or electroni c 
CRF unless transmitted to the Sponsor or designee electronically (e.g., laboratory 
data).  The investigator is responsible for verifying that data entries are accurate and 
correct by physically or electronically signing the CRF.  
• The investigator must ma intain accurate documentation (source data) that supports 
the information entered in the CRF.  
• The investigator must permit study -related monitoring, audits, IRB/IEC review, and 
regulatory agency inspections and provide direct access to source data documen ts.  
• The Sponsor or designee is responsible for the data management of this study 
including quality checking of the data.  
• Study monitors will perform ongoing source data verification to confirm that data 
entered into the CRF by authorized site personnel a re accurate, complete, and 
verifiable from source documents; that the safety and rights of participants are being 
protected; and that the study is being conducted in accordance with the currently 
approved protocol and any other study agreements, ICH GCP, a nd all applicable 
regulatory requirements.  
• Records and documents, including signed ICF, pertaining to the conduct of this study 
must be retained by the investigator for 25 years from the issue of the final CSR/ 
equivalent summary unless local regulations or institutional policies require a longer 
retention period.  No records may be destroyed during the retention period without 
the written approval of the Sponsor.  No records may be transferred to another 
location or party without written notification to t he Sponsor.  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 194 
 Source Documents  
• Source documents provide evidence for the existence of the participant and 
substantiate the integrity of the data collected. Source documents are filed at the 
Investigator’s site.  
• Data reported on the CRF or entered in the eCRF that are transcribed from source 
documents must be consistent with the source documents or the discrepancies must 
be explained. The investigator may need to request previous medical records or 
transfer records, depending on the study. Also, current me dical records must be 
available.  
• Definition of what constitutes source data can be found in the SRM.  
Study and Site Closure  
GSK or its designee reserves the right to close the study site or terminate the study at any 
time for any reason at the sole discret ion of GSK. Study sites will be closed upon study 
completion. A study site is considered closed when all required documents and study 
supplies have been collected and a study site closure visit has been performed.  
The Investigator may initiate study site c losure at any time, provided there is reasonable 
cause and sufficient notice is given in advance of the intended termination.  
Reasons for the early closure of a study site by the Sponsor or Investigator may include 
but are not limited to:  
• Failure of the in vestigator to comply with the protocol, the requirements of the 
IRB/IEC or local health authorities, the Sponsor's procedures, or GCP guidelines  
• Inadequate recruitment of participants by the investigator  
• Discontinuation of further study treatment developme nt 
T M F -1 4 6 2 4 3 5 8  C O N FI D E N TI A L  
  2 0 7 4 9 7  
 Pr ot o c ol A m d 0 4  
 1 9 5  
 Ok e n, M. M., Cr e ec h, R. H., T or m ey, D. C., H ort o n, J., D avis, T. E., Mc F a d d e n, E. T., C ar b o n e, P. P.: T oxicity A n d 
R es p o ns e Crit eri a Of T h e E ast er n C o o p er ativ e O nc ol o gy Gr o u p. A m J Cli n O nc ol 1 9 8 2; 5: 6 4 9 -6 5 5, [ Ok e n , 1 9 8 2]  
 C CI - T hi s s e cti o n c o nt ai n e d Cli ni c al O ut c o m e A s s e s s m e nt d at a c oll e cti o n q u e sti o n n air e s or i n di c e s, w hi c h ar e pr ot e ct e d b y t hir d 
p art y c o p yri g ht l a w s a n d t h er ef or e h a v e b e e n e x cl u d e d. 
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 196 
 14.4.  Appendix 4:  Modified Diet in Renal Disease (MDRD) 
Formula  
The MDRD formula for calculating the estimated glomerular filtration rate (eGFR) is 
as follows:  
eGFR =  175 × (S cr)-1.154 × (Age)-0.203 × (0.742 if female) × (1.212 if African 
American)  
GFR is expressed in mL/min/1.73 m2, SCr is serum creatinine expressed in mg/dL, 
and age is expressed in years.  
The link below will auto -calculate the creatinine clearance:  
http://nephron.org/cgi -bin/MDRD_GFR/cgi    
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 197 
 14.5.  Appendix 5: New York Heart Association Classification  
The New York Heart Association (NYHA) Functional Classification: Class I, II, III or IV 
Heart Failure [ New York Heart Association , 1994] provides a simple way of classifying 
the extent of heart failure. It places participant s in one of 4 categories based on the level 
of limitation  experienced during physical activity:  
Class  Symptoms  
Class I  
(Mild)  No limitation of physical activity. Ordinary physical activity does not cause undue 
fatigue, palpitation or dyspnea (shortness of breath).  
Class II  
(Mild)  Slight limitation of physical activity. Comfortable at rest, but ordinary physical 
activity results in fatigue, palpitation or dyspnea.  
Class III  
(Moderate)  Marked limitation of physical activity. Comfortable at rest, but less than ordinary 
physical activity results in fatigue, palpit ation or dyspnea.  
Class IV  
(Severe)  Unable to carry out any physical activity without discomfort. Symptoms of cardiac 
insufficiency at rest. If any physical activity is undertaken, discomfort is increased.  
The Criteria Committee of the New York Heart Association  (NYHA) . 1994 . Nomenclature and Criteria for Diagnosis of 
Diseases of the Heart and Great Vessels. 9th Ed. Boston, Mass: Little, Brown & Co.; 1994:253 -256. 
 
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 198 
 14.6.  Appendix 6: Adverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow -up, and Reporting  
Definition of AE  
AE Definition  
• An AE is any untoward medical occurrence in a clinical study participant, 
temporally associated with the use of a study treatment, whether or not considered 
related to the study treatment.  
• NOTE: An AE can therefore be any unfavorable and unintended sign (including 
an abnormal laboratory finding), symptom, or disease  (new or exacerbated) 
temporally associated with the use of a study treatment.  
 
Events Meeting  the AE Definition  
• Any abnormal laboratory test results (hematology, clinical chemistry, or 
urinalysis) or other safety assessments (e.g., ECG, radiological scans, vital signs 
measurements), including those that worsen from baseline, considered clinically 
significant in the medical and scientific judgment of the investigator (i.e., not 
related to progression of underlying disease).  
• Exacerbation of a chronic or  intermittent pre -existing condition including either an 
increase in frequency and/or intensity of the condition.  
• New conditions detected or diagnosed after study treatment administration even 
though it may have been present before the start of the study.  
• Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction.  
• Signs, symptoms, or the clinical sequelae of a suspected overdose of either study 
treatment or a concomitant medication. Overdose per se will not be reported as an 
AE/SAE unles s it is an intentional overdose taken with possible suicidal/self -
harming intent. Such overdoses must be reported regardless of sequelae.  
• "Lack of efficacy" or "failure of expected pharmacological action" per se will not 
be reported as an AE or SAE. Such i nstances will be captured in the efficacy 
assessments. However, the signs, symptoms, and/or clinical sequelae resulting 
from lack of efficacy will be reported as AE or SAE if they fulfill the definition of 
an AE or SAE.  
 
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 199 
 Events NOT  Meeting the AE Definition  
• Any clinically significant abnormal laboratory findings or other abnormal safety 
assessments which are associated with the underlying disease, unless judged by 
the investigator to be more severe than expected for the participan t’s condition.  
• The disease/disorder being studied or expected progression, signs, or symptoms of 
the disease/disorder being studied, unless more severe than expected for the 
participant’s condition.  
• Medical or surgical procedure (e.g., endoscopy, appendect omy): the condition that 
leads to the procedure is the AE.  
• Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital).  
• Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) 
present or detected at the start of the study that do not worsen.  
Definition of SAE  
If an event is not an AE per definition above, then it cannot be an SAE even if serious 
conditions are met (e.g., hospitalization for signs/symptoms of the disease under s tudy, 
death due to progression of disease).  
A SAE is defined as any untoward medical occurrence that, at any dose:  
a. Results in death  
b. Is life -threatening  
The term 'life -threatening' in the definition of 'serious' refers to an event in which the 
participant  was at risk of death at the time of the event.  It does not refer to an event, 
which hypothetically might have caused death, if it were more severe.  
c. Requires inpatient hospitalization or prolongation of existing hospitalization  
In general, hospitalization signifies that the participant has been detained (usually 
involving at least an overnight stay) at the hospital or emergency ward for observation 
and/or treatment that would not have been appropriate in the physician’s office or 
outpatient setting.  Complications that occur during hospitalization are AE.  If a 
complication prolongs hospitalization or fulfills any other serious criteria, the event is 
serious.  When in doubt as to whether “hospitalization” occurred or was necessary, the 
AE mus t be considered serious.  
Hospitalization for elective treatment of a pre -existing condition that did not worsen 
from baseline is not considered an AE.  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 200 
 A SAE is defined as any untoward medical occurrence that, at any dose:  
d. Results in persistent disability/incapacity  
• The term disability means a substantial disruption of a pers on’s ability to conduct 
normal life functions.  
• This definition is not intended to include experiences of relatively minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, 
influenza, and accidental trauma (e.g., sprained ankl e) which may interfere with or 
prevent everyday life functions but do not constitute a substantial disruption.  
e. Is a congenital anomaly/birth defect  
f. Other situations:  
• Medical or scientific judgment must be exercised in deciding whether SAE 
reporting is appropriate in other situations such as important medical events that 
may not be immediately life -threatening or result in death or hospitalization but 
may jeopardize the participant or may require medical or surgical intervention to 
prevent one of the oth er outcomes listed in the above definition. These events must 
usually be considered serious.  
Examples of such events include invasive or malignant cancers, intensive 
treatment in an emergency room or at home for allergic bronchospasm, blood 
dyscrasias or c onvulsions that do not result in hospitalization, or development of 
drug dependency or drug abuse.  
g. Is associated with liver injury and impaired liver function defined as:  
• ALT 3 x ULN and total bilirubin* 2 x ULN (>35% direct), or 
• ALT 3 x ULN and INR** >1.5 
* Serum bilirubin fractionation should be performed if testing is available; if 
unavailable, measure urinary bilirubin via dipstick.  If fractionation is unavailable and 
ALT 3 x ULN and total bilirubin 2 x ULN, then the event is still to be reported as an 
SAE.  
** INR testing not required per protocol and the threshold value does not apply to 
participants receiving anticoagulants.  If INR measurement is obtained, the value is to 
be recorded on the SAE form . 
h. Refer to Appendix 9, Section 14.9 for liver chemistry follow -up procedures.  
 
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 201 
 Definition of Cardiovascular Events  
Cardiovascular Events (CV) Definition:  
Investigators will be required to fill out the specific CV event page of the CRF for the 
following AEs and SAEs:  
• Myocardial infarction/unstable angina  
• Congestive heart failure  
• Arrhythmias  
• Valvulopathy  
• Pulmonary hypertension  
• Cerebrovascular events/stroke and transient ischemic attack  
• Peripheral arterial thromboembolism  
• Deep venous thrombosis/pulmonary embolism  
•   Revascularization  
 
Recording AE and SAE  
AE and SAE Recording  
• When an AE/SAE occurs, it is the responsibility of the investigator to review all 
documentation (e.g., hospital progress notes, laboratory, and diagnostics reports) 
related to the event.  
• The investigator will then record all relevant AE/SAE information in the CRF.  
• It is not acceptable for the investigator to send photocopies of the participant’s 
medical records to GSK or designee  in lieu of completion of the GSK /AE/SAE 
CRF page.  
• There may be instances when copies of medical records for certain cases are 
requested by GSK. In  this case, all participant identifiers, with the exception of the 
participant number, will be redacted on the copies of the medical records before 
submission to GSK.  
• The investigator will attempt to establish a diagnosis of the event based on signs, 
sympt oms, and/or other clinical information. Whenever possible, the diagnosis 
(not the individual signs/symptoms) will be documented as the AE/SAE.  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 202 
 Assessment of Intensity  
The investigator will make an assessment of intensity for each AE and SAE reported 
(aside from corneal events) during the study and assign it to 1 of the following 
categories:  
• Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic 
observations only; intervention not indicated.  
• Grade 2: Moderate; minimal, local or noninvasi ve intervention indicated; 
limiting age appropriate instrumental ADL*.  
• Grade 3: Severe or medically significant but not immediately life -threatening; 
hospitalization or prolongation of hospitalization indicated; disabling; limiting 
self-care ADL**.  
• Grade 4 : Life -threatening consequences; urgent intervention indicated.  
• Grade 5: Death related to AE.  
*Instrumental ADL refer to preparing meals, shopping for groceries or clothes, using 
the telephone, managing money, etc.  
**Self -care ADL refer to bathing, dressin g and undressing, feeding self, using the 
toilet, taking medications, and not bedridden.  
Corneal events associated with belantamab mafodotin  will be graded according to 
the grading scale provide in Appendix 8. 
 
Assessment of Causality  
• The investigator is obligated to assess the relationship between study treatment 
and each occurrence of each AE/SAE.  
• A "reasonable possibility" of a relationship conveys that there are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot 
be ruled out.  
• The investigator will use clinical judgment to determine the relationship.  
• Alternative causes, such as underlying disease(s), conc omitant therapy, and other 
risk factors, as well as the temporal relationship of the event to study treatment 
administration will be considered and investigated.  
• The investigator will also consult the Investigator’s Brochure (IB) and/or Product 
Information , for marketed products, in his/her assessment.  
• For each AE/SAE, the investigator must  document in the medical notes that 
he/she has reviewed the AE/SAE and has provided an assessment of causality.  
• There may be situations in which an SAE has occurred and t he investigator has 
minimal information to include in the initial report to GSK. However, it is very 
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 203 
 Assessment of Causality  
important that the investigator always make an assessment of causality for 
every event before the initial transmission of the SAE data to GSK . 
• The investig ator may change his/her opinion of causality in light of follow -up 
information and send an SAE follow -up report with the updated causality 
assessment.  
• The causality assessment is one of the criteria used when determining regulatory 
reporting requirements.  
Follow -up of AE and SAE  
• The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by GSK 
to elucidate the nature and/or causality of the AE or SAE as fully a s possible. This 
may include additional laboratory tests or investigations, histopathological 
examinations, or consultation with other health care professionals.  
• New or updated information will be recorded in the originally completed CRF.  
• The investigator will submit any updated SAE data to GSK within 24 h of receipt 
of the information.  
 
Reporting of SAE to GSK  
SAE Reporting to GSK  via Electronic Data Collection Tool  
• The primary mechanism for reporting SAE to GSK will be the electronic data 
collection tool. 
• If the electronic system is unavailable, then the site will use the paper SAE data 
collection tool (see next section) in order to report the event within 24 h. 
• The site will enter the SAE data into the electronic system as soon as it becomes 
availabl e. 
• The investigator or medically -qualified sub -investigator must show evidence 
within the eCRF (e.g., check review box, signature, etc.) of review and verification 
of the relationship of each SAE to IP/study participation (causality) within 72 h of 
SAE ent ry into the eCRF.  
• After the study is completed at a given site, the electronic data collection tool will 
be taken off -line to prevent the entry of new data or changes to existing data.  
• If a site receives a report of a new SAE from a study participant or re ceives 
updated data on a previously reported SAE after the electronic data collection tool 
has been taken off -line, then the site can report this information on a paper SAE 
form (see next section).  
• Contacts for SAE reporting can be found in the SRM.  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 204 
  
SAE Reporting to GSK via Paper CRF  
• Facsimile transmission of the SAE paper CRF is the preferred method to transmit 
this information to the SAE coordinator. Details provided in the SRM.  
• In rare circumstances and in the absence of facsimile equipment, notificat ion by 
telephone is acceptable with a copy of the SAE data collection tool sent by 
overnight mail or courier service.  
• Initial notification via telephone does not replace the need for the investigator to 
complete and sign the SAE CRF pages within the design ated reporting time 
frames.  
• Contacts for SAE reporting can be found in the SRM.  
 
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 205 
 14.7.  Appendix  7: Contraceptive Guidance and Collection of 
Pregnancy Information  
Definitions  
Woman of Childbearing Potential (WOCBP)  
A woman is considered fertile following menarche and until becoming post -menopausal 
unless permanently sterile (see below).  
If fertility is unclear (e.g., amenorrhea in adolescents or athletes) and a menstrual cycle 
cannot be confirmed before first dose of study intervention, additional evaluati on should 
be considered.  
Women in the following categories are not considered WOCBP  
1. Premenarchal  
2. Premenopausal female with 1 of the following:  
• Documented hysterectomy  
• Documented bilateral salpingectomy  
• Documented bilateral oophorectomy  
For individuals with permanent infertility due to an alternate medical cause other 
than the above, (e.g., Mullerian agenesis, androgen insensitivity), investigator 
discretion should be applied to determining study entry.  
Note:  Documentation can come from the site personnel’s: review of participant’s 
medical records, medical examination, or medical history interview.  
3. Postmenopausal female  
• A postmenopausal state is defined as no menses for 12 months without an 
alternative medical cause. A high follicle stimu lating hormone (FSH) level in 
the postmenopausal range may be used to confirm a postmenopausal state in 
women not using hormonal contraception or hormonal replacement therapy 
(HRT). However, in the absence of 12 months of amenorrhea confirmation with 
more than one FSH measurement is required (in questionable cases a blood 
sample with simultaneous FSH >40 MIU/mL and estradiol <40 pg/mL 
[<147  pmol/L ] is confirmatory ).  
• Females on HRT and whose menopausal status is in doubt will be required to 
use one of the non -estrogen hormonal highly effective contraception methods if 
they wish to continue their HRT during the study.  Otherwise, they must 
discontinue HRT to allow confi rmation of postmenopausal status before study 
enrollment . 
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 206 
 Contraception Guidance  
• CONTRACEPTIVESa ALLOWED DURING THE STUDY INCLUDE:  
• Highly Effective Methodsb That Have Low User Dependency  
• Implantable progestogen -only hormone contraception associated with  inhibition of 
ovulationc 
• Intrauterine device (IUD)  
• Intrauterine hormone -releasing system (IUS)c 
• Bilateral tubal occlusion  
• Vasectomized partner  
• Note: Vasectomized partner is a highly effective contraceptive method provided that 
the partner is the sole sexual partner of the woman of childbearing potential and the 
absence of sperm has been confirmed. If not, an additional highly effective method of 
contraception should be used. Spermatogenesis cycle is approximately 90 days.  
• Highly Effective Methodsb That Are User Dependent  
• Combined (estrogen - and progestogen -containing) hormonal contraception associated with 
inhibition of ovulationc 
• oral 
• intravaginal  
• transdermal  
• injectable  
• Progestogen -only hormone contraception associated with inhibition of ovulationc 
• oral 
• injectable  
• Sexual abstinence  
• Note: Sexual abstinence is considered a highly effective method only if defined as 
refraining from heterosexual intercourse during the entire period of risk associated with 
the study intervention. The reliability of sexual abstinence needs to be evaluated in 
relation to the duration of the study and the preferred and usual lifestyle of the 
participant.  
a. Contraceptive use by men or women should be consistent with local regulations regarding the use of 
contraceptive met hods for those participating in clinical studies.  
b. Failure rate of <1% per year when used consistently and correctly. Typical use failure rates differ from those 
when used consistently and correctly.  
c. Male condoms must be used in addition to hormonal contraception. If locally required, in accordance with 
Clinical Trial Facilitation Group (CTFG) guidelines, acceptable contraceptive methods are limited to those 
which inhibit ovulation as the primary mode of action.  
 
Note: Periodic abstinence (calendar, s ympto -thermal, post -ovulation methods), withdrawal (coitus interruptus), 
spermicides only, and lactational amenorrhea  method (LAM) are not acceptable methods of contraception for this 
study. Male condom and female condom should not be used together (due to  risk of failure with friction).  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 207 
 Collection of Pregnancy Information  
Male participants with partners who become pregnant  
• Investigator will attempt to collect pregnancy information on  the female partner of a 
male study participant who becomes pregnant while participating in this study.  This 
applies only to male participants who receive study treatment.  
• After obtaining the necessary signed informed consent from the pregnant female 
partner directly, the investigator will record pregnancy information on th e 
appropriate form and submit it to GSK within 24 h of learning of the partner’s 
pregnancy.  
• The female partner will also be followed to determine the outcome of the pregnancy. 
Information on the status of the mother and child will be forwarded to GSK  
• Gene rally, follow -up will be no longer than 6 to 8 weeks following the estimated 
delivery date. Any termination of the pregnancy will be reported regardless of fetal 
status (presence or absence of anomalies) or indication for procedure.  
Female participants wh o become pregnant  
• Investigator will collect pregnancy information on any female participant, who 
becomes pregnant while participating in this study .  
• Information will be recorded on the appropriate form and submitted to GSK within 
24 h of learning of a par ticipant's pregnancy.  
• Participant will be followed to determine the outcome of the pregnancy. The 
investigator will collect follow up information on participant and neonate, which will 
be forwarded to GSK . Generally, follow -up will not be required for longer than 6 to 
8 weeks beyond the estimated delivery date.   
• Any termination of pregnancy will be reported, regardless of fetal status (presence or 
absence of anomalies) or indication for procedure.  
• While p regnancy itself is not considered to be an AE or SAE, any pregnancy 
complication or elective termination of a pregnancy will be reported as an AE or 
SAE.  
• A spontaneous abortion is always considered to be an SAE and will be reported as 
such.   
• Any SAE occu rring as a result of a post -study pregnancy which is considered 
reasonably related to the study treatment by the investigator, will be reported to GSK 
as described in Appendix 6, Section 14.6.  While the investigator is not obligated to 
actively seek this informati on in former study participants, he or she may learn of an 
SAE through spontaneous reporting.  
Any female participant who becomes pregnant while participating will discontinue study 
treatment.  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 208 
 14.8.  Appendix 8: Corneal Event Grading and Mitigation Strategy  
Corn eal events should be graded according to the guidelines provided in Table 33. 
In order to minimize the corneal findings , prophylactic preservative -free artificial tears 
should be administered in each eye at least 4 to 8 times daily, beginning on C1D1  until 
the End of Treatment (EOT). Allow at least 5 -10 min between administration of artificial 
tears and steroid eye drops  (if administered) . In the event of ocular symptoms (i.e., dry 
eyes), the use of artificial tears may be increased up to every 2  h as needed.  
While not  yet clinically demonstrated, it is theoretically possible that the application of a 
cooling eye mask during belantamab mafodotin  administration, and in the first few hours 
after infusion may subsequently decrease ocular side effects. On the day of infusio n, the 
following may be considered:  
• Beginning with the start of each belantamab mafodotin  infusion, participant s may 
apply cooling eye masks to their eyes for approximately 1 h or as much as tolerated 
by the participant .   
• Participant s are encouraged to continue using the cooling eye mask beyond the first 
hour for up to 4 h. Further use beyond 4 h is at the participant ’s discretion.  
Contact lenses are prohibited while the participant is on study treatment.  
The GSK grading scale for cor neal events was developed to capture both corneal findings 
and visual acuity changes in participants treated with belantamab mafodotin and to 
provide recommendations for dosing decisions.  This GSK scale is different from CTCAE 
criteria for eye disorders wh ich relies mainly on participant’s symptoms and participant’s 
ability to attend to ‘activities of daily living’ and which (CTCAE) is to be used for 
grading of the adverse  events.   
A summary of prophylactic interventions for corneal events associated with belantamab 
mafodotin  is provided in Table 32. In addition to reporting eye disorders using CTCAE 
4.03 criteria, corneal events associated with belantamab mafodotin  must also be graded 
according to the guidelines provided in Table 33. Additional guidance on visual acuity 
changes is provided in  Table 34. 
In the FTIH study (BMA117159),  eye examinations showed that most participants 
continued to receive belantamab mafodotin  dose when either a GSK Scale Grade 2 
corneal examination finding or a 2-3-line decrease in visual acuity was reported. With 
this dosing paradigm, participants general ly showed improvement in both corneal 
examination findings and visual acuity  over time. Therefore, the dosing guideline has 
been adjusted to allow dosing with belantamab mafodotin  if only one component on the 
GSK corneal event scale indicates Grade 2 corne al event.  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 209 
 Table 32 Prophylactic Measures for Corneal Events Associated with 
Belantamab Mafodotin  
Prophylactic 
Measurea Dose and Administration  Timing  
Preservative -free 
artificial tears  Administer in each eye at least 
4 to 8 times daily Administer daily beginning on Cycle 1 
Day 1 until EOT. Allow 5 -10 min 
between administration of artificial tears 
and steroid eye drops  
Cooling eye mask  May apply cooling eye mask to 
both eyes for approximately 1 h 
or as much as tolerated  During belantamab mafodotin  infusion 
administration in the first hour for up to 
4 h, as tolerated  
a. Dose modifications and treatment for ocular toxicities are discussed in Section 8.2.1  
 
 
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 210 Table 33 Grading Scale for Corneal Events Associated with Belantamab Mafodotin  
Measure  
 Grade 1 per GSK Scale  Grade 2 per GSK Scale  Grade 3 per GSK Scale  Grade 4 per GSK Scale  
Ophthalmic exam 
findings  Mild superficial keratopathy 
(change from baseline)  
 Moderate punctate  keratopathy  
and/or  
Mild/patchy microcysts  
and/or  
Mild/patchy  Epithelial or stromal 
edema  
and/or  
Sub-epithelial haze (peripheral)  
and/or  
Active stromal opacity (peripheral)  Severe punctate  keratopathy  
and/or  
Diffuse microcysts  
and/or  
Diffuse Epithelial or stromal edema  
and/or  
Sub-epithelial haze (central)  
and/or  
Active stromal opacity (central)  Corneal ulcer  
Visual Acuity b, c Change of 1 line from baseline  Change of 2 -3 lines from baseline and 
not worse than 20/200b Change of more than 3 lines from 
baseline and not worse than 20/200b 
 Worse than Vision 20/200b 
 
Note: Standardized guidance for grading ophthalmic findings associated with belantamab mafodotin  is provided to sites in the ophthalmology SRM. Ophthalmic exam findings as 
described must be present in a participant to utilize GSK’s scale.  
a. Grading is based on most severe finding. If eyes differ in severity, GSK grading should be based on the more severe eye.  
b. Change in visual acuity should be due to corneal events. If change in vision is for reason other than corneal events, ophthal mic exam findings wil l drive event grading.   
c. See  Table 34 for additional guidance on how to grade changes in visual acuity depending on baseline vision. If a participant has a baselin e visual acuity of 20/200 or worse in an 
eye, ophthalmic exam findings will drive event grading.  
 
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 211  Table 34 Guidance for Assessing Changes in Visual Acuity for GSK 
Grading Scale  
Baseline Vision  
(best corrected)  Grade 1 per 
GSK scale  Grade 2 per GSK scale  Grade 3 per 
GSK scale  Grade 4 per GSK 
scale  
20/15 to 20/16  
From -0.12 to -0.1 20/20  
0 20/25 to 20/30 or 20/32  
0.1 to 0.18 or 0.2  20/40 to 20/200  
0.3 to 1.0  Worse than 20/200  
>1.0 
20/20  
0 20/25  
0.1  20/30 to 20/40  
0.18 to 0.3  20/50 to 20/200  
0.4 to 1.0  Worse than 20/200  
>1.0 
20/25  
0.1 20/30 to 20/32  
0.18 to 0.2  20/40 to 20/50  
0.3 to 0.4  20/60 to 20/200  
0.48 to 1.0  Worse than 20/200  
>1.0  
20/30 to 20/32  
0.18 to 0.2  20/40  
0.3  20/50 to 20/60 or 20/63  
0.4 to 0.48 or 0.5  20/70 to 20/200  
0.56 to 1.0  Worse than 20/200  
>1.0 
20/40  
0.3 20/50  
0.4  20/60 to 20/70 or 20/80  
0.48 to 0.56 or 0.6  20/100 to 20/200  
0.7 to 1.0  Worse than 20/200  
>1.0 
20/50  
0.4 20/60 to 20/63  
0.48 to 0.5  20/70 to 20/100  
0.56 to 0.7  20/125 to 20/200  
0.8 to 1.0  Worse than 20/200  
>1.0  
20/60 to 20/63  
0.48 to 0.5  20/70 to 20/80  
0.56 to 0.6  20/100 to 20/125  
0.7 to 0.8  20/150 to 20/200  
0.88 to 1.0  Worse than 20/200  
>1.0  
20/70 to 20/80  
0.56 to 0.6  20/100  
0.7  20/125 to 20/150 or 
20/1600.8 to 0.88 or 0.9  20/200  
1.0  Worse than 20/200  
>1.0 
20/100  
0.7 20/125  
0.8  20/150 to 20/160 or 
20/2000.88 to 0.9 or 1.0  N/A Worse than 20/200  
>1.0  
20/125  
0.8 20/150 to 20/160  
0.88 to 0.9  20/200  
1.0  N/A Worse than 20/200  
>1.0  
20/150 to 20/160  
0.88 to 0.9  20/200  
1.0  N/A N/A Worse than 20/200  
>1.0  
Worse than 
20/160  
>/= 1.0  N/A N/A N/A Any further 
reduction from 
baseline is 
considered Grade 4  
Note: The Visual acuity is presented as Snellen equivalent and logMAR value.  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 212 14.9.  Appendix 9: Liver Safety: Required Actions, Follow -up 
Assessments, and Study Treatment Rechallenge Guidelines  
Liver chemistry stopping and increased monitoring criteria  have been designed to 
assure participant  safety and evaluate liver event etiology.  
Liver Chemistry Stopping Criteria – Liver Stopping Event  
ALT-absolute  ALT 5 x ULN  
ALT Increase  ALT 3 x ULN persists for 4 weeks  
Bilirubin1, 2 ALT 3 x ULN and total bilirubin 2 x ULN (>35% direct bilirubin)  
INR2  ALT 3 x ULN and INR >1.5 
Cannot Monitor  ALT 3 x ULN and cannot be monitored weekly for 4 weeks  
Symptomatic3 ALT 3 x ULN associated with symptoms (new or worsening) believed to be related 
to liver injury or hypersensitivity  
Required Actions and Follow -up Assessments following ANY Liver Stopping Event  
Actions  Follow Up Assessments  
• Immediately  discontinue study treatment   
• Report the event to GSK  within 24 h 
• Complete the liver event form and complete 
an SAE data collection tool if the event also 
meets the criteria for an SAE2 
• Perform liver event follow up assessments as 
described in the Follow Up Assessment 
column  
• Monitor the participant  until liver chemistries 
resolve, stabilize, or return to within baseline 
(see MONITORING  below)  
MONITORING:  
If ALT≥3xULN AND total bilirubin  2xULN 
or INR >1.5:  
• Repeat liver chemistries (include ALT, AST, 
alkaline phosphatase, total bilirubin  and INR ) 
and perform liver event follow up 
assessments within 24 h 
• Monitor participant s twice weekly until liver 
chemistries resolve, stabilize or return to 
within baseline  • Viral hepatitis serology4 
• Obtain INR and recheck with each liver chemistry 
assessment until the transaminase values show 
downward trend  
• Blood sample for pharmac okinetic (PK) analysis of 
belantamab mafodotin  and a blood sample for 
, obtained  within  70 days after last dose5 
• Serum creatine phosphokinase (CPK) and lactate 
dehydrogenase (LDH) , gamma glutamyl 
transferase [GGT], glutamate dehydrogenase 
[GLDH], and serum albumin . 
• Fractionate bilirubin, if total bilirubin 2 x ULN  
• Obtain complete blood count with differential to 
assess eosinophilia  
• Record the appearance or worsening of clinical 
symptoms of liver injury, or hypersensitivity, on the 
liver report form  
• Record use of concomitant medications on the 
concomitant medications report form including 
acetaminophen, herbal remedies, other over the 
counter medications  
CCI
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 213 • A specialist or hepatology consultation is 
recommended  
For All other criteria  (bilirubin <2xULN and 
INR 1.5): 
• Repeat liver chemistries (include ALT, AST, 
alkaline phosphatase, bilirubin  and INR ) and 
perform liver event follow up assessments 
within 24-72 hours  
• Monitor participant s weekly until liver 
chemistries resolve, stabilize or return to 
within baseline  
RESTART/RECHALLENGE  
• Restart/rechallenge is allowed per 
protocol but do not resume study 
intervention unless GSK approval is 
granted; If restart/rechallenge is not 
granted , permanently discontinue study 
intervention and continue pa rticipant in the 
study for any protocol specified follow up 
assessments. Refer to Restart/Rechallenge 
guidelines in Appendix 9 Section 14.9 • Record alcohol use on the liver event alcohol 
intake form  
If ALT 3xULN AND total bilirubin 2xULN  or 
INR >1.5  obtain the following in addition to the 
assessments listed above :: 
• Anti-nuclear antibody, anti -smooth muscle 
antibody, Type 1 anti -liver kidney microsomal 
antibodies, and quantitative total immunoglobulin 
G (IgG or gamma globulins).  
• Serum acet aminophen adduct assay should be 
conducted (where available) to assess  potential 
acetaminophen contribution to liver injury unless 
acetaminophen use is very unlikely in the 
preceding week (e.g. where the participant has 
been resident in the clinical unit t hroughout)  
• Liver imaging (ultrasound, magnetic resonance, or 
computerized tomography) and /or liver biopsy to 
evaluate liver disease; complete Liver Imaging 
and/or Liver Biopsy forms.  
• Liver biopsy may be considered and discussed 
with local specialist if available, for instance:  
o In patients when serology raises the 
possibility of autoimmune hepatitis (AIH)  
o In patients when suspected DILI progresses 
or fails to resolve on withdrawal of study 
intervention  
o In patients with acute or chronic atypical 
presentati on:  
• If liver biopsy conducted complete liver biopsy 
form.   
1. Serum bilirubin fractionation should be performed if testing is available. If serum bilirubin fractionation is not 
immediately available, discontinue study treatment for that participant  if ALT 3 x ULN and bilirubin 2 x ULN.  
Additionally, if serum bilirubin fractionation testing is unavailable, record presence of detectable urinary 
bilirubin on dipstick , indicating direct bilirubin elevations and suggesting liver injury.  
2. All events of ALT 3 x ULN and total bilirubin 2 x ULN (>35% direct bilirubin) or ALT 3 x ULN and INR >1.5, 
which may indicate severe liver injury (possible ‘Hy’s Law’), must be reported as an SAE ; the INR threshold 
value will not apply to participant s receiving anticoagulants  
3. New or worsening symptoms believed to be related to liver injury (such as fatigue, nausea, vomiting, right upper 
quadrant pain or tenderness, or jaundice) or believed to be related to hypersensitivity (such as fever, rash or 
eosinophilia)  
4. Includes: Hepatitis A IgM antibody; Hepatitis B surface antigen and Hepatitis B Core Antibody (IgM); Hepatitis C 
RNA; Cytomegalovirus IgM antibody; Epstein -Barr viral capsid antigen IgM antibody (or if unavailable, obtain 
heterophile antibody or monospot tes ting); Hepatitis E IgM antibody . If hepatitis delta antibody assay cannot be 
performed, it can be replaced with a PCR of hepatitis D RNA virus (where needed) [ Le Gal , 2005].  
5. Record the date/time of the PK /  blood sample draw and the date/time of the last dose of study treatment 
prior to blood sample draw on the CRF. If the date or time of the last dose is unclear, provide the participant ’s best 
approximation. If the date/time of the last dose cannot be approximated OR a PK /  sample cannot be 
collected in the time period indicated above, do not obtain a PK /  sample. Instructions for sample handling 
and shipping are in the SRM.  
CCI
CCI
CCI
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 214 Liver Chemistry Increased Monitoring Criteria and Actions with Continued Study 
Intervention  Liver Monitoring Event  
Criteria  Actions  
ALT 3 x ULN but <5 x ULN and  total 
bilirubin <2 x ULN  or INR 1.5, without  
symptoms believed to be related to liver injury 
or hypersensitivity and who can be monitored 
weekly for 4 weeks  
 • Notify the GSK medical monitor within 24 h of 
learning of the abnormality to discuss participant  
safety.  
• Participant can continue study treat ment   
• Participant must return weekly for repeat liver 
chemistries (ALT, AST, alkaline phosphatase, 
bilirubin) until they resolve, stabili ze or return to 
within baseline  
• If at any time participant meets the liver chemistry 
stopping criteria, proceed as de scribed above  
• If, after 4 weeks of monitoring, ALT <3 x ULN and 
bilirubin <2 x ULN, monitor participants twice 
monthly until liver chemistries normalize or return 
to within baseline.  
 
14.9.1.  Liver Safety Drug Restart or Re -Challenge Guidelines  
A participant who met liver chemistry stopping criteria cannot resume study treatment 
unless all of the following conditions are met:  
• GSK approval is granted (as described below),  
• Institutional Review Board/Independent Ethics Committee (IRB/IEC)  approval is 
obtained, and  
• Separate ICF for study treatment restart/rechallenge is signed by the participant  and 
the participant is informed of any associated risks . 
If GSK approval to restart/rechallenge participant with study treatment is not  granted, 
then participant must permanent ly discontinue study treatment and may continue in the 
study for protocol -specified follow -up assessments.  
14.9.1.1.  Rechallenge Following Liver Stopping Events that are Possibly Related 
to Study Treatment  
Following drug-induced liver injury , drug rechallenge is associated with a 13% 
mortality across all drugs in prospective studies [Andrade , 2009]. Clinical outcomes 
vary by drug, with nearly 5 0% fatality with halothane readministered within one month 
of initial injury. However, some drugs seldom result in recurrent liver injury or fatality.   
Risk factors for a fatal drug rechallenge outcome include:  
• Hypersensitivity with initial liver injury ( e.g., fever, rash, eosinophilia)  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 215 • Jaundice or bilirubin >2 x ULN with initial liver injury (direct bilirubin >35% of 
total)  
• Ongoing severe liver injury defined by: ALT ≥3 × ULN, bilirubin ≥2 × ULN 
(direct bilirubin >35% of total), or INR ≥1.5  
• SAEs or fatal ity has earlier been observed with drug rechallenges [ Hunt , 2010; 
Papay , 2009].  
• Evidence of drug -related preclinical liability (e.g. reactive metabolites; 
mitochondrial impairment)  
Rechallenge refers to resuming study treatment following study treatment induced liver  
injury ( DILI ). Because of the risks associated with rechallenge after DILI , this should 
only be considered for a participant for whom there is compelling evidence of benefit 
from a critical or life -saving medicine, there is no alternative approved medicin e 
available, and a benefit:risk assessment of rechallenge is considered to be favorable.  
Approval by GSK for rechallenge with study treatment can be considered where:  
• The Princip al Investigator (PI) requests consideration of rechallenge with study 
treatment for a participant who is receiving compelling benefit with study treatment 
that exceeds risk, and no effective alternative therapy is available.   
• IRB/IEC  approval for rechallenge with study treat ment must be obtained . 
If the rechallenge is approved by GSK in writing:  
• The participant must be provided with a clear description of the possible benefits and 
risks of study treatment administration, including the possibility of recurrent, more 
severe liv er injury or death.   
• The participant must also provide signed informed consent specifically for the 
rechallenge with study treatment.  Documentation of informed consent must be 
recorded in the study file. 
• Study treatment must be administered at the dose s pecified by GSK.  
• Participants approved by GSK for rechallenge with study treatment must return to 
the clinic twice a week for liver chemistry tests until stable liver chemistries have 
been demonstrated and then standard laboratory monitoring may resume as per 
protocol.  
• If after study treatment rechallenge, participant meets protocol -defined liver 
chemistry stopping criteria, study treatment should be permanently discontinued.  
• GSK Medical Monitor, and the IRB /IEC  as required, must be informed of the 
partici pant’s outcome following study treatment rechallenge.  
• GSK to be notified of any adverse events, as per Section 10.2.4  and Appendix 6 
(Section 14.6).  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 216 14.9.1.2.  Restart Following Transient Resolving Liver Stopping Events NOT 
Related to Study Treatment  
Restart refers to resuming study treatment following liver stopping events in which there 
is a clear underlying cause (other than DILI)  of the liver event (e.g., biliary obstruction, 
pancreatic events, hypotension, acute viral hepatitis). Furthermore, restart is not permitted 
following liver stopping event when the underlying cause was alcohol -related hepatitis . 
Approval by GSK for study treatment restart can be considered where:  
• Principle Investigator requests consideration for study treatment restart if liver 
chemistries have a clear underlying cause (e.g., biliary obstruction, hypotension and 
liver chemistries have improved to normal or  are within 1.5 x baseline and ALT 
<3 x ULN).  
• Possible study treatment -induced liver injury has been excluded by the principle 
investigator and the study team. This includes the absence of markers of 
hypersensitivity (otherwise unexplained fever, rash, eos inophilia). Where a study 
treatment has an identified genetic marker associated with liver injury (e.g. lapatinib, 
abacavir, amoxicillin/clavulanate), the presence of the marker should be excluded. If 
study treatment -related liver injury cannot be excluded , the guidance on rechallenge 
as stated in previous section will apply.  
• There is no evidence of alcoholic hepatitis.  
• IRB/IEC  approval of study treatment restart must be obtained, as required.  
If restart of study treatment is approved by GSK in writing:  
• The participant must be provided with a clear description of the possible benefits and 
risks of study treatment administration, including the possibility of recurrent, more 
severe liver injury or death.  
• The participant must also provide signed informed consen t specifically for the study 
treatment restart.  Documentation of informed consent must be recorded in the study 
file. 
• Study treatment must be administered at the dose specified by GSK.  
• Participants approved by GSK for restart  of study treatment must retur n to the clinic 
once a week for liver chemistry tests until stable liver chemistries have been 
demonstrated and then laboratory monitoring may resume as per protocol.  
• If participant meets protocol -defined liver chemistry stopping criteria  after study 
treatment restart , study treatment should be permanently discontinued . 
• GSK Medical Monitor, and the IRB/I EC must be informed of the participant’s 
outcome following study treatment restart.  
• GSK to be notified of any adverse events, as per Section 10.2.4 . 
 
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 217 14.9.1.3.  References:  
Andrade RJ, Robles M, Lucena MI.  Rechallenge in drug -induced liver injury: the 
attractive hazard.  Expert Opin Drug Saf. 2009;8:709 -714. 
Hunt, CM.  Mitochondrial and immunoalle rgic injury increase risk of positive drug 
rechallenge after drug -induced liver injury: A systematic review.  Hepatol. 2010;52:2216 -
2222.  
James LP, Letzig L, Simpson PM, Capparelli E, Roberts DW, Hinson JA et al. 
Pharmacokinetics of Acetaminophen -Adduct in  Adults with Acetaminophen Overdose 
and Acute Liver Failure. Drug Metab Dispos . 2009; 37:1779 -1784  
Le Gal F, Gordien E, Affolabi D, Hanslik T, Alloui C, Dény P et al.   Quantification of 
Hepatitis Delta Virus RNA in Serum by Consensus Real -Time PCR Indicate s Different 
Patterns of Virological Response to Interferon Therapy in Chronically Infected 
Patients.   J Clin Microbiol. 2005;43:2363 –2369  
Papay JI, Clines D, Rafi R, Yuen N, Britt SD, Walsh JS et al. Drug -induced liver injury 
following positive drug rechal lenge.  Regul Tox Pharm. 2009;54:84 -90.  
 
 
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 218 14.10.  Appendix 1 0:  Genetic s 
Naturally occurring genetic variation may contribute to inter -individual variability in 
response to medicines, as well as an individual's risk of developing specific diseases.  
Genetic factors associated with disease characteristics may also be associated with 
response to therapy, and could help to explain some clinical study outcomes. For 
example, genetic variants associated with age -related macular degeneration (AMD) are 
reported to ac count for much of the risk for the condition [ Gorin , 2012] with certain 
variants reported to influence treatment response [ Chen , 2012]. Thus, knowledge of the 
genetic etiology of disease may better inform understanding of disease and the 
development of medicines. Additionally, genetic variability may impact the 
pharmac okinetics (absorption, distribution, metabolism, and elimination), or 
pharmacodynamics (relationship between concentration and pharmacologic effects or the 
time course of pharmacologic effects) of a specific medicine and/or clinical outcomes 
(efficacy and/ or safety) observed in a clinical study.  
Therefore, where local regulations and IRB/IEC allow, a blood sample will be collected 
for DNA analysis.  
CCI
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 219 14.10.2.  Study Population  
Any participant  who is enrolled in the study can participate in genetic research.  
Participant  participation in the genetic research is voluntary and refusal to participate will 
not indicate withdrawal from the clinical study. Refusal to participate will involve no 
penalty or loss of benefits to which the participant  would otherwise be entitled.  
14.10.3.  Study Assessments and Procedures  
A key component of successful genetic research is the collection of samples during 
clinical studies. Collection of samples, even when no a priori hypothesis has been 
identified, may enable future genetic analyses to be conduc ted to help understand 
variability in disease and medicine response.  
• A 6 mL blood sample  will be taken for Deoxyribonucleic acid (DNA) extraction.  
A blood sample is collected at the baseline visit, after the participant  has been provided 
informed consent f or genetic research. Instructions for collection and shipping of the 
genetic sample are described in the laboratory manual. The DNA from the blood sample 
may undergo quality control analyses to confirm the integrity of the sample.  If there are 
concerns re garding the quality of the sample, then the sample may be destroyed. The 
blood sample is taken on a single occasion unless a duplicate sample is required due to an 
inability to utilize the original sample.  
The genetic sample is labelled (or “coded”) with t he same study -specific number used to 
label other samples and data in the study. This number can be traced or linked back to the 
participant  by the Investigator or site staff. Coded samples do not carry personal 
identifiers (such as name or social security  number).  
Samples will be stored securely and may be kept for up to 15 years after the last 
participant  completes the study, or GSK may destroy the samples sooner. GSK or those 
working with GSK (for example, other researchers) will only use samples collect ed from 
CCI
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 220 the study for the purpose stated in this protocol and in the ICF. Samples may be used as 
part of the development of a companion diagnostic to support the GSK medicinal 
product.  
Participant s can request their sample to be destroyed at any time.  
14.10.4.  Informed Consent  
Participant s who do not wish to participate in the genetic research may still participate in 
the study. Genetic informed consent must be obtained prior to any blood being taken.  
14.10.5.  Participant  Withdrawal from Study  
If a participant  who has conse nted to participate in genetic research withdraws from the 
clinical study for any reason other than being lost to Follow -up, the participant  will be 
given a choice of one of the following options concerning the genetic sample, if already 
collected:  
• Continue to participate in the genetic research in which case the genetic DNA sample 
is retained  
• Discontinue participation in the genetic research and destroy the genetic DNA 
sample  
If a participant  withdraws consent for genetic research or requests sample  destruction for 
any reason, the investigator must complete the appropriate documentation to request 
sample destruction within the timeframe specified by GSK and maintain the 
documentation in the site study records.  
Genotype data may be generated during th e study or after completion of the study and 
may be analyzed during the study or stored for future analysis.  
• If a participant  withdraws consent for genetic research and genotype data has not 
been analyzed, it will not be analyzed or used for future researc h. 
• Genetic data that has been analyzed at the time of withdrawn consent will continue 
to be stored and used, as appropriate.  
14.10.6.  Screen and Baseline Failures  
If a sample for genetic research has been collected and it is determined that the 
participant  does not  meet the entry criteria for participation in the study, then the 
investigator should instruct the participant  that their genetic sample will be destroyed.  
No forms are required to complete this process as it will be completed as part of the 
consent and s ample reconciliation process. In this instance a sample destruction form will 
not be available to include in the site files.  
14.10.7.  Provision of Study Results and Confidentiality of Participant ’s 
Genetic Data  
GSK may summarize the genetic research results in the CSR, or separately and may 
publish the results in scientific journals.  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 221 GSK may share genetic research data with other scientists to further scientific 
understanding in alignment with the informed consent. GSK does not inform the 
participant , family members , insurers, or employers of individual genotyping results that 
are not known to be relevant to the participant ’s medical care at the time of the study, 
unless required by law. This is due to the fact that the information generated from genetic 
studies is g enerally preliminary in nature, and therefore the significance and scientific 
validity of the results are undetermined. Further, data generated in a research laboratory 
may not meet regulatory requirements for inclusion in clinical care.  
14.10.8.  Germline Control  
US Food and Drug Administration states that an in vitro companion diagnostic device 
(IVD) could be essential for the safe and effective use of a corresponding therapeutic 
product to:  
• Identify participants who are most likely to benefit from a particular th erapeutic 
product;  
• Identify participants likely to be at increased risk for serious adverse reactions as a 
result of treatment with a particular therapeutic product;  
• Monitor response to treatment for the purpose of adjusting treatment (e.g., schedule, 
dose, discontinuation) to achieve improved safety or effectiveness;  
• Identify participants in the population for whom the therapeutic product has been 
adequately studied, and found safe and effective, i.e., there is insufficient 
information about the safety and  effectiveness of the therapeutic product in any other 
population.  
Global regulatory requirements for IVD companion diagnostic tests are evolving.  If a 
DNA -based IVD companion diagnostic device might be needed to identify participants 
who are appropriate for the GSK medicinal product(s) under investigation in this 
protocol, then GSK should collect and retain DNA samples from participants who carry 
the genetic variant of interest as well as DNA samples from participants who do not carry 
the genetic variants  of interest to validate the performance of the companion diagnostic.  .  
Therefore, where local regulations and IRB/IEC allow, a sample will be collected for 
DNA analysis.   Any IVD companion diagnostic research objectives should be described 
in participa nt ICFs.  
14.10.9.  References  
Chen H, Yu KD, Xu GZ. Association between Variant Y402H in Age -Related Macular 
Degeneration (AMD) Susceptibility Gene CFH and Treatment Response of AMD: A 
Meta -Analysis. PloS ONE . 2012;7:e42464  
Gorin MB. Genetic insights into age -relate d macular degeneration: Controversies 
addressing risk, causality, and therapeutics. Mol. Asp. Med. 2012;33:467 -486. 
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 222 14.11.  Appendix 1 1: Operating Characteristics of Safety Stopping 
Rule for Expansion Cohort  
 

TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 223 14.12.  Appendix 12: Eye care specialist’s qualifications and 
requirements  
For examiners with a degree in optometry or ophthalmology, those involved in eye 
evaluations in the protocol must be able to provide comprehensive eye care to patients, 
ranging from routine check -ups to treatment and ongoing management of visu al disease. 
This includes, as a minimum, the ability to perform the following activities:  
• Comprehensive eye exams  
• Visual acuity with manual refraction tests and analysis of results  
• Slit lamp tests and analysis of results  
• Intraocular pressure examination  
• Dilated fundoscopic examination  
• Diagnosis and treatment of ocular issues and diseases such as keratopathy or 
glaucoma  
• Communication with patients on the effect of belantamab mafodotin on the eye.   
 
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 224 14.13.  Appendix 1 3: Alternative Health Care Approaches  
Home Health care (General Visit)  
Where applicable country , local regulations and infrastructure allow, home healthcare 
may be permitted.  Home healthcare is defined as a remote visit(s) that is/are performed 
at the participant’s home by qualified personnel (e.g. nurse  practitioner, physician’s 
assistant ).  Please  refer to SRM for additional details.  
Activities that may be done as part of a home healthcare visit will follow the schedule 
provided in the SoA (Section 3) and could include:  
• Collection of blood and urine samples including:  
• Safety assessments which may include routine blood and urine sampling  
• PK and ADA specimen collection  
• Efficacy assessments  
• Biomarker, immunogenicity and genetic assessments  
• Pregnancy tests  
• 12-Lead ECG  
• Other assessments as clinically indicated  
Note:  Biological samples should not be collected if they cannot be processed in 
a timely manner or appropriately stored until their intended use. Please refer to 
the SRM/lab manual for sample collection and storage requirements.  
• Measurement of vital signs (BP, heart rate, body temperature) and weight.  
• Physical examination  
• Administration of study treatments  (subcutaneous delivery only, no i.v. or infusions).  
• Administration of medication  
• Identification and reporting of concomitant medications.  
• Dosing diary review for medication compliance.  
• Identification and reporting of AEs/SAEs.  
Note: The investigator or other qualified medical professional must ensure reporting 
of AEs and SAEs is completed in accordance w ith the protocol and applicable 
regulations and that the appropriate medical intervention, therapeutic intervention, 
and/or support measures are instituted, as necessary.  
The participant should be informed of any potential risks associated with Home 
Healthcare and sign a Informed Consent Form if required  by local law or regulations . 
IRB/Ethics committee should be informed and/or approve of this change in approach and 
the process documented in study files.  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 225 Home Healthcare (Ophthalmologic Exam)  
Where ap plicable country and local regulations and infrastructure allow, protocol -
required eye exams may be done in the participant’s home  or alternative location .  
Activities that may be done as part of remote  eye exam must follow the schedule 
provided in the SoA  (Section  3) and include  (refer to SRM for additional details) :  
• Visual Acuity   
• Slit lamp exam  
• Ophthalmoscopy  
• Other assessments as clinically indicated  
The particip ant should be informed of any potential risks associated with Home 
Healthcare Ophthalmologic exams and sign a revised Informed Consent Form if required. 
IRB/Ethics committee should be informed if required and/or approve of this change in 
approach and the process documented in study files.  
Telemedicine  
Where applicable country and local regulations and infrastructure allow, telemedicine 
visits may be permitted.  Telemedicine visits are defined as online (virtual) visits which 
will use secure video conferenc e, phone calls, a web portal and/or mobile application as a 
way of communicating with and monitoring the participant’s progress.  Telemedicine 
visits are conducted by an investigator , site staff  or other qualified medical professional s 
and may be done in conjunction  with visits from Home Healthcare personnel (see above).  
Refer to SRM for additional details.  
Activities that may be done as part of a telemedicine visit include:  
• Medical evaluation of the participant  
• Identification and reporting of concomitant medications.  
• Dosing diary review for medication compliance.  
• Identification, management, and reporting of AEs and SAEs.   
Note: The investiga tor, site staff  or other qualified medical professional must ensure 
reporting of AEs and SAEs is completed in accord ance with the protocol and 
applicable regulations and that the appropriate medical intervention, therapeutic 
intervention, and/or support measures are instituted, as necessary. Participants 
utilizing telemedicine can report AEs at any time via an app, phon e call or 
videoconference with site staff.  
The participant should be informed of any potential risks associated with the virtual 
medium and sign a revised Informed Consent Form if required. IRB/Ethics committee 
should be informed if applicable and/or appro ve of this change in approach and the 
process documented in study files.  
 
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 226 14.14.  Appendix 1 4: Protocol Amendment History  
The Protocol Amendment Summary of Changes Table for the current amendment is 
located directly before the Table of Contents (TOC).  
14.14.1.  Protocol Ame ndment 3 ( 13-Jul-2020)  
Amendment 3: 13 -JUL -2020  
Where this Protocol Amendment applies:  
Protocol Amendment 3 applies to all participants in all countries and at all sites.  
Overall rationale for Amendment  3:  
Protocol Amendment 3 includes updated duration of contraception for female participants 
to align with this guidance of child bearing potential based on review of guidelines on 
aneugens.  
Additionally, upon review of safety data from Study 205678 (DREAMM -2), it was 
determined that ocular changes associat ed with belantamab mafodotin treatment were 
mostly limited to the corneal epithelium [GSK Document Number 2013N175128  V08, 
2020]. Therefore, fu rther collection of ocular safety data in belantamab mafodotin studies 
will be focused on corneal changes. Review of this data also indicated that the use of 
corticosteroid eye drops was ineffective in preventing or mitigating changes to the 
corneal epithe lium associated with belantamab mafodotin [Lonial , 2020].  The 
discontinuation of corticosteroid eye drops as prophylaxis was communicated to the sites 
via a Protocol clarification letter dated 21 October 2019. Protocol Amendment 3 includes 
chan ges to ophthalmologic assessments based on these findings.   
Preclinical data from xenograft mouse models and emerging clinical data from Arm A in 
Amendment 2 suggests greater activity of belantamab mafodotin in combination with 
lenalidomide. Given this, d oses higher than 2.5 mg/kg of belantamab mafodotin will not 
be evaluated in combination with lenalidomide/ dexamethasone in Arm A in Amendment 
3.  
Furthermore, in order t o reduce increased exposure of belantamab mafodotin over time 
and potentially improve the benefit/risk for participants, reduced dose levels and 
extended dosing schedules for belantamab mafodotin will be evaluated in Amendment 3.  
• Arm A (Belantamab mafodotin + Len/Dex; 28 -day cycle): As per above, i n 
Arm A Part 2, an alternate dosing schedu le of STRETCH (Q8W) dosing may be 
explored for the 1.9 mg/kg dose level if emerging data (from either this study or 
across the program) suggests that this schedule may further optimize the 
tolerability or offers an improved benefit/risk profile . To enable this, a potential 
extended dosing schedule has been introduced via this amendment, where 
belantamab mafodotin at 1.9 mg/kg will be administered once every 8 weeks 
(STRETCH ) and will be evaluated dependent on emerging data. The cycle 
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 227 duration will remain 28  days/4 weeks. Up to 12 participants will be enrolled in 
this new cohort.  
• Arm B (Belantamab mafodotin + Bor/Dex; 21 -day cycle): Similarly, in Arm B 
Part 2, 2 new dosing schedules (STRETCH and Step -Down [S/D] STRETCH) 
and one new (reduced) dose level (dose level -1 at 1.9 mg/kg) of belantamab 
mafodotin has been added.  In the extended dosing schedule, belantamab 
mafodotin will be administered every 6 weeks ( STRETCH ). The cycle duration 
will remain 21 days/3 weeks. Additionally, a S/D STRETCH schedule with a f irst 
dose of 2.5mg/kg dose at C1D1 followed by subsequent planned doses of 
1.9 mg/kg dose starting on Day 1 of alternate 21 -day/3 -week cycles C3 onwards 
(C3, C5, C7, and so on) will be evaluated. Furthermore, as target engagement and 
responses have been sh own to occur at 1.9 mg/kg (and lower dose levels) in the 
first-time in human (FTIH) study BMA117159, belantamab mafodotin dose at a 
reduced dose level of 1.9 mg/kg in combination with SoC will be additionally 
explored in Arm B Part 2. To evaluate these add itional dose levels and schedules, 
4 new dosing cohorts (2.5 mg/kg STRETCH , 2.5 → 1.9 mg/kg S/D STRETCH , 
1.9 mg/kg SINGLE (Q3W dosing) and 1.9 mg/kg STRETCH) are being added. 
Up to 12 participants will be enrolled in each of these 4 new cohorts.  
Protocol A mendment 3 includes the following:  
Section # and 
Name  Description of Change  Brief Rationale  
Belantamab Mafodotin Program Level Changes  
Section 1, Treatment 
Groups and 
Treatment Duration, 
Section 8.1.6.1 and 
Section 8.1.6.2  Added “or end of study” to Arm A and 
Arm B text on continuing treatment until: 
“progressive disease (PD), intolerable 
AEs, consent withdrawal, or death”  To make text consistent with 
Section  6.3 
Section 3, Table 4 
and Table 10  Removed requirement for fasting 
glucose test at Screening. Fasting 
glucose and HbA1c to be done as 
clinically indicated and at End of 
Treatment  Glucose included in chemistry panel 
and fasting glucose/HbA1c to be 
assessed as clinically indicated on -
treatment.  
Section 3, Table 4 – 
Table 8, Table 10, 
Section 10.6.10 , and 
Table 27  Removed troponin and B -type natriuretic 
peptide (BNP) testing.  Based on clinical experience to date 
with belantamab mafodotin , and  as 
reviewed by the GSK cardiac safety 
panel, it was agreed that troponin 
and B -type natriuretic peptide (BNP)  
was not required unless clinically 
indicated  
Section 3, Table 4  Acceptable BM aspirate/biopsy changed 
from within 21 to within 28 days prior to 
first dose.  Broaden window to avoid excessive 
procedures.  
Section 3, Table 5 - 
Table 8  ECG footnote: timing f or obtaining 
triplicate ECGs updated  Broaden collection period for ease of 
use in clinic  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 228 Section # and 
Name  Description of Change  Brief Rationale  
Section 3, Table 5 – 
Table 8  PK blood sampling footnote: timing for 
obtaining EOI PK samples increased, 
language pertaining to collection 
following dosage delay clarified.  Clarification; Broaden collection 
period for ease of use in clinic  
Section  3, Table 5 – 
Table 8, Table 10, 
Section  10.6.7  Ocular exams: timing for on -study exams 
changed from every 4 weeks prior to Day 
1 dosing, to prior to belantamab 
mafodotin for the first 6 doses. Also 
changes to further exam schedule based 
on presence/absence of new corneal 
events.  Ocular substudy safety  data from 
Study 205678 data indicated that 
participant symptoms should 
determine the need for 
ophthalmology exams.   
 
Additional collection of digital 
photography is not needed based on 
sufficient collection of ocular 
photography in Study 205678.  
Section 3, Table 5 – 
Table 8; Section 
4.3.1; Section  14.8 Corneal events management: removed 
text on prophylaxis with steroid eye 
drops.  Steroid eye drops not beneficial in 
preventing or mitigating corneal 
events associated with belantamab 
mafodotin, based on fin dings from 
ocular substudy from Study 205678.  
Section 3, Table 5 – 
Table 8, and Section 
10.6.11  Genetic sample: added text permitting 
recollection of genetic sample as 
necessary.  Enables genetic testing to proceed if 
original sample is damaged, unable 
to be processed, or if insufficient 
DNA was extracted.  
Synopsis, Section  3 
Table 10, 
Section  4.3.1, 
Section  7.1, 
Section  7.3, 
Section  10.2.8 and 
Appendix 7  Duration of contraception after last dose 
of belantamab mafodotin changed to 6 
months for males and 4 months for 
females  Based on review of global guidelines 
on aneugens.  
Synopsis, Section 
4.2.3  Updated description of belantamab 
mafodotin ADC and MoA  Revised program language  
Section 4.2.4  Updated clinical experience language for 
studies BMA117159 and 2 05678  Updated relevant clinical data 
available.  
Section 4.3  Updated benefit/risk assessment  Incorporation of revised program 
safety language  
Synopsis, Section 
7.1, Table 17  Left ventricular ejection Fraction (LVEF) 
by ECHO value for adequate organ 
system  function changed from 45% to 
40% Based on clinical experience to date 
with belantamab mafodotin , and  as 
reviewed by the GSK cardiac safety 
panel, it was agreed that a reduction 
in LVEF was acceptable for 
participants enrolling in the study.  
Synopsis, Sec tion 
7.2, Section 9.2.3  Removed exclusionary ECG QTcF 
parameter  Aligned with Cardiac Safety Panel 
recommendations (Dec 2019)  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 229 Section # and 
Name  Description of Change  Brief Rationale  
Synopsis, Section 
7.3 Lifestyle Restrictions  
• Clarified language regarding use of 
bandage contact lenses and when 
contact lenses may be restarted 
following end of study treatment  
• Moved the sentence about 
administration of live/live -
attenuated vaccine to prohibited 
concomitant medication.  Program clarifications and revisions  
 
 
 
 
The text was moved to a more 
appropriate section  
Section 8.2.1,  
Table 22  Removed the requirement for 
prophylactic corticosteroid eyedrops  Based on ocular substudy safety data 
from Study 205678 data  
Section 8.2.1,  
Table 23  Inclusion of dose modification guidelines 
for cutaneous reactions and 
hypersensitivity associated with 
lenalidomide.  Aligned with updated approved 
lenalidomide labelling.  
Section 8.7.2  Added administration of live/live -
attenuated vaccine text. See the change 
for Section 7.3 above.  
 
Added restriction on use of 
live/attenuate d virus vaccines for at least 
70 days after the last dose of 
belantamab mafodotin  To enhance patients’ safety, the 
period for prohibited use of live/live -
attenuated vaccines has been 
extended  
 
 
Section 9.2.6  Addition of reaction management 
language for belantamab mafodotin 
infusion reactions  Clarification  
Section 10.3  Updates to belantamab mafodotin, 
lenalidomide and bortezomib overdose 
language; addition of dexamethasone 
overdose section  Clarification of overdose information  
Section 10.6.7  Updated spe cifications for ophthalmic 
examinations  Revised safety language and 
adjustments for added cohorts  
Study Design Changes  
Section 3, Section 
10.2.1, Section 
12.4.2.2 and Section 
14.9 Adverse event assessment period 
increased from 45 days to at least 70 
days  after the last dose  Aligned with recent updated 
information regarding belantamab 
mafodotin half -life 
Synopsis, Section 
7.1 Removal of IMWG reference pertaining 
to disease progression in Inclusion 
Criteria #6  Due to varied global standards, 
wording in the  listed criterion has 
been adjusted to introduce flexibility 
based on global differences  
Section 3, Table 5 
and Table 6  Serum pregnancy test collection window 
expanded to 10 -14 days  To provide greater flexibility to sites 
in determining pregnancy status  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 230 Section # and 
Name  Description of Change  Brief Rationale  
Section 3, Table 5 – 
Table 8  Criteria for collection of BM aspirate for 
 and  updated to achieving 
VGPR or better  Criteria for collection of BM aspirate 
for  and  updated to 
provide a more detailed disease 
response profile  
 
Synopsis, Table 1, 
Table 5, Figure 1, 
Section 6.1, Section 
6.2, Section 6.5.2, 
Table 18, Section 
8.1.1, Section 8.2.1, 
Section 12.2.1  Addition of a potential new treatment 
cohort with introduction of Q8W 
(STRETCH) schedule for Arm A 
(belantamab mafodotin with Len/Dex)  Evaluate other dosing regimens for 
optimal treatment  
Synopsis, Table 2, 
Table 9, Figure 2, 
Sectio n 6.1, Section 
6.2, Section 6.5.2, 
Table 18, Section 
8.1.2.1, Section 
8.1.3, Section 8.2.1, 
Section 12.1.2, 
Section 12.2.2  Addition of new treatment cohorts and 
introduction of Q6W (STRETCH) and 2.5 
→ 1.9 mg/kg  Step-Down (S/D) 
schedules for Arm B (belantam ab 
mafodotin with Bor/Dex)  Evaluate other dosing regimens for 
optimal treatment  
Section 6.1.1, 
Section 6.1.2, 
Section 6.5.1, Table 
13, Section 8.1.1.1  SINGLE and SPLIT doses at 3.4 mg/kg 
removed from Arm A; Decreased 
number of dose levels for exploration 
and defined maximum dose as 2.5 
mg/kg for belantamab mafodotin  3.4 mg/kg dose is not currently being 
explored  
Synopsis, Section 
6.2, Section 6.3, 
Section 12.2  Revised numbers of participants  Adjusted numbers to accommodate 
new dosing regimen cohorts and 
addition replacements for non -DLT 
evaluable participants  
Section 6.5  Provide justification for lower dosing and 
different regimens for belantamab 
mafodotin treatment  Revised due to updated analysis of 
safety information  
Synopsis, Section 
7.1, Section 10.2.8  WOCBP and male participants in Arm B: 
change the restriction of contraceptive 
period after bortezomib  Added due to the changes in the 
bortezomib label  
Section 7.3  The prohibition for blood donation in Arm 
A was changed from 120 days to 28 
days  Alignment with lenalidomide label  
Section 8.2.1, Table 
20, Table 21  Removed requirement that dose 
modifications be “after Cycle 1” from Part 
2. To provide greater flexibility to sites 
in managing hematological toxicity  
CCI
CCI
CCI
CCI
CCI
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 231 Section # and 
Name  Description of Change  Brief Rationale  
Section 8.2.1, 
Section 8.6, 
Appendix 13, SoA 
Table 4 – Table 10  Added telemedicine and collection of 
data/follow -up by telephone  Covid -19-related changes  
Section 10.9  Revised text for immunogenicity 
assessments  Update and clarification  
Section 12.4.3.1  Pharmacokinetic analysis methods 
updated from population PK approach to 
standard noncompartmental analysis, 
data permitting.  Pharmacokinetic analysis methods 
and population PK approach updated 
to align with program level guidance  
Section 12.4.4  Updated text on PK/PD assessments  Revised to match plans for analysis  
Section 12. 4.8.1.2 
and 
Section  12.4.8.2.2  Interim analysis wording modified  Added additional details around 
planned interim analysis  
Section 12.4.9  Final Analysis section added  Clarification  
Section 12.4.5.3  Revised text on biomarkers analyses  Update and clarfication  
Section 14.9  Actions and follow -up assessments 
modified in liver stopping events table  Clarification  
Section 14.9.1.2  Addition of statement regarding liver 
stopping event due to hepatitis  Clarification of protocol in the event 
of alcohol -related hepatitis  
Administrative Changes  
Title Page  Sponsor signatory changed   
Synopsis  Corrected dose reduction guideline for 
dexamethasone from 75 years of age 
to >75 years of age  Typographical error  
Table 1 and Table 2; 
Figure 5, Figure 6, 
Figure 7; Table 18  Tables and figures to specify dosing 
regimens  Added to clarify cohort differences 
and schedules  
Synopsis; Section 2, 
Section 6.1.2.3, 
Section 8.1.1.1, Clarified dose descriptions administered 
on Day 1 of SIN GLE dose and on Day 1 
and Day 8 of SPLIT dose regimens.  Clarification  
CCI
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 232 Section # and 
Name  Description of Change  Brief Rationale  
Section 8.1.2.1 and 
Table 18  
Synopsis; Section 3, 
Section 7.3, Section 
8.2.1, Section 9.2.5, 
Section 10.6.7  Replaced reference to ophthalmologist 
and optometrist with “qualified eye care 
specialist”  To clarify the definition of an eye care 
professional  
Section 6.5  Description of new dosing schedules in 
Arm B  Rationale added for explanation and 
justification  
Synopsis; Section 
7.1 Clarification of inclusion criteria 
contraception language pertaining to 
WOCBP in Arm A vs Arm B.  Clarification  
Section 3, Table 4  Clarification to Pregnancy Test for 
WOCBP footnote regarding differences 
between Arm A and Arm B  Clarification  
Section 3, Table 5 -
Table 8; 
Section  10.6.1  Clarification to Physical Assessment 
footnote that dose  should be re -
calculated for body weight change 
>10%.  Clarification  
Section 3, Table 4 -
Table 9   testing 
footnote: clarification of  
 testing requirements.  Clarification  
Section 3, Table 4 – 
Table 8  BM aspirate footnote: clarified BM 
aspirate sampling  Clarification  
Section 3, Table 5 – 
Table 8  Footnotes added to study assessments 
for BM aspirate,  and PK blood 
sampling for belantamab mafodotin  Clarification  
Section 3, Table 5 – 
Table 8  Corneal Eve nts Management: Added “In 
the event of ocular symptoms (e.g., dry 
eyes), the use of artificial tears may be 
increased up to every 2 hours as 
needed” to footnote.  To align with existing language in 
Appendix 8  
Section 3, Table 5 
and Table 6  Updated Footnote  #9: Day 21 corrected 
to Day 22  To align with standard of care (SoC; 
dexamethasone) dosing schedule  
Section 3, Table 5 
and Table 6  Pharmacokinetic sampling for 
belantamab mafodotin Dose 2: wording 
change for delay of Dose 2  Clarification  
CCI
CCI
CCI
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 233 Section # and 
Name  Description of Change  Brief Rationale  
Section 3, Tab le 7 
and Table 8  Administration of dexamethasone: 
footnote updated to remove “weekly” 
from “reduced to 10  mg weekly”  To align with SoC dosing schedule.  
Section 3, Table 8  Hematology and clinical chemistry 
footnote: removed “to be performed 
every 3 weeks 3 days” and corrected 
“72 h prior” to “24 h prior”  
EORTC QLQ -30 and QLQ -MY20 
collected in Part 2 only changed to Part 1 
and Part 2  Corrections  
Section 3, Table 10  Addition of BM sampling considerations 
to BM aspirate/biopsy for Disease 
Assessment   
Section 4.3.1, Table 
11 Updated Data summary/risk rationale 
and mitigation strategy items throughout 
table  
Added Embryo -fetal toxicity section to 
overlapping toxicities section  Updating to include recent 
information  
Section 4.3.2  Added discussion of bene fits from study 
205678 to benefit assessment  Updating to include recent 
information  
Section 4.3.3  Updated benefit/risk conclusions to 
include preliminary safety data from Arm 
B Updating to include recent 
information  
Section 6.3  Language regarding study completion, 
study analyses and end of study updated  Clarification  
Section 8.1.1.2  Language throughout section 
streamlined for clarity  Clarification  
Section 8.1.1.2 and 
Section 8.1.2.2, 
Section  8.1.4.4  For dexamethasone, added text referring 
to the produc t label and removed 
DECADRON reference.  Clarification  
Section 8.1.3.2 and 
Section 8.1.4.3  Removed references to REVLIMID and 
VELCADE -specific product information, 
replaced with referral to local prescribing 
information  Broadened references for regional 
variance  
Section 8.2.1, 
Table  21 Added missing footnote  Correction/clarification  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 234 Section # and 
Name  Description of Change  Brief Rationale  
Section 8.2.1, Table 
22 Added directions for use of cooling eye 
masks to reflect information in SOA  Clarification to align with SOA  
Section 8.2.1, 
Table  23 Removed instruction to not dose below 
5 mg daily for Days 1 to 21 of 28 -day 
cycle.  Correction/clarification  
Section 10.6.8, 
Secction 10.11  Updated text for PRO measures and HR -
QoL assessments  Revised instructions and conduct  
Section 10.7.1  Arm A, receiving belantamab mafodotin: 
Q3W corrected to Q4W  Correction to align with Arm A cycle 
length  
Section 13  Reference list updated as necessary  Correction  
Section 14.8, Table 
34 Corrections to values for changes in 
visual acuity  Correction/clarification  
Section 14.12  Appendix added to define eye care 
specialist qualifications and requirements  Definition of eye care specialist 
required due to language changes 
throughout document.  
Section 14.13  Added appendix on telemedicine 
procedures  Added to facilitate  adequate care and 
data collection  
Editorial/Document Formatting Changes  
Whole document  Minor editorial and document formatting 
revisions  Minor, therefore have not been 
summarized  
Whole document  GSK2857916, GSK’916 replaced with 
belantamab mafodotin  Use generic name  
Whole document  Abbreviate the Step -Down regimen as 
S/D; Abbreviate Q6W regimen as 
‘STRETCH’  Ease of reference for dose regimen 
concepts  
 
14.14.2.  Protocol Amendment 2 (26-APR-2019 ) from the Final Version (28 -
FEB-2018)   
Amendment 2  26-APR -2019  
Where this Protocol Amendment Applies  
Protocol Amendment 2 applies to all countries and sites.  
Overall Rationale for the Amendment:  
i) In December 2018, GSK paused enrolment in the belantamab mafodotin  in 
combination with lenalidomide/dexamethasone (Arm A) o f study 207497 due to two 
similar events of pneumonia and sepsis in the setting of febrile neutropenia resulting in 
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 235 death in the first two patients enrolled in Arm A. The pause in enrolment in Arm A 
occurred per protocol, to assess the dose exploration in this treatment arm. GSK used this 
as an opportunity to review the data and conduct an evaluation to assess factors that led to 
these neutropenic/infection events while amending the protocol . Protocol for study 
207497 is being amended to: a) to change ECOG eligibility criteria in Arm A from 0 -2 to 
0-1, b) to include additional guidance for management of neutropenia / prophylaxis of 
infections to be implemented across the study on resuming Arm A and c) more stringent 
hematological monitoring for both Arm A an d Arm B.  
ii) Regulatory feedback encouraged generation of additional data (safety, PK, PD, 
clinical activity) at lower dose levels of belantamab mafodotin  to support dose selection 
for future Phase 3 studies with belantamab mafodotin  in combination with standard of 
care (SoC) agents.  Administration of belantamab mafodotin  divided as two equal 
administrations a week apart will also be evaluated to see if this dosing schedule would 
result in improvement of benefit/risk due to ~25% reduction in the maximum 
concentration while maintaining similar exposure over a cycle compared  to the full 
administration on Day 1 . 
iii) Protocol Amendment 2 also incorporates the Protocol Clarification letter (dated 
28-Feb-2019) previously issued to study sites, that provided updated guidance on grading 
corneal events and dosing participants with belan tamab mafodotin .  
iv) Administrative corrections and general program updates are also included in 
Amendment 2.  
 
Protocol Amendment 2 includes the following:  
Section # and 
Name  Description of Change  Brief Rationale  
Revised Study Design for 207497  
Section 2  
Schedule of  
Activities Tables  Added SoA Tables 3 and 5 pertaining 
to the belantamab mafodotin  SPLIT 
dosing cohorts based on the 
amendment 02 -edited existing SoA 
tables (renumbered as Table 2 and 
Table 4, respectively). Additional PK 
timepoints were includ ed for SPLIT 
dosing.  To align with revised study design 
regarding SPLIT dosing  
Section 4 
Objectives and 
Endpoints  Table 8: Combined previous Table 6 
and Table 7 into a single table  To align with revised study design  
Section 5.1 Overall 
Design  Revised study design  Based on emerging data  
Section 5.1.1 
Arm A Figure 2: Replaced Figure with Study 
Design for Arm A  
Updated section to specifically refer To clarify and to align with revised 
study design  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 236 Section # and 
Name  Description of Change  Brief Rationale  
to Arm A  
 Figure 3: Updated dose -finding 
criteria pertaining to Arm A and 
changed number of figure from 4 to 3  To align with revised study design 
and number of participants in the 
protocol  
 Table 10: Added table for operating 
characteristics of the dose escalation 
rules for Arm A  To align with revised study design  
Section 5.1.2 
Arm B Added section specific to Arm B  
 
Figure 4: Replaced Figure with Study 
Design for Arm B and updated figure 
number from 3 to 4  
 To clarify and to align with revised 
study design  
Section 5.2 
Number of 
Participants  Updated number of participants  To align with revised study design  
Section 5.4 
Scientific Rationale 
for Study Design  Edited rationale and removed 
reference to recommended phase 2 
dose (RP2D)  To clarify the scientific rationale 
and to align with revised study 
design and strategy across the 
belantamab mafodotin  
development program  
Section 5.5.1 
Starting dose of 
belantamab 
mafodotin  Added language for divided 
administration of belantamab 
mafodotin  (SPLIT dosing)  To align with revised study design  
Section 7.1 
Treatments 
Administered  Sections 7.1.1.1, Section  7.1.2.1 – 
Added guidance for SPLIT dosing 
schedule for belantamab mafodotin  
and language for potential 
exploration of alternate dosing 
schedule  To provide consistency and 
alignment with revised study 
design  
Section 9.6.1 
Physical 
Examinations  Included timeframe for the SPLIT 
dosing cohorts  To align with revised study design 
and new SoA Table 3 and Table 5 
in Section 2  
Section 11 
Statistical 
Considerations  Edited section to include distinct 
sections for Arm A and Arm B  To align with revised study design  
Section 11.1.1.2 
(Arm A) and Edited statistical hypotheses for Part To align with revised study design  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 237 Section # and 
Name  Description of Change  Brief Rationale  
11.1.2.2  (Arm B) 
Part 2  2 
Section 11.2.1.2 
(Arm A) and 
11.2.2.2 (Arm B) 
Sample size 
determination Part 
2 Added language on sample size 
estimation  To clarify calculation of sample 
size 
Section 11.3 
Population for 
analysis  Removed definition of “all evaluable 
population”  To align with revised study design  
Section 11.4.1 
Analyses of clinical 
activity  Updated primary and secondary 
endpoints  To be consistent with changes in 
Section 4 - Obje ctives/Endpoints  
Section 11.4.7 
Section 11.4.7.1.1 
(Arm A) and 
Section 11.4.7.2.1 
(Arm B) Interim 
Analysis Part 1  Added language on analyses 
performed during dose escalation  To clarify based on the revised 
study design  
Section 13 
Appendices  Appendix 11 – Appendix added to the 
protocol  To align with protocol updates  
Study Specific Safety Changes  
Section 2  
Schedule of  
Activities Tables  Table 2 & Table 4: Added 
requirement for ANC prior to dosing  Changes made following safety 
events and to enhance safety 
monitoring  
 
 Table 2: Clarified lenalidomide 
administration timing in relation to 
belantamab mafodotin  administration 
timing  Information added to provide 
clarity and keep consistency with 
PK sample collection and add a 
safety window between 
administration of belantamab 
mafodotin  and lenalidomide.  
 
 Table  2 & Table 4: Added an 
additional hematology sample 
collection on Day 15 for Cycles 1 -8 Changes made to add additional 
safety monitoring  
 
Section 3.3.1 Risk 
Assessment  Table 7: Updated table to highlight 
overlapping toxicities for belantamab 
mafodotin  with SoC  To clarify risks associated with 
administration of belantamab 
mafodotin  with Len/Dex and 
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 238 Section # and 
Name  Description of Change  Brief Rationale  
Bor/Dex  
Table 7: Added language for 
methods of contraception in Arm A 
and B  Added clarification for method of 
contraception in accordance to the 
safety profile of each drug 
including requirements from 
REVLIMID REMS program.  
 Table 7: Updated information on 
thrombocytopenia and neutropenia 
risks related to belantamab mafodotin  
and revised mitigation strategy  Updated based on data from the 
FTIH study BMA117159  
Section 6.1 
Inclusion Criteria  For Arm A, changed ECOG 
performance status from 2 to 1  The changes were made following 
safety events and to enhance 
safety monitoring  
 
 Table 13: Increased limit for Absolute 
Neutrophil Count and Platelets   
 Table 13: Removed Coagulation 
section and updated footnote  
Added language for contraception 
methods and female partner of male 
participants  
Added inclusion criteria for WOCBP 
participants assigned to treatment A   
Section 7.1 
Treatments 
Administered  Added recommendation for time of 
administration of lenalidomide  To clarify and to keep consistency 
with PK sample collection and add 
a safety window between 
administration of belantamab 
mafodotin  and lenalidomide  
 Added guidance for dose 
modification of dexamethasone  To provide guidance and align 
with addition of Section 7.2.2  
Section 7.1.5.3 
Lack of tolerability 
in Treatment A or 
B  Added language for participant who 
meets stopping criteria for 
belantamab mafodotin  To clarify follow up for participant 
who meets stopping criteria  
Section 7.2.1 Dose 
Modification After 
Cycle 1  Table 16:  
• Added monitoring for 
Neutropenia  Updated based on emerging data  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 239 Section # and 
Name  Description of Change  Brief Rationale  
 • Edited dose modification 
guidelines for thrombocytopenia 
to reflect the SINGLE day and 
SPLIT dosing schedules   
 • Added immediate hospitalization 
for participants presenting with 
febrile neutropenia   
 • Corneal events monitoring 
removed and presented in a 
separate table (Table 17)   
 • Added language clarifying 
infusion reaction symptoms  To clarify recommendations for 
infusion reactions  
 Table 19: Added monitoring for  
hematological toxicity  Updated information based on 
emerging data  
Section 7.2.2 Dose 
Modification 
Guidelines for 
Dexamethasone  Added section, Table 20 and Table 
21 To provide guidance for dose 
modifications for dexamethasone  
Section 7.7.2 
Prohibited 
Medication  Added caution statement for CYP 
inhibitors/inducers  Updated information based on 
emerging data  
Section 8.1 
Discontinuation of 
Study Treatment  Added Pregnancy and Safety 
stopping criteria to the list of reasons 
for discontinuation  To align with  Section 9.2.8 and 
Appendix 7  
Section 8.2.5 
Corneal 
Supportive Care 
Guidelines  Removed section – content moved to 
Section 9.6.7 Ophthalmic 
Examinations  To provide cohesion and group 
related content  
Section 11.4.7.1.2 
(Arm A) and 
11.4.7.2.2 (Arm B) 
Interim Analysis 
Part 2  Added language on safety monitoring 
and stopping rules during cohort 
expansion  To align with strategy across the 
belantamab mafodotin  
development program  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 240 Section # and 
Name  Description of Change  Brief Rationale  
Belantamab Mafodotin  Program Level Changes  
Section 2  
Schedule of  
Activities Tables  Table  2 & Table 4: Edited 
hematologic examination timeframes 
to include additional testing during 
each cycle  To align with strategy across the 
belantamab mafodotin  
development program  
 Table 2, Table 4, Table 6: Changed 
duration of collection of AE /SAE from 
30 days to 45 days  Changed throughout the protocol  
Revised to align with duration of 
5 half-lives of belantamab 
mafodotin  
 Table 2 & Table 4: Revised Corneal 
Event prophylaxis to also include 
prednisolone acetate  To align with strategy across the 
belantamab mafodotin  
development program  
Section 3.3.1 Risk 
Assessment  Table 7: Updated data and mitigation 
strategy on risks related to 
belantamab mafodotin  
(thrombocytopenic events, 
neutropenic events, IRR, 
cardiotoxicity, nephrotoxicity, 
pulmonary toxicity, 
immunosuppression, potential for 
other laboratory abnormalities)  Edited based on updated data 
from the FTIH study (BMA117159) 
and to align with strategy  across 
the belantamab mafodotin  
development program  
Section 6.2 
Exclusion Criteria  Changed the definition of invasive 
malignancies to be excluded  
 
Increased QTcF from 470 msec to 
480 msec  To clarify the definitions  
 
 
QTcF increased to align with GSK 
internal standards for oncology 
trials as determined by GSK 
Cardiac Safety Panel  
  
Changed uncontrolled arrhythmias to 
untreated arrhythmias  
 
Reduced timeframe for history of 
myocardial infarction, acute coronary 
syndromes prior to Screening   
Based on emerging data as 
determined by GSK Cardiac 
Safety Panel   
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 241 Section # and 
Name  Description of Change  Brief Rationale  
Section 7.1 
Treatments 
Administered  Sections 7.1.1.1, 7.1.2.1 and Table 
11 – Changed duration of 
administration of belantamab 
mafodotin  from “30 min” to “30 min to 
1 h” To add flexibility in the duration of 
administration of belantamab 
mafodotin  
 Removed language indicating that 
participants will be removed from 
study for lack of tolerability  To align with strategy across the 
belantamab mafodotin  
development program  
Section 7.1.12.4 
Participants 
Achieving CR  Removed section  Section not relevant for 
GSK2857916  
Section 7.2.1 Dose 
Modification After 
Cycle 1  Table 15: Added table for 
recommendations for dose reduction 
of belantamab mafodotin  To clarify and align with revised 
study design  
 Table 18: Added recommendation for 
use of prophylactic antimicrobials  Changes to dose modification 
guidelines for belantamab 
mafodotin  related to Corneal 
Events further clarified dose 
modifications based on visual 
acuity or findings on ophthalmic 
examination  
Section 8.2.5 
Corneal Event 
Stopping Criteria  Added clarity on use of GSK scale 
and CTCAE scale for AESI reporting 
purposes and dose modifications  
Removed duplicate text within 
section 8.2.5  Alignment throughout protocol. 
Both the CTCAE and GSK scale 
are to be utilized for reporting of 
corneal events and clarified that 
the GSK scale is to be utilized for 
dose modification decisions . 
Section 9.2.7 
Adverse Events of 
Special Interest  Added clarity on use of GSK scale 
and CTCAE scale  Alignment throughout protocol  
Section 9.2.8  
Pregnancy  Edited timeframe for performance of 
pregnancy test prior to the first dose 
of study treatment from 72 h to 24 h  To keep protocol consistency for 
pregnancy monitoring across the 
belantamab mafodotin  
development program  
Section 9.6.10  
Laboratory 
Assessments  Table 22: Removed INR analysis  To align with GSK liver monitoring 
requirements, INR test will not be 
required unless a liver event 
occurs  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 242 Section # and 
Name  Description of Change  Brief Rationale  
Section 13 
Appendices  Removed Appendix 3 – International 
Myeloma Working Group (IMWG) 
Criteria for Relapse -Refractory 
Multiple Myeloma  Included references to the IMWG 
Criteria in lieu of an appendix for 
clarification purposes  
 Appendix 10 – Labelling changed to 
Appendix 8 - Added clarity on use of 
GSK scale and CTCAE scale – 
Updated GSK grading scale  To align with S ection 9.2 and 
throughout the protocol  
 
 Appendix 9 – PK collection updated 
from 30 days to 45 days (5 half -lives)  Revised to align with duration of 5 
half-lives of belantamab mafodotin  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 243 Section # and 
Name  Description of Change  Brief Rationale  
Additional Changes in Assessments  
Section 2  
Schedule of  
Activities Tables  Table 1: Edited FISH testing to 
include identification of amplifications 
and deletions  Acceptability of positive results for 
high risk abnormalities by FISH 
has been extended beyond 60 
days, as the listed abnormalities 
are myeloma -defining and do not 
change the course of the disease  
 Table 2 & Table 4: Clarified timings 
for vital signs, ECG collections and 
PK sample collection  
 Additional ECG timepoints added 
to assess at the Cmax of the free 
cytotoxic drug (cys -mcMMAF) and 
to detect any delayed effects on 
QTc 
 
 Table 2 & Table 4: Added additional 
PK timepoints  
 Additional PK timepoints added to 
capture the Cmax of the free 
cytotoxic drug (cys -mcMMAF) and 
to better define the kinetics of cys -
mcMMAF and the elimination 
phase of ADC and cys -mcMMAF  
 
 Table  2 & Table 4: Added additional 
 sample collection timepoint  To study the effect of genetic 
variations on response  
Protocol Clarification and Alignment Changes  
Section 2  
Schedule of  
Activities Tables  Table 2: Changed timeframe from 
pregnancy testing in WOCBP  To provide consistency and 
alignment throughout the protocol  
 
Section 5.3 
Participant and 
Study Completion  Edited definition of participant 
completion  To clarify study completion  
 Edited definition for end of study for 
Arms A and B  To clarify definition for end of 
study  
Section 5.5.2 
Starting dose of Added “planned” to “cycle”  To clarify between time bound 
assessments and cycle bound 
CCI
CCI
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 244 Section # and 
Name  Description of Change  Brief Rationale  
SOC  assessments  
Section 6.1 
Inclusion Criteria  Added “autologous” to “stem cell 
transplant”  To clarify inclusion criteria  
 
Section 7.2.1 Dose 
Adjustments Due 
to Body Weight or 
Body Surface Area  Moved content to relevant context in 
Section 7.1  To clarify protocol  
Section 7.2.2. 
belantamab 
mafodotin  Dose 
Modification in Part 
1 (Dose 
Escalation)  Moved content to Section 5.1  To clarify protocol  
Section 5.1.3 
Criteria for 
belantama b 
mafodotin  Dose -
Limiting Toxicity in 
Part 1  Moved this Section (previously 
Section 7.2.3) into Section 5.1  To clarify protocol  
Section 7.2.1  
Dose Modification 
After Cycle 1  Removed presented scenarios – to 
be provided as an Appendix to the 
SRM  To clarify protocol  
Section 9.6.3 Vital 
Signs  Added language for timeframe of vital 
signs assessment on days of 
bortezomib administration  To provide consistency and 
alignment throughout the protocol  
Section 9.6.7 
Ophthalmic 
Examinations  Added clarification for supportive 
care.  
 To provide consistency and 
alignment throughout the protocol  
Administrative Changes  
Title Page  Removed author list  
 
Removed Medical Monitor 
information and added reference to 
the Study Reference Manual  To follow current GSK template  
(i.e., Transcelerate protocol 
template)  
Section 1 Synopsis  Changed text in Synopsis to reflect 
changes to the text of main body of Refer to individual items listed 
throughout this table  
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 245 Section # and 
Name  Description of Change  Brief Rationale  
the protocol  
Section 9.6.7 
Ophthalmic 
Examinations  Clarification of  examination 
requirement for each visit.  
 
Added statement on the central 
collection of photographs  Administrative change  
Section 9.6.10 
Laboratory 
assessments  Table 22: Removed “fasting” 
requirement for glucose analysis  Based on additional data, fasting 
glucose is not required at every 
visit as routine glucose is included 
in chemistry panel  
Section 13 
Appendices  Removed Appendix 7 – Calculation 
of Body Surface Area  Removed to prevent copyright 
infringement  
 Appendix 12 – Included list of 
changes pertaining to Amendment 01  To follow current GSK template 
(i.e., Transcelerate protocol 
template)  
Editorial/Document Formatting Changes  
Whole document  Minor editorial and document 
formatting revisions  Minor, therefore have not been 
summarized  
14.14.3.  Protocol Amendment 1 (7 -MAY -2018):  
Protocol Amendment 1 include following:  
• additional authors who contributed to protocol amendment were added  
• change in the Primary Medical Monitor  
• Changes made in the Schedule of Activities tables. The SOA tables have been 
modified  to reflect that the disease assessments need to be performed at regular 
intervals instead of being linked to the administration of study drugs. Revisions have 
also been made in the timings and frequency of some assessments.  
• Minor correction made in the pa rticipants’ eligibility criteria; participants with prior 
allogenic SCT will now be excluded (Section 6).  
• Clarification made on dose delays of study drugs by giving examples of different 
scenarios (Section 7.2).  
• All routine and disease evaluation related b lood and urine tests now will be done 
locally; centrally only if unable to perform locally (Table 16)  
• Administrative changes made throughout the document.  
 
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 246 Section # and 
Name  Description of Change  Brief Rationale  
Title Page  Authors list was updated.  Additional authors who 
contributed to protocol 
amendment were added to the 
list; authors who are no longer 
involved with the study were 
removed.  
Medical 
monitor/Sponsor 
Information Page  GSK Medical Monitor change  Change in the Primary Medical 
Monitor  
Section 2  
Schedule of 
Activities Tables  Significant changes made in the 
Schedule of Activities tables.  
• The SOA Table 2 & Table 3 have 
been modified to reflect that the 
disease assessments need to be 
performed at regular intervals 
instead of being linked t o the 
administration of study drugs. For 
this purpose, an additional column 
for fixed time interval assessments 
was added.  
• Time period windows have been 
added for vital signs, drug infusions, 
PK sampling and imaging.  
• Revisions have also been made in 
the timings and frequency of 
following assessments; Spot urine 
for albumin/creatinine ratio, ECHO, 
imaging and EORTC QLQ -C30 AND 
QLQ -MY20 questionnaires.  
• Timepoints for response 
assessments under disease 
evaluation modified.  
• Removal of flow cytometry for bone 
marrow aspirate.  
• Added whole body PET/CT to 
confirm CR, sCR.  
• Timings of Triplicate ECG at the End 
of Infusion (EOI) corrected . 
 
• Language on the genetic research  
 
• Cycle bound assessments 
have been separated from 
time bound assessments to 
clarify activities.  
 
 
 
 
• This change was made to 
avoid deviations from 
administration timings of 
these assessments.  
• To align the assessments in 
both treatment arms.  
 
 
 
 
• Per IMWG response criteria  
 
 
• Flow cytometry is not used in  
IMWG (Rajkumar  2016)  
• Based on IMWG (Rajkumar 
2016)  
• ECG recordings must  be 
made prior to EOI instead of 
post-infusion as stated in the 
original version of the 
protocol.  
 
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 247 Section # and 
Name  Description of Change  Brief Rationale  
sample collection modified.  • To add more clarity.  
 
Synopsis and 
Section 4 
Secondary 
Objectives  Definition of  
 modified.  The change was made to 
provide precise definition of 
 
Section 6  
Study Population  Minor correction made in the 
participants’ eligibility criteria; 
participants with prior allogenic SCT will 
now be excluded.  
To reflect the ab ove, inclusion criterion 
#9 deleted and exclusion criterion # 4 
added in synopsis and main body of the 
protocol.  Participant s with Allogenic SCT 
are now excluded to avoid 
unpredictable toxicity .  
 
Section 7.2.4 
Dose 
Modification After 
Cycle  1 Clarificati on provided regarding dose 
delays of study drugs by giving 
examples of different scenarios.  The change was made to 
provide guidance on dose 
interruptions and reductions.  
Section 8.2.7  
Infusion Related 
Reaction 
Management and 
Stopping Criteria  Clarification provided on management of 
infusion -related reactions and stopping 
criteria.  The change was made to add 
more clarity.  
Section 9.2  
Adverse Events  Guidance provided on the grading of 
adverse events.  
 Added language specifying 
grading for clarity  
Section 9.2.6  
Disease -Related 
Events and/or 
Disease Related  Sentence on the reporting of 
progression disease as a serious 
adverse event modified.  Updated text to ensure PD is 
not reported as a SAE  
Section 9.6.7.1  
Ocular 
Examination and Added slit lamp in full anterior segment 
examination for clarity  The change was made to add 
more clarity.  
CCI
CCI
TMF-14624358  CONFIDENTIAL  
  207497  
 Protocol Amd 04  
 248 Section # and 
Name  Description of Change  Brief Rationale  
Procedures  
Section 9.7.1  
Blood Sample 
Collection for 
Pharmacokinetics  Amount of blood volume needed for 
belantamab mafodotin , Lenalidomide 
and Bortezomib Pharm acokinetics 
samples removed.  Information on the PK blood 
volume will be contained in the 
SRM.  
Table 16  
List of Clinical 
Laboratory Tests  All routine and disease evaluation 
related blood and urine tests will now be 
done locally; they may be performed 
centr ally only if unable to be performed  
locally  For ease of performing 
assessments and to provide 
more flexibility to sites.  
Appendix 8  
Assessment of 
Intensity  The intensity assessment scale for 
AE/SAE changed  from mild, moderate 
and severe into grades.  Per new protocol template  
Whole Document  Administrative corrections were made 
throughout the protocol to correct minor 
inconsistencies and rectify the 
typographical errors  Provide clarity and correction.  
 
Signature Page for  207497 TMF-14624358 v1.0
Signature Page for TMF-14624358 v1.0Reason for signing: Approved Name: 
Role: Approver
Date of signature: 30-Jun-2022 12:13:18 GMT+0000
PPD